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Children with severe intellectual disability have an increased prevalence of refractory seizures. 
Steroid treatment may improve seizure outcomes, but the mechanism remains unknown. Here 
we demonstrate that short term, daily delivery of an exogenous steroid 17β-estradiol (40 ng/g) 
in early postnatal life significantly reduced the number and severity of seizures, but did not 
improve behavioural deficits, in mice modelling mutations in the Aristaless-related homeobox 
gene (ARX), expanding the first (PA1) or second (PA2) polyalanine tract. ARX polyalanine 
expansion mutations in children cause intellectual disability and developmental delay, 
frequently presenting with comorbidities such as autism, dystonia, and refractory seizures and 
infantile spasms. Frequency of observed seizures on handling (n = 14/treatment/genotype) were 
significantly reduced in PA1 (32% reduction) and more modestly reduced in PA2 mice (14% 
reduction) with steroid treatment compared to vehicle. Spontaneous seizures were assessed (n 
= 7/treatment/genotype) at 7 weeks of age coinciding with a peak of seizure activity in untreated 
mice. PA1 mice treated with steroids no longer present with the most severe category of 
prolonged myoclonic seizures, while treated PA2 mice had a complete absence of any seizures 
during this analysis. Despite the reduction in seizures, 17β-estradiol treated mice showed no 
improvement in behavioural or cognitive outcomes in adulthood. For the first time we show 
that these deficits due to mutations in Arx are already present before seizure onset and do not 
worsen with seizures. ARX is a transcription factor and Arx PA mutant mice have deregulated 
transcriptome profiles in the developing embryonic brain. At postnatal day 10, treatment 
completion, RNAseq identified 129 genes significantly deregulated (log2FC >± 0.5, P-
value<0.05) in the frontal cortex of mutant compared to wild-type mice. This list reflects genes 
deregulated in disease and was particularly enriched for known genes in neurodevelopmental 
disorders and those involved in signalling and developmental pathways. 17β-estradiol treatment 
of mutant mice significantly deregulated 295 genes, with only 23 deregulated genes overlapping 
between vehicle and steroid treated mutant mice. Furthermore, when we investigated 
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populations of inhibitory interneurons in the cortex of PA mice immediately following estradiol 
treatment at P10, we saw no improvement to cell density, despite seeing a marked change in 
the expression of interneuron associated genes both due to disease, and changing with 
administration of estradiol at the same developmental timepoint. We conclude that 17β-
estradiol treatment recruits processes and pathways to reduce the frequency and severity of 
seizures in the Arx PA mutant mice but does not precisely correct the deregulated transcriptome, 
cellular deficits, mortality, or behavioural and cognitive deficits. Our outcomes show that 
although estradiol may not represent the ideal therapeutic option for PA patients currently, our 
data provides insights into developing novel drugs by broadening our understanding of the 
mechanisms of disease caused by Arx PA mutations, particularly by uncovering pathways that 
may overlap with other neurodevelopmental disorders and present convergent targets for future 

































This thesis is presented in a conventional format, consisting of an introduction covering the 
background of the research conducted in this thesis and a thorough review of the current 
literature (Chapter 1), a chapter containing materials and methods (Chapter 2), followed by 
three results chapters (Chapters 3-5) and a final discussion and conclusions chapter (Chapter 
6).  Figures and tables are independently numbered within each chapter. While Chapters 3 and 
4 provide the basis for my published paper, here they are presented in the conventional format, 
and include additional data. The publication (submitted to Neurobiology of Disease) is included 
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The Aristaless-related homeobox gene: 
understanding its role in intellectual disability 






Intellectual disability (ID) is defined as impaired cognitive function paired with a deficit in 
adaptive behaviour before the age of 18. ID affects approximately 1 in 50 people worldwide 
and is estimated to cost Australia $14 billion per year (WHO, 2019, Australian Institute of 
Health and Welfare 2008). In first world countries, a genetic cause is responsible for 
approximately 40% of cases (Willemsen and Kleefstra, 2014, Chiurazzi and Pirozzi, 2016, Ellis 
et al., 2020). Children with ID often have a range of debilitating comorbidities, including autism 
spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), dystonia, and 
intractable epilepsy and infantile spasms. It is often not understood whether the causes of these 
comorbidities have a singular causative mechanism, or whether there are multiple pathways at 
play. In terms of understanding these disorders in order to treat them, it is vital to investigate 
the mechanisms behind their pathogenesis.  
 
Epileptic conditions are complex and often have significant long-term implications on ongoing 
health and cognition. Cognitive function is suspected to be impaired with persistent and severe 
seizures, particularly early in childhood and infancy. The distribution of IQ scores in children 
with epilepsy are often skewed to lower values and learning difficulties are frequently reported 
(Farwell et al., 1985, Neyens et al., 1999, Prasad et al., 2014). Many children also regress in 
mental development after experiencing severe seizures (Neyens et al., 1999). While cognition 
is a source of concern for infants with spasms very early in life, it can be difficult to elucidate 
how much of a child’s intellectual disability was pre-existing and the extent that was caused by 
spasms early in key periods of brain development (Nabbout and Dulac, 2003).  
 
The brain is a highly complex organ, comprised of multiple cell types, acting in synchrony to 
perform cognitive functions. Neurons in the brain can be classed as excitatory (output of 
neuronal activity) or inhibitory (inhibiting excitation). The development, migration and 
function of these cells is dependent on tightly controlled regulation of genes during embryonic 
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development, and throughout childhood, adolescence, and adulthood. Disruption of these genes 
can lead to the neurodevelopmental disorders (NDDs), such as intellectual disability, epilepsy 
and autism (Paciorkowski et al., 2011, Olivetti and Noebels, 2012). There are currently more 
than 1200 genes implicated in intellectual disability, each with small numbers of cases, making 
this disorder a collection of rare genetic diseases (Chiurazzi and Pirozzi, 2016). One such gene 
is the Aristaless-related homeobox gene (ARX), a highly conserved transcription factor, playing 
a regulatory role in key events of proliferation and migration of inhibitory neurons in the brain 
(Kitamura et al., 2002, Stromme et al., 2002, Turner et al., 2002). When ARX function is 
interrupted in humans, phenotypes arising include intellectual disability and developmental 
delay as key features, as well as varying comorbidities of infantile spasms, epileptic syndromes, 
dystonia, ADHD and ASD, through to severe brain malformations (Shoubridge et al., 2010). 
Seizures and spasms associated with ARX mutations, like many other genetic NDDs, are often 
resistant to current anti-epileptic therapies. In addition, intellectual disability and 
developmental delay can have a serious impact on the quality of life of affected children and 
their families. We need to better understand the pathogenesis of ARX mutations, to enable 
identification of novel strategies to treat children with these disorders. 
 
1.2 ARX & neurodevelopmental disorders 
1.2.1 The Aristaless-related homeobox gene 
The Aristaless-related homeobox gene (ARX) is located on the X-chromosome and spans a 
12.25 kB genomic region. The ARX gene has five coding exons, with a 1686 bp open reading 
frame and a 562 amino acid length protein (Gécz et al., 2006). ARX is a paired-like 
homeodomain transcription factor, comprised of various domains, including a highly conserved 
DNA-binding homeodomain, an Aristaless or OAR domain, and four polyalanine tracts (Figure 
1.1). Consistent with critical roles in development for homeobox transcription factors, ARX is 
a transcriptional regulator consistently implicated in the development and migration of 
cholinergic and cortical interneurons (Kitamura et al., 2002, Poirier et al., 2004, Colombo et 
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al., 2007). When ARX function is interrupted in humans, phenotypes arise that invariably 
include intellectual disability and developmental delay.  
 
1.2.2 Mutations in ARX  
The number and profile of mutations in ARX has grown since 2002 when this was first identified 
as an intellectual disability gene (Bienvenu et al., 2002, Stromme et al., 2002). In addition to 
the variable degrees of  intellectual disability, mutations in ARX frequently present with a wide 
spectrum of comorbidities, including autism, dystonia, and childhood-onset epilepsy and 
malformation phenotypes of the brain and genitalia (Bienvenu et al., 2002, Kitamura et al., 
2002, Stromme et al., 2002, Turner et al., 2002).  While all patients with ARX variants have 
intellectual disability, the broad spectrum of specific cognitive deficits and behavioural 
phenotypes of ARX patients makes it difficult to determine the aetiologies of their intellectual 
disability, particularly when the pathophysiological mechanisms of the disease are complex and 
poorly understood. The varied nature of these mutations, their positions within the domains of 
the ARX protein, and their associated phenotypes is outlined in Figure 1.1. 
 
ARX function is critical to normal brain development and postnatal life. When mutations in 
ARX result in a complete loss of function, patients have a catastrophic malformation phenotype 
of X-linked lissencephaly with abnormal genitalia (XLAG or now called LIS2, OMIM 
#257320) and die early in life (Kitamura et al., 2002).  This syndrome results in severe brain 
malformations, like lissencephaly and hydrocephaly, with abnormally developed genitalia such 
as a small penis and undescended testes. Mutations contributing to these severe phenotypes 
include nonsense mutations as well as some missense mutations in the conserved homeodomain 
of ARX, shown to interfere with or abolish the normal DNA-binding properties of this region 
(Shoubridge et al., 2010). Missense mutations that occur across the length of the ARX gene lead 
to milder phenotypes of intellectual disability with and without comorbidities (Stromme et al., 
2002, Wallerstein et al., 2008, Shoubridge et al., 2010, Sirisena et al., 2014). While mutations 
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occur across the entire gene, approximately 60% of all reported mutations result in expansions 
of the first and second polyalanine tracts of ARX (Shoubridge et al., 2010).  
 
1.2.3 Expanded polyalanine tract mutations 
There are four polyalanine tracts in ARX, and expansion mutations of the first two tracts make 
up more than half of reported cases of mutations found in patients. Mutations in these tracts 
cause a wide variety of different phenotypes, with all patients featuring intellectual disability 
of varying degrees of severity, with some exhibiting severe infantile spasms, epilepsy and 
dystonia. The length of the expansion generally correlates with the severity of the phenotype 


































Figure 1.1: Pathogenic mutations within the ARX gene and their associated 
phenotypes. A schematic of the ARX genes and various functional domains with their 
respective amino acid positions listed. Mutations are associated with the broad range of 
phenotypes seen in patients, with phenotypes listed from most severe to least severe. 
Mutations are listed with position and amino acid change. Functional domains of ARX; OP 
(octopeptide), NLS (nuclear location sequence), PA (polyalanine tract), acid (acidic), arist 
(Aristaless), and homeodomain. Phenotypes associated with ARX mutations; XLAG (X-
linked lissencephaly with abnormal genitalia), HYD-AG (hydrocephaly with abnormal 
genitalia), PROUD (Proud syndrome), OHTAHARA (Ohtahara syndrome), IEDE 
(idiopathic epileptic-dyskinetic encephalopathy), WEST (West syndrome), XMESID (X-
linked myoclonic seizures, spasticity and intellectual disability), PRTS (Partington 
syndrome) and MRX (non-specific X-linked mental retardation). Figure from (Friocourt 
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Figure 1.2: Phenotypic variability associated with expansions of the first and second 
polyalanine tracts in ARX. Diagram shows the expansion of the first (orange) and second 
(blue) polyalanine tracts of the ARX gene. Each circle represents the proportion of patients with 
the number of alanines per tract, and where this number places them on the spectrum of clinical 
phenotypes (ranging from infantile spasms to severe infantile spasms and Ohtahara syndrome). 
With increasing numbers of alanines per tract, there is an increase in clinical severity. Other 
domains of ARX include the DNA-binding homeodomain and the Aristaless (OAR) domains 































Expansions in the first polyalanine tract result in a variety of clinical presentations. The most 
common expansion mutation is the c.340ins(GCG)7 mutation, which leads to the addition of 
seven alanines, resulting in a total of 23 alanines compared to the normal 16. X-linked infantile 
spasms with associated comorbidities make up the phenotype of about half of reported families 
with expansions of the first polyalanine tract expansions. These comorbidities include severe 
intellectual disability, dystonia, autism spectrum disorder, developmental delay and a 
hypsarrhythmic EEG patterns, also termed West syndrome (Wohlrab et al., 2005, Guerrini et 
al., 2007, Poirier et al., 2008, Wallerstein et al., 2008). Several severe and often early onset 
seizure phenotypes have been reported, including early infantile epileptic encephalopathy 
(EIEE) and infantile epileptic-dyskinetic encephalopathy (IEDE) (Guerrini et al., 2007) 
(Shinozaki et al., 2009, Absoud et al., 2010). Interestingly, the same mutation in this tract has 
resulted in different phenotypes, patients with or without infantile spasms. The mechanisms 
contributing to this pleiotropy are not yet understood.  
 
Expansions of the second polyalanine tract are overwhelmingly the most common mutation in 
ARX, resulting from the mutation c.429-452dup, expanding the tract from 12 to 20 alanines. 
The mutation accounts for 40% of all mutations in ARX, and of those with expanded polyalanine 
tract mutations, makes up almost 70% (Shoubridge et al., 2010). In comparison to patients with 
mutations of the first polyalanine tract, with quite a severe epileptic phenotype, the majority of 
patients with mutations of the second tract present with Partington syndrome, a phenotype 
comprised of non-syndromic intellectual disability, associated with dystonic movement of the 
hands (Stromme et al., 2002, Partington et al., 2004). A smaller subset of patients present with 
X-linked infantile spasms/West syndrome (Stromme et al., 2002, Kato et al., 2004, Partington 
et al., 2004). Furthermore, the behavioural aspects of PA2 patients shine light on the finer 
details of psychiatric disturbances in these patients. Children with PA2 mutations have been 
described as having emotional instability, self-aggression, and deficits in social behaviour, with 
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only 56.3% of patients described to have “adequate personal relationships” (Bienvenu et al., 
2002, Stromme et al., 2002, Dubos et al., 2018). Again, the spectrum of phenotypes observed 
within patients with the same mutation, and indeed even within families, has been noted but not 
explained (Turner et al., 2002).  
 
While few studies have investigated the effects of these polyalanine expansion mutations in 
human patients, one study by Curie and colleagues in 2018, performed post-mortem brain 
examinations, to examine human ARX expression at different foetal stages, and the adult brain, 
in patients with c.429-452dup mutations. There was strong expression of ARX in the second 
trimester brain, particularly in neuronal progenitor cells in the cortex, in migratory streams of 
cells leaving the ganglionic eminences. Interestingly, while there were no major brain 
malformations in these patients, striatal volume and hippocampal size were decreased, and there 
was reduced grey matter in the brain, possibly caused by a loss of neurons. The precentral gyrus, 
part of the primary motor cortex, was also thinner in these patients. This structural malformation 
may explain the specific motor phenotype of Partington syndrome in c.429-452dup patients 
(Curie et al., 2018).  
 
1.2.4 Current treatments for seizures in ARX patients 
The current intervention for infantile spasms includes adrenocorticotropic hormone (ACTH) 
and vigabatrin as first-line treatments (Pellock et al., 2010). ACTH therapy induces the release 
of adrenal steroids, through which steroid-dependent action on melanocortin receptors, reduces 
neuronal excitability (Brunson et al., 2002). Vigabatrin serves as a gamma aminobutyric acid 
(GABA) analogue for the enzyme responsible for GABA catabolism. Thereby, it acts to inhibit 
GABA being broken down within the brain, increasing inhibition and reducing excitability 
(Pesaturo et al., 2011). New anti-epileptic drugs as topiramate, and diet regimes such as the 
ketogenic or Atkins diet have shown promising effectiveness (Song et al., 2017). However, in 
many ARX patients, spasms and seizures are refractory to these treatments, and in fact, ACTH 
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can have very severe side effects. These include increased susceptibility to infection due to 
immunosuppression, hypertension, osteoporosis and metabolic disorders (Riikonen and 
Donner, 1980, Riikonen, 2004). Among children treated for infantile spasms with ACTH, the 
most common form of death in childhood was infection (Riikonen, 1996). Furthermore, follow 
up studies in children receiving ACTH therapy show that only 16% of the patients had normal 
development following treatment, with 47% continuing to have refractory seizures (Hancock 
et al., 2013).  
 
West syndrome and infantile spasms are notoriously difficult to treat. Spasms persist in 33-56% 
of patients treated with ACTH therapy (Song et al., 2017). Further to the lack of effectiveness 
of ACTH, there have been no new treatments discovered for infantile spasms in the last few 
years (Specchio et al., 2020). While the lack of reliable animal models for infantile spasms is a 
contributing factor, the variability in the causes of infantile spasms has made pre-clinical and 
clinical studies difficult (Specchio et al., 2020). The outlook for patients and their families at 
this stage is poor, but pre-clinical trials using exogenous steroids have shown promising results 
for future treatments. Understanding the role that ARX plays in brain development and function 
is critical to understanding what is happening in the brains of patients, and why current 
treatments are not effective for treating these disorders.  
 
 
1.3 ARX & interneurons 
1.3.1 Interneuron function 
The prefrontal cortex (here after referred to as cortex) of the brain is a highly complex region, 
comprising approximately 80% of all cells in the brain, and performing intricate functions that 
are dependent on balanced circuitry. The circuits of the cortex are comprised of two types of 
cells: excitatory neurons, and inhibitory interneurons. Interneurons comprise approximately 
20% of neural cells in this region (Meinecke and Peters, 1987). The diverse cell populations of 
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the cortex assist in the control of excitatory activity, providing balance of excitation and 
inhibition. These circuits play an important role in the control of information processing in the 
cortex. GABA is a neurotransmitter found exclusively in interneurons. GABAergic signalling 
is required to drive key developmental processes, such as cell migration, axonal and dendritic 
remodelling, and synapse formation (Sernagor et al., 2010). Hence, interneurons are key 
regulators of both excitatory and inhibitory outputs of the cortex, as well as modulators of 
cortical developmental and plasticity.  
 
There are a variety of ways in which interneurons control inhibition in the cortex. Direct 
inhibition achieves local inhibitory action from a distant interneuron. An example of this is the 
axons of neocortical interneurons that cross the corpus callosum of the brain to directly 
innervate their contralateral hemispheric targets (Higo et al., 2007, Tomioka and Rockland, 
2007). Feedforward inhibition, on the other hand, reduces the excitatory spike counts of 
pyramidal (excitatory) neurons by competing with dendritic excitation or reducing spike output. 
This process involves interneurons receiving excitatory input from an external sources, and in 
turn inhibiting pyramidal neurons (Buzsáki, 1984). The various dendritic domains of excitatory 
neurons have dedicated classes of interneurons that target them, and these form the feedforward 
circuits. 
 
1.3.2 Interneuron migration 
Interneurons migrate from the ganglionic eminences, a transitory brain structure in the 
telencephalon that is present only in early, embryonic brain development. The ganglionic 
eminences form at approximately embryonic day 11 in the mouse and can be divided into three 
distinct sub-areas; the lateral ganglionic eminence (LGE), medial ganglionic eminence (MGE) 
and the caudal ganglionic eminence (CGE). Early in development, most interneurons residing 
in the cortex are derived from the MGE and CGE, with the LGE aiding in the migration of 
interneurons during the mid-stage of cortical development (Tan and Breen, 1993, De Carlos et 
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al., 1996, Buchsbaum and Cappello, 2019). GABAergic interneurons migrate tangentially from 
the MGE primarily, to the cortex, where they can then migrate radially into the cortical layers 
(described in Figure 1.3). Labelling cells of the MGE with DiI crystals demonstrates that these 
cells migrate to the developing cortex, where they are dispersed as GABAergic interneurons 
(Lavdas et al., 1999). Furthermore, MGE and LGE tissue from embryonic mice transplanted 
into the adult mouse brain, showed that transplanted neuronal precursors from the MGE 
dispersed and differentiated into multiple adult brain regions, extensively towards the cortex 
(Wichterle et al., 1999). 
 
Interneuron migration is a tightly regulated process influenced in particular by homeobox 
transcription factors. The vertebrate distal-less (Dlx) genes, encoding the homeobox proteins 
Dlx-1 and Dlx-2, are expressed in the striatum and pallidum structures of the developing brain. 
A role for these genes in interneuron migration is demonstrated by a Dlx-1 and Dlx-2 double 
knockout mouse model showing a 70% reduction in the number of cortical interneurons coupled 
with abnormal migration of interneurons out of the LGE, resulting in the accumulation of only 
partially differentiated neurons in the LGE, and a loss of normal olfactory bulb interneurons. 
These double knockout mice do not survive into postnatal life, dying on postnatal day 0 
(Anderson et al., 1997). The thyroid transcription factor 1 (Nkx2.1) is another homeobox gene 
expressed in the precursor cells of the pallidum. Nkx2.1 knock out mice not only die at postnatal 
day 0, but do not develop a MGE structure at all, due to a loss of cells migrating from the 
pallidum to the striatum (Sussel et al., 1999). These studies highlight that homeobox genes are 












Figure 1.3: Mouse cortical development. (A) Provides a schematic diagram of a coronal 
section of the developing telencephalon of a mouse at embryonic day 14. The grey box is 
enlarged in (B). (B) Provides a schematic diagram of the cellular composition of the developing 
mouse cortex, with radially migrating excitatory pyramidal neurons, and tangentially migrating 
inhibitory interneurons, which then switch to radial migration in the dorsal cortex. Key: Ctx: 
cerebral cortex; CP: cortical plate; GE: ganglionic eminences; IZ: intermediate zone; LGE: 
lateral ganglionic eminence; MGE: medial ganglionic eminence; MZ: marginal zone; SP: 
subplate; Str: striatum; SVZ: sub ventricular zone; VZ: ventricular zone. Figure taken from 






1.3.3 Interneuron subtypes 
When considering the cells in the brain, interneurons have the largest diversity in terms of their 
morphology, connectivity, and physiology. Interneurons can be categorised based on their 
morphology, the markers they possess on their surface, and their subsequent function. 
Interneuron progenitor cells undergo complex migration. Both the site of origin and the 
migratory path influence the differentiation into the eventual subtype of the mature interneuron. 
For example, during migration to the cortex interneurons from the MGE gives rise to 
parvalbumin-positive and somatostatin-positive (STT) interneurons, while the CGE gives rise 
to less common interneuron subtypes, such as neurogliaform, bipolar and vasoactive intestinal 
polypeptide (VIP) positive interneurons (Wichterle et al., 2001, Fogarty et al., 2007). This 
indicates that there are dedicated progenitor populations designated to differentiate into specific 
subtypes, defined by the gene expression within different regions. From the population of 
Nkx2.1 expressing progenitors, expression of Lhx6, a known target of Nkx2.1, is required for 
the differentiation of parvalbumin and somatostatin-positive interneurons (Sussel et al., 1999, 
Fogarty et al., 2007). The most prevalent interneuron subtypes are parvalbumin and 
somatostatin-positive interneurons (Jinno and Kosaka, 2003). Parvalbumin is present on the 
surface of basket or chandelier interneurons. These subtypes specifically target the soma of 
excitatory neurons. Somatostatin is present on the membranes of Martinotti cells, which target 
the dendrites of excitatory neurons. Approximately 10-12% of GABAergic interneurons are 
calbindin-positive, and other smaller subsets include VIP, calretinin and neuropeptide-Y-
positive interneurons (Gulyás et al., 1991). The functional diversity of the most common 







Table 1.1: Overview of interneuron markers and their respective interneuron subtypes. 
 Developmental origin Cell types Targets 
Parvalbumin (PV+) MGE 
Basket interneurons 
Chandelier interneurons 
Excitatory cell dendrites and axons 
Somatostatin (STT+) MGE Martinotti cells Excitatory cell dendrites 











1.3.4 ARX & interneuron migration and function 
ARX expression peaks between embryonic days 12.5 and 15.5, continuing to be expressed 
throughout embryogenesis, before being downregulated in postnatal life (Figure 1.4 A) (Miura 
et al., 1997, Kitamura et al., 2002). ARX is highly expressed in the embryonic brain, ovaries, 
and testes and to a lesser degree in other tissues including skeletal muscle and pancreas (Figure 
1.4 A) (Miura et al., 1997, Kitamura et al., 2002, Heller et al., 2005, Biressi et al., 2007). Within 
the embryonic brain ARX is expressed in neural progenitor cells and immature neurons through 
the subpallium, a region which includes the LGE and MGE (Figure 1.4 B) (Lee et al., 2014). 
These cells further develop into various regions of the brain; the striatum, globus pallious and 
cholinergic nuclei, as well as differentiating into the interneurons that migrate tangentially to 
the cortex, olfactory bulb and hippocampus (Miura et al., 1997, Poirier et al., 2004). In human 
patients with loss of function mutations in ARX, a classical lissencephaly phenotype can arise, 
seen in MRIs of patients (Figure 1.5). This is the result of disorganised neuronal migration. The 
abnormal neuronal migration leads to a smooth and thickened cortex without gyri, with an 
accumulation of cells in the sub cortical layers, and a wider, extra layer resulting below the 
normal cortical plate (Figure 1.5) (Romero et al., 2018). This phenotype is a result of the loss 
of ARX’s function in migration of both inhibitory and excitatory neural progenitor cells 


























Figure 1.4: Expression and migration of Arx positive cells in the developing brain. (A) 
Expression of Arx in the mouse telencephalon from embryonic day 8.5 to postnatal day 8. 
Expression of Arx peaks with proliferation and differentiation of developing neuronal cells. (B) 
Migration patterns of interneurons from the ganglionic eminences to the cortex, with Arx 
expression highlighted in orange. Arrows indicate direction of migration of neuronal progenitor 
cells. Figure (B) adapted from (Lee et al., 2014). 
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Figure 1.5: Comparison of normal cortical development and impaired development with 
loss of ARX function. MRI images from patients describe normal imaging of the brain 
compared to the agryia/classical lissencephaly phenotype seen in patients with loss of function 
mutations in ARX. Schematic diagrams show mechanism leading to lissencephaly. Key: mature 
neurons (blue), immature neurons (red), radial glial cells (purple), intermediate progenitors 
(green), ventricular zone (VZ), intermediate zone (IZ), cortical plate (CP), marginal zone (MZ) 






Some of the most compelling studies on ARX function come from knocking out the Arx gene 
in mice. A study by Kitamura and colleagues showed that when Arx was knocked out in male 
mice by disrupting exon 2, the mice had severe brain malformations and died early in postnatal 
life, generally around postnatal day 2. Compared to wild-type mice, the brains were smaller, 
the cortical plate was thinner, and there was a deficit in tangential migration of GABAergic 
interneurons from the MGE to the cortex, and a complete failure of radial migration from the 
LGE. The mice also showed a reduction in the proliferation and migration of excitatory neurons 
(Kitamura et al., 2002). Focusing on interneuron migration, a study by Colombo and colleagues 
in 2007 used these Arx deficient mice to show that not only was tangential migration towards 
the cortex reduced, radial migration of cells towards the cortex was also reduced, and these 
deficits lead to abnormal accumulation of neuropeptide-Y and calretinin-positive interneurons 
in the MGE. These mice had reduced expression of Map2 in the brain, a marker of differentiated 
neurons. Together, this data highlights the critical function of Arx in promoting interneuron 
migration in the brain, but also in differentiating cells to allow proper targeting to their correct 
position in the layers of the cortex (Colombo et al., 2007).   
 
Using a different approach, Friocourt and colleagues in 2008 used in uteru electroporation to 
either knock down or overexpress Arx in the progeny of pregnant female mice. Here, inhibition 
of Arx caused cortical progenitor cells to exit the cell cycle prematurely and impaired their 
migration towards the cortex. Conversely, overexpression of Arx lengthened the cell cycle. 
Interestingly, both inhibition and overexpression of Arx impaired the migration of GABAergic 
interneurons from the ganglionic eminences to the cortex. Inhibition of Arx also decreased 
neuronal motility, while overexpression of Arx affected the radial migration of pyramidal 
neurons. This study demonstrates the importance of Arx regulation and strict control of cellular 




ARX is thought to regulate neuronal migration through transcriptional activity. A study by 
Colasante and colleagues in 2009 used microarrays, quantitative PCR and RNA in situ 
hybridisation techniques with the Arx deficient mouse model, to investigate the role of Arx 
regulating gene expression in the telencephalon. They found that when Arx was lost, many 
critical developmental genes were upregulated or downregulated. Ebf1, a neuronal transcription 
factor, with roles in the radial migration of neurons, had increased expression with the loss of 
Arx, indicating a strong interaction between the two proteins. Cxcr4 and Cxcr7, genes found to 
be repressed with loss of Arx, also have critical roles in neuronal migration, and are present in 
developing interneurons. Interestingly, it was found that genes Lmo1, Lmo3 and Lmo4, were 
more strongly upregulated in the MGE compared to the LGE, indicating differing impacts of 
the repressive role of Arx in different regions of the brain (Figure 1.4 B) (Colasante et al., 2009, 
Lee et al., 2014). A subsequent study focusing specifically on the cortical interneurons between 
embryonic days 13.5 and 15.5, highlight 14 known Arx target genes enriched and five 
downregulated in migrating interneurons (Friocourt and Parnavelas, 2011). 
 
An indirect way of studying Arx and its transcriptional activity, is by studying knock out mouse 
models of Npas1 and Npas3. These genes are expressed in the progenitor neurons of the basal 
ganglia, and have opposing effects on the brain when their function is lost. Npas1 knock out 
mice exhibit increased inhibition in the cortex, with excess STT and VIP interneurons. There 
was also increased expression of Arx in the MGE and CGE. Contrary, Npas3 knock out mice 
featured a loss of cortical inhibition, with a reduction of STT and VIP interneurons, and 
decreased expression of Arx in the ganglionic eminences (Stanco et al., 2014). Importantly, this 
study shows that Npas1 is a key regulator of Arx enhancer activity, and overexpression of Arx 
leads to an increase of progenitor cells in the CGE, leading to this excess inhibition and 




When partial loss of Arx is modelled by expansion mutations of the first and second polyalanine 
tracts of the gene, disruptions to gene regulation are observed. A transcriptome wide RNA 
sequencing study performed within our laboratory, analysed the developing telencephalon of 
these mouse models at embryonic day 12.5 found a large number of deregulated genes in mice 
with mutations of the first and second polyalanine tracts of Arx. This allowed a thorough 
transcriptomic profile of “Arx responsive genes” to be compiled. These genes were enriched in 
pathways involved in key neurodevelopmental processes, such as cell to cell adhesion, neuronal 
development and neuronal membrane properties, or were strongly associated with 
neurodevelopmental disorders like intellectual disability and epilepsy (Mattiske et al., 2016). 
Furthermore, another mouse model with an expansion of the second polyalanine tract features 
deregulated interneuron development genes in the forebrain of pups at embryonic day 15.5. 
Genes involved in processes involving synaptic transmission, central nervous system 
development and DNA interaction (Dubos et al., 2018). These gene expression studies are 
particularly interesting, as these partial loss of function models of Arx still have a significant 
impact on the transcriptome of these mice and can help to investigate pathophysiology and 
pathways associated with neurodevelopmental disorders in which Arx is implicated.  
 
In terms of specific interneuron deficits in these mice, there are prominent features in two mouse 
models with expansion mutations of the first polyalanine tract (PA1). In one of these mouse 
models, there was an overall reduction in calbindin and neuropeptide-Y positive interneurons  
in the cortex and striatum of six week old mice (Price et al., 2009). Furthermore, there is a wave 
of elevated apoptosis in the cortex in the first postnatal week of life in these mice (Siehr et al., 
2020). Interestingly, in an alternate PA1 mouse model, the model used in our laboratory, while 
there is a scarcity of neuropeptide-Y, somatostatin, and GABA positive cells in the cortex, there 
is no overall loss of calbindin positive interneurons, but instead a deficit in normal migration of 
these cells (Kitamura et al., 2009, Lee et al., 2017). Lee et al. found that there was a specific 
spatial loss of approximately 50% of calbindin positive cells in the cortex of these mice at 
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postnatal day 0 compared to wild-type mice. When looking at specific regions of the brain, this 
was shown to be due to a lag in migration of these cells. Calbindin positive cells were found to 
be arrested in the ventral subpallium of the cortex, while migrating to the cortex through the 
process of tangential migration, which Arx is known to play a pivotal role in (Figure 1.6). This 
suggested that the halt in migration of the calbindin positive cells was in fact due to slowed 
migration rather than changes to cell proliferation or the cells exiting the mitotic cycle (Lee et 
al., 2017). Tangential migration of somatostatin positive interneurons is also suppressed in this 
PA1 mouse model (Kitamura et al., 2009). Importantly, this research indicates that even a 
partial loss of Arx function can have drastic effects on correct interneuron positioning and 















Figure 1.6: Accumulation of arrested calbindin positive (Cb+) cells in the ventral cortex. 
Coronal sections were used to investigate the density of Cb+ cells in the ventral telencephalon 
of PA1 and PA2 mice at postnatal day 0. The region screened is seen in (A) in the yellow box. 
Yellow arrow indicates direction of normal migration of Cb+ positive cells. Cells were counted 
within bins 1, 2 and 3, identified in (A). Quantification of Cb+ cells was conducted within these 
boxes, demonstrating the distribution of Cb+ cells was increased in Bin 1 in PA mutant mice 





1.4 Arx mouse models 
1.4.1 Expanded polyalanine tract mutations 
There have been several mouse models created with the mutations expanding the polyalanine 
tracts of Arx, representative of those present in patients. At present, there are two PA1 mouse 
models. Kitamura and colleagues developed a mouse modelling the expansion of the first 
polyalanine tract (PA1), an Arx(GCG)7/Y mouse model. This mouse presents with a phenotype of 
X-linked infantile spasms, or West syndrome, recapitulating the phenotype seen in PA1 
patients. This mouse has 40-60% less Arx protein when compared to the wild-type mice. Most 
of the mice with this mutation died before three months of age, with some living to 5-6 months, 
with deaths presumably caused by the seizures observed in 70% of mutant mice. The mice also 
presented with impaired learning and cognitive function, with deficits in spatial learning and 
procedural learning. Arx(GCG)7/Y mice also had increased locomotor activity and high anxiety 
when compared to the wild-type mice (Kitamura et al., 2009). This is the PA1 mouse model 
we have used in our study.  
 
Price and colleagues developed an  independent PA1 model in 2009, the Arx(GCG)10+7 mouse 
(Price et al., 2009). The seizure phenotype of the Arx(GCG)10+7 mouse is similar to the Arx(GCG)7/Y 
mouse model, with 75% of adult mice having abnormal EEG results (reminiscent of a seizure), 
compared to 70% in the Arx(GCG)7/Y mouse model. The Arx(GCG)10+7 mouse also presented with 
infantile spasms quite early in development.  The Arx(GCG)10+7 mouse display subnormal anxiety 
levels, presenting as a less fearful model than their wild-type counterparts. Similar to the 
Kitamura PA1 model these mice showed a lack of learned fear responses and autistic-like 
behaviour (Price et al., 2009). We refer to this model as the alternate PA1 mouse. 
 
Although both PA1 models show similar phenotypes, there are some distinct differences 
reported (Table 1.2). While it is unknown why exactly the two models differ, it is interesting to 
note the differences in the expansion of the PA1 tract in each model. The Kitamura mouse 
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model (Arx(GCG)7/Y) mimics the length of the expansion of the tract seen in mice, with the 
addition of seven GCG repeats (the human codon usage) (Kitamura et al., 2009). The Price et 
al. mouse model, the Arx(GCG)10+7 mouse, utilised the mixed codon usage seen in mice (GCG, 
GCC and GCT), and added eight repeats to expand the tract to 23 alanines, the length seen in 
human patients (Price et al., 2009). While both models present with seizures and behavioural 
deficits, the interneuron subtypes determined to be affected in these models differ, which may 
contribute to differences in the phenotype of each model.  
 
Kitamura and colleagues also generated a mouse model of the most commonly mutated 
polyalanine tract 2, but the Arx432-455dup/Y mice were not as extensively studied in the initial 
report (Kitamura et al., 2009). The Shoubridge laboratory has been investigating the Arx(GCG)7/Y 
or PA1 and Arx432-455dup/Y or PA2 models derived from the Kitamura laboratory in a comparative 
manner. Overwhelmingly, they have shown that the PA2 model presents with a very similar 
phenotype to the PA1 model in terms of seizures and behavioural deficits (Jackson et al., 2017). 
This is the second of the two mouse models utilised in my study.  
 
In terms of seizures, video-EEG analysis, all PA2 mutant males showed abnormal epileptic 
activity, with bursts of high frequency spikes, and low amplitude oscillatory discharges. These 
episodes of abnormal epileptic activity lasted up to 90 seconds in duration.  This was visually 
correlated to physical movement capture by video monitoring, varying from mouth movement, 
head movement, tail extension, and mild myoclonic seizures or rearing and falling with clonus 
of the forelimbs. Seizures were categorised (in conjunction with the Video-EEG data) into four 
categories, providing a powerful tool to assess the severity and frequency of the types of seizure 
in these mouse models using non-invasive video seizure monitoring. Category 1 was movement 
phenotypes, such as head and tail movements; category 2 was mild myoclonic seizures; 
category 3 was severe myoclonic seizures, lasting longer than 10 seconds; with category 4 
where mice were found dead presumably from a lack of recovery after a seizure. There was a 
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wide variability in seizure severity and frequency between individual mice, similar to that seen 
in patients with these mutations. However, the first myoclonic seizures were observed at 
postnatal days 18 and 19 in the PA1 and PA2 mice, with most seizures observed after one month 
of age. By weaning (postnatal day 21), myoclonic seizures had been witnessed in 18% of PA1 
mice and 42% of PA2 mice. By postnatal day 70, as many as 73% of PA1 and 97% of PA2 
mice had an observed seizure.  Both PA1 and PA2 mice likely died from their seizures, with 
45% of the PA1 cohort dying and only 15% of PA2 mice surviving to postnatal day 70.  
 
Behavioural testing in these two strains also demonstrated similar phenotypic presentations 
between the PA1 and PA2 mice generated by Kitamura.  Prior to this study, no behavioural 
phenotyping data had been published on the PA2 mouse. There was increased anxiety in both 
mice coupled to decreased exploratory behaviour in the open field apparatus. Increased 
exploratory behaviour with a decreased fear response was demonstrated in both strains using 
an elevated zero maze. Despite these seemingly conflicting data, these tests assess different 
types of anxiety, in relation to open spaces and height respectively. Further testing of cognitive 
function indicated a decreased capacity in both mouse models (Y-maze test) with autistic-like 
traits (sociability testing) demonstrated in these mice, both characteristic features of human 
patients with these mutations (Jackson et al., 2017). The similarities between these two mouse 
models was thought to be driven by overlapping deregulated transcriptomes of these two 
mutations, as described by Mattiske and colleagues, in early embryogenesis at embryonic day 
12.5  (Mattiske et al., 2016). 
 
An independent PA2 mouse model has more recently been developed by Dubos and colleagues 
(Dubos et al., 2018). These mice are a partially humanised model, with the c.428_451 dup24 
mutation duplication, creating the Arxdup24/0 mouse. Interneuron migration was altered in these 
mice, with a deficit in cells expressing Arx, calretinin, calbindin, somatostatin and Chat 
(expressed by cholinergic cells), in the embryonic brain and at postnatal day 0. Interestingly, 
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only 8% of mutant pups had infantile spasms, and at the adult stage, mutant mice had no 
spontaneous seizures. When injected with a pro-epileptic drug, pentylenetetrazol (PTZ), mutant 
mice had no difference to seizure susceptibility. The mice exhibited hyperactivity in the open 
field test and displayed altered anxiety and contextual fear learning in the fear conditioning test. 
The mice also had significant deficits to fine motor skills such as grasping and reaching, 
comparative to patients with expansions of the second polyalanine tract (Dubos et al., 2018). 
These mice recapitulate the milder PA2 phenotype of patients, thus providing a useful future 
model to compare alongside the Kitamura et al. mice, to examine the convergent cell and 
molecular contributors to the phenotype in PA2 patients.  
 
While the phenotypes reported do vary slightly between the two PA1 and the two PA2 mouse 
models, the spectrum of phenotypes between the different models, and within individual mice, 
recapitulates the spectrum of phenotypes reported in human patients. Differences align between 
the varied interneuron subtype deficits we see between the two PA1 mouse models, indicating 
a possible difference in pathogenesis at the cellular model of these mice, though both show a 
very similar seizure phenotype. The Kitamura et al. PA2 mouse model represents the more 
severe end of the seizure phenotype that is reported in a small number of PA2 patients. Although 
PA2 patients show a variety of seizure phenotypes, generally PA1 patients all have severe 
epileptic phenotypes. The interneuron deficits between the Kitamura PA2 mouse and the 
Kitamura PA1 are also quite similar, shown in Lee et al. (Lee et al., 2017). The Dubos Arxdup24/0 
mice show the milder phenotype seen in the majority of PA2 patients. Meanwhile, both PA1 




Table 1.2: Overview of phenotypic differences between the two different PA1 and PA2 mouse models. 
 PA1 PA2 
 Kitamura et al. 2009 
model 
Price et al. 2009 model Kitamura et al. 2009 model Dubos et al. 2018 model 
Seizures 70% mice had abnormal 
EEG patterns 
70% mice with observed 
seizures 
75% mice had abnormal 
EEG patterns 
Pups had infantile 
spasms 
100% mice had abnormal 
EEG patterns 
97% mice with observed 
seizures 
8% of pups had infantile 
spasms 
No seizures in adult mice 
No increase to induced 
seizure susceptibility 
Fear/anxiety ↓ Fear response 
↑ Anxiety 
 
↓ Fear response 
Subnormal anxiety 
↑ Anxiety 





Locomotion/exploration ↑ Locomotor activity 
↓ Exploratory behaviour 
 ↑ Locomotor activity 
↓ Exploratory behaviour 
↓ Fine motor skills 
Cognition ↓ Cognitive function  ↓ Cognitive function ↓Contextual fear learning 
Autistic-like behaviour Yes Yes Yes No 
Mortality 45% mice died before two 
months of age 
 85% mice died before two 






1.4.2 Other Arx mouse models 
Looking at conditional loss of Arx can have advantages to studying the function of Arx without 
other severe sides of a phenotype interfering with studying brain development. Two main 
conditional knock-out models will be discussed. One such model is the Arx-/Y; Dlx5/6CIG 
(hemizygous males) and Arx-/+; Dlx5/6CIG (heterozygous females) mice. These mice have a near 
complete loss of Arx from the ventral forebrain from embryonic day 14.5 onwards. All 
hemizygous males exhibit abnormal EEG activity and spontaneous seizures, with similar 
features to the epileptic spasms seen in infantile spasms patients and the PA1 and PA2 Arx 
mouse models described, such as whole body flexion and extension, forelimb clonus and 
rearing. Interestingly, heterozygous females also showed a seizure phenotype, not seen in the 
other Arx mouse models, with about 50% presenting with seizures, similar to those seen in the 
hemizygous male mice (Marsh et al., 2009). 
 
No major anatomical differences were seen in the brains of the hemizygous or heterozygous 
mice, nor were there any differences to body or brain weights. However, specific interneuron 
deficits were observed at P14, P17 and in the adult brain. Similar to the Price et al. PA1 mouse, 
the most severe loss was seen in calbindin positive interneurons. Smaller reductions were 
observed in calretinin positive cells, and no change was observed in parvalbumin positive cells. 
This shows that when Arx is knocked out in the interneurons of the brain, interneuron subtype 
specific development is supressed (Marsh et al., 2009). 
 
More extensive studies of specific interneuron development have since gone on to be studied 
in this mouse model, involving crossing the mouse with a fluorescent marker to study migration 
and development of the affected cell types. There was a great deal of variability in the number 
of Arx positive cells in the brain at embryonic day 18.5, P14 and in the adult brain, but an 
almost complete loss of Arx was still seen. At P14, there was a reduction of Arx positive 
neurons in the upper layers of the cortex, but with some preseveration of these cells in the 
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deeper layers. This study also found that the calbindin positive cells were actually increased in 
the ventral regions of the cortex, including the striatum, at embryonic day 14.5, but decreased 
in the dorsal telencephalon (Marsh et al., 2009). This indicates that Arx is pivotal for migration 
of these cells, and without this migratory guidance, these cells are halted, shown in the expanded 
polyalanine tract mutation models as well (Lee et al., 2017). 
 
Further, no differences were observed at embryonic day 18.5 or postnatal day 14 in the cortex, 
but there was a loss in the hippocampus at this later time point. While there was a trend towards 
loss of calretinin positive cells in the cortex, this did not reach significance. However, the study 
did show a loss of neuropeptide-Y positive cells in the ventral region of the forebrain, which 
persisted to postnatal day 14. No differences in somatostatin positive cells were observed. 
Parvalbumin, not expressed until postnatal day 14, was shown to be reduced in the hippocampus 
but increased in the cortex (Marsh et al., 2016). 
 
Another mouse model, a conditional knock-out Arx−/Y; Emx1Cre mouse, selectively removes 
Arx from the dorsal telencephalon. Interestingly, this mouse model did not show any difference 
to the number of interneurons compared to the brains of their wild-type litter mates. Predictably, 
these mice did not present with the seizure phenotype we see in most of the other Arx mouse 
models. When a large battery of behaviour tests was performed on these mice, spatial learning 
and memory was found to be comparable to wild-type mice, but fear-based memory was 
impaired, something seen in other Arx models. These mice were less anxious however, and 
more exploratory, and, comparable to the PA1 and PA2 mice, were more hyperactive than wild-
type mice. These mice also presented with autistic-like behaviour, with social deficits shown 
through sociability testing (Simonet et al., 2015). 
 
Anatomically, the Arx−/Y; Emx1Cre mouse had smaller cortices, amygdalas and white matter 
tracts compared to wild-type, hypothesised to be the cause of the decreased anxiety phenotype 
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seen in this model. This study, while surprising compared to the usual phenotype seen in 
patients with ARX mutations, with no seizures or spatial leaning deficits, sheds light on the 
function of Arx in different regions of the brain. The loss of Arx in the progenitor cells in the 
mouse led to structural, function and behavioural deficits, through a loss of cortical connections 
and reduced cortical and amygdala volumes, but showed a longer lifespan due to the lack of a 
seizure phenotype (Simonet et al., 2015). The lack of interneuron deficits coupled with a no 
seizures or grip strength deficiency, provides further evidence to the importance of interneurons 
on these particular aspects of Arx/ARX mutant phenotypes. This mouse also further shows that 
cognitive dysfunction is not simply due to the epilepsy phenotype of these patients, and that 
some behaviours are due to the Arx mutation itself, further shown in that some patients present 
without seizures but with intellectual disability, particularly PA2 patients (Turner et al., 2002). 
 
A mouse model with selective Arx loss in the cerebral cortex has proven useful to understanding 
the spatial importance of the gene in the brain. The developing brains of this model had a 
specific loss of cortical progenitor cells, particularly in the intermediate zone. Furthermore, 
later in brain development, there was a loss of neurons in the upper layers of the cortex, but not 
within the deeper layers (Colasante et al., 2015). Transcriptional profiling in embryonic life at 
E14.5, interestingly showed that with this loss of Arx, there was overexpression of Cdkn1c, a 
key inhibitor of cell cycle progression. This data provides evidence that Arx is a direct regulator 
of Cdknc1c transcription, and inhibition of this process contributes to the loss of neurons and 










1.4.3 Benefits and limitations of mouse models for research 
Animal models remain vital to understanding mechanisms of disease and to find methods and 
drugs to treat diseases. When using mouse models for research however, it is important to 
consider the benefits and limitations. The mouse is closely related to humans, being a mammal, 
can produce multiple progeny reasonably quickly, and strains are inbred, meaning they will be 
highly conserved and similar between individuals. The mouse is genetically and physiologically 
like humans, making it a useful model for pre-clinical screening of potential therapies for 
disorders. Furthermore, mice being inbred means they do not capture the genetic variation 
existing in the human population, something that could be key to the phenotypic variation seen 
in patients with Arx mutations. In general, however, mice are not human, and using mouse 
models to test novel therapeutic strategies is only part of pre-clinical investigation.  
 
Embryonic development differs in the mouse, with gestation being 18 days compared to 270 
days in humans. This means that the timing of key developmental milestones between mouse 
and human do not readily match up, and much of what occurs while still in utero in human 
development occurs postnatally in the mouse, particularly in the brain. For instance, 
neurogenesis occurs up to postnatal day 0 in the mouse, with neuronal pruning occurring up to 
day 21 postnatal, while this all occurs in utero in humans. Telencephalic neuronal migration 
occurs before 20 weeks gestation in humans, while this occurs up to embryonic day 16 in 
mouse, with cortical positioning occurring to postnatal day 10 (Pressler and Auvin, 2013, 
Semple et al., 2013, Olivetti et al., 2014). The mouse does recapitulate many aspects of human 
brain development however, with the basic steps of neurogenesis remaining conserved between 
both models, as well as the general migratory patterns of inhibitory and excitatory neurons 
(Buchsbaum and Cappello, 2019). However, there are differences in the numbers of neuronal 
progenitors, their expansion and division capacity, as well as the complexity of the human 
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cortex compared to that of the mouse. This unsurprisingly results in the higher cognitive 
functions a human can perform (Buchsbaum and Cappello, 2019).  
 
Cognitive testing batteries are thorough and allow research into intellectual disability in mouse 
models. These behavioural tests investigate both exploratory behaviours through open field test 
for example, as well as learned behaviour like Y-maze and Barnes maze, which test more 
complex memory, both working and long-term (Wahlsten, 2011). However, these tests have 
their limitations. Many memory-based tests work from hippocampal or spatial memory. If the 
hippocampus is not the most weakened region of the brain in a disease of interest, these tests 
may not show the full extent of impaired learning, compared to a test that works from cortical 
learning (Wahlsten, 2011). High mortality rates of mouse models can also impair the ability to 
perform cognitive testing, as it can be difficult to reach the required sample sizes for large scale 
studies.  
 
Additionally, there can be discrepancies between clinical trials and treatment studies between 
mice and humans, often having quite different outcomes (Lee et al., 2012). An increased 
understanding of the molecular mechanisms behind neurodevelopmental disorders has since 
lead to the production of more physiologically or genetically relevant mouse models which 
recapitulate the human phenotypes, providing a platform to enhance the capacity for 
translatable outcomes arising from pre-clinical trials (Gross et al., 2015, Berry-Kravis et al., 
2018).  Although limitations do need to be considered when using these models, particularly 
differences in brain structure and development, overall, genetically modified mice provide a 
clinically relevant model for assessing cognitive function and investigating the 
neuropathological basis of diseases and testing drugs. Mouse models provide important 
information on the mechanisms of disease and subsequent treatments, allowing for more robust 
and reproducible results when moving to human clinical trials. One relevant example for ARX 
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and my project, is the recent work investigating the role of exogenous steroids to alleviate the 
severity of otherwise intractable seizures.   
 
 
1.5 Exogenous steroids as a treatment for infantile spasms and seizures 
While conventional therapies aren’t effective for the refractory seizures we see in some patients 
with ARX mutations, a study performed by our collaborators, Olivetti and colleagues, found 
that short-term β-estradiol (E2) given to the Arx(GCG)10+7 PA1 mouse model between postnatal 
days 3 and 10 improved the seizure outcomes of these mice (Olivetti et al., 2014). In the 
developing male mouse brain, there is a surge of E2 due to the conversion of testicular 
testosterone to E2, and heightened estrogen receptor expression in the brain (Wonders and 
Anderson, 2006, McCarthy, 2008, Sugiyama et al., 2008). This period overlaps with 
interneuron migration and the positioning of interneurons in the cortical layers, occurring 
between embryonic day 11 and postnatal day 10. E2 is a short-acting exogenous steroid and has 
roles in modulating neuronal excitability and neurotransmitter release. E2 induces changes to 
gene expression via the estrogen receptor, inducing effects on developing neurons, to produce 
long-term transcriptional changes. These pathways have been shown to play roles in the 
proliferation of progenitor cells, neuronal migration, synaptogenesis and dendritic spine 
formation, all key developmental milestones in the brain (McCarthy, 2008, Boulware and 
Mermelstein, 2009). These processes are part of the normal maturation process of neuronal 
cells, and it was hypothesised that by improving these processes in the brains of PA1 mice, their 
phenotype would be improved.  
 
To determine the appropriate timing of treatment, E2 was given both at an early postnatal age 
and again later in life, between postnatal days 33 and 40. The late-treated group of mice showed 
no difference to seizure frequency as determined through EEG, while the early-treated group, 
given E2 between postnatal days 3 and 10, showed a 64% reduction in seizures. This mouse 
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model shows spasms between postnatal days 7 and 11, and when treated with E2 no mice 
displayed spontaneous spasms compared to about one third of mice treated with a vehicle 
(Olivetti et al., 2014). 
 
To investigate a potential mechanism of action for E2, the interneurons of mice treated with E2 
or a vehicle were investigated. With E2 treatment, mice had 30% more neuropeptide-Y 
interneurons in the somatosensory cortex compared to wild-type mice, where vehicle treated 
mutants had a 36% decrease in this subtype of interneuron, meaning E2 rescued the phenotype 
to above the wild-type level. This was shown for calbindin-positive interneurons as well, 
however no deficit in this subtype was seen in the vehicle treated mutants, indicating that 
estradiol increased the calbindin-positive cell number in the brain to 42% above wild-type mice 
treated with vehicle. Interestingly, E2 also increased calbindin-positive interneurons in wild-
type mice, who do not show a deficit in these cells in the normal brain.  E2 rescued the reduced 
numbers of cholinergic interneurons to wild-type levels (Olivetti et al., 2014). These results 
show that E2 promotes migration and recovery of neurons in the brain, even independent of the 
impact of a mutation in Arx.  
 
Furthermore, E2 also changed the expression of genes normally regulated by Arx. Normally 
Arx represses Ebf3, Lmo1 and Shox2 and activates Lhx7, Cxcr4, Cxcr7 and Lgi1 in interneurons 
(Friocourt and Parnavelas, 2010, Mattiske et al., 2016). Quantitative real-time PCR was 
performed on the brains of mutant mice treated with E2. Shox2 expression was decreased, Lgi1 
expression was upregulated, and Ebf3 expression was repressed (Olivetti et al., 2014). These 
results show that not only does E2 improve the interneuron deficits in PA1 mutant mice, it also 
acts upon downstream targets of Arx. The findings of this study provide promising research for 




Further to this initial study on the Price et al. PA1 mouse model, investigations on apoptosis in 
the brain of these mice, found that E2 treatment did not diminish this wave of cell death. The 
treatment however did still rescue the populations of Arx positive cells in the cortex. This 
indicates the apoptosis in the brain is not solely responsible for the seizure phenotype in this 
PA1 mouse model, as the treatment was still effective at improving seizure outcomes in the 
mice (Siehr et al., 2020). This study shows the importance of using treatment trials to help 
understand the pathophysiological mechanisms of disease.  
 
Following the Olivetti study, other research groups have attempted to reproduce the effect of 
E2 on alleviating infantile spasms in different models of the disorder. One such study used a 
betamethasone-NMDA model of infantile spasms in rats, where betamethasone is given in utero 
around embryonic day 15. The rats were then treated with the same dosage of E2 used in the 
Olivetti study, between postnatal days 3 and 10. At postnatal days 12, 13 and 15, the rats were 
subject to NMDA triggered spasms. ACTH was used as a positive control, as this treatment is 
known to alleviate these induced spasms in this animal model. It was shown that E2 treatment 
had no effect on the spasms in this model (Chachua et al., 2016). 
 
Interneuron populations were investigated in these rats, the number of GAD67 positive cells, a 
marker for interneurons, was 23% higher in the brains of E2 treated rats compared to those 
treated with vehicle. A battery of behavioural tests was also performed, showing no difference 
to anxiety traits but instead altered the exploration pattern in the novel objection recognition 
test. The behavioural results found in this study showed a trend towards E2 treated male rats 
shifting to a more female style of exploratory behaviour. Weight gain was also noted in E2 
treated rats, not noted in the Olivetti study (Chachua et al., 2016). 
 
While this study provided behavioural data for animals treated with E2, an investigation not 
performed in the Olivetti study was to show any difference in cognition in the mice. There are 
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limitations to this study when looking at E2 for a model other than one with an Arx mutation. 
Given that the primary deficit in the PA1 mouse brain is an interneuron deficiency, which E2 
rescued to treat seizures in the mouse, it is reasonable to say that E2 may not have worked in 
this model as it did not show a deficit in interneurons in the first place, therefore not providing 
any additional benefits to rescue spasms. It is likely that given ACTH is used as a positive 
control in this study, the pathophysiology of the spasms is different to those seen in the Arx 
mouse models, and hence E2 may not rescue the phenotype in this induced spasm rat model. 
Another study performed in a different induced spasm rat model also attempted to validate 
whether E2 could alleviate infantile spasms. This model was induced at postnatal day 3 and 
presents with multiple clusters of spasms between postnatal days 4 and 13, with other seizure 
types also occurring after postnatal day 9. This model also presents with cognitive deficits to 
learning, memory and sociability behaviour, so has a phenotype more similar to the PA1 Arx 
mouse model. However, when treated with the same dosage of E2 as the Olivetti study between 
postnatal days 3 and 10, no difference was seen in spasm or seizure frequency, and there were 
no differences to mortality, or behavioural deficits. There was also no difference in weight 
between vehicle and E2 treated rats, different again to the Chachua study (Galanopoulou et al., 
2017). 
 
This induced spasm model does present with a deficit in interneurons, however these are 
predominantly in parvalbumin-positive cells, and this subtype was not affected by E2 in the 
Olivetti study. Again, it was concluded that different types of interneuron deficits can cause 
spasms, and that E2 may not act upon all the cellular causes of these spasms.  It is also 
interesting to note that mice and rats, though genetically close, have different 
neurodevelopment milestones at different times. It is possible that the postnatal day 3 to 10 




While not an infantile spasms model, a study into the effects of E2 on prematurely born rabbits 
has also been performed. Premature birth can lead to disrupted interneuron migration and 
development, due to neurological complications and a drop in estrogen levels. Estrogen can 
drop 100-fold in premature newborns, due to the termination of the in utero environment. This 
change in estrogen can interrupt neurogenesis and the maturation of interneurons. This study 
found that parvalbumin and somatostatin-positive interneurons were significantly deficient in 
the brains of prematurely born rabbits, and an overall loss of GAD67 positive cells. Estradiol 
treatment not only restored parvalbumin-positive interneurons in the cortex of prematurely born 
rabbit pups, but also increased the number of Arx expressing interneuron progenitor cells 
(Panda et al., 2018).  
 
1.6 Concluding remarks 
The seizures and intellectual disability associated with mutations in ARX can be devastating for 
children and their families. However, these pre-clinical studies show promise for exogenous 
steroids like estradiol as a potential therapy to alleviate the burden of comorbidities that are 
strongly associated with intellectual disability that may lead to damage to cognitive functioning, 
impaired quality of life due to the side effects of current anti-epileptic therapies, seizures 
interfering with day to day activities, or even early death. The mouse models developed for the 
expanded polyalanine tract mutations mirror the spectrum of patient phenotypes and provide an 
excellent resource for investigating E2 and other potential treatments. Understanding the 
molecular and cellular effects of these mutations will not only help us find potential pathways 
to be targeted by therapeutic interventions, but also to help us further understand the 







1.7 Project overview 
By understanding how treatment affects these mice and the mechanisms behind the 
improvement to the clinical phenotype, we may be able to understand the relatively unknown 
pathophysiological mechanisms of mutations in ARX, and their involvement in intellectual 
disability and its associated comorbidities. The experimental aims of my PhD project addressed 
the following questions. 
 
1. Does estradiol treatment alleviate seizure frequency and severity in a different model of PA1 
mice, as well as in PA2 mice, modelling the most common human mutation of ARX? 
2. Does the reduction of seizures driven by estradiol treatment, change the behavioural and 
cognitive outcomes in PA1 and PA2 mice? Or does estradiol treatment directly change these 
behavioural deficits? 
3. What are the molecular and cellular effects underpinning the mechanisms of pathogenesis in 
PA1 and PA2 mice? What are the improvements to these when PA1 and PA2 mice are treated 
with estradiol? 
 
To dissect our research questions, I undertook the following aims. 
Aim 1: To study the effects of short-term, daily estradiol treatment between postnatal days 3 
and 10, in PA1 and PA2 mice, on seizure severity and frequency. 
Aim 2: To investigate if estradiol treatment can improve behavioural and cognitive outcomes 
in PA1 and PA2 mice. We will examine if improvements are due to a direct effect of estradiol 
treatment or due to improving seizure outcomes.  
Aim 3: To perform unbiased transcriptomic analysis using RNA sequencing on the brains of 
PA1 and PA2 mice compared to wild-type mice at postnatal day 10, to determine the impact of 
ARX mutations on the postnatal cortex and assess the changes to gene expression being driven 




I hypothesised that estradiol treatment given early in postnatal life, would improve seizure 
outcomes in PA1 mice, as well as PA2 mice, given the overlapping phenotype of these two 
mouse models. Further, I predicted that the improvement in seizure severity and frequency early 
in brain development, due to estradiol treatment, would improve the cognitive deficits in both 
PA1 and PA2 mice. I hypothesised that these treatment effects would be due to estradiol’s 
strong action on gene expression in the brain, by impacting pathways and genes targeted or 
associated with Arx, and those involved with brain development and cellular migration, 























































2.1 General reagents 
PBS: Phosphate Buffered Saline; 10X: 1.37M NaCl, 27mM KCl, 100mM Na2HPO4, 20mM 
KH2PO4, adjusted to pH 7.4 
TBS: Tris Buffered Saline; 10X: 50mM Tris-Cl, 150mM NaCl, adjusted to pH 7.4 
TBE: Tris/Borate/EDTA; 10X: 89mM Tris, 89mM boric acid, 2mM EDTA, pH 7.6 
4% PFA: Paraformaldehyde; 0.1M NaOP, 4M NaOH, 4M NaCl, 4% PFA powder, pH 7.4 
 
2.2 Animals 
2.2.1 Animal husbandry 
All animal procedures were approved by the Animal Ethics Committee (AEC) of The 
University of Adelaide, Adelaide. ArxGCG7/+ (RBRC03654) and Arx432-455dup/+ (RBRC03653) 
heterozygous females, called PA1 and PA2 mice respectively throughout this thesis, were 
imported from RIKEN Bioresource Centre, Japan (Kitamura et al., 2009), and were maintained 
on the C57BL/6N-Hsd background.   
 
Breeding animals were housed in individually ventilated cages under constant temperature and 
humidity with a 12-hour light/dark cycle, with standard chow and sterile water available ad 
libitum. PA1 and PA2 heterozygous females were bred as trios with wild-type C57BL/6N-Hsd 
stud males to produce wild-type and hemizygous males for this study. There were no abnormal 
parenting behaviours in our heterozygous female mothers to report. Multiple breeding trios 
were set up concurrently to ensure an adequate number of litters (and hemizygous male pups) 
would be born within the same time frame. Females were separated and single housed once 
visibly pregnant (approximately two weeks post-conception) with access to autoclaved 
sunflower seeds and crushed standard chow soaked in sterile water, refreshed daily.  
 
Litters of male mice were weaned from their mothers at approximately postnatal day 21 to day 
23 (P21-P23) upon the smallest pup reaching 8 grams of body weight as a minimum.  Mice 
64 
 
were co-weaned with male pups from other litters of the same mutant strain and treatment group 
where possible. Hemizygous males were weighed, monitored and scored daily from P3 on a 
Clinical Record Sheet for general health and welfare, appearance and any observed seizure 
activity. Experimental male mice were housed in individually ventilated cages under constant 
temperature and humidity with a 12-hour light/dark cycle. Mice were given environmental 
enrichment in the form of red plastic dome houses, crinkled nesting paper, and a cardboard 
toilet roll or small cardboard box. Experimental mice were given a diet of 10% fat chow, 
autoclaved sunflower seeds and sterile water available ad libitum, as well as standard chow 
soaked in sterile water in an accessible feeding dish, refreshed daily. 
 
2.2.2 Drug preparation and injections 
A 5mg/mL stock of 17β-estradiol (E2) (Sigma) was dissolved in sterile-filtered 100% dimethyl 
sulfoxide (DMSO) (Sigma). This was stored in a glass bottle away from light for up to four 
months at 4°C. For injection, 4ng/µL of E2 in 0.75% DMSO was prepared in sterile sesame oil 
(Sigma). The vehicle injection control was similarly prepared, minus the E2. Aliquots of E2 
and vehicle injection stocks were given batch numbers, and stored away from light in 2mL 
amber glass vials (Sigma) at 4°C. Each batch was re-labelled with a colour code by a ‘non-
involved’ member of the lab, with the information stored in a secure location until the end of 
the study. Drugs were referred to by their codes throughout the experimental trials until data 
analysis was complete, ensuring the investigators were blinded to treatment identity.  
 
For these studies, only male pups were injected. Expansions of the first and second polyalanine 
tracts of Arx result in an X-linked disorder, meaning only male mice are affected by the disease. 
We treated hemizygous male mice, as well as wild-type male control mice. Daily injections 
were performed for seven days, between P3 and P10 inclusive, at the same time of day between 
8:00 am and 10:00 am. Drugs were taken out of 4°C storage 15 minutes prior to injection and 
warmed to 37°C. Pups were gently removed from their home cage and placed in a plastic tub 
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with tissue and used bedding from their home cage and placed on a 37°C slide warmer. Mice 
were visually sexed at P3. Pups were weighed before injection, with the dose of E2 achieving 
40ng/g. For example, mice weighing 1.5g received 50ng of E2. Table 2.1 shows the upper and 
lower weight limits for each weight range, and the subsequent dose of E2 given if the mouse 
weighed within that bracket. A sterile BD Ultra-Fine II short needle insulin syringe (0.3mL, 
0.25mm 31G x 8mm) (Becton-Dickinson) was used for injections. Pups were injected 
subcutaneously with the drug, alternating injecting site daily between the neck and left and right 
hips of the pup. Pups were toe tagged for identification and genotyping purposes on P4. Once 
injected, pups were returned to dam in home cage and monitored post-injection, to ensure the 
mother did not reject injected pups. All male mice in each litter were treated with the same drug 
(blinded to the investigator by colour code). To reduce the cannibalisation/rejection rates of 
litters during the treatment phase, the female littermates (within an experimental litter) were 
injected with vehicle, ensuring all pups in the litter smelt the same to the mother. 
 
At the end of the injection phase, male mice were humanely killed by decapitation for tissue 
collection for RNA sequencing analysis at P10 in the afternoon following their last injection, 
no less than six hours after injection, between 14:00 and 16:00. Otherwise, animals for 













A small piece of toe tissue was removed with sterile technique at postnatal day 4 or 5 for 
genotyping and to provide an individual identification mark (Figure 2.1). Tissue was stored at 
-20°C until analysed. Genomic DNA was extracted as per manufacturer’s instructions for the 
High Pure PCR Template Preparation Kit (Roche) or the Maxwell® RSC Tissue DNA kit 
(Promega). 
 
Genotyping polymerase chain reaction (PCR) of all pups was performed using Taq polymerase 
(cloned in house) and FailSafeTM PCR 2X PreMix J (Epicentre) for 35 cycles of 30 seconds 
denaturation at 94°C, 20 seconds annealing at 60°C and 40 seconds elongation at 72°C. Primers 
to amplify the Arx knock-in region were described previously (Kitamura et al., 2009). We also 
included an Sry sexing PCR as part of our genotyping protocol as described previously (Lee et 
al., 2014). All genotyping primers are listed in Table 2.2. PCR products were separated by 
electrophoresis at 110V for 25 minutes on a 2% agarose (w/v) in 1X TBE gel, and the correct 
PCR product was confirmed by comparison to the migration measured against a 1kB+ 
molecular weight ladder, viewed under UV light using GeneSnap software (SynGene).  
 
In addition to the genotyping described above, all heterozygous female breeders and 
experimental male pups were genotyped to confirm either the PA1 or PA2 genotype. This 
specific genotyping PCR was performed using Long Template Expand Taq polymerase (Roche) 
and FailSafeTM PCR 2X PreMix J (Epicentre) for 35 cycles of 30 seconds denaturation at 94C, 
40 seconds annealing at 60C and 40 seconds elongation at 68C. Primers used to amplify the 
PA1 and PA2 regions are listed in Table 2.2. PCR products were separated by gel 
electrophoresis at 80V for 45 minutes on a 2% agarose (w/v) in 1X TBE gel, and the correct 
PCR product was confirmed by comparison to the migration measured again a 1kB+ molecular 







Figure 2.1: Mouse toe tagging numbering system. Diagram showing numbering system for 
toe tagging identification (mouse viewed from below). In this example, the third toe of the paw 
on the right fore limb, and of the paw on the left hind limb (circled in red) would be cut, giving 
a mouse identification number of 48. Diagram adapted from (Paluch et al., 2014).
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Table 2.1: Mouse weight range brackets with lower and upper weight limits, with correct volume of drug to inject. 
Lower weight (g) 1.375 1.625 1.875 2.125 2.375 2.625 2.875 3.125 3.375 
Higher weight (g) 1.624 1.874 2.124 2.374 2.624 2.874 3.124 3.374 3.624 
Volume injected (µL) 15 17.5 20 22.5 25 27.5 30 32.5 35 
Lower weight (g) 3.625 3.875 4.125 4.375 4.625 4.875 5.125 5.375 5.625 
Higher weight (g) 3.874 4.124 4.374 4.624 4.874 5.124 5.374 5.624 5.874 
Volume injected (µL) 37.5 40 42.5 45 47.5 50 52.5 55 57.5 
Lower weight (g) 5.875 6.125 6.375 6.625 6.875 7.125 7.375 7.625 7.875 
Higher weight (g) 6.124 6.374 6.624 6.874 7.124 7.374 7.624 7.874 8.124 
Volume injected (µL) 60 62.5 65 67.5 70 72.5 75 77.5 80 
Lower weight (g) 8.125 8.375 8.625 8.875 9.125 9.375 9.625 9.875 
Higher weight (g) 8.374 8.624 8.874 9.124 9.374 9.624 9.874 10.124 




Table 2.2: Mouse genotyping PCR primers. 
Detection Primer Name Direction Primer Sequence 
Length 
(bp) 




Sex Sry-F Forward CACTGGCCTTTTCTCCTACC 20 
60 349 




Reverse TGTTCAATGGCCGATCCCAT 20 
60  
 mArx jjr Reverse CTTTAGCTCCCCTTCCTGGCACAC 24 
 mArx kkf Forward AAAGGCGAAAAGGACGAGGAAAGG 24 
PA1 
mutation 





Reverse ACCTCTCCACGGGGACCT 18 
PA2 
mutation 
mARX-Dp24 Forward AGGGGAGCGTCAGGACAG 18 
60 282 
 mARX-Dp24 Reverse AACAGCTCCTCCTCGTCGT 19 
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2.2.4 Behavioural analyses 
Behavioural testing was performed at approximately one and two months of age. Tests were 
conducted in the light cycle, always beginning at 9:00 and ending by 13:00. Tests at one month 
of age ran for one week and were performed in a conventional order for behaviour testing, 
running from the least stressful to the most stressful test (Wahlsten, 2011): open field and 
inverted grid (day 1), elevated zero maze (day 2), Y-maze (day 3) and sociability and social 
novelty (day 4). Tests at two months of age ran for two weeks and were performed in the same 
order in the first week, followed by Barnes maze for five days in the second week of testing. 
All testing was conducted using ANYmaze video tracking software (Stoelting). Behavioural 
apparatuses were thoroughly cleaned with F10 Veterinary Detergent between mice to remove 
olfactory traces. Environment (room appearance, lighting, background noise, temperature, 
humidity, and clothing of tester) was kept consistent for each round of behavioural testing. For 
all behaviour tests performed, several parameters could be measured using the AnyMaze 
software. While we have only reported those of interest or with significant differences, we have 













Table 2.3: Parameters measured for each behavioural test using the AnyMaze software. 
 
Behavioural test Parameters measured 
Open field Time spent in zones 
Distance spent in zones* 
Total distance travelled* 
Average speed of mouse 
Speed of mice in zones 
Time spent stationery in zones 
Total time spent stationery 
Elevated zero maze Time spent in zones* 
Distance spent in zones 
Total distance travelled* 
Average speed of mouse 
Speed of mice in zones 
Time spent stationery in zones 
Total time spent stationery 
Number of head dips* 
Y-maze Time spent in zones* 
Distance spent in zones 
Total distance travelled* 
Average speed of mouse 
Sociability & social novelty Time spent interacting with stranger/familiar mice* 
Time spent in stranger/familiar mouse zone 
Total distance travelled 
Average speed of mouse 
Barnes maze Latency to find escape hole* 
Distance travelled to find escape hole 
Number of false entries 
 
*indicates parameter reported in this thesis (Chapter 3)
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2.2.4.1 Inverted grid 
Mice were placed on a wire grid (bar diameter of 1mm, 1cm apart) with an area of 10cm by 
18cm taped off around the edge to prevent mice from climbing on to the top of the wire grid. 
The mouse’s tail was pulled gently so that it gripped on to the grid, and the grid was quickly 
flipped to suspend the mouse upside down. The grid was suspended approximately 50cm above 
a plastic-coated pillow surface. Mice were timed for the duration they remained suspended from 
the wire grid for a maximum time of 120 seconds, which was considered a successful trial. If 
the mouse fell in the first 10 seconds it was trialled for a second time, and if it fell again it was 
counted as a fail. Time the mice held on to the grid was measured as ‘latency to fall’. Numbers 
of successful and failed attempts were also recorded.  
 
2.2.4.2 Open field 
Baseline locomotor activity and anxiety-like behaviour was quantified in the open-field, under 
stress-inducing conditions. Mice were placed in a 40cm by 40cm, well-lit (overhead light) 
plexiglass box, lined with black contact, in the south-west corner. Wild-type mice will typically 
spend time exploring the entire box, while mice with an abnormal fear and anxiety response 
will spend more time in the outer, darker areas of the open field apparatus (periphery), and 
won’t spend as much time in the central zone of the apparatus. Wild-type mice will typically 
spend time exploring the entire box, while mice with an abnormal fear and anxiety response 
will spend more time in the outer, darker areas of the open field apparatus (Wahlsten, 2011). 
Time and distance spent in the periphery or centre zone of the open field was recorded over a 






2.2.4.3 Elevated zero maze 
Anxiety-like and exploratory behaviours were investigated using the elevated zero maze. The 
elevated zero maze is comprised of a circular elevated platform, 40cm above the floor (a 
diameter of 50cm, and a platform 5cm wide). The maze is split into four quadrants; two closed 
quadrants with 27cm high walls and two open quadrants with no walls. Mice were alternately 
placed in the centre of the northern or southern open quadrant and allowed to explore. Wild-
type mice typically explore the open quadrants of the elevated zero maze more than mice with 
an abnormal fear response, who tend to spend more time in the closed, darker quadrants 
(Wahlsten, 2011). Mice were recorded for a 5-minute period, measuring distance and time spent 
in open or closed quadrants. Head dipping behaviour was manually recorded (exploratory 
behaviour where a mouse looks over the side of the maze platform).   
 
2.2.4.4 Y-maze 
Hippocampal dependent spatial memory and exploratory behaviour was measured using the Y-
maze. The Y-maze is comprised of three arms shaped as a ‘Y’, each 35cm long and 5cm wide 
with 10cm walls. The arms are at a 120° angle to each other. Each of the test walls had a 
different marking in black tape to allow mice to spatially differentiate between the left and right 
arms. There are two stages of the Y-maze test; training and testing.  
 
2.2.4.4.1 Stage 1: Training 
During Stage 1, mice were placed in the southern arm of the Y-maze. The mice explored the 
maze for a ten-minute period, with one of the lateral arms closed and the other open (alternated 





2.2.4.4.2 Stage 2: Testing 
Thirty minutes after Stage 1, mice were placed in the southern arm of the Y-maze for Stage 2 
of this test. All three arms were open for exploration for a duration of five minutes. Mice with 
intact hippocampal learning and memory will display a preference for the novel environment 
of a previously unexplored arm, and mice with a memory impairment will not recognise the 
novel arm, resulting in a greater or equal amount of time spent in the familiar, previously 
explored arm of the maze (Wahlsten, 2011). 
 
2.2.4.5 Sociability 
Sociability testing was carried out to investigate social behaviour and autistic-like traits. The 
test is comprised of a rectangular, plexiglass box with three separate chambers divided by walls. 
Each chamber it 20cm by 40.5cm with 22cm high walls connected by closable doors. The 
sociability test is conducted in three stages. Each stage is five minutes long, and all stages are 
performed in a row for each mouse, before moving on to the next mouse.  
 
2.2.4.5.1 Stage 1: Habituation 
The mouse was placed in the middle chamber with doors to the left and right chambers left 
open, for a duration of five minutes. 
 
2.2.4.5.2 Stage 2: Sociability 
A wild-type, age-matched male stranger mouse (Stranger 1; no previous interaction with the 
testing mice) was placed in a round wire cage, with bars wide enough to allow nose contact. 
The stranger cage was placed in the left or right chamber (alternating between each test mouse). 
An empty cage was placed in the opposite chamber. The test mouse was placed in the middle 
chamber and allowed to access all chambers for a period of five minutes. The time the test 
mouse spent interacting with Stranger 1 was recorded as an index of social behaviour. 
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Interaction was measured manually and defined as the time the test mouse spent sniffing, 
interacting with, or climbing on the cage of Stranger 1.  
 
2.2.4.5.3 Stage 3: Preference for social novelty 
A second wild-type, age-matched male stranger mouse (Stranger 2) was placed in the 
previously empty cage in the previously empty chamber. The test mouse was allowed to access 
all chambers for a five-minute period. The time the test mouse spent interacting with Stranger 
1 and Stranger 2 was measured as an index of preference for social novelty. 
Mice usually have a preference for social novelty, and those with normal social behaviour will 
typically spend more time interacting with Stranger 2 (novel mouse) than the Stranger 1 mouse 
(familiar mouse) in Stage 3, and a preference for social interaction by spending time with 
Stranger 1 in Stage 2. Mice displaying autistic-like behaviour will have altered social behaviour 
and will not interact with stranger mice as preferentially as wild-type mice do in sociability or 
preference for social novelty tests (Wahlsten, 2011).  
 
2.2.4.6 Barnes maze 
The Barnes maze was used to investigate spatial learning and memory as well as cognitive 
flexibility. The Barnes maze is comprised of a round table 91cm in diameter, with an overhead 
light above the table. The maze has 20 equally spaced holes around the outside edge. However 
only one leads to a real escape box underneath the table. All other holes are blocked and have 
no escape box. The Barnes maze was conducted over four training days.  
 
2.2.4.6.1 Days 1-4: Training 
A four-day training period was used to measure spatial learning. Each day, the test mouse was 
placed in the centre of the Barnes maze table under an opaque plastic container. Once the 
container was lifted, the test mouse was given three minutes to find the escape box and learn 
its location. If the mouse failed to find the escape box, it was guided to the box and had the 
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plastic container kept over it for one minute in order to learn its location. Mice were tested three 
times on each testing day, with the score averaged. Outcomes were recorded as latency to locate 
the escape box over the training period. 
 
 
2.2.5 Seizure monitoring and analysis 
Mice received daily injections between day 3 and day 10 and remained with their mothers until 
weaning. From the start of treatment (postnatal day 3) until postnatal day 70, all mice for 
behavioural testing and seizure monitoring were handled and weighed daily. Any observed 
seizures occurring during this daily handling were recorded. Spontaneous seizures were 
assessed during non-invasive video monitoring (with offline analysis) across the peak period of 
seizures (previously determined in untreated mice to occur between postnatal days 35 and 60) 
(Jackson et al., 2017). Video monitoring for seizure activity was conducted three times a week 
in four hour blocks from 11:00 until 15:00 during light cycle, on PA1 and PA2 hemizygous 
males and age matched control wild-type littermates, between the ages of P38 and P56. Cage 
mates were placed in a Perspex covered 17.5cm by 31cm cage, with a small piece of Nectragel 
(Able Scientific) and food available ad libitum during the filming period. Natural behaviour 
was captured and automatically saved in 50-minute video files by a Sony FDR-AXP35 4K 
Handycam or a Panasonic HC-VX980M 4K Video Camera. Activity levels and seizure activity 
were viewed offline using VLC Media Player (version 2.1.3). Videos were analysed by 
observers blinded to genotype and treatment.  Seizure activity was scored using a defined 
scoring system based on categorisation of seizures compared directly to video-
electroencephalography in untreated mutant mice from a previous study (Jackson et al., 2017). 
In brief, seizures in mutant mice were characterised into four categories: (1) rapid and jerky 
movements around the cage and stationary seizures, (2) mild repetitive myoclonic jerks 
(duration less than 10 secs), (3) prolonged myoclonic seizures lasting longer than 10 seconds 
and (4) found dead. Myoclonic seizures were recorded for length of seizure in seconds.  
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2.2.6 Animal dissections and tissue collection 
Animals for RNA sequencing analysis were humanely killed by decapitation at postnatal day 
10, and behavioural/seizure monitoring animals were humanely killed at approximately 
postnatal day 70 by CO2 asphyxiation, if not euthanised for humane reasons prior to end point. 
The brain was dissected, and the cortex was separated from the cerebellum and cut in half 
sagitally along the cerebral fissure. The left half of the cortex was minced and snap frozen in 
liquid nitrogen and stored at -80°C. The right half of the cortex was fixed in either 4% PFA or 
10% formalin (Sigma).  
 
Samples fixed in 4% PFA were washed three times in high-volume, cold 1X PBS for five 
minutes per wash on a rocker, before being transferred to 30% sucrose in PBS to equilibrate. 
Samples were then embedded in OCT medium (TissueTek, ProSciTech) and stored at -80°C. 
Samples fixed in 10% formalin were washed three times in high-volume, cold 1X PBS for five 
minutes per wash on a rocker, and stored in 70% ethanol at 4°C.  
 
Other tissue was also dissected from the animals; testes, pancreas, and forelimb muscle. The 
left testis, left forelimb muscle and pancreas were snap frozen in liquid nitrogen and stored at -
80°C. The right testis and right forelimb muscle were fixed in either 4% PFA or 10% formalin. 
Fixed samples were washed and embedded as per procedures described above. 
 
2.2.7 Statistical analysis 
All data analysis was performed using GraphPad Prism version 7.0 (GraphPad Software Inc.). 
Data normality was confirmed using a D’Agostino and Pearson normality test. Statistical 
significance of the difference between means of each genotype (PA1 and PA2), treatment 
groups, and wild-type littermates was determined using either a one-way or two-way analysis 
of variance (ANOVA) followed by a Tukey’s HSD post-hoc test. Where comparisons were 
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made between two treatment groups of the same genotype (PA1 or PA2), without wild-type 
littermates included, a two-tailed unpaired t-test was performed to determine significance. 
 
2.3 Gene expression analysis 
2.3.1 RNA extraction 
RNA was extracted from the cortex of hemizygous male mice and age-matched male wild-type 
littermates using Trizol (ThermoFisher). Frozen cortex samples were thoroughly homogenised 
in 1mL of Trizol, and the sample passed through a P1000 pipette tip until completely 
homogenised. Samples were left at room temperature (RT) for five minutes. 200µL of 
chloroform was then added to the tube, and shaken vigorously for one minute, then left for two 
minutes at RT for layers to separate. The tube was then centrifuged at 10,000 x g for 15 minutes 
at 4°C. The RNA was then extracted and purified as per manufacturer’s instructions for the 
RNeasy Mini Kit (Qiagen) and RNase-Free DNase kit (Qiagen). RNA was eluted in 50µL of 
RNase-Free H2O. RNA concentration was determined using a UV spectrophotometer 
(Nanodrop). RNA quality was also determined using gel electrophoresis. 3µL of RNA was 
combined with 5µL of 2X loading dye, with RNA then separated by electrophoresis at 80V for 
60 minutes on a 1% agarose (w/v) in 1X TBE gel. The correct products were confirmed by 
comparison to the migration measured again a 1kB+ molecular weight ladder, viewed under 
UB light using GeneSnap software (SynGene).  
 
2.3.2 RNA sequencing 
Illumina’s TruSeq stranded RNA sample preparation protocol was used to process samples 
prior to sequencing. 56 mouse RNA samples were sequenced on an Illumina NextSeq Platform. 
The primary sequence data was generated using the Illumina bc12fastq.2.19.1.403 pipeline. The 
per base sequence quality was >95% bases above Q30 across all samples. The reads were also 
screened for the presence of any Illumina adapter/overrepresented sequences and cross-species 
contamination. The cleaned sequence reads were then aligned against the Mus musculus 
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genome (build version nm10). The TopHat aligner (v2.1.1) was used to map reads to the 
genomic sequences. The counts of reads mapping to each known gene were summarised and 
used for computing differential gene expression with ‘edgeR’. edgeR version 3.12.1 was used 
to perform differential expression analysis. Low counts were filtered out (cpm<1) and the 
default TMM normalisation method of edgeR was used to normalise the counts between 
samples. A generalised linear model was then used to quantify the differential expression 
between the groups (treatment and genotype). Transcripts that were significantly different 
within genotype and treatment group comparison, were then selected by applying a p-value cut 
off of <0.05 and a log2 fold-change of ±0.5.  
 
2.3.3 RNA sequencing validation  
2.3.3.1 Reverse transcription cDNA synthesis 
cDNA was prepared as described in SuperScriptIII reverse transcriptase (ThermoFisher) 
manual, with 1µg of RNA primed by random hexanucleotides. Template negative and reverse 
transcriptase negative controls (where template or SuperScriptIII was replaced with H2O) were 
included to determine product specificity. Synthesised cDNA was diluted by adding 20µL of 
H2O. Samples were stored at -20°C.  
 
2.3.3.2 Polymerase chain reaction (PCR) 
The efficiency of reverse transcription was determined using PCR. The primers used were 
specific to the ubiquitously expressed housekeeping gene, Beta-Actin. Primers used are listed 
in Table 2.4. For this reaction, cDNA was amplified with 1µL of Taq DNA polymerase (Roche), 
1x PCR buffer with MgCl2 (Roche), single stranded DNA primers (Table 2.4) and H2O to make 
the reaction up to 50µL. The PCR cycle conditions were as follows: initial denaturation at 94°C 
for 5 minutes, 35 cycles of denaturation at 94°C for 30 seconds, annealing for 30 seconds at 
60°C, extension at 72°C for 30 seconds, and a final extension at 72°C for 10 minutes. PCR 
products were visualised on a 1% agarose (w/v) gel in 1X TBE buffer with ethidium bromide 
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added (0.2µg/mL) for 45 minutes at 100V, with 1kB+ molecular weight ladder, and viewed 




Table 2.4: Housekeeping primer set. 
























2.3.3.3 Quantitative real-time PCR (RT-PCR) 
Genes selected for validation studies were assayed as described in the TaqMan® PreAmp 
Master Mix Kit user guide (Applied Biosystems). Pre-designed TaqMan® Gene Expression 
Assays were selected from ThermoFisher. Reactions were set up in a 96-well plate, with each 
well containing 2µL of cDNA template (of a 1ng/µL to 50ng/µL stock), 1µL of the 20X 
TaqMan® Gene Expression Assay (FAMTM dye-labelled MGB probe) and 1µL of the 20x 
TaqMan® Endogenous Control Assay (VIC® dye-labelled MGB probe), 10µL of the 2x 
TaqMan® Gene Expression Master Mix and RNase-free H2O. Each validation gene was 
quantified using a FAM labelled TaqMan® probe, with the expression values normalised to the 
reference gene, Beta-Actin, labelled with VIC.  
 
Reactions were run on the Applied Biosystems StepOnePlusTM Real-Time PCR System using 
a standard run with the following conditions: activation at 50°C for 2 minutes, 95°C incubation 
for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds and extension at 60°C for 1 
minute. The signal emitted from the dye was recorded at the end of each cycle. All samples 
were analysed in triplicate. The efficiency of the assay was determined by amplification of the 
standard curve of a diluted control cDNA sample (in this case, an untreated wild-type cortical 
sample from an age-matched control).  Expression values were calculated using the 
StepOnePlusTM software (v2.3), using the standard curve method. Table 2.5 refers to all 


















Gene name Oligo name Probe label Species Amplicon length 
Arc Mm01204954_g1 FAM Mouse 145 
Arx Mm00545903_m1 FAM Mouse 104 
Beta-Actin 
ACTB Control Mix, 
pre-developed 
Taqman assay reagent 
VIC Mouse  
Calb2 Mm00801461_m1 FAM Mouse 80 
Chrna2 Mm00460630_m1 FAM Mouse 63 
Egr1 Mm00656724_m1 FAM Mouse 182 
Fos Mm00487425_m1 FAM Mouse 59 
Gbp3 Mm00497606_m1 FAM Mouse 79 
Inhba Mm00434339_m1 FAM Mouse 65 
Lgi3 Mm00507490_m1 FAM Mouse 95 
Lhx1 Mm01297482_m1 FAM Mouse 60 
Lmo1 Mm01168131_m1 FAM Mouse 70 
Ncald Mm01137205_m1 FAM Mouse 64 
Ndnf Mm00549567_m1 FAM Mouse 74 
Nkx2-1 Mm00447558_m1 FAM Mouse 95 
Npy Mm01410146_m1 FAM Mouse 130 
Npy2r Mm01218209_m1 FAM Mouse 86 
Nt5e Mm00501910_m1 FAM Mouse 77 
Nxph2 Mm00801892_m1 FAM Mouse 91 
Pcp4l1 Mm01295270_m1 FAM Mouse 63 
Spp1 Mm00436767_m1 FAM Mouse 114 
Th Mm00447557_m1 FAM Mouse 61 
Wnt10a Mm00437325_m1 FAM Mouse 69 
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2.3.4 Gene enrichment analysis 
Venn diagrams for gene expression data analyses were created using 
http://bioinformatics.psb.ugent.be/webtools/Venn. Statistical analysis of the enrichment of 
gene expression data was performed using Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) Functional Annotation Bioinformatics Microarray Analysis 
(Huang da et al., 2009, Huang da et al., 2009). DAVID uses multiple databases to create 
annotation clusters. These clusters are then given overarching theme names and ranked. 
Annotation clusters were ranked by enrichment score calculated by DAVID. PANTHER 
(Protein Analysis Through Evolutionary Relationships) was used for pathway enrichment 
analysis (Thomas et al., 2003, Mi et al., 2013). 
 
Our lists of deregulated genes were compared with a number of reference lists of genes 
associated with autism and intellectual disability, epilepsy, inhibitory neurons, and estrogen 
response element containing genes. The statistical significance of the overlap of genes between 













2.4 Immunofluorescence  
2.4.1 Tissue sectioning 
Cortex from mice was coronally embedded in OCT and stored at -80°C until sectioning. The 
samples were sectioned by the University of Adelaide Histology Department. Coronal sections 
of 10µm thickness (~2-3 cells thick) at 100µM apart were taken serially using a Leica Crytostat 
(Leica Biosystems) at -24°C. Sections were fixed to SuperfrostTM Plus microscope slides 
(ThermoFisher). Frozen cortical sections were stored at -20°C until analysis. At least four 
sections across the right hemisphere were used for immunofluorescence analysis. Sections 
analysed align to sections 100-124 of the Nissl stained postnatal day 7 coronal brain of the 
Allan Brain Atlas reference guide. 
 
2.4.2 Immunofluorescence  
Frozen cortical sections were first air-dried for one hour at room temperature prior to 
immunofluorescence staining. The following procedure was performed in a humidified 
chamber (a dark box lined with damp paper towel) to prevent tissue from drying. Rinses and 
washes were performed in Coplin jars. 
 
Tissue sections were permeabilised in 1X PBS + 0.5% Triton-X for 5 minutes. Slides were then 
rinsed in 1X PBS, before being incubated with blocking solution (10% horse serum and 10% 
BSA in 1X PBS + 0.1% Triton) at room temperature, for 30 minutes. Slides were incubated 
with primary antibodies overnight at 4°C, followed by incubation with secondary antibodies at 
room temperature for 2 hours. Between each antibody staining, slides were washed three times 
with 1X PBS + 0.01% Tween 20. Following secondary staining and washing, slides were 
mounted with ProLong Gold Antifade Reagent with DAPI (Life Technologies) to stain the cell 
nuclei and mount coverslips. All antibodies used and antibody dilutions are listed in Table 2.6 




2.4.3 Microscopy  
All immunofluorescence images were captured using a Zeiss Axio Imager.M2 microscope 
equipped with Axio Vision software (version 5.1). Immunofluorescence imagers were acquired 
by Zeiss AxioCam mRM camera. All comparative images within the same batch were captured 
with the same exposure times. 
 
Captured images were processed by Image J for quantification analysis. To ensure comparable 
signals were obtained across all genotypes within an independent experiment for quantification, 
all images within the same batch were captured with the same microscope settings within one 
session.  
 
2.4.4 Interneuron analysis 
Images from a section were first stitched together using Microsoft Image Compositor 
(Microsoft), and imported into Image J (FIJI) for processing and analysis. Manual cell counts 
were performed using the Cell Counter plugin for Image J. The counting method used was 
derived from Lee et al. 2017. Cells that were considered for analysis had a circular-like cell 
body (calbindin) or cytoplasmic and/or nuclear staining (neuropeptide-Y) with clear boundaries 
of the structure, with a clear nucleus from DAPI staining. Counts were exported into Excel and 
a cell density of number of cells/mm2 were derived as an outcome (positive cells counted/area 
of section counted in mm2).  
 
 
2.4.5 Statistical analysis 
For statistical analysis of interneuron cell counts, PA1 and PA2 mice were pooled. A one-way 
ANOVA was performed to determine statistical significance between PApool mice treated with 





Table 2.6: Primary antibodies used for immunofluorescence. 
Protein Species Affinity Cat # Company Dilution 
Calbindin Rabbit Polyclonal PC253L Merck 1:1000 
Neuropeptide-Y Sheep Polyclonal AB1583 Merck 1:1000 
 
Table 2.7: Secondary antibodies used for immunofluorescence. 
Host Target Conjugate Clonality Cat # Company Dilution 
Goat α Rabbit Alexa 555 Polyclonal A27039 ThermoFisher 1:400 
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Children with severe intellectual disability have an increased prevalence of refractory seizures. 
Exogenous steroid treatment may improve seizure outcomes, but the mechanism responsible 
for these improvements remains unknown. Further, it is unclear whether these treatments can 
improve cognition and behavioural deficits, either through direct action, or by improving 
seizure outcomes. Here we demonstrate that short term, daily delivery of the exogenous steroid, 
17β-estradiol (40 ng/g) in early postnatal life significantly reduced the number and severity of 
seizures, but did not improve behavioural deficits, in mice modelling mutations in the 
Aristaless-related homeobox gene (ARX), expanding the first (PA1) or second (PA2) 
polyalanine tract. Frequency of observed seizures on handling (n = 14/treatment/genotype) 
were significantly reduced in PA1 (32% reduction) and more modestly reduced in PA2 mice 
(14% reduction) with treatment compared to vehicle. Spontaneous seizures were assessed (n = 
7/treatment/genotype) at 7 weeks of age coinciding with a peak of seizure activity in untreated 
mice. PA1 mice treated with estradiol no longer present with the most severe category of 
prolonged myoclonic seizures, while treated PA2 mice had a complete absence of any seizures 
during this analysis. Despite the reduction in seizures, 17β-estradiol treated mice showed no 
improvement in behavioural or cognitive outcomes after peak seizure onset. For the first time 
we show that these deficits due to mutations in Arx are already present prior to seizure onset 
and do not worsen with seizures. This comprehensive seizure and behavioural analysis provides 
a basis for further investigations into the molecular mechanism of estradiol treatment, and an 
understanding of the pathways that are impacted to achieve a reduction in the frequency and 
severity of seizures in the Arx PA mutant mice, and why the behavioural outcomes are not 







Epilepsy is a devastating neurodevelopmental disorder that affects approximately 50 million 
people worldwide with recent estimates of active epilepsy as high as 1.2% in developed 
Western countries (Zack and Kobau, 2017). This disorder is characterised by involuntary 
seizures, due to an imbalance of excitatory and inhibitory neuronal activity in the brain (WHO, 
2019).  One form of epilepsy in early infancy is infantile spasms, including X-linked infantile 
spasms syndrome (ISSX; MIM# 308350). This disorder has a prognosis of severe epilepsy 
coupled with intellectual disability persisting throughout childhood and adolescence (Olivetti 
and Noebels, 2012, Hrachovy and Frost, 2013). Children with neurodevelopmental disorders 
often have complex overlapping phenotypes. For example, patients with severe intellectual 
disability have a 15-20% greater incidence than the general population of co-morbid features 
including recurrent seizures and autism spectrum disorder (ASD). As many as half of 
intellectual disability cases and epileptic syndromes are believed to be caused by genetic 
mutations (Willemsen and Kleefstra, 2014, Chiurazzi and Pirozzi, 2016, Ellis et al., 2020). The 
increasing list of genes responsible are involved in various pathways including development 
and maintenance of neuronal and brain function and cortical architecture (Paciorkowski et al., 
2011, Olivetti and Noebels, 2012).  
 
The Aristaless-related homeobox gene (ARX) [NM_139058.2] (MIM#300382) is known to play 
a pivotal role in the development of the brain, specifically the migration and differentiation of 
interneurons (Miura et al., 1997, Kitamura et al., 2002, Kitamura et al., 2009, Lee et al., 2014). 
Interneurons are small, locally projecting neurons that use the neurotransmitters γ-aminobutyric 
acid (GABA), acetylcholine and other neuropeptides, to modulate excitation within neural 
networks. Due to the importance of excitatory and inhibitory balance, it is not surprising that 
dysfunction of GABA interneurons in the cerebral cortex is involved in neuropathology 
including epilepsy, schizophrenia, autism and intellectual disability syndromes (Le Magueresse 
and Monyer, 2013, Smith-Hicks, 2013). Mutations in ARX invariably lead to intellectual 
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disability, with a wide spectrum of other neurological comorbidities, including autism, 
dystonia, and epilepsy (Kitamura et al., 2002, Shoubridge et al., 2010). Over half of all 
mutations in ARX patients are expansions of the first or second polyalanine tracts. Clinical 
presentation of families with expansion mutations in the first tract (PA1) generally present with 
phenotypes of infantile spasms and seizures (81%) (Shoubridge et al., 2010, Marques et al., 
2015), while patients with mutations in the second tract (PA2) present with non-syndromic 
intellectual disability (68%), with dysarthria, dystonic hand movements (20%) and infantile 
spasms (26%) (Partington et al., 2004, Shoubridge et al., 2010, Marques et al., 2015, Jackson 
et al., 2017). The mechanisms underpinning this clinical variability remain unclear. 
 
Children with infantile spasms associated with severe intellectual disabilities respond poorly to 
anti-convulsant medication. Adrenocorticotrophic hormone (ACTH) therapy is known to 
stimulate production and release of corticosteroids, as a frontline treatment for these disorders 
but often has low efficacy, high relapse rates and severe side effects that alongside early-onset 
seizures, are thought to further exacerbate the behavioural and cognitive deficits in affected 
children (Hrachovy and Frost, 2013). Second to the effects of anti-convulsant therapy, 
persistent and severe seizures can have dramatic effects on the regression of cognition of 
children with epilepsy (Farwell et al., 1985, Neyens et al., 1999, Prasad et al., 2014). A 
preclinical trial in a different Arx PA1 mouse model (Price et al., 2009) found that short-term 
17β-estradiol (E2) given daily in the first postnatal week alleviated the severe seizure phenotype 
in adult male mice (Price et al., 2009, Olivetti et al., 2014). Estradiol being a exogenous steroid, 
plays important roles in the developing brain in synaptogenesis and morphology of neurons and 
glial cells, and can induce long-term changes in gene expression in the brain via activation of 
estrogen receptor and non-receptor pathways. 17β-estradiol treatment of PA1 mice partially 
restored the interneuron migration deficits in the neocortex, increased populations of 
neuropeptide-Y and calbindin positive interneurons, and changed the expression of several 




The migration of these inhibitory cells along with other stages of cortical laminar positioning 
occur in mice from embryonic day 9 until postnatal day (P) 10. In the developing male mouse 
brain, there is a surge of intrinsic estradiol and conversion of testicular testosterone into 
estradiol during this period of brain development (McCarthy, 2008). While much research into 
estradiol’s effects on the epileptic brain has been focused on the pro-epileptic activity of the 
hormone in the adult brain, its neuroprotective effects in the developing nervous system are still 
being explored. Estradiol has long-lasting transcriptional actions via estrogen receptors α and 
β, with genes regulated by estradiol being involved in cell proliferation, neuronal migration, 
synaptogenesis and cell survival. Estradiol also regulates GABAergic neuronal populations and 
increases the numbers of inhibitory neurons in the pyramidal layers of the cortex (Nakamura 
and McEwen, 2005, Velíšková, 2006).  
 
Here we investigate the role of early estradiol treatment in mice modelling the PA1 and the 
more frequent PA2 ARX mutations (originally reported by Kitamura et al. 2009). Our study 
explores the effect of estradiol on the seizure phenotype in Arx mutant mice and extends the 
investigation to the impact of this treatment on cognitive outcomes before and after the peak 
onset of seizures. We hypothesised that estradiol would reduce the severity and frequency of 
seizures in both PA1 and PA2 mice, given their overlapping phenotypes. We predicted that by 
improving the epilepsy phenotype, the impact of seizures on cognitive and behavioural deficits 
in these mice might be improved.
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3.3 Materials and Methods 
3.3.1 Optimisation of drug preparation and injections 
We performed a pilot study to optimise the drug preparation and injections. The original 
protocol was to dissolve 17β-estradiol in vegetable oil. As vegetable oil can contain high levels 
of phytoestrogens, we chose sterile sesame oil (Sigma) for the vehicle (Kuhnle et al., 2008). 
17β-estradiol was first dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma). The LD50 of 
DMSO is 6.2mL/kg. Doses of DMSO above 10% can cause increased apoptosis in the brain as 
well as Tau protein phosphorylation (Hanslick et al., 2009). The concentration of DMSO 
required to dissolve our dose of 17β-estradiol was 0.075mL/kg in the final solution of sesame 
oil, estradiol and DMSO, or 0.075%. The concentration we used is in a non-toxic range of the 
DMSO toxicity curve (Figure 3.1). 
 
The DMSO, 17β-estradiol and sesame oil solution needed to be warmed in a water bath or 
incubator at 37°C to form a homogenous solution before pipetting into glass vials ready for 
injection. Injection of the drug was optimised in an injection pilot study prior to the 
experimental study performed for this chapter. As the sesame oil solution for injections was 
viscous, a larger volume than needed for each pup was drawn up into the syringe, and then 
adjusted to the volume required based on the weight of the pup. This procedure was also made 
easier with warming, by leaving syringes on a microscope slide warmer before injecting pups. 
 
When injecting the pups, we first used the back of the neck as the subcutaneous injection site. 
This process left pockets of sesame oil when the mice were euthanised on P10, after seven days 
of injections. For the next litter, we trialled swapping the injection site from the neck, to the left 
hip and the right hip, for the seven days of injection. This protocol resolved the issues with oil 
pockets upon euthanisation on P10. During the pilot study, we found above average rates of 
cannibalisation and neglect of injected pups by the mother, compared to their uninjected, female 
littermates. We hypothesised this was due to the smell of the estradiol/vehicle solution 
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remaining on the skin following injections. To overcome this, we trialled injecting the non-
experimental, female pups of the litter with vehicle, to ensure all pups smelt the same. This 
protocol reduced rates of cannibalisation. These injection protocols were adopted for the larger 
















Figure 3.1: DMSO toxicity curve for apoptosis of neurons in P7 mice. Number of apoptotic 
neurons recorded for mice at P7 treated with different doses of DMSO. Mice did not have 
significantly greater apoptosis than mice treated with 9 mL/kg until the dose was greater than 
0.1 mL/kg. The dose of DMSO used for estradiol preparation in our study is marked with a red 







3.4.1 Estradiol treatment trial strategy 
Four staggered rounds of breeding were conducted for this study. A variety of dams from 
different lineages within the two mouse colonies were chosen for breeding purposes. This 
ensured adequate genetic diversity within our experimental cohort. A list of the mice used for 
estradiol treatment trial is in Appendix 3.  
 
PA1 and PA2 mutant male mice and their wild-type male littermates were treated with daily 
subcutaneous injection of 17β-estradiol (40ng/g) for seven days between P3 and P10, as 
described in Chapter 2 (2.2.2).  Following treatment, mice remained with their mothers until 
weaned at P21. We then performed behaviour testing before and after the peak period of 
seizures, where we performed video seizure monitoring. Mice were euthanised at the end of the 















Figure 3.2: Estradiol study timeline. Timeline showing the experimental course of the mouse 
treatment study. Estradiol or vehicle was administered between P3 and P10 (green). Behaviour 
testing (blue) was performed before and after the peak of seizures, and video seizure monitoring 
(purple) was performed between P42 and P56. Spontaneous seizures upon handling were 
recorded across the entire lifespan of the mice (P0 – P70). PA1 mice are consistently 
represented in light orange (vehicle treated) and dark orange (estradiol treated), while PA2 mice 










3.4.2 Estradiol treatment reduces seizure frequency and severity in PA mutant mice. 
To address the hypothesis that 17β-estradiol would reduce seizure severity in Arx PA1 and PA2 
mutant mice, we chose to measure seizure outcomes using two methods; observed seizures 
occurring on handling and recorded across the lifespan of the mice (until P70), and spontaneous 
seizures occurring during non-invasive video monitoring during the peak period of seizures in 
untreated mice (between P35 and P60). An established scoring system was used throughout the 
evaluation of seizures, with a score of 1 applied to rapid, jerky movement around the cage, a 
score of 2 given to myoclonic seizures less than 10 seconds in duration, and a score of 3 given 
to prolonged myoclonic seizures, lasting longer than 10 seconds (Jackson et al., 2017).  
 
Estradiol treatment significantly reduced the overall proportion of adult PA1 mutant mice 
experiencing seizures on handling, with a 32% reduction compared to vehicle treated mice. 
Within the PA2 cohort, a 14% reduction was noted with estradiol treatment (44% versus 58%, 
respectively) but this did not reach significance (p = 0.4243) (Figure 3.3 A). In PA1 mice, both 
the total number of observed seizure events and the number of severe seizures (scores of 3 or 
4) were significantly reduced in estradiol treated animals compared to vehicle treated mutant 
mice. However, this was not significant in the PA2 cohort. (Figure 3.3 B).  
 
Despite these dramatic reductions to the number and severity of observed seizures recorded on 
daily handling of the mice, the age of seizure onset remained unchanged between PA1 mice 
treated with either vehicle or estradiol. The average age of seizure onset in mice treated with 
vehicle was postnatal day 40.78 ± 6.71 (mean ± SEM), compared to postnatal day 44.50 ± 1.50 
in the estradiol treated cohort (Figure 3.4). However, the effect of estradiol on the age of seizure 
onset differed between the two Arx mutations. Estradiol actually accelerated the onset of 
seizures in the PA2 mice, with estradiol treated mice having their first seizure at postnatal day 
26 ± 2.5 (mean ± SEM) (Figure 3.4). These data demonstrate that observed seizures on handling 
the Arx mutant mice are reduced in both severity and frequency with estradiol treatment, 
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however, the specific intragenic mutation produced a differential response to estradiol, with 
accelerated epileptogenesis in PA2 mice compared to PA1. Mice observed having a seizure 
upon daily handling that subsequently went on to die from a presumed seizure (found dead in 
their cage) within 2-4 days of having seizure are shown as stars on Figure 3.4. Interestingly, 
two of the three PA2 mice treated with estradiol in this category died during this early time 
point, whilst the third mouse died after a subsequent seizure at a later time point (P56). Within 
the PA2 vehicle cohort, five mice were found dead between P12 and P25 but none of these mice 
were recorded as having an observed seizure on handling during this period.  However, we 
cannot rule out that seizures may have occurred outside of the times we were handling and 
observing the animals as part of daily health checks (P3 to P70) or outside the times captured 
by video seizure monitoring during P35 to P60.  
 
In untreated mutant mice the peak of observed seizures clustered between P35 and P60 (Jackson 
et al., 2017). To exclude any influence of induced stress due to handling of the mice, we 
investigated seizures in a spontaneous setting via non-invasive video monitoring (12 hours per 
mouse over a period of four days) during this peak period. At P45 to P48, 36% (4/11) of PA1 
mice treated with vehicle displayed a large number of clusters of individual seizure events 
ranging from rapid, jerky movement around the cage (score 1) through to severe myoclonic 
seizures of increasing duration (score 2 and 3) (Figure 3.5). Although 30% (3/10) of the 
estradiol treated PA1 mice displayed seizures across this same period of time, both the number 
and severity of seizure events were significantly reduced (Figure 3.5). This trend is even more 
striking in the PA2 cohort; 33% (4/12) of vehicle treated mice displaying a total of 28 seizure 
events across all scoring categories, compared to seizures being completely absent in the 
estradiol treated mice (0/7) during this same monitoring period (Figure 3.5). Further, when 
looking at the observed seizures on handling that PA2 mice experienced, only one mutant 
mouse treated with estradiol experienced seizures during this same period of time. We observed 
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that there were no seizures in vehicle or estradiol treated wild-type mice by either the observed 
















































Figure 3.3: Early estradiol treatment diminishes observed seizure severity and frequency 
in PA mutant mice. PA1 and PA2 mutant mice exhibit reduced seizure frequency (A) and 
seizure severity (B) when treated with estradiol compared to their vehicle treated counterparts 
(percentage seizure occurrence – percentages do not include repeated seizures from the same 
mouse). (B) Shows increasing seizure severity with darker shade of grey (key). (PA1: (A) two-
tailed t-test, p<0.0001, df = 70; (B) Chi square test, p = 0.0036, df = 11.26, 2)). Analysis across 
five separate breeding rounds each for PA1 mice (estradiol; n = 14; dark orange (dashed line); 
vehicle; n = 13 light orange (solid line)) and PA2 mice (estradiol; n = 16; dark blue (dashed 
line) vs vehicle; n = 19; light blue (solid line)). # p<0.05 indicates significant difference between 
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Figure 3.4: Estradiol treatment did not delay the age of first observed seizure in PA 
mutant mice. Estradiol treatment did not delay the age of first seizure in either mutant strain 
(PA2: two-tailed t-test, p = 0.0002, F = 1.463 (10,7), df = 17). Mice marked with a star died of 
a seizure (found dead in cage) within 2-4 days of having an observed seizure on handling. 
Median ± min/max is presented for PA1 and PA2 mice from vehicle and estradiol treatment 
groups. Each dot represents an individual animal at the age of their first seizure. Analysis across 
five separate breeding rounds each for PA1 mice (estradiol; n = 14; dark orange; vehicle; n = 
13 light orange and PA2 mice (estradiol; n = 16; dark blue; vehicle; n = 19; light blue. # p<0.05 
indicates significant difference between estradiol and vehicle treated animals across the 













































Figure 3.5: Seizure severity and frequency are reduced in PA mutant mice treated with 
estradiol. PA1 and PA2 mice exhibit reduced seizure frequency and severity when treated with 
estradiol (PA1; n = 10; dark orange) (PA2; n = 7; dark blue) compared to their vehicle treated 
counterparts (PA1; n = 11 light orange) and (PA2; n = 12; light blue). Each dot represents an 
individual seizure event measured during 12 hours of video footage per mouse. Increased 
seizure scores increase with severity from “no seizure” (0) to “prolonged myoclonic seizure” 
(3) on the Y-axis. # indicates significant difference between estradiol and vehicle treated PA 
mice (one-way ANOVA, Tukey’s HSD post hoc analysis, F (3, 135) = 11.28, p<0.0001). 
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3.4.3 Estradiol treatment does not improve mortality in PA mutant mice 
Despite the significant improvements in frequency and severity of seizures in both the PA1 and 
PA2 mutant mice treated with estradiol, the median survival rates of these animals were not 
significantly extended compared to vehicle treated animals (Figure 3.6). Survival was recorded 
from P0 to P70. These data excluded mice that were cannibalised by their mother prior to P10 
as this occurred in both WT and mutant mice and was not considered to be due to the mutant 
phenotype. Mice still alive at the completion of the experimental period were culled at P70. 
Considering the animals that died before the experimental end point at P70, 62% of PA1 mice 
treated with vehicle died compared to 64% treated with estradiol (Figure 3.6). Similarly, 37% 
of PA2 mice treated with vehicle died before the experimental end point at P70, compared to 
31% treated with estradiol (Figure 3.6). The mean age of death (excluding survival to end point 
cull) in vehicle treated compared to estradiol treated mutant mice was not significantly different 
for either PA1 or PA2 mice; PA1 vehicle treated mice 53 ± 5.1 (mean ± SEM) compared to 52 
± 5.5 in PA1 estradiol treated mice, with PA2 vehicle treated mice was 45 ± 4.6, compared to 
37 ± 5.2 in PA2 estradiol treated mice (Figure 3.7). While it appeared that PA2 mice treated 
with estradiol may exhibit a faster rate of death compared to their vehicle treated counterparts, 










































Figure 3.6: Early estradiol does not improve mortality in PA mutant mice. Estradiol did 
not improve mortality in either PA1 or PA2 mice. Analysis across five separate breeding rounds 
each for PA1 mice (estradiol; n = 14; dark orange (dashed line) vs vehicle; n = 13 light orange 
(solid line)) and PA2 mice (estradiol; n = 16; dark blue (dashed line) vs vehicle; n = 19; light 
blue (solid line)). There were no WT mice treated with vehicle and estradiol that died during 






















































Figure 3.7: Age of death in PA mutant mice treated with vehicle or estradiol. PA1 and PA2 
mice treated with estradiol (PA1; n = 13; dark orange) (PA2; n = 18; dark blue) do not exhibit 
any improvement to age of death when compared to their vehicle treated counterparts (PA1; n 
= 14; light orange) (PA2; n = 21; light blue). Individual dots represent individual mice 






3.4.4 Body and tissue weights are unaffected by estradiol in PA mutant mice 
Further to our seizure and mortality findings, we confirm in this study that compared to WT 
littermates, the PA mutant mice have reduced testes weight and reduced body weight, consistent 
with previous reports (Kitamura et al., 2009, Jackson et al., 2017). Here we demonstrate that 
there were no improvements to the reduced body weight of mutant mice compared to WT 
littermates with estradiol treatment (significance tested and shown at four different stages of 
their lifespan) (Figure 3.8).  
 
Cortex and testes were collected from PA1, PA2 and WT mice treated with estradiol or vehicle 
upon euthanisation at P70. These tissues were weighed for analysis. Similarly, there was no 
change to the weight of the testes or brain in WT, PA1 or PA2 mice following estradiol 
treatment (Figure 3.9). However, we demonstrated that PA1 and PA2 mutant mice have 

































































Figure 3.8: Body weights of PA mutant mice treated with vehicle or estradiol. PA1 and 
PA2 mice treated with estradiol (PA1; n = 13; dark orange) (PA2; n = 18; dark blue) or vehicle 
(PA1; n = 14; light orange) (PA2; n = 21; light blue) do not exhibit any improvement to body 
weight through the duration of the study (postnatal day 0 to postnatal day 70), compared to their 
WT littermates, treated with either estradiol (n = 30; dark grey) or vehicle (n = 23; light grey). 
Data is shown at mean weight on each day of the study ± SEM. Data analysed across all groups 
in one-way ANOVA, Tukey’s HSD post hoc analysis at each time point. *p<0.05 significance 
compared to WT littermates at postnatal P10 (F (5, 91) = 7.668, p<0.0001), P21 (F (5, 81) = 
14.31, p<0.0001), P45 (F (5, 65) = 7.979, p<0.0001), and P60 (F (5, 44) = 8.797, p<0.0001) 


























































































Figure 3.9: Testes and cortex weights of PA mutant mice treated with vehicle or estradiol. 
Testes (left and right combined) and cortex (left and right combined) were weighed following 
euthanised and tissue collection of mice at postnatal day 70. From WT mice, 27 vehicle-treated 
testes were weighed (light grey) and 18 estradiol-treated testes were weighed (dark grey), and 
26 vehicle-treated cortices were weighed (light grey) and 18 estradiol-treated cortices were 
weighed (dark grey). From PA1 mice, 5 vehicle-treated testes and 5 vehicle-treated cortices 
were weighed (light orange), and 2 estradiol-treated testes and 3 estradiol treated cortices were 
weighed (dark orange). From PA2 mice, 6 vehicle-treated testes were weighed (light blue) and 
4 estradiol-treated testes were weighed (dark blue), along with 7 vehicle-treated cortices (light 
blue) and 4 estradiol-treated cortices (dark blue). * p<0.05 significance compared to WT 
littermates (one-way ANOVA, Tukey’s HSD post hoc analysis; testes data: F (5, 56) = 8.337, 












3.4.5 Behavioural deficits are present in PA mutant mice prior to seizure onset, and do 
not improve with estradiol treatment.  
Both PA1 and PA2 mice have been shown to exhibit increased locomotor activity, abnormal 
anxiety-like behaviour and reduced sociability and autistic-like behaviour at two months of age 
(Kitamura et al., 2009, Jackson et al., 2017). Here we undertook a battery of behavioural tests 
between P30 and P37 (one month of age – prior to peak seizure onset), and again at P56 and 
P70 (two months of age – after peak seizure onset), with and without estradiol treatment. Open 
field, elevated zero maze, Y-maze, three-chambered sociability tests, inverted grid and the 
Barnes maze (two months only), were performed to determine the locomotor, anxiety-like and 
autistic-like behaviour, neuromuscular strength, and memory of PA mutant mice, at one and 
two months of age, to investigate their cognitive function over disease progression, and in 
response to estradiol treatment. 
 
3.4.5.1 Anxiety-like behaviour 
We demonstrated that the anxiety-response in the open field test in PA mutant mice was 
different compared to WT littermates. There was no significant difference in the total distance 
the mice travelled during the five minute duration of the open field test in PA mutant mice 
compared to their wild-type littermates (Figure 3.10 A). We demonstrated that the anxiety-
response in PA mutant mice was different compared to WT littermates and did not regress over 
the duration of the study. At two months of age, WT littermates displayed normal exploratory 
behaviour with an average of 84% (vehicle) and 80% (estradiol) of the total distance travelled 
in the open field periphery. Contrary to this, PA1 mutant mice spent significantly more time in 
the periphery versus the central field of the open field apparatus, with an average of 91% 
(vehicle) and 96% (estradiol) (Figure 3.10 B). This was also observed in the PA2 cohort, in 
both treatment groups with an average of 95% (vehicle) and 93% (estradiol) (Figure 3.10 B). 
These results are indicative of decreased exploratory behaviour in both PA mutant mice 
compared to WT littermates, with increased anxiety-like behaviour (increased fear of venturing 
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into the central field, choosing to stay in the safety of the periphery). These differences are 
shown in the tracking maps from the respective genotypes in the open field test (Figure 3.10 
C). We also analysed the time PA mutant mice spent immobile during the test, to determine if 
this was the cause of decreased distance in the periphery. There was no significant difference 
in the time immobile versus mobile in PA mutant mice compared to their WT littermates, with 
or without treatment. There were no significant differences observed between the two ages 
sampled in either PA mutant cohort, indicating there was little change due to disease 
progression or age of the mice in either genotype. This data indicates that early estradiol 
treatment did not improve anxiety or fear behaviour in adult PA mutant mice. 
 
The elevated zero maze was also used to investigate anxiety-like behaviour in PA mutant mice. 
As with the open field test, there was no significant difference observed in the total distance PA 
mutant mice travelled during the five minute duration of the test, indicating no deficits in total 
activity during the testing period compared to WT mice (Figure 3.11 A). We showed no 
significant differences in the outcomes of this test, even having previously shown a deficit to 
fear response and anxiety-like behaviour in untreated PA1 and PA2 mice using this apparatus. 
Mice with an altered anxiety or fear response tend to spend more time in the closed arms of the 
test, fearing the open spaces. We observed no significant differences in the time PA mutant 
mice spent in the open versus the closed arms of the test at either one or two months of age with 
no difference due to estradiol treatment (Figure 3.11 B). There appeared to be a trend towards 
less head dips in PA1 mice treated with vehicle compared to WT mice, indicative of reduced 
exploratory behaviour (Figure 3.12). However, this was not significant, possibly due to the 
broad range in the number of head dips recorded in mice during this test, indicated by the large 



















































































% distance in periphery 
* * * * * * * * 
1 2 1 2 
1 2 1 2 
115 
 
Figure 3.10: Estradiol does not improve anxiety-like behavioural deficits in PA mutant 
mice. Anxiety-like and fear response behaviour was measured using the open field test. (A) 
The total distance the mice travelled in the open field apparatus during the duration of the test 
at one month and two months of age. (B) The percentage of the total distance travelled that the 
mice spend in the periphery of the open field test measured in distance (m) is shown at one 
month and two months of age. WT mice treated with vehicle (n = 17/12; light grey) and estradiol 
(n = 8/8; dark grey); PA1 mice treated with vehicle (n = 6/5; light orange) and estradiol (n = 
4/3; dark orange); PA2 mice treated with vehicle (n = 11/6; light blue) and estradiol (n = 5/5; 
dark blue). *p<0.05 (two-way ANOVA with Tukey’s HSD post hoc analysis; PA1: F (3, 55) = 
14.801, p<0.0001); PA2: F (3, 64) = 24.91, p<0.0001). (C) Representative tracking maps of 
mice travelling in the open field apparatus from wild-type (n = 2; grey), PA1 (n = 1; orange) 










































































































































































































Figure 3.11: PA mutant mice do not exhibit an anxiety-like deficit in the elevated zero 
maze. Anxiety-like and fear response behaviour was measured using the elevated zero maze. 
(A) The total distance the mice travelled in the elevated zero maze apparatus during the duration 
of the test at one month and two months of age. (B) The percentage of the total time that mice 
travelled in the open arms or closed arms of the elevated zero maze, measured in seconds (s) is 
shown at one month and two months of age. WT mice treated with vehicle (n = 17/12; light 
grey) and estradiol (n = 8/8; dark grey); PA1 mice treated with vehicle (n = 6/5; light orange) 
and estradiol (n = 4/3; dark orange); PA2 mice treated with vehicle (n = 11/6; light blue) and 










































Figure 3.12: PA mutant mice do not show significant differences in number of explorative 
head dips in the elevated zero maze. Anxiety-like and fear response behaviour was measured 
using the elevated zero maze. The number of head dips recorded manually during the duration 
of the elevated zero maze at one and two months of age. WT mice treated with vehicle (n = 
17/12; light grey) and estradiol (n = 8/8; dark grey); PA1 mice treated with vehicle (n = 6/5; 
light orange) and estradiol (n = 4/3; dark orange); PA2 mice treated with vehicle (n = 11/6; light 



































































































































3.4.5.2 Autistic-like behaviour 
Sociability testing measures several behavioural traits seen in mouse autism models. The mouse 
being tested is placed in a central chamber, with an empty chamber on one side and a chamber 
containing another mouse in the other. The time spent interacting with the other mouse is 
measured (sociability). The next phase of the test includes placing a novel mouse in third 
(previously empty) chamber. The time the test mouse then spends interacting with this new and 
novel mouse (social novelty: novel) is compared to the time spent interacting with the existing 
or familiar mouse (social novelty: familiar). As expected, WT littermates chose to interact with 
another mouse over an inanimate object (empty chamber) (sociability phase: Figure 3.13), and 
then chose to interact with novel (or stranger) animal over the familiar (or known) animal 
(social novelty phase: Figure 3.14). This pattern of behaviour is indicative of normal social 
interaction and memory recall. In contrast, the PA1 mutant mice of both vehicle and estradiol 
treatment groups showed significantly reduced sociability (Figure 3.13) and social novelty 
(Figure 3.14) compared to WT mice. The interaction times with other mice in the test chambers 
were reduced, regardless of whether the mouse occupant was novel or familiar. This 
behavioural deficit was the same for PA2 mutant mice. There was no significant difference 
between the two age points in either PA cohort, indicating reduced sociability was already 
present at one month of age and did not change with disease progression or age. 
 
Interestingly, in PA1 estradiol treated mice there was a significant difference between the time 
spent interacting with both stranger and familiar mice in the social novelty phase compared to 
vehicle treated mice, but only at one month of age. Similarly, PA2 mice treated with estradiol 
spent an increased amount of time interacting with stranger and familiar mice compared to their 
vehicle treated counterparts, but this was only significant at two months of age. This may 
indicate small improvements to social cognitive behaviour in PA mice treated with estradiol, 
however, the samples sizes for these groups were small, and given the similarities in phenotype 
between PA1 and PA2 mice in this test, we combined PA1 and PA2 mice to create a PApool 
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group (green) for these measures to strengthen our findings. We demonstrated that PApool 
mutant mice of both vehicle and estradiol treatment groups showed significantly reduced 
sociability (Figure 3.15) and social novelty (Figure 3.16) compared to WT mice. Again, the 
overall time interacting was reduced in mutant mice, regardless of whether it was with the 
stranger or familiar mouse. There was no significant difference between the two time points in 























































































Figure 3.13: Estradiol does not improve social deficits in PA mutant mice. Autistic-like 
behaviour was measured using the sociability test. Social interaction of PA mutant mice at one 
and two months of age was measured by the time in seconds (s) the mice spent interacting with 
a stranger mouse. WT mice treated with vehicle (n = 15/9; light grey) and estradiol (n = 8/6; 
dark grey); PA1 mice treated with vehicle (n = 6/4; light orange) and estradiol (n = 3/2; dark 
orange); PA2 mice treated with vehicle (n = 9/5; light blue) and estradiol (n = 5/4; dark blue).  
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Figure 3.14: Estradiol does not improve social preference deficits in PA mutant mice. 
Autistic-like behaviour was measured using the social novelty test. Social interaction of PA 
mutant mice at one and two months of age was measured by the time in seconds (s) the mice 
spent interacting with either a stranger or familiar mouse. WT mice treated with vehicle (n = 
15/9; light grey) and estradiol (n = 8/6; dark grey); PA1 mice treated with vehicle (n = 6/4; light 
orange) and estradiol (n = 3/2; dark orange); PA2 mice treated with vehicle (n = 9/5; light blue) 
and estradiol (n = 5/4; dark blue).  *p<0.05 (one-way ANOVA with Tukey’s HSD post-hoc 
analysis of PA mutant mice compared to WT). # indicates significant difference between PA 
mutant mice treated with either vehicle or estradiol. *p<0.05 (PA1; two-way ANOVA, F (3, 











































































Figure 3.15: Estradiol does not improve social deficits in PApool mutant mice. Autistic-like 
behaviour was measured at one and two months of age by the time in seconds (s) the mice spent 
interacting with a new mouse in the sociability test. WT mice treated with vehicle (n = 15/9; 
light grey) and estradiol (n = 8/6; dark grey); PApool mice treated with vehicle (n = 15/9; light 
green) and estradiol (n = 8/6; dark green). *p<0.05 (two months; one-way ANOVA, F (3, 26) 
= 21.85, P<0.0001).  
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Figure 3.16: Estradiol does not improve social preference deficits in PApool mutant mice. 
Autistic-like behaviour was measured at one and two months of age by the time in seconds (s) 
the mice spent interacting with a familiar mouse (white bars) or stranger mouse (coloured bars) 
in the social novelty test. WT mice treated with vehicle (n = 15/9; light grey) and estradiol (n = 
8/6; dark grey); PApool mice treated with vehicle (n = 15/9; light green) and estradiol (n = 8/6; 
dark green). *p<0.05 (two months; two-way ANOVA, F (3, 52) = 13.44, P<0.0001). 
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3.4.5.3 Learning and memory 
Spatial learning and memory were assessed in PA mutant mice using two different behavioural 
tests; Y-maze and Barnes maze. Y-maze assesses short-term memory while the Barnes maze 
assesses the learning and memory of mice over a one week duration. In the Y-maze, mice were 
exposed to one arm of a Y-shaped apparatus, which became the familiar arm to the mice. After 
30 minutes, mice were re-exposed to the Y-maze, with both arms open for them to explore. The 
time that the mouse spends in the familiar or novel arm is then assessed, with WT mice usually 
preferring to spend more time exploring the novel arm. The arms of the Y-maze have shapes 
on them to assist the mice in remembering which the familiar and novel arms are. 
 
Interestingly, when looking at the total distance mice travelled during the duration of the final 
exploration of testing in the Y-maze, there were groups of PA mutant mice that travelled 
significantly more distance than WT mice, possibly indicative of hyperactivity in the PA 
cohorts (Figure 3.17 A). A memory deficit in the Y-maze in untreated PA1 and PA2 mutant 
mice has been reported previously (Jackson et al., 2017). In this study however, we did not see 
a significant difference between the time the mutant mice spent in the familiar arm versus the 
novel arm compared to their WT littermates, at either one or two months of age (Figure 3.17 
B). There was also no significant difference in the time spent in each arm between mice treated 
with either vehicle or estradiol (Figure 3.17 B). These results indicated no deficits in short-term 
memory in PA mutant mice either before or after the peak of seizure onset.  
 
To assess the impact of treatment on cognition and learning, the Barnes maze tested the amount 
of time each mouse required to locate an escape hole (in relation to false holes) in the testing 
apparatus, with improving or shorter times gained during subsequent testing. This test is 
conducted at two months of age. All groups tested showed normal adaptive function and 
memory, demonstrating shorter times to find the escape hole over a progressive four-day testing 
period (Figure 3.18). This was shown through a multi-way ANOVA using mixed effects for 
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multiple comparisons. We found that when analysing four groups together (WT and PApool 
from each treatment), there was a significant difference in latency to find the escape hole 
between days 1 and 4 of testing (p = 0.0003). However, while this tells us that the mice are 
learning in this test, we are not seeing any difference due to genotype or treatment. Although 
we have previously demonstrated a memory deficit when testing via the Barnes maze in 
untreated PA mutant mice (Jackson et al., 2017), in the current trial we did not detect a 
significant difference between the PA mutant mice of either treatment group and their WT 
littermates. This difference is likely due to the limited numbers of animals achieving the age 
required to perform this test. Of note, there was no difference in the performance of WT or 
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Figure 3.17: PA mutant do not exhibit a short-term memory deficit in the Y-maze. Short-
term memory and exploratory behaviour were measured using the Y-maze. (A) The total 
distance the mice travelled in the Y-maze during the duration of the test at one month and two 
months of age. (B) The percentage of total time travelled that the mice spent in either the 
familiar or novel arms of the Y-maze, measured in seconds (s) is shown at one and two months 
of age. (C) WT mice treated with vehicle (n = 17/12; light grey) and estradiol (n = 8/8; dark 
grey); PA1 mice treated with vehicle (n = 6/5; light orange) and estradiol (n = 4/3; dark orange); 
PA2 mice treated with vehicle (n = 11/6; light blue) and estradiol (n = 5/5; dark blue). *p<0.05 
(two-way ANOVA with Tukey’s HSD post hoc analysis; PA1: F (3, 56) = 8.303 p=0.0001); 
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Figure 3.18: PA mutant mice do not display learning and memory deficits in the Barnes 
maze. Learning and memory was measured using the Barnes maze at two months of age only. 
The latency to find the escape hole was measured in seconds (s) across a four-day testing period. 
Mice were measured from WT treated with estradiol (n = 10; dark grey) or vehicle (n = 8; light 
grey) with A) PA1 and PA2 mice were combined as a PApool group. PApool treated with estradiol 
(n = 6; dark green) or vehicle (n = 6; light green). B) PA1 mice treated with estradiol (n = 4; 
dark orange) and vehicle (n = 2; light orange). C) PA2 mice treated with estradiol (n = 4; dark 






















3.4.5.4 Neuromuscular strength 
We chose to test neuromuscular strength due to the prominent phenotype of dystonia, 
particularly in the hands, of PA2 patients. The impact of Arx genotype and 17β-estradiol 
treatment on the neuromuscular strength in PA mutant mice was determined using the inverted 
grid test, at two months of age. WT littermates decreased latency to fall from the grid averaged 
76 seconds (vehicle) and 90 seconds (estradiol) compared to PA1 mice with 25 seconds 
(vehicle) and PA2 mice for 23 seconds (estradiol) (Figure 3.19 A). Pooling the data for the 
mutant mice (PApool group) to increase the sample size, both vehicle and estradiol had 
significantly decreased latency to fall from the grid compared to their respective WT groups 































































Figure 3.19: PA mutant mice display reduced neuromuscular strength. Neuromuscular 
strength measured using the inverted grid test at two months of age (one-way ANOVA, F (3,31) 
= 7.920, P=0.0005). The latency for mice to fall from the inverted grid was measured in seconds 
(s). WT mice treated with vehicle (n = 11; light grey) and estradiol (n = 7; dark grey); PA1 mice 
treated with vehicle (n = 6; light orange) and estradiol (n = 3; dark orange); PA2 mice treated 
with vehicle (n = 4; light blue) and estradiol (n = 4; dark blue). In the second graph, PA1 and 
PA2 mice were combined as a PApool group. WT mice treated with vehicle (n = 11; light grey) 
and estradiol (n = 7; dark grey); PApool mice treated with vehicle (n = 10; light green) and 













3.5.1 Reproducibility of phenotypic outcomes in different mouse models 
Here we present a comprehensive seizure and behavioural assessment of the impact of early 
postnatal estradiol treatment on the development of seizures in mice modelling the two most 
common ARX polyalanine expansion mutations. Our data demonstrates that despite the 
sustained benefit of short term 17β- estradiol treatment early in postnatal life on the frequency 
and severity of seizures in both PA1 and PA2 mutant mouse models, there were no significant 
improvements to survival, anxiety, sociability, cognitive or neuromuscular deficits in treated 
mice in adult life. 
 
Importantly, our data provides support for reproducible anti-epileptogenic outcomes previously 
reported in a comparable Arx PA1 mutant mouse, studied on a different genetic background 
(Olivetti et al., 2014). We have characterised the reduction in seizure frequency and severity in 
both PA mutant mice using a scoring matrix via video monitoring correlated to video-EEG 
(Jackson et al., 2017). Here we expand these findings to indicate that short term, early 17β-
estradiol administration also reduced seizures in the PA2 mutant mouse that models the most 
frequently reported polyalanine tract expansion mutation in ARX patients. The findings from 
our study also demonstrates that behavioural deficits in these models are present prior to seizure 
onset, and that seizure onset does not appreciably exacerbate deficits to intellectual and adaptive 
functioning or autistic-like behaviour, at least in these genetic mice modelling Arx mutations.   
 
There were some interesting outcomes from our seizure analysis approach that require 
addressing. Unsurprisingly, there was a stark difference in the outcomes of seizures recorded 
on handling of the mice, compared to seizures recorded during video seizure monitoring. 
Seizures recorded on handling are likely to be higher due to the impact of stress on the mice. 
While measures are taken to make weighing and observing have minimal impact on the mice, 
it is still time away from their home environment in the hands of a human observer. Video 
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seizure monitoring on the other hand allows the mice to remain in a home cage environment 
with their littermates for a portion of time, a much less stressful situation. This allows a more 
“natural” occurrence of seizures, so that we may determine a truer incidence of frequency.  
 
There was also a surprising increase in the occurrence of observed seizures in estradiol treated 
PA2 early in postnatal life compared to their vehicle treated counterparts, whereas treated PA1 
mice had no difference in the onset of observed seizures. It is possible that estradiol treatment 
can induce seizures in specific situations and studies, however these differences are usually 
observed in females (Hom et al., 1993, Velíšková, 2006, Younus and Reddy, 2016, Azcoitia et 
al., 2019). There was no increase in seizure occurrence in PA2 mice with estradiol treatment in 
our seizure monitoring results, however this is performed at approximately 1.5 months of age. 
It is difficult to determine the reason for this increase in seizure onset PA2 mice, but this result 
may be limited by the caveats of recording seizures on handling as described above.  
 
 
3.5.2 Relating behavioural testing to patient phenotypes 
The battery of behavioural tests performed in my study builds on our extensive phenotyping of 
these mice (Jackson et al., 2017) and assesses a variety of different behavioural domains. The 
open field and elevated zero maze measure anxiety-like behaviour, the Y-maze measures 
exploration, the sociability test measures aspects of social cognition, the Barnes maze measures 
spatial learning, and the inverted grid measure motor deficits and neuromuscular strength 
(Wahlsten, 2011).  These behavioural domains align closely with behavioural deficits reported 
in patients with expansion mutations in ARX. For example, in a cohort of French patients 
carrying the dup24 mutation in PA2 deeply phenotyped hyperactivity was detected in 47.6% of 
patients (Dubos et al., 2018). In the Y-maze, we found that both PA1 and PA2 mice spent 
significantly more time moving during the test than their wild-type littermates, leading to a 
higher total distance travelled, a measure of hyperactivity. Dubos et al. also demonstrated that 
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only 14.3% of PA2 patients were assessed as “calm”, with 19% having a diagnosis of severe 
anxiety (Dubos et al., 2018). In our mice we show that PA2, and PA1 mice, display anxiety-
like behaviour in the open field test, with mice spending more time in the periphery, indicative 
of increased fear. We also found strong evidence for reduced social cognition in PA mutant 
mice. In agreement, only 56.3% of PA2 patients displayed what is described as adequate 
interpersonal relationships, defined by the Vineland Adaptive Behavioural Scale (Dubos et al., 
2018). Other studies on PA2 patients have reported deficits in social behaviour, autism 
spectrum disorder, severe developmental delay and mental retardation, emotional instability, 
self-aggression and language delays (Bienvenu et al., 2002, Stromme et al., 2002, Partington et 
al., 2004, Gestinari-Duarte Rde et al., 2006, Reish et al., 2009). Hence, anxiety-like and 
hyperactivity behaviour and social behaviour in the PA mouse models closely mimics 
phenotypes in the ARX PA2 patients. We contend that the PA mutant mice provide a useful tool 
to examine the effectiveness of treatments on behaviour. Interestingly, many studies into the 
clinical phenotypes of PA1 patients lack the detailed reports of behavioural phonotypes, likely 
due to a combination of severe intellectual disability phenotypes and limited affected patient 
numbers. This lack of deep phenotyping of PA1 patients makes it difficult to compare the 




3.5.3 No change to the survival of mice with estradiol treatment 
Despite a striking reduction in the frequency and severity of seizures there was no improvement 
to mortality of either PA1 or PA2 mice with estradiol treatment. We report that there was no 
statistical difference in the numbers of estradiol and vehicle treated PA1 or PA2 hemizygous 
male mice that were found dead. This was a novel finding. The cause of death could not be 
confirmed by post-mortem examination due to the timing of death occurring overnight. 
However, death due to a seizure can be hypothesised when deceased mice show extension of 
the hind legs, a marker of death according to a modified Racine scale (Butler et al., 1995).  On 
examination in the mornings, we could not contribute death to any obvious cause. While the 
immediate cause of death in PA mutant mice is unclear, the lack of progressive deterioration 
and presence of convulsive seizures suggests that sudden unexpected death in epilepsy 
(SUDEP), or prolonged status epilepticus, is a possible diagnosis. Although 17β-estradiol 
treatment decreased the frequency and severity seizures in mutant PA Arx mouse models, the 
residual amount of seizures still present particularly evident upon handling, could account for 
the premature mortality in these mice. 
 
3.5.4 Behavioural deficits are present prior to seizure onset 
The distribution of IQ scores in children with epilepsy and infantile spasms are often skewed 
to lower values, and patients experience difficulties learning in school, or regress in mental 
development (Farwell et al., 1985, Neyens et al., 1999, Prasad et al., 2014). However, it can 
often be difficult to elucidate how much of a child’s intellectual disability was pre-existing and 
how much was caused by epilepsy in key periods of brain development (Nabbout and Dulac, 
2003). In the case of genetic conditions in which intellectual disability is an invariable feature, 
such as ARX mutations, determining the impact of persistent and severe seizures, particularly 
early in childhood and infancy, upon cognitive function remains challenging. A cardinal finding 
of our study is the relative differential response of seizure severity compared to behavioural and 
cognitive deficits following estradiol treatment. We predicted that seizure onset would lead to 
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a worsening of cognitive and behavioural impairments in the PA1 and PA2 mutant mice. An 
extension of this prediction would be that 17β-estradiol treatment alleviating seizures might 
improve cognitive and behavioural deficits. In contrast to our predictions, we demonstrate that 
behaviour did not improve with alleviation of seizures and that the deficits were already present 
before and did not decline further after the point of seizure onset. This provides important 
evidence separating the impact of seizures upon behavioural deficits in PA1 and PA2 mice. 
 
An epileptic encephalopathy is defined as a condition where seizures or frequent interictal 
discharges exacerbate neurocognitive dysfunction beyond what would be expected on the basis 
of underlying aetiology (Nickels and Wirrell, 2017). This occurs in intractable epileptic 
disorders that start early in life, such as Ohtahara syndrome (OS), also known as Early Infantile 
Epileptic Encephalopathy (EIEE). Infants with these severe epileptic encephalopathies 
generally present with poor cognitive outcomes, with profound intellectual disability in 50% of 
patients if they survive severe spasms and seizures in infancy. These disorders have many 
different genetic aetiologies. Both of these conditions are reported in patients with expanded 
polyalanine tract mutations in ARX (Shoubridge et al., 2010, Marques et al., 2015). Closer 
examination of the clinical spectrum in patients with ARX mutations in the first polyalanine 
tract (100% of who had seizures), indicates that developmental delay is reported in 25% of 
cases. The onset of seizures spanning from 0 to 18 months of age (median 4 months). 
Furthermore, only 26% of individuals with expansions of the second polyalanine tract exhibit 
seizures, despite 100% of these patients having intellectual disability (Jackson et al., 2017). Our 
findings on the broader behavioural phenotypes of PA1 and PA2 mice support the idea that the 




3.5.5 Estradiol and cognition and behaviour 
In this study we demonstrated that estradiol did not improve behavioural and cognitive 
outcomes in PA1 or PA2 mice. Studies predict that estradiol exerts pro-cognitive effects 
through two mechanisms; by enhancing synaptic plasticity, and inducing long-term potentiation 
of NMDA receptors (Gould et al., 1990, Woolley and McEwen, 1992, Woolley and McEwen, 
1994, Smith et al., 2016). However, to this date, no studies have shown an effect on intellectual 
disability with estrogen. In fact, many studies on the cognitive effects of estradiol are focused 
on the complete abolition of estrogens by ovariectomy in female mice. When menopause is 
induced in female mice, spatial memory performance in the Y-maze is impaired. Long-term 
estradiol treatment then recovered this cognitive deficit (Schroeder et al., 2017). In a surgical 
menopause rat model, seven months of estradiol treatment also had benefits to spatial memory 
(Koebele et al., 2020). These studies however are difficult to compare to our experiments, as 
they show that a baseline level of estrogen in female rodents is key to normal cognition, rather 
than supplementing the existing estrogens in the brain with a lower dose such as the 40ng/g 
given to our PA mutant mice. 
 
In general, few studies have been conducted on the effects of estradiol treatment in non-
ovarectomised, female rodent models. Estradiol treatment has been explored in an induced 
Alzheimer’s disease model, where estradiol given in the early stages of pathogenesis 
ameliorated memory impairment (tested using the Morris water maze) and restored numbers of 
depleted hippocampal neurons (Zheng et al., 2017). This treatment was given over a 60 day 
period in a continuous release pellet. A further study investigated the effects of knocking out 
estrogen receptor β (ERβ) in the nervous system, on behaviour in male mice. ERβ abolition 
resulted in decreased social interaction and aggressive behaviour, as well as increased 




Estradiol, 17β-estradiol in particular, has been shown to have strong anti-inflammatory action 
in the brain, by stimulating a non-genomic, signalling cascade that inhibits the translocation of 
the nuclear factor kappa (NF-kB) transcription factor, which activates inflammatory genes 
(Ghisletti et al., 2005). This might indicate that any effects estradiol is having on cognition in 
inflammatory diseases such as Alzheimer’s disease, is possibly due to its anti-inflammatory 
properties. Estradiol has been shown to have positive influences in other inflammatory 
neurological diseases, such as Parkinson’s disease, schizophrenia and multiple sclerosis (Pozzi 
et al., 2006). We did not see any effects of estradiol treatment on social, memory or locomotor 
outcomes in our cohort. The phenotype of Arx mutations are not associated with an increase of 
inflammation in the brain. This could be the reason for estradiol not eliciting positive effects on 
behavioural deficits in our models. When considering these studies, it is also possible that in 
our study, estradiol was not given for a long enough duration of time for behavioural effects to 
become apparent, or at a high enough dose to improve behavioural deficits. The behavioural 
deficits in PA mutant mice, particularly in social interaction, may also be too severe to expect 
an improvement with short term estradiol treatment. The mechanisms behind estradiol and 
cognition in male mice, remain unclear, and requires further investigation.  
 
3.5.6 Reproducibility of behaviour testing outcomes 
We have previously demonstrated a memory deficit in the Barnes maze and the Y-maze in 
untreated PA mutant mice (Jackson et al., 2017). However, in this study, we did not detect any 
differences between PA1 and PA2 mice and their WT counterparts in either of these behavioural 
tests. This could be due to a number of reasons for each test. 
 
The limited sample size of mice reaching the age required to perform the Barnes maze (two 
months of age), due to the mortality of more severely affected animals meant that many were 
dead prior to the two month time point. This may have resulted in a less robust result from this 
study compared to Jackson et al. (2017).  Untreated PA mutant mice also have a severe 
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phenotype and many die before reaching behaviour testing milestones. In the current work, due 
to the intensive injection protocol in early postnatal life, this limited the number of mice able 
to be tested across different time points. However, numerous studies have examined the 
reproducibility and replicability of behaviour tests in rodents, and despite these two studies 
being performed on the same colonies of mice within the same laboratory, variations between 
studies from the same research groups have been documented before. In our case, it appeared 
that neither WT nor mutant mice seemed to exhibit “learning” in the Barnes maze. This is a 
potential caveat of this test as a measure of cognition in this model, and makes it difficult to 
determine any differences between genotypes in this instance.  
 
Variability in the experimenter has been shown to have an effect on the outcomes of behavioural 
testing. This can include the experimenter’s stress levels or mood, and even body odour (Hånell 
and Marklund, 2014). Increased handling of animals over time, such as over the progression of 
a study, has also been shown to alter behavioural outcomes, as the mice become more 
accustomed to human handling (Hånell and Marklund, 2014). Nevertheless, for this study we 
performed testing across four separate cohorts at different times throughout the study to 
decrease any effects of situational factors such as stress and mood, and variability in the 
experimenter was kept to a minimum, ensuring the same colour clothing was worn, perfumes 
were not used, and handling was kept the same across all rounds of testing.  
 
In a study by Crabbe et al., identical mouse strains and a mutant mouse strain were tested 
simultaneously in three different laboratories (Crabbe et al., 1999). They showed that despite 
their best efforts to keep laboratory environments the same, they found large effects at each site 
on behavioural variables. Six of eight behavioural measures had differing effects based on the 
site of the experiments (Crabbe et al., 1999). Locomotor tests show robust replicability between 
different studies (Wahlsten et al., 2006). Short-term anxiety tests on the other hand have been 
reported to be particularly susceptible to environmental factors, giving different outcomes in 
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behavioural phenotypes of mice (Hurst & West 2010). This may explain the different outcomes 
we observed between tests measuring anxiety-like behaviour in our study, with significant 
results seen in the open field test, but not the elevated zero maze for example. Tests of 
spontaneous behaviour, such as the three-chambered sociability tests, can be considered more 
robust than tests that use hunger or fear as a motivator however, as these tests reduce the stress 
on the animal. All tests used in our study use spontaneous behaviour, with the exception of an 
overhead light which causes the animals to want to “hide” during the open field and elevated 
zero maze.  
 
Despite the variation we observe between the current study and the previous study on untreated 
mice by Jackson and colleagues (2017), all variables were maintained as constant as possible 
in these experiments, shown by reduced variability between individual rounds of behavioural 
testing, indicating that differences between these studies may be due to laboratory factors, or 
potential small genetic differences in the inbred mouse strain, including short DNA repeat 
sequences or copy number variations, which can impact gene expression and hence mouse 
behaviour (Lathe, 2004). It can be argued that having some level of variation between 
behavioural studies is important for improving the validity of behaviour research, as this mimics 




3.5.7 Side effects of estradiol treatment 
During this study, the systemic effects of estradiol on infant male mice, even though given at a 
relatively low dose for a short period of time, were considered. Testes were weighed at postnatal 
day 70 upon euthanisation, and we observed no difference in weight in WT or PA mutant mice 
when treated with estradiol. There was also no impact to testes descent (physically observed) 
in treated mice. We observed no difference in body weight, including no “rescue” of the small 
body weight of PA mutants compared to their WT littermates. This was considered interesting 
given the weight gain and arrested testes descent in the Chachua et al. study in 2016, where the 
same dose of estradiol was given to an induced infantile spasms rat model. It is likely that our 
Arx mutant mouse models and the induced seizure model have different underlying 
pathogenesis and hence a different response to estradiol treatment. The weight difference 
between PA1 and PA2 mutant mice is significant and has been reported previously and may be 
too large to be rescued to WT baseline weight with a short dose of estradiol treatment. Long-
term seizures over the duration of the PA mouse’s lifetime may also be impacting their 










3.6 Study outcomes  
In this study we provide evidence to begin understanding the relationship between seizures and 
cognitive and behavioural deficits in a genetic model of a neurodevelopmental disorder. We 
demonstrated that behavioural and cognitive outcomes did not improve in the Arx PA mutant 
mice, despite significant alleviation of the frequency and severity of seizures achieved with 
early, postnatal estradiol intervention. Behavioural deficits were already present prior to the 
peak onset of seizures in these mice, and did not appear to regress with seizures, providing 
evidence for separating the impact of seizures upon behavioural deficits in Arx expanded 
polyalanine tract mutant mice. Furthermore, we provide reproducible outcomes of seizure 
alleviation in a different PA1 mouse model, as well as the more frequent mutation seen in 
human patients, PA2. Reproducible outcomes are key for finding novel therapies for disorders, 
particularly those with a lack of effective treatments for intellectual disability, behavioural 
impairments and early onset seizures, which remain a therapeutic challenge. This study 
highlights the need to elucidate molecular mechanisms of the intellectual disability phenotype, 
as necessary first steps towards a treatment for neurodevelopmental disorders, as the multiple 


















The deregulated transcriptome in PA1 and PA2 
Arx mutant mice is not restored by early 
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ARX is a transcription factor, which is key to the development and migration of neurons in the 
developing brain. Arx PA mutant mice have deregulated transcriptome profiles in embryonic 
development. It remains unclear to what extent the transcriptome at postnatal day 10 would 
remain deregulated from the downstream effects of a partial loss of Arx expression early in 
development. Further, the impact of early postnatal treatment with estradiol would have on the 
transcriptome of PA1 and PA2 mutant mice remains to be elucidated. At postnatal day 10, 
following completion of seven days of daily delivery of 17β-estradiol or vehicle treatment, 
RNAseq identified 129 genes significantly deregulated (Log2FC >± 0.5, P-value<0.05) in the 
frontal cortex of mutant compared to wild-type mice. When comparing genes deregulated in 
PA mutant mice to wild-type littermates, these were particularly enriched for known genes in 
neurodevelopmental disorders and those involved in signalling and developmental pathways. 
Following completion of seven days of daily delivery of 17β-estradiol, mutant mice had 295 
significantly deregulated genes, with only 23 deregulated genes overlapping between vehicle 
and estradiol treated mutant mice. Estradiol treatment did not “restore” deficits due to the loss 
of function of Arx, but instead acted through a different mechanism to reduce seizure frequency 
and severity in PA1 and PA2 mice. Many of the genes estradiol treatment deregulated were Arx 
responsive genes, and neurodevelopmental disorder associated genes. We conclude that 17β-
estradiol treatment recruits processes and pathways to reduce the frequency and severity of 
seizures in the Arx PA mutant mice but does not precisely correct the deregulated transcriptome 







The Aristaless-related homeobox gene (ARX) [NM_139058.2] (MIM#300382) is known to play 
an important role in the migration and differentiation of inhibitory and excitatory neurons, 
particularly interneurons (Miura et al., 1997, Kitamura et al., 2002, Kitamura et al., 2009, Lee 
et al., 2014). ARX encodes a transcription factor, and regulates the migration of interneurons 
through regulation of gene expression during neurodevelopment. Arx is highly expressed in the 
developing (embryonic) brain during cellular proliferation and the first wave of neuron 
migration from the ganglionic eminence to the developing cortex (Colombo et al., 2007, 
Friocourt et al., 2008, Colasante et al., 2009, Lee et al., 2014).  Although few studies have 
investigated ARX expression in human patients, one study of ARX in patients with expansion 
mutations of the second polyalanine tracts found that there was very strong expression of ARX 
in neuronal progenitor cells of the cortex in the second trimester brain during foetal 
development (Curie et al., 2018). 
 
Given the embryonic expression pattern of Arx, previous investigations focused on disruption 
of the transcriptome in forebrain of PA mutant mice at embryonic day 12.5 (Mattiske et al., 
2016). Mattiske et al. (2016) found 852 genes deregulated in PA1 mice, and 78 in PA2 mice, 
in the developing telencephalon. These genes were enriched in pathways involved in key 
neurodevelopmental processes, such as neuron development, cell adhesion, and neuronal 
membranes. Deregulated genes were also found to be strongly associated with causative genes 
for neurodevelopmental disorders, including intellectual disability, autism and epilepsy, such 
as Twist1 and Hdac4. Other Arx deficient mouse models demonstrate an impact on many critical 
neurodevelopment genes in the key brain regions involved in neuron migration, including other 
neuronal transcription factors such as Ebf1 (Colasante et al., 2009). Our laboratory has also 
demonstrated that there was a delayed migration of calbindin-positive interneurons in the cortex 
of newborn PA mice (Lee et al., 2017). These studies in Arx mouse models show that disruption 
of Arx’s transcriptional regulation activity disrupts critical stages of brain development, 
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particularly in inhibitory interneurons, leading to an imbalance of excitation in the cortex, and 
the subsequent phenotypes of patients and mice.  
 
The preclinical trial in the Price et al. Arx PA1 mouse model, utilising short-term 17β-estradiol 
(E2) given daily in the first postnatal week, alleviated the severe seizure phenotype for an 
extended period, through to adulthood in male mice (Price et al., 2009, Olivetti et al., 2014). 
Estradiol can induce long-term changes in gene expression in the brain via activation of 
estrogen receptors and non-receptor pathways. 17β-estradiol treatment of PA1 mice partially 
restored the interneuron migration deficits in the neocortex, increased populations of 
neuropeptide-Y and calbindin positive interneurons, and impacted the expression of several 
genes normally regulated by Arx (Olivetti et al., 2014). Interestingly, 17β-estradiol also 
changed the expression of genes normally regulated by Arx. Arx represses Ebf3, Lmo1 and 
Shox2 and activates Lhx7, Cxcr4, Cxcr7 and Lgi1 in interneurons (Colasante et al., 2008, 
Mattiske et al., 2016). Gene expression analysis (quantitative real-time PCR) in the brains of 
mutant mice treated with E2, showed that Shox2 expression was decreased, Lgi1 expression 
was up regulated, and Ebf3 expression was repressed (Olivetti et al., 2014). E2 is known to 
have strong transcriptional behaviour in the central nervous system, with signalling mediated 
by classical estrogen receptors, ERα and ERβ, in the nucleus, cell membrane and cytoplasm, as 
well as ER-independent signalling mechanisms (Azcoitia et al., 2019). These signalling 
pathways regulate transcriptional activity in neurons and glial cells (McCarthy, 2008, Azcoitia 
et al., 2019). The findings of this study provide evidence to support the notion of exogenous 
steroids such as estradiol as potential treatment options for infantile spasms and epilepsy. 
However, potential mechanisms of action need to be determined. Exploring how estradiol acts 





The aim of the current study was to generate an unbiased map of mRNA expression changes in 
the cortical transcriptome at P10 due to Arx PA mutations. We first analysed genome wide 
transcriptomic changes using RNA sequencing in the neocortex of PA1 and PA2 mutant mice 
compared to their wild-type littermates. This was to establish the impact of these Arx mutations 
on gene expression in the brain at postnatal day 10. Building on this, we investigated the effects 
of seven days of E2 treatment (postnatal days 3-10) on the transcriptome of the neocortex of 
PA mutant mice at postnatal day 10. Here our comparison was between mutant mice treated 
with either E2 or a vehicle. This strategy was adopted to elucidate the molecular mechanisms 
driving the seizures and intellectual disability due to Arx PA mutations, persisting in early 
postnatal life, and to address if E2 would “repair” the dysregulated transcriptome, or recruit 












4.3.1 PA1 and PA2 mice have a deregulated cortical transcriptome at postnatal day 10. 
To capture the molecular disruptions that persist in early postnatal life contributing to Arx 
associated clinical phenotypes, we undertook transcriptome wide RNA sequencing from brains 
of mice at postnatal day 10. The first consideration was what I will term “genes changed by 
disease”, with mutant mice being compared to wild-type (WT) littermates. Compared to age-
matched, vehicle treated WT mice (n = 6), analysis of PA1 mice (n = 4) revealed 63 genes 
deregulated by Log2 fold change greater than ± 0.5 with a p-value of less than 0.05. The 
majority (65%) of these genes were found at a decreased level of expression compared to WT 
(Table 4.1). PA2 mice (n = 4) demonstrated 80 genes deregulated using the same fold cut-off, 
with 46% of genes having decreased expression when compared to WT mice (Table 4.1). These 
gene lists are outlined in Appendix 4. 
 
Given the highly similar neurological phenotypes between the PA1 and PA2 mice coupled with 
similar reductions in Arx protein abundance (Jackson et al., 2017) and the similar responses to 
estradiol treatment observed in our current study we chose to also analyse the gene expression 
data combining the four males from each of the PA1 and PA2 mice as a single mutant group 
(PApool). This analysis indicates 58 genes are deregulated using the same fold cut-off, with 62% 
demonstrating a decreased level of expression compared to the pooled WT controls (Table 4.1). 
Prior to gene enrichment analysis, we chose twelve genes for biological validation of our RNA 
sequencing approach by gold standard quantitative real-time PCR (qRT-PCR), on a different 
set of mouse cortical samples to those used for RNA sequencing analysis. Of these genes, 100% 






Table 4.1: Number of genes deregulated by disease in PA1, PA2 and PApool mice 
compared to wild-type littermates.  
 
Genes deregulated by disease 
 PA1 PA2 PA
pool
 
vs WT 63 80 58 
↑ 22 (35%) 43 (54%) 22 (38%) 

































Figure 4.1: Overlapping genes deregulated in PA1 and PA2 mutant mice with disease. (A) 
Venn diagram displaying overlap of deregulated genes in PA1 (orange), PA2 (blue) and PApool 
(green) groups, as well as core overlapping genes (yellow).  (B) Graph showing log fold change 
values of genes from the core overlap lists in (A). Key interneuron genes are highlighted in the 
dashed box in (B). 
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There were only fourteen genes deregulated that overlapped in both mutant mice. This equated 
to 22% and 18% of genes deregulated in PA1 and PA2 mice respectively (Figure 4.1 A). Of 
this core overlap group, 57% (8/14) of genes were decreased in expression (Figure 4.1 B). On 
examination, three of the downregulated genes in this core overlap group, Th, Tacr1 and 
Akr1c18, are highly associated with interneuron development and function (Figure 4.1 B). 
Interestingly, the genes in the core overlap group repressed due to disease have a larger change 
in expression (log fold change) than genes with increased expression in this group. 
 
To better understand the profile of genes deregulated by disease at P10, we identified enriched 
genes by comparing deregulated genes in PA1, PA2 and PApool to relevant gene lists (Appendix 
6). To do this, we sought to determine the number of known neurodevelopmental disease 
associated genes, Arx responsive genes and interneuron associated genes enriched in our data 
set, to investigate the functions of the gene expression that was deregulated with PA mutations.  
 
Arx target and responsive genes (that were identified in Mattiske et al. 2016), were significantly 
enriched in the list of deregulated genes in the PApool group (10/58, 17% p<1.288e-5), and in 
each of the PA1 (13/63, 21%, p<7.366e-8) and PA2 groups (9/80, 11%, p<9.641e-4) (Table 4.2). 
Genes known to be associated with autism and intellectual disability (Gene Dx Xpanded Panel 
(GeneDx, 2020)) were significantly enriched in the PApool group (5/58, 12%, p<0.001), as well 
as in the PA2 group (7/80, 11%, p<0.0004067) (Table 4.2). Known epilepsy genes (from 
colleagues in the Neurogenetics Research Program/Professor Jozef Gecz) were not significantly 
enriched in any group of genes deregulated by disease (PA1; 2/63, 3%, p<0.100: PA2; 2/80, 
2%, p<0.343: PApool; 3/58, 5%, p<0.058) (Table 4.2). Furthermore, we found that genes 
containing high-affinity estrogen response elements (EREs) were significantly enriched in the 




Genes associated with inhibitory neuron regulation or development (in house curated reference 
list) were also significantly enriched in the PApool group (10/58, 17%, p<6.957e-16), as well as 
in the PA1 (5/63, 8%, p<8.197e-7) and PA2 groups (8/80, 10%, p<5.649e-8) (Table 4.2). 
Interestingly, the majority of these enriched interneuron genes were downregulated in their 
expression for all three genotypes (PA1, PA2 and PApool) (11/13, 84.6%) (Figure 4.2). These 
included Th and Tacr1, associated with somatostatin positive interneurons, Akr1c18, associated 
with the function and development of parvalbumin interneurons, and Chat, which plays a key 
role in cholinergic interneurons. We contend that reduced expression of these inhibitory neuron 
genes, as well as the genes associated with autism and intellectual disability, are likely 














Table 4.2: Neurodevelopmental disorder and key brain development genes deregulated 
by disease in PA1, PA2, PApool and core overlap gene lists. 
 
 











Figure 4.2: Genes associated with interneurons are downregulated in PA1 and PA2 
mutant mice. Graph showing log fold change values of genes from enriched interneuron genes. 










































































Interneuron genes deregulated with disease
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To extend our consideration of the profile of genes deregulated by PA mutants in early postnatal 
life, we used the Database for Annotation, Visualisation and Integrated Discovery (DAVID) to 
analyse pathways and ontology terms enriched within disease-deregulated transcriptomes. 
Enrichment clusters were ranked by enrichment score, with two clusters overlapping between 
PA1 and PA2 mice: glycoproteins and glycoprotein receptors (Figure 4.3). Other enriched 
functions of note were PI3K-Akt signalling, neurotransmitter biosynthesis, and synaptic 
processes (Figure 4.3). Many of the clusters are associated with brain and neuron development 
or signalling that when disrupted may be predicted to contribute to the phenotypic features of 
the PA mutant mice.  
 
To identify specifically enriched pathways populated by genes deregulated by disease, we used 
the PANTHER (Protein Analysis Through Evolutionary Relationships) Classification System. 
This database allowed us to rank pathways using the p-value calculated by PANTHER 
following the input of lists of deregulated genes. Outcomes were reported as the overlap of 
genes in our data, out of the total number of genes involved in that process (Table 4.3).   In the 
PApool group, six pathways were found to be significant using this tool. Of interest were the 
nicotinic acetylcholine receptor signalling pathway (neuroprotective), the JAK/STAT 
signalling pathway (regulation of cell division and apoptosis), and the 5HT receptor mediated 
pathway (mediating excitatory and inhibitory neurotransmission) (Table 4.3). The JAK/STAT 
pathway was also enriched in genes deregulated in the PA1 mice, and the nicotinic 
acetylcholine receptor signalling pathway was enriched in genes deregulated in PA2 mice 










Figure 4.3: Enrichment analysis of genes deregulated by disease in PA mutant mice. Heat 
map showing significant gene enrichment terms in deregulated genes in PA1, PA2 and PApool 
groups from DAVID cluster annotation analysis. Clusters with enrichment scores of <0.9 are 
not shown. Heat map is based on maximum, minimum and 50th percentile score in data set 











Table 4.3: Pathways enriched through PANTHER analysis in PApool (green), PA1 
(orange) and PA2 (blue) mice.  
Term Overlap P-value Genes 
Nicotinic acetylcholine receptor signalling pathway 3/68 0.00101467 
Chrna2, Chat, 
Myh8 
Vitamin D metabolism and pathway 1/8 0.0229697 Cyp27a1 
JAK/STAT signalling pathway 1/14 0.03985599 Socs1 
Plasminogen activating cascade 1/15 0.04264235 Plaur 
5HT3 type receptor mediated signalling pathway 1/16 0.04542077 Slc6a4 
5HT4 type receptor mediated signalling pathway 1/16 0.04542077 Slc6a4 
Blood coagulation 2/38 0.006381749 Procr, Plaur 
Apoptosis signalling pathway 2/102 0.041129164 Tnfsf10, Atf3 
JAK/STAT signalling pathway 1/14 0.043221871 Stat5a 
Plasminogen activating cascade 1/15 0.046237826 Plaur 























4.3.2 Estradiol treatment targets genes outsides of the deregulated transcriptome of PA1 
and PA2 mutant mice. 
To investigate the impact of estradiol treatment at the transcriptome level, we first analysed WT 
mice treated with vehicle compared to WT mice treated with estradiol. There were 56 genes 
deregulated by Log2 fold change greater than ± 0.5 with a p-value of less than 0.05 in the WT 
cohort when treated with estradiol (Table 4.4). Genes deregulated in the WT mice estradiol 
treatment group that overlapped with the PA mutant groups were removed from subsequent 
analysis of PA1, PA2 and PApool groups (Appendix 7).  This included only four genes in PA1 
and two genes in each of PA2 and PApool that overlapped with WT mice. 
 
The aim of this experiment was to determine the impact of estradiol treatment on PA mutant 
mice, by comparing them to their vehicle treated PA mutant counterparts. Analysis of PA1 mice 
with estradiol treatment compared to PA1 mice treated with vehicle resulted in 124 genes 
deregulated by Log2 fold change greater than ± 0.5 with a p-value of less than 0.05 (Table 4.6). 
The majority (75%) of genes were found to have increased levels of expression compared to 
vehicle treated PA1 mice (Table 4.4). This was in contrast to the smaller response of genes with 
increased expression due to genotype alone (PA1 mice compared to WT (35% upregulated)). 
PA2 mice treated with estradiol treatment compared to PA2 mice treated with vehicle, resulted 
in 158 genes deregulated at the same cut off values (Table 4.4). Estradiol treated PA2 mice, in 
contrast to PA1 mice, showed a larger proportion of genes with decreased levels of expression 
(77%). Again, this differed to the response of gene expression of disease changed genes (PA2 
versus WT mice) having increased or decreased expression (54% versus 46%, respectively). In 
the estradiol treated PApool mice there were 55 genes deregulated by the same cut off, with 64% 
having increased expression (Table 4.4). Genes changed with estradiol treatment are listed in 




We randomly chose nine genes for the validation of our RNA sequencing data, using gold 
standard quantitative real-time PCR. For this biological validation, we used a different set of 
mouse cortical samples than those used for RNAseq analysis, with 44% (4/9), 22% (2/9) and 




Table 4.4: Number of genes deregulated by estradiol treatment and those containing 
estrogen response elements (EREs) in PA1, PA2 and PApool mice compared to wild-type 
littermates. 
 
Genes deregulated by E2 treatment 
 WT PA1 PA2 PA
pool
 
vs VEH 56 124 158 53 
↑ 27 (48%) 93 (75%) 36 (23%) 33 (62%) 
↓ 29 (52%) 31 (25%) 122 (77%) 20 (38%) 
ERE 12 (21%)* 22 (18%)* 22 (15%) 8 (15%) 
 




We next determined if the profile of genes deregulated by estradiol treatment were enriched for 
genes containing estrogen response elements (EREs). To achieve this, I compared genes 
changed with treatment to a list of mouse genes containing high-affinity mouse EREs 
(Bourdeau et al., 2004). ERE-containing genes were significantly enriched in the WT gene list 
(12/56, 21%, p<0.012) and in PA1 mice treated with estradiol (22/124, 18%, p<0.010) but not 
in PApool (8/53, 15%, p<0.190) or PA2 mice (22/158, 15%, p<0.106) (Table 4.4). 
 
The number of genes with altered expression in response to estradiol treatment in PA1 and PA2 
mice was much larger in comparison to genes deregulated by the Arx mutations alone. 
Moreover, there was very little overlap (Figure 4.4). Genes deregulated by estradiol treatment 
were quite different between genotypes, with only small numbers of overlapping genes (8 genes 
in PA1 mice, 12 genes in PA2 mice and 3 in PApool) (Figure 4.4). Interestingly, all of the genes 
deregulated by disease that were also changed with estradiol treatment were deregulated in the 
opposite direction with treatment (Figure 4.5). When we analysed the proportion of genes 
deregulated by estradiol in all three mutant groups (PA1, PA2 and PApool), the response to 
estradiol treatment between these three groups was strikingly different. Only 11 genes 



























Figure 4.4: Overlapping response between the disease deregulated transcriptome and the 
estradiol deregulated transcriptome of PA mutant mice. Venn diagram showing genes 
overlapping between the disease-deregulated transcriptome and the estradiol-treated 
transcriptome of PA1, PA2 and PApool mice.   
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Figure 4.5: Estradiol treatment reverses the expression of genes deregulated by disease in 
PA mutant mice. Table gives numbers of overlapping genes between disease and estradiol 
deregulated transcriptomes of PA mutant mice. Graphs showing the direction of deregulation 
between genes overlapping between disease (light bars) and estradiol (dark bars) changed genes 

























Figure 4.6: Comparison of response size to estradiol treatment in PA mice. Venn diagram 
displaying overlapping genes between the estradiol treated transcriptomes of PA1 (orange), 
PA2 (blue) and PApool (green) mice. List of 11 genes overlapping between the PA1 and PA2 
mutant mouse response to estradiol treatment. 
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Extending the data from genes deregulated by Arx mutations, both neurodevelopmental 
disorder and inhibitory neuron associated genes were enriched in the genes deregulated in 
estradiol treated mice. Genes associated with inhibitory neurons were significantly enriched in 
the list of genes deregulated with estradiol treatment (PApool; 6/55, 11%, p<8.962e-9: PA1; 
7/128, 6%, p<6.424e-8; PA2; 9/161, 6%, p<6.609e-10) (Table 4.5). In contrast to the consistent 
downregulation of interneuron associated genes due to genotype alone, these genes were not 
trending in a particular direction with estradiol, with approximately equal proportions being 
increased or decreased in expression with treatment in PA mutant mice. Genes associated with 
autism and intellectual disability were significantly enriched in all groups treated with estradiol 
(PApool: 9/53, 13%, p<2.083e-5: PA1; 15/124, 10%, p<0.000003: PA2; 10/158, 6%, p<0.016) 
(Table 4.5). Epilepsy associated genes were enriched to a very low level, and variably 
depending upon the mutant group considered (PA1; 6/124, 5%, P<0.014: PApool; 1/53, 2%, 
p<0.431: PA2; 3/158, 2%, P<0.442) (Table 4.5).  
 
Analysis of deregulated genes that overlap with known Arx target and responsive genes 
(Mattiske et al., 2016) showed these were also significantly enriched in genes deregulated by 
E2 treatment in all three genotype; PApool (12/53, 22%, p<1.215e-7), PA1 (15/124, 12%, 
p<1.404e-5) and PA2 (20/158, 12%, p<2.166e-7) (Table 4.5). Interestingly, there were no Arx 
responsive genes deregulated due to disease that were altered by estradiol treatment. This 
suggests that while estradiol treatment is impacting genes that are Arx targets, they are different 
to those that were initially affected by disease. Of note, Twist1 was identified as being 
downregulated in estradiol changed genes in the PApool group. Twist1 has also been identified 
as a key gene deregulated in the forebrain of PA1 and PA2 mutant mice at embryonic day 12.5. 
Dysregulation of the Arx-Hdac4-Twist1 pathway was predicted to contribute to phenotypic 
outcomes, with Twist1 thought to be a facilitator for a portion of genes deregulated in PA mutant 
mice (Mattiske et al., 2016). 
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Table 4.5: Neurodevelopmental disorder and key brain development genes deregulated 
by estradiol in PA1, PA2 and PApool.  
 
 






When we consider the functionality or pathways responding to estradiol (via DAVID analysis), 
there are four enrichment clusters that overlap between two or three of the mutant groups, 
including transcription regulation and glycoproteins. Many of the enriched clusters identified 
by DAVID analysis are known to be direct responses to the estrogen receptor pathway 
according to KEGG (Kanehisa and Goto, 2000, Kanehisa, 2019, Kanehisa et al., 2019), and 
include transcription regulation, glycoproteins, synaptic function, and G-coupled protein 
receptors (Figure 4.7). Of note, genes involved in transcription regulation included Shox2 and 
Ebf3. In the Olivetti et al. estradiol study in a different PA1 mouse model, both of these genes 
were significantly downregulated with treatment (Olivetti et al., 2014). We see this same 
downregulation in Shox2 and Ebf3 in PA2 mice in our study, however not in the PA1 mice, 
possibly due to the variation between samples.  
 
To extend our functional analysis, we used the PANTHER database to analyse specific 
pathways enriched the deregulated genes with estradiol treatment. The nicotinic acetylcholine 
receptor signalling pathway was significantly enriched in both the PApool and PA2 groups (Table 
4.6). Of further interest in the PApool list was the Wnt signalling pathway (key signalling 
pathway in neurodevelopment) (Table 4.6). This was quite interesting, as ARX has been shown 
to interact with components of the Wnt signalling pathway in a proteomics study (Cho et al., 
2017). Furthermore, the dopamine receptor mediated signalling pathway was enriched in PA1 
mice (regulation of motor behaviour, memory, and reward) (Table 4.6). Interestingly, the only 
pathway overlapping between the PANTHER analysis of disease deregulated genes and 







Figure 4.7: Enrichment analysis of genes deregulated with estradiol treatment in PA 
mutant mice. Heat map showing significant gene enrichment terms in deregulated genes in 
PA1, PA2 and PApool groups from DAVID cluster annotation analysis. Clusters with enrichment 
scores of <1.0 are not shown. Heat map is based on maximum, minimum and 50th percentile 
score in data set (legend in figure). Clusters with # are pathways and functions known to be 





Table 4.6: Pathways enriched through PANTHER analysis in PApool, PA1 and PA2 mice. 
Term Overlap P-value Genes 
Nicotinic acetylcholine receptor signalling pathway  3/68 8.69E-04 
Myh2, Myo3b, 
Chrna6 
5-Hydroxytryptamine degradation  1/5 0.01367582 Aldh3a1 
Inflammation mediated by chemokine and cytokine 




Cytoskeletal regulation by Rho GTPase  2/70 0.015912295 Myh2, Myo3b 
Salvage pyrimidine ribonucleotides  1/10 0.027168031 Upp2 
Wnt signalling pathway  3/278 0.041044604 Myh2, En2, Fat2 





Dopamine receptor mediated signalling pathway  2/52 0.043775525 Flna, Dbh 
Nicotinic acetylcholine receptor signalling pathway  4/68 0.002207847 
Acta2, Myh2, 
Myo3b, Chrna6 
Cytoskeletal regulation by Rho GTPase  3/70 0.018914596 
Acta2, Myh2, 
Myo3b 
Insulin/IGF pathway-mitogen activated protein kinase 
kinase/MAP kinase cascade  













4.4.1 Ongoing effects to the transcriptome from a partial loss of Arx. 
My study found that the postnatal brain transcriptome remains deregulated in early postnatal 
life, with genes deregulated in PA1 and PA2 mutant mice at P10, compared to their WT 
littermates. These genes were involved with key neurodevelopmental processes and inhibitory 
interneurons, as well as including known Arx target and responsive genes. Arx is highly 
expressed during embryonic brain development in mice and humans, with expression detected 
as early as 8 days post conception (dpc) in the mouse brain (Bienvenu et al., 2002). Arx 
expression decreases throughout development, with lower levels of expression detected in 
newborn mouse brains, and throughout postnatal life and adulthood (Bienvenu et al., 2002, 
Mattiske et al., 2016). While it has also been shown that Arx remains expressed in the adult 
brain at low levels, it is likely that this is within a small population of neural precursor cells 
(Poirier et al., 2004). As such, the majority of studies into the effects of a partial loss of Arx on 
gene expression have been focused in the embryonic brain.  
 
In gene expression studies on the developing brain in mice, from embryonic day 12.5, 14.5, 
15.5 and 18.5, with a loss of Arx or due to expanded PA mutations, Arx has consistently been 
shown to repress Ebf3, Lmo1, Lmo3, Lmo4 and Shox2 (Fulp et al., 2008, Colasante et al., 2009, 
Quillé et al., 2011, Mattiske et al., 2016). This repressive function has also been identified in 
neuroblastoma cells transfected with Arx (Quillé et al., 2011). However, at P3, in the brains of 
the Price et al. PA1 mouse model, there was no difference noted to Ebf3 and Lmo1 due to Arx 
mutations, while Shox2 expression was increased (Olivetti et al., 2014). From these studies, a 
comprehensive list of Arx target genes, or genes impacted by Arx dosage, was devised in our 
laboratory and was used to determine the numbers of known Arx target or responsive genes in 
our data sets at P10. Arx target genes were significantly increased in our disease changed gene 
analysis, in PA1, PA2 and PApool mice (21%, 11% and 17% of genes respectively). These genes 
included Lmo1 which showed increased expression in PA1 mice. This was fascinating, as even 
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though Arx expression is low at P10, may still elicit some repressive function on Lmo1, which 
when lost leads to increased expression of the gene.  These high proportions of Arx responsive 
genes expressed at postnatal day 10 in PA mutant mice may indicate “ripple effects” in gene 
expression caused by the early partial loss of Arx due to the expanded polyalanine tract 
mutations, even when Arx’s expression is minimal.  
 
The gene enrichment clusters found in our study are similar to those reported in these studies 
into embryonic gene expression with loss of Arx.  In genes with expression changed by disease, 
we found neurogenesis, cell signalling, and processes associated with cell migration were 
deregulated. Cell cycle processes and neurogenesis were both found to be deregulated by Arx 
mutations in the embryonic, developing brain, indicating that these functions appear to remain 
deregulated in postnatal life (Fulp et al., 2008, Dubos et al., 2018). It has also been shown that 
in the Price et al. PA1 mouse model, there was elevated apoptosis in the cortex of mice in the 
first postnatal week of life (Siehr et al., 2020). Our PANTHER analysis showed that the 
apoptotic pathway was deregulated by the PA1 mutation, however not in PA2 mice. This was 
an interesting finding and may warrant further investigation in the future. Furthermore, genes 
involved in autism, epilepsy and intellectual disability were deregulated in embryonic studies 
of gene expression with Arx mutations, again, similar to our study in postnatal life. From our 
analysis, the disturbed transcriptomic profiles of mice with Arx mutations closely aligned from 
embryonic development to early postnatal life, and despite the lower levels of Arx expression, 
indicate these “ripple effects” from early, embryonic loss of Arx may cause sustained 
perturbation of these processes throughout brain development. 
 
Interestingly, with estradiol treatment, the expression of Shox2 and Ebf3 was decreased in this 
PA1 model (Olivetti et al., 2014). In PA2 mice in our study, estradiol treatment also decreased 
the expression of both Shox2 and Ebf3, however, these were both unchanged in PA1 mice, 
largely due the variation between samples in both of these genes. Further to these genes, Twist1, 
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a key Arx target gene and validated to be part of a core pathway of transcriptional regulators 
controlled by Arx function at embryonic day 12.5, was decreased with estradiol treatment in 
our PApool group (Mattiske et al., 2016). It is attractive to speculate that the expression of these 
key Arx target genes being decreased with estradiol treatment may be contributing to the 
improvements to severity and frequency of seizures we observed in this study (Chapter 3 of this 
thesis).   
 
4.4.2 Interneuron genes and genes associated with neurodevelopmental disorders are 
deregulated by disease and estradiol treatment.  
Arx is strongly expressed in the developing brain during the key events of proliferation and 
migration of interneurons to the cortex but has very limited expression in postnatal life 
(Colombo et al., 2007, Friocourt et al., 2008, Colasante et al., 2009, Lee et al., 2014).  Given 
this expression pattern, our laboratory’s previous investigations focused on understanding the 
disruption of the transcriptome in the forebrain of PA mutant mice at embryonic day 12.5 
(Mattiske et al., 2016). Further, it was  also demonstrated that there was a delayed migration of 
calbindin-positive interneurons in the cortex of newborn PA mice (Lee et al., 2017). Interneuron 
associated genes were also downregulated in the forebrain of PA2 mice at embryonic day 15.5 
(Dubos et al., 2018). From these studies we contend that the initial disruption to the 
transcriptome and subsequent impaired interneuron migrations caused by these mutations in 
Arx drive the seizures and behavioural deficits measured in the PA mutant mice. Later in 
postnatal life (genes deregulated due to altered functionality of mutant Arx) in particular, 
interneuron associated genes were enriched for, with overwhelmingly decreased expression. 
Interestingly, of the interneuron genes overlapping between PA1 and PA2 mutant mice, Th and 
Tacr1 are associated with somatostatin positive interneurons, while Akr1c18 is associated with 
parvalbumin positive interneurons. Neither of these subtypes have been previously shown to be 
disturbed in our PA1 and PA2 models at P10, so this is a novel finding. 
174 
 
Despite the significantly enriched number of inhibitory neuron genes deregulated by disease 
and with estradiol treatment, we did not see changes in genes coding for Calb1 and Calb2, 
involved in calbindin positive interneurons. Previously, this interneuron subtype was shown to 
have delayed migration in our PA mutant mouse models. However, from this data, we cannot 
speculate on potential migratory deficits in these cells due in part to the bulk RNA sequencing 
approach taken within this study. Many subsets of interneurons are lowly expressed in the brain. 
Given their importance to the PA mutant phenotype and in Arx function more broadly, single-
cell RNA sequencing could be a useful future strategy to determine the impact of disease and 
treatment on these specific subtypes of inhibitory neurons.  
 
In the current study we demonstrate a modest number of deregulated genes from the cortex at 
P10. This is in comparison to the larger number of deregulated genes detected at embryonic day 
12.5 in wildtype compared to Arx PA mutant mice (vehicle treated mice only) (Mattiske et al., 
2016). Genes included Tnn and Ngfr, regulators of differentiation, growth, and migration of 
neuronal populations (Degen et al., 2007, Lin et al., 2015), while Tacr1 is part of the family of 
G coupled-protein receptors, highly concentrated in the central nervous system (UniProt, 2020). 
Consistent with clinical phenotypes known to present in patients with ARX expansion 
mutations, Cpz is associated with autism spectrum disorders and/or intellectual disability (Loch 
et al., 2018). Despite reduced Arx expression within the brain at P10, the genes with deregulated 
expression in mutant mice were enriched for Arx responsive genes and genes known to be 
associated with autism and intellectual disability. The genes overlapping in mutant animals at 
P10 are important in brain development, including metal ion binding, known to be involved in 
cognitive decline in Down syndrome (Malakooti et al., 2014) and Alzheimer’s disease 
(Cristóvão et al., 2016), as well as signal transduction and glycoproteins, both heavily involved 
in neurotransmitter release and modifying neuronal functioning (as shown in KEGG pathway 
analysis) (Kanehisa and Goto, 2000, Kanehisa, 2019, Kanehisa et al., 2019). Although epilepsy 
associated genes were not significantly enriched in the mutant mice at P10, genes associated 
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with inhibitory neurons were. Th is a gene of particular interest. Downregulation of Th was 
validated in both PA1 and PA2 vehicle-treated mice compared to WT and is an enzyme that 
assists in the formation of dopamine, a neurotransmitter, as well as having an association with 
interneurons (Mao et al., 2019, Yang et al., 2020, Zhang et al., 2020). Th was unaltered with 
estradiol treatment, as well as other interneuron genes downregulated with disease. This 
supports the notion that disturbed function of these inhibitory cells are likely to play a critical 
role in the seizure phenotype due to mutations in Arx, and that the lack of “rescuing” of these 
genes might be associated with the remaining seizures we see with treatment in mutant mice, 
as well as the unaltered cognitive and behavioural phenotype.  
 
Of note, we did not find that epilepsy associated genes were significantly enriched in genes 
deregulated by disease in PA mutant mice. This was perhaps not surprising, as many known 
epilepsy causative genes are overwhelmingly associated with excitatory neurons. While 
mutations in Arx can cause seizures and epilepsy in patients, these are due to a disruption to 
inhibition in the brain, with dysregulation of interneuron migration and function. Arx mutations 
therefore do not cause channelopathies as many epilepsy disorders are, and rather, cause 
“interneuronopathies”, a smaller subset of epilepsy-associated disorders.  
 
4.4.3 Differences between PA1 and PA2 mutant mice. 
Given the striking similarity in behavioural and seizure phenotypes, we were somewhat 
surprised by the difference in gene expression in PA1 and PA2 mice. This difference related to 
both genes changed by disease and in response to estradiol treatment. This difference in the 
number of genes changed in each of the two genotypes was also observed at embryonic day 
12.5 (Mattiske et al., 2016). We were also uncertain if 17β-estradiol treatment would “rescue” 
the deregulated transcriptome of the PA mutant mice at P10, or if this treatment would target 
alternative pathways to reduce seizure frequency and severity. In the previous study in an 
alternate PA1 mutant mouse model, the same strategy of 17β-estradiol treatment altered 
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expression of three downstream targets of Arx, namely Shox2, Ebf3 and Lgi1 (Olivetti et al., 
2014). In the current study, we demonstrated only minimal overlap in the genes deregulated by 
disease (PA mutant mice compared to WT mice – vehicle treated only) compared to genes 
deregulated by 17β-estradiol treatment (vehicle treated mice compared to estradiol treated mice 
– PA mutant mice only). Despite these small numbers of genes that overlapped between these 
two comparisons, the genes that did overlap in PA1 and PA2, were deregulated in the opposite 
direction when treated with estradiol. In the PA1 gene list, there were some key genes of note, 
including Ptgs2 (involved in schizophrenia, another neurodevelopmental disorder) and Slc17a8 
(highly involved in synaptic vesicle function in excitatory neurons) (Wei and Hemmings, 2004, 
UniProt, 2020). In PA2, these genes included Arc (a master regulator of synaptic plasticity, and 
associated with epilepsy and schizophrenia), and Nppa (a regulator of neuropeptide hormone 
activity) (Haug et al., 2000, Huentelman et al., 2015). Though these genes may play a role in 
the alleviation of the seizure phenotype of PA mutant mice, these modest number of disease 
genes deregulated when treated with estradiol indicates that treatment in early postnatal life is 
less likely to be “repairing” the gene expression pathways deregulated by the PA mutant 
genotype and more likely recruiting new pathways to affect the reduction in seizures.  
 
4.4.4 Estrogen response genes in our analysis. 
Genes containing known conserved estrogen response elements (ERE) were only enriched to 
very low levels in PA mutant mice with estrogen treatment compared to vehicle treatment. 
Estradiol signalling can occur by direct genomic signalling where there is estrogen receptor 
dimerization and binding to EREs, as well as via indirect signalling, where estradiol can 
influence the expression of genes without EREs. As many as one third of estrogen responsive 
genes lack ERE-like elements (Vrtačnik et al., 2014). Hence, using DAVID, we analysed 
pathways and ontology terms enriched within the data that were known effects of 17β-estradiol 
signalling. Many of our enriched clusters were known to be direct or indirect effects of the 
estradiol pathway (Kanehisa and Goto, 2000, Kanehisa, 2019, Kanehisa et al., 2019).  Our data 
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demonstrates that 17β-estradiol treatment in early postnatal life recruits pathways impacting 
synaptic function, signal transduction, transcriptional regulation, and hormone activity 
responsible in reducing the frequency and severity of seizures in PA mutant mice.  
 
4.4.5 Environmental effects on transcriptomic results.  
An obviously surprising outcome in our transcriptomic findings is the striking difference 
between PA1 and PA2 mice, despite their similar phenotype. There are some limitations in the 
RNAseq approach taken that may partially contribute to this result. Cortex samples used for 
this RNAseq analysis were only taken at P10, one time point. This means that environmental 
overlay may have impacted the transcriptomic results of individual samples, and without a 
larger group of mice at multiple time points, these effects may lead to differences that were not 
averaged out. These environmental effects may include stress, seizure activity (though no 
seizures were observed in our mice this early), or maternal parenting differences. However, we 
attempted to keep the study as robust as possible, by treating all cohorts of mice the same from 







4.5 Study outcomes 
This investigation provides an unbiased study into the transcriptomic profile of PA1 and PA2 
mice at postnatal day 10 (without estradiol treatment) to determine the impact of partial loss of 
Arx early in development. In addition, the impact of estradiol treatment on these mice was 
investigated to understand how estrogen might be improving the seizure frequency and severity 
in adolescence. We have shown that significant numbers of genes associated with 
neurodevelopmental disorders and interneuron genes, and known Arx target and responsive 
genes had deregulated expression in both PA mice. Given the dramatic reduction to seizure 
occurrence, we were somewhat surprised to find that estradiol treatment did not appear to 
“rescue” the deregulated transcriptome of PA mutant mice at postnatal day 10. Instead, estradiol 
treatment recruited molecular and cellular pathways to reduce the frequency and severity of 
seizures rather than restoring pathways initially deregulated in Arx PA mutant mice driving 
pathogenesis. Investigating gene expression and pathways disrupted due to mutations in Arx 
and the subsequent response to treatment is vital for looking for therapeutic targets, even those 
that could potentially be delivered prenatally to the foetus in utero. We conclude that 17β-
estradiol treatment recruits processes and pathways to reduce the frequency and severity of 
seizures in the Arx PA mutant mice but does not precisely correct the deregulated transcriptome 
nor improve mortality or behavioural and cognitive deficits. We chose to focus our 
investigations on the effects of these expanded polyalanine tract mutations on the interneurons 












Interneuron genes are deregulated with Arx PA 
mutations, but are not rescued directly with 

















The lack of effective treatments for intellectual disability and neuropsychiatric disturbances 
remains a significant challenge and highlights the continued need to elucidate the molecular 
and cellular drivers of the intellectual disability phenotype as the first necessary steps toward a 
treatment. Many NDD genes have been linked to the function, development and migration of 
interneurons, an inhibitory cell type in the brain. Interneurons balance excitation and inhibition 
in the cortex, providing a balance to the overall network. The Aristaless-related homeobox gene, 
ARX, is a transcription factor strongly expressed in immature neurons and interneurons in the 
embryonic brain. When ARX function is compromised, intellectual disability with associated 
comorbidities like severe epilepsy and infantile spasms can be the result. The transcriptomic 
profile of interneuron genes at postnatal days 3 and 10 in untreated PA mutant mice was 
analysed, demonstrating that many interneuron deficits were already present at this early stage 
of postnatal brain development, particularly somatostatin and parvalbumin positive 
interneurons. We contend that early disruption of Arx function results in deregulation of 
interneuron associated genes early in postnatal life, contributing to the disease phenotype. 
Further, to determine the effect of estradiol on the abundance of calbindin and neuropeptide-Y 
interneurons, we used immunofluorescent microscopy at postnatal day 10, immediately 
following treatment. These two interneuron subtypes have been previously shown to be 
deficient in PA mutant mice, and rescued with estradiol. Despite differences in the expression 
of multiple interneuron genes at postnatal day 10 following estradiol treatment, we did not 
determine any significant differences in the number of calbindin and neuropeptide-Y 
interneurons in PA mutant mice. Despite changes to gene expression of specific interneurons, 
our data suggests that rescue of interneuron deficits/cell density, is unlikely to be the sole cause 





The cortex of the brain is highly diverse, made up of a number of cell types which perform a 
variety of functions, dependent on balanced neural circuits. GABAergic inhibitory interneurons 
are vital to controlling neuronal excitability and balancing the synchrony of neural networks in 
the brain. If there is a dysfunction in interneurons in the brain, this can lead to aberrant firing 
of excitatory cells, due to a lack of inhibition and an imbalance of these networks. These 
networks play a pivotal role in the control of memory and information processing functions of 
the cortex, and if disrupted, can be associated with a wide spectrum of neurodevelopmental 
disorders such as intellectual disability, epilepsy, schizophrenia and autism (Benes and Berretta, 
2001, Lewis et al., 2005, Rubenstein, 2010, Olivetti and Noebels, 2012).  
 
Many neurodevelopmental disorders, particularly intellectual disability and epilepsy, share 
similar developmental origins, with causative genes for these disorders overlapping. Of these 
disease associated genes, some have been linked to the function, development, and migration 
of cortical interneurons. The Aristaless-related homeobox gene, ARX, is a transcriptional 
repressor, strongly expressed in neural progenitor cells and immature neurons in the 
developing, embryonic brain, peaking between embryonic days 12.5 and 15.5 in the mouse 
cortex in particular (Miura et al., 1997, Kitamura et al., 2002, Poirier et al., 2004, Colombo et 
al., 2007). When Arx is completely knocked out in a mouse model, the male mice have severe 
brain malformations, with a thinner cortical plate, a deficit in tangential migration of 
interneurons to the cortex, and a complete lack of radial migration of interneurons. These mice 
also had significantly reduced numbers of excitatory neurons (Kitamura et al., 2002). In utero 
knock down of Arx causes progenitor cells to prematurely exit the cell cycle and impaired the 
migration of interneurons into the cortex, as well as the radial migration of excitatory neurons 
(Friocourt et al., 2008). This demonstrates the dramatic effects of a loss of Arx on interneuron 
migration, and is reflected in the severe phenotypes in human patients due to complete loss of 
function mutations.   
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In mice with mutations expanding the first and second polyalanine tracts of Arx, there is a 
deficit in the number of interneurons, as well as their migration. In 2017 Lee et al. showed an 
overall reduction in GABAergic interneurons in the postnatal day 0 brain of both PA1 and PA2 
mice. When looking at specific interneuron subtypes, there was a 40-50% loss of calbindin 
positive cells in the cortex. These cells were found to be arrested in the ventral subpallium of 
the cortex, where migration of these cells had been halted or delayed (Lee et al., 2017). This 
same PA1 mouse has also been shown to have reduced numbers of neuropeptide-Y positive 
interneurons in the brain at one month of age (Kitamura et al., 2009). Furthermore, 
transcriptomic studies of the embryonic brain of PA mutant mice have shown deregulation of 
key interneuron functional and developmental genes, however we have not yet performed RNA 
sequencing of the brain in postnatal life (Mattiske et al., 2016, Dubos et al., 2018). These mouse 
models have demonstrated that even a partial loss of Arx due to these expanded tracts can 
impact the normal functioning and migration of these key inhibitory cells of the brain. 
 
Arx is mostly expressed embryonically. To understand the ongoing effects of these mutations 
throughout postnatal life, there have been few studies in the postnatal brain of these PA1 and 
PA2 mouse model. A recent study involving an alternate PA1 mouse model found that early 
postnatal treatment with 17β-estradiol restored some of the interneuron deficits at 
approximately one month of age, particularly in neuropeptide-Y and cholinergic cells (Olivetti 
et al., 2014). Furthermore, in rats, treatment with estradiol increased the number of inhibitory 
cells in an induced seizure rat model, and in a premature birth model in rabbits (Chachua et al., 
2016, Panda et al., 2018). Taken together, these studies suggest that estradiol may be able to 
improve interneuron populations in the brain, even in the presence of a functional deficit in Arx.  
 
To investigate the effects of these mutations in early postnatal life, we established the status of 
the expression of interneuron associated genes aligned with the commencement of estradiol 
treatment at P3, and immediately following treatment at P10, using RNA sequencing.  We 
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suspected that genes involved with the development, migration and function of interneurons 
would be deregulated in PA mutant mice. RNA sequencing was used to determine the changes 
to gene expression in the prefrontal cortices of PA1 and PA2 mutant mice and their wild-type 
littermates. We then investigated the effects of early estradiol treatment on the cell density of 
interneuron subtypes within the cortex. Previous studies in PA1 and PA2 mice, with and without 
estradiol treatment, have shown deficits to calbindin and neuropeptide-Y positive interneurons 
in the cortex, early and later in development (Kitamura et al., 2009, Olivetti and Noebels, 2012, 
Olivetti et al., 2014, Lee et al., 2017). Hence, I chose to focus on these two interneuron 
subtypes, investigating with immunofluorescent analysis of a specified region of the prefrontal 
cortex at postnatal day 10. We hypothesised that treatment with estradiol would improve the 
numbers of neuropeptide-Y and calbindin positive interneurons in the postnatal day 10 cortex 











5.3.1 Deregulated interneurons in untreated PA1 and PA2 mutant mice at postnatal day 
3 and postnatal day 10.  
Further to our RNA sequencing analysis comparing vehicle and estradiol treated PA mutant 
and WT mice at postnatal day 10, discussed extensively in Chapter Four of this thesis, we also 
performed RNA sequencing of postnatal day 3 (P3) and day 10 (P10) cortex samples from 
completely untreated PA mutant and their WT littermates. Here we complete a characterisation 
of the impact of disrupted Arx function on the expression of interneuron associated genes at 
these two early postnatal time points.  
 
We demonstrate that the transcriptomes of mutant mice at P3 and P10 were disrupted due to 
expanded polyalanine tract mutations, compared to their WT counterparts. Compared to age-
matched, untreated WT mice (n = 6), analysis of PA1 at P3 (n = 4) found 497 genes deregulated 
with a Log2 fold change greater than ± 0.5 and a p-value of less than 0.05. PA2 mice had 110 
genes deregulated with the same cut-off value, and when combining these two groups to create 
a PApool group, we found 130 genes deregulated. At P10, compared to age-matched, untreated 
WT mice (n = 6), PA1 mice (n = 4) had 179 genes deregulated with a Log2 fold change greater 
than ± 0.5 and a p-value of less than 0.05. PA2 mice had 135 genes deregulated, and PApool 
mice had 134 genes deregulated (Table 5.1).  
 
Table 5.1: Genes deregulated by disease in untreated PA1, PA2 and PApool mice compared 
to untreated wild-type littermates at the same time points.  
 Untreated PA1 PA2 PApool 
P3 vs. P3 WT 497 110 130 




To understand the interneuron genes disrupted by the disease genotype in PA mutant mice, we 
investigated enriched genes within these lists. Utilising the in house curated reference list of 
inhibitory neuron associated genes. At P3, there were 15, five and seven interneuron associated 
genes disrupted in PA1, PA2 and PApool groups, respectively (Table 5.2). Interestingly, these 
genes were significantly enriched in all three groups; PA1 (15/497, 3%, p<9.212e-13), PA2 
(5/110, 5%, p<6.271e-6) and PApool (7/130, 5%, p<2.573e-8) (Table 5.2).  
 
At P10, there were 13 interneuron associated genes disrupted in PA1 mice, six disrupted in 
PA2, followed by eleven genes disrupted in the PApool group (Table 5.2). As we also saw at P3, 
there was significant enrichment of interneuron genes in PA1 mice (13/179, 7%, p<4.491e-16), 
PA2 mice (6/135, 4%, p<8.183e-7) and PApool mice (11/134, 8%, p<2.233e-14) (Table 5.2). 
Perhaps not surprisingly, these percentages are similar to those in vehicle treated mutant mice 
at P10, with 8%, 10% and 17% of deregulated genes being interneuron genes, including 












































Col25a1, Cryab, Fign, 
Frem1, Hspb3, Itih5, 
Ndst4, Npy, Pvalb, 
Slc18a3, Sncg, Spp1, 
Tac2, Th, Tll1 
Cartpt, Crh, Fosb,  
Npy, Tac2 
Cryab, Hspb3, Npy, 
Slc18a3, Spp1, Tac2, Tll1 
Significant enrichment 
of interneuron genes * * * 
P-value p = 9.212e
-13
 p = 6.271e
-6




Akr1c18, Chat, Chrna2, 
Fosb, Frmd7, Has2, 
Mybpc1, Pde11a, Pvalb, 
Sla18a3, Spp1, Tacr1, Th 
Akr1c18, Fosb, Frmd7, 
Mybpc1, Myh8, Spp1 
Akrc1c18, Chat, Chrna2, 
Fosb, Frmd7, Has2, 
Mybpc1, Pvalb, Spp1, 
Tacr1, Th 
Significant enrichment 
of interneuron genes * * * 
P-value p = 4.491e
-16
 p = 8.183e
-7





Focusing our investigation of the disruptions to key interneuron genes and the pattern of 
deregulation between the two time points of P3 or P10, the Calb1 gene, responsible for the 
calbindin protein expressed by calbindin positive interneurons, was not significantly different 
between WT or PA mutant mice at either time point (Figure 5.1). This was interesting given 
the migration impediment in these interneuron subtypes exhibited at P0 in PA1 and PA2 mice, 
previously established by Lee et al. 2017. Disruption to the Pvalb gene, responsible for the 
parvalbumin protein on parvalbumin positive interneurons, was observed at both timepoints in 
PA1 group, and at P10 in the PApool group (Figure 5.1). The disruption to Pvalb persisted from 
P3 and was still present at P10. There was no deficit to parvalbumin abundance reported in Lee 
et al. 2017, however this gene is not strongly expressed until approximately postnatal day 14 
(Allen Brain Atlas).  
 
Disruption to expression of the Chat gene at P10 in PA1, PA2 and PApool groups was also found 
from our RNAseq analysis (Figure 5.1). This gene plays key roles in cholinergic interneurons, 
a subtype previously shown to be deficient in the alternate PA1 mutant mouse model (Olivetti 
et al., 2014). We also detected disruption to the Th gene in all three mutant groups, at both P3 
and at P10 (Figure 5.1). Th is also a key player in cholinergic interneurons. This is the first time 
deregulated expression of these genes in PA1 and PA2 mice has been reported. We 
demonstrated significant deregulation of the Npy gene at P3 in all three mutant groups (Figure 
5.1). At postnatal day 3 this deregulation was significant in meeting our cut off values for our 
RNA sequencing data, being a p-value >0.05 paired with a log2 fold change of ± 0.5, however 
at P10, Npy was deregulated with a p-value >0.05, but did not meet the log2 fold change criteria. 
Fascinatingly, all interneuron gene deficits in PA1 and PA2 mice, apart from Chat which was 
not detected at P3, persisted from P3 to P10. 
 
Three additional interneuron associated genes were also disrupted in these mutant groups. 
These genes did not overlap completely with each mutant group. Spp1 was downregulated in 
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PA1 and PApool at both P3 and P10, and Slc18a3 downregulated in PA1 only. Fosb was an 
interesting finding, being significantly upregulated in PA2 mice at P3, but significantly 





























































































































































































Figure 5.1: RNA sequencing outcomes of key interneuron associated genes in untreated 
PA mutant mice at postnatal day 3 and day 10. Gene expression as counts per million (CPM) 
for selected interneuron associated genes enriched in untreated PA mutant mice compared to 
untreated WT littermates. Dots represent values for individual animals. PA1 mice at P3 (n = 4; 
blue) and P10 (n = 4; blue); PA2 mice at P3 (n = 4; blue) and P10 (n = 3; blue); PApool mice at 
P3 (n = 8; green) and P10 (n = 7; green); WT mice at P3 (n = 6; grey) and P10 (n = 6; grey). * 






To identify which genes corresponded to specific interneuron subtypes, we analysed expression 
data using Gemma to assign cell populations to the gene most abundantly expressed (Zoubarev 
et al., 2012). A table of these interneuron subtypes with the genetic markers identified in our 
analysis is listed in Appendix 10. From this investigation, we found that these interneuron genes 
enriched in PA1, PA2 and PApool mice were primarily associated with vasoactive intestinal 
polypeptide (VIP), somatostatin (SST), neuron-derived neurotrophic factor (NDNF), 
parvalbumin (PVALB), interferon gamma-induced GTPase (IGTP) and synuclein-γ (SNCG) 
interneuron subtypes. The types of interneurons most enriched for genes deregulated in PA 
mutant mice at both P3 and P10 included VIP, SST and PVALB (Figure 5.2). In the case of 
PA2 mice, there was a change from P3 (VIP and SST) to also include PVALB at P10 (Figure 
5.2). In the pooled data, we see a change in the enrichment of genes expressed in interneuron 
subtypes, with VIP at P3 disrupted, to SST and PVALB at P10 (Figure 5.2). This investigation 
identified SST, VIP and PVALB as the most common interneuron subtypes with deregulated 













































Figure 5.2: Enrichment of different interneuron subtypes with genes deregulated in 
untreated postnatal day 3 and day 10 PA mice. Pie charts display subtypes of interneurons 
based on deregulated interneuron gene expression in untreated PA mutant mice at P3 and P10 
(PA1 = orange, PA2 = blue, PApool = green). Patterns represent each interneuron subtype, as 
described in figure. Proportions of each subtype is based on deregulated interneuron associated 
genes in Table 5.2. Key for interneuron subtypes is as follows; VIP: vasoactive intestinal 
polypeptide; SST: somatostatin; NDNF: neuron-derived neurotrophic factor; PVALB: 





5.3.2 Estradiol treatment does not alter interneuron abundance in the PA1 and PA2 
mouse prefrontal cortex. 
Immunofluorescence microscopy of the prefrontal cortex at P10 was performed in a specific 
region of the cortex for all animals studied (Figure 5.3). Representative examples of calbindin 
and neuropeptide-Y positive cells were observed (Figure 5.4 A&B). The cell density analysis 
first separated WT mice treated with either estradiol or vehicle. For this experiment we chose 
to combine these into a WT combined treatment group, to look for any changes in interneuron 
populations compared to mutant mice. We did not observe any deficits to calbindin-positive 
cell density in vehicle treated PApool mice compared to their WT littermates (Figure 5.4 C). 
Again, with neuropeptide-Y, we did not observe any decrease or difference in cell density due 
to disease, when comparing mutant mice to their WT littermates (Figure 5.4 D). We did not see 
any differences to cell density in either of these interneuron subtypes in mutant mice 





































Figure 5.3: Region of the cortex used for immunofluorescence analysis. Representative 
DAPI stained image of the brain in a WT mouse illustrating the region of the brain analysed 

















Figure 5.4: Abundance of calbindin and neuropeptide-Y positive interneurons in the 
prefrontal cortex. (A) Immunofluorescence analysis of calbindin (Cb) interneurons in coronal 
brain sections of PA mutant mice at P10 and was superimposed with DAPI staining and imaged 
with 20x objective. Arrows depict representative examples of Cb positive cells in a WT and a 
PA mouse. Scale bar 100µm. (B) Immunofluorescence analysis of neuropeptide-Y (Npy) 
interneurons in coronal brain sections of PA mutant mice at P10 and was superimposed with 
DAPI staining and imaged with 20x objective. Arrows depict representative examples of Npy 
positive cells in a WT and a PA mouse. Scale bar 100µm. (C) Density of Cb positive cells in 
WT mice (n = 6; white; vehicle = solid dots; estradiol = circles) and PApool mice (PA1 = squares; 
PA2 = triangles) treated with vehicle (n = 6; light green) or estradiol (n = 5; dark green). (D) 
Density of Npy positive cells in WT mice (n = 6; white; vehicle = solid dots; estradiol = circles) 
and PApool mice (PA1 = squares; PA2 = triangles) treated with vehicle (n = 4; light green) or 








5.4.1 Novel findings from this study 
As part of our investigation into the effects of short-term 17β-estradiol treatment on PA1 and 
PA2 mutant mice, we performed microscopy analysis of the cortex at postnatal day 10, 
immediately following treatment. Interestingly, at the cessation of treatment, we reported no 
significant difference in the cell density of calbindin and neuropeptide-Y interneurons with 
estradiol. However, we also did not observe any significant deficit in these cells in mutant mice 
compared to WT. Previously our laboratory reported a lag in the migration of calbindin positive 
interneurons at P0 in both PA1 and PA2 mice, with an accumulation of cells being arrested 
when they should have migrated into the cortical layers (Lee et al., 2017). This outcomes was 
supported by our analysis, demonstrating no difference to Calb1 (encoding calbindin) in our 
gene expression data at P10 either with or without treatment. This could indicate that this deficit 
of calbindin positive cells in the cortex is in fact caused by slow migration, as opposed to a 
complete loss of this interneuron subtype. As we did not carry out detailed microdissection of 
the cortical tissue, our results are based on the entire cortical region studied. This is a limitation 
in determining any lag in the migration of these cells at P10, manifested by changes to the 
density of calbindin cells in different layers.  
 
Furthermore, our collaborators showed reduced density of neuropeptide-Y cells in the adult 
brain, and an increase with estradiol treatment (Olivetti et al., 2014). In agreement, we 
determined a modest reduction in the expression of the Npy gene expression in PA1 mutant 
mice compared to WT animals at the earlier time point of P10. However, we did not find any 
significant differences to density of Npy positive interneurons.  The expression of Npy is known 
to increase in the brain from approximately P14, meaning we cannot rule out that changes to 
the density of Npy positive interneurons at later stages of development may occur and 
contribute to the sustained reduction in seizures observed in estradiol treated mice (Lein et al., 
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2007). Although we detect differences in gene expression of multiple interneuron associated 
genes at P10 of development, our data indicates to us that the many other genes (and pathways) 
regulated by estradiol treatment are likely to be participating in the alleviation of seizures, as 
opposed to increased inhibition in the brain as the sole mechanism.  
 
We also completed a comprehensive investigation of key genes involved in interneuron 
function, migration and development, in untreated PA1 and PA2 mutant mice at P3 and P10. 
This is the first time the transcriptomic profile of these mice has been investigated at these time 
points. We demonstrated a substantial and significant deregulation of interneuron associated 
genes at both time points in PA1, PA2 and PApool mice. Most of these interneuron deficits were 
sustained from P3 through to P10, indicating no improvement throughout brain development 
during this period. Parv and Th both increased in expression from P3 to P10, remaining 
decreased compared to WT still, however Npy maintained around the same expression. This 
decrease in Npy expression in PA mutant mice compared to WT was not reflected in our 
immunofluorescence data. Interestingly, key interneuron subtypes that were deregulated were 
somatostatin and parvalbumin positive interneurons. At postnatal day 0, Lee et al. did not 
observe any differences to these two interneuron subtypes in the cortex of mutant mice (Lee et 
al., 2017). However, both of these cells increase in population throughout postnatal life. The 
differences in interneuron deficits between studies in each of the two mouse models for the PA1 
and PA2 mutations are outlined in Table 5.3, with results from this study summarised in Table 
5.4. These will be discussed further in 5.4.2. 
 
An interesting outcome of our gene expression data was the reduction in Chat and Th at P10 in 
both PA1 and PA2 mice. Chat and Th are expressed by cholinergic neurons, which use 
acetylcholine (ACh) as their primary neurotransmitter (Ahmed et al., 2019). Changes to the 
function of cholinergic neurons can lead to disruptions in motor control, which provides a 
possible explanation for the reduced neuromuscular strength we observed in PA mutant mice 
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in Chapter 3 (Bordia et al., 2016, Ahmed et al., 2019). Disruptions of these neurons can also 
reduce the capacity of behavioural flexibility, memory and social behaviour in mice. As such, 
our findings are consistent with these deficits not being rescued with estradiol treatment, and 
are likely to contribute to the sustained intellectual disability phenotype, despite the reduction 
in seizures we observed (Albert-Gascó et al., 2017, Martos et al., 2017, Okada et al., 2018, 




Table 5.3: Interneuron deficits present in the PA1 and PA2 mouse models from different studies at different timepoints.  
 
 Embryonic Postnatal day 0 Approx. 1 month Adult Publication 
PA1 
Kitamura model 
 ↓ Npy, Sst, GABA ↓ Chat  Kitamura et al. 2009 
 ↓ Cb, GABA   Lee et al. 2017 
PA1 
Price model 
  ↓ Npy, Cb  Price et al. 2009 
   
↓ Npy, Cb 
Npy, Cb ↑with E2 
Olivetti et al. 2014 
PA2 
Kitamura model 
  ↓ Chat  Kitamura et al. 2009 
 ↓ Cb, GABA   Lee et al. 2017 
PA2 
Dubos model 
↓ Cb, Cr, Chat ↓ Cb, Sst  ↓ Cb, Chat Dubos et al. 2018 
 
Legend: Neuropeptide-Y (Npy), calbindin (Cb), calretinin (Cr), somatostatin (Sst), cholinergic (Chat), parvalbumin (Parv), gamma 




Table 5.4: Interneuron deficits in PA mutant mice in this study. 
 
  P3 P10 
  Untreated Untreated Vehicle E2 
PA1 
Gene expression ↓ Npy, Sst, Parv 
↓ Npy, Sst, Parv, 
Chat 
↓ Sst, Parv, Chat  
Cell density   No change - Npy, Cb No change - Npy, Cb 
PA2 
Gene expression ↓ Npy, Sst ↓ Npy, Sst, Chat ↓ Sst, Parv, Chat  
Cell density   No change - Npy, Cb No change - Npy, Cb 
 
Legend: Neuropeptide-Y (Npy), calbindin (Cb), somatostatin (Sst), cholinergic (Chat), parvalbumin (Parv).
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5.4.2 Differences in interneuron findings between studies 
The discrepancies in interneuron findings between our findings and published studies, are 
described in Tables 5.3 and 5.4. A major contributor in differences reported may be due to the 
time period studied. Most interneuron investigations in the Kitamura et al. mouse models have 
been performed early in development, while many of the Price et al. PA1 mouse studies have 
been performed in adulthood. The expression of interneuron populations changes across 
different stages of brain development. For example somatostatin and parvalbumin subtypes 
primarily disturbed in our gene expression data, are expressed highly from P14-P28 compared 
to embryonic and early postnatal life (Lein et al., 2007). This highlights that a systematic 
evaluation of changes to interneuron subtype expression and changes to cell density of 
interneuron populations within different cortical layers, with and without treatment, is 
warranted. 
 
We also observed some differences in the interneuron subtypes improved with estradiol 
treatment, when compared to the study in the Price et al. PA1 mouse model. Olivetti and 
colleagues showed an improvement in neuropeptide-Y and calbindin interneuron density in 
response to treatment. Again, this was reported in the adult brain in specific brain regions. It is 
possible that the effects of estradiol on this subset of interneurons requires additional time to 
manifest in a significant change to cellular density in the brain, as opposed to our study, where 
we examined the brain immediately following treatment. This may contribute to the increase in 
interneuron associated genes we observed at P10, immediately following treatment cessation, 
but no with limited effect at the cellular level. 
 
From our studies, we contend that the effect of estradiol on interneurons is only part of the 
impact of estradiol treatment leading to alleviation of seizures in PA mutant mice. A number of 
pathways and genes are deregulated with estradiol treatment. As such, the direct effects of 
treatment may not be easily detected at the cellular level in the brains of these mice. The exciting 
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aspect of this conclusion is that the additional pathways estradiol is targeting may provide 





5.4.3 Future experiments for interneurons in PA mutant mice 
There are multiple ways interneurons are able to be investigated in the brains of PA mutant 
mice, and with advances in transcriptomic techniques we believe a single-cell RNA sequencing 
approach would be beneficial. This would allow a comprehensive investigation of the gene 
expression profiles of individual cell types impacted by mutations in Arx, including progenitor 
inhibitory and excitatory neurons. Given the small number of cells of the brain that are affected 
by the mutations in Arx, this approach would have the ability to determine small and direct 
effects in different subsets of specific neural cell types (Aevermann et al., 2018, Chen et al., 
2019). This type of deep investigation could potentially determine specific and novel treatment 
targets to treat multiple aspects of the disease phenotype, including cognition and mortality, not 
just seizures.  
 
By investigating treatments that target interneurons more directly, we could potentially treat the 
intellectual disability side of the PA mutant phenotype. Despite improving seizure frequency 
and severity with estradiol, cognitive effects remained unchanged, with deficits to anxiety, 
social cognition, and hyperactivity. Interneuron dysfunction is responsible for a number of 
neurodevelopmental disorders, such as autism, epileptic syndromes, and even schizophrenia, 
and hence treatments targeting these specific cells may help alleviate phenotypes for patients 
with these other disorders. Hence, investigating these important cells is key for not just patients 














5.5 Study Outcomes 
Through a comprehensive study of interneuron associated genes in untreated mutant mice at P3 
and P10, we showed disruptions to Npy, as well as deregulation of somatostatin, parvalbumin 
and vasoactive intestinal protein positive interneurons. This disruption to interneurons was 
sustained throughout this early period of development. We conclude that this early disruption 
to genes involved in the function and development of interneurons, caused by these partial loss 
of function mutations in Arx, is at least partially responsible for the intellectual disability and 
seizure phenotype we see in PA mutant mice. However, despite estradiol improving seizure 
frequency and severity in both PA1 and PA2 mice, we did not detect any increase to the cell 
density of calbindin and neuropeptide-Y positive interneurons at P10, immediately following 
the last dose of treatment. We believe that further analysis on the interneuron deficits in PA 
mutant mice would be beneficial for finding novel treatment targets for children with these 

















































6.1 Novel findings of this project 
My PhD project provides novel insights into the behavioural and molecular phenotype of the 
Arx PA1 and PA2 mouse models, and contributes to the understanding of how 17β-estradiol 
treatment works to reduce the frequency and severity of seizures in these mice. For the first 
time, I have shown that there are abnormal behavioural traits present early in postnatal life prior 
to the peak of seizure onset in PA mutant mice, and that there is no regression of behavioural 
deficits or cognition between one and two months of age. PA1 and PA2 mutant mice have been 
shown to have deficits to social cognition, anxiety and fear response, and learning and memory 
at two months of age (Jackson et al., 2017). However, determining the impact of severe and 
recurring seizures on the behavioural profile of these mice had not yet been examined. The 
behavioural deficits I established allowed me to determine whether or not improving seizures 
in PA mice via 17β-estradiol treatment would subsequently improve these behaviour deficits. 
Unfortunately, despite my hypothesis, a cardinal finding of my project was that 17β-estradiol 
treatment had no effect on behaviour in these mice, nor did the reduction in seizures reduce 
behavioural deficits later in development. Despite 17β-estradiol treatment not improving the 
behavioural and cognitive phenotype of PA mutant mice, I showed efficacy in its use as anti-
epileptic treatment when given in early postnatal life, at least in mice. This is the first time that 
17β-estradiol treatment has been shown to reduce seizure frequency and severity in the 
Kitamura et al. PA1 mouse model, as well as the PA2 mouse model, with the second model 
mirroring the most frequent ARX mutation seen in humans. This provides much needed 
reproducibility of results in two independent models of Arx mutations, with our collaborators 
demonstrating a reduction in seizures in a different PA1 mouse model (Price et al. model). 
Despite our work demonstrating the effectiveness of 17β-estradiol as a treatment for seizures, 
we unfortunately cannot report that the improvement by reduction in seizure frequency and 




To better understand the role of Arx in early postnatal life and the effects of estradiol treatment, 
we performed unbiased RNA sequencing on postnatal day 10 brains of PA1 and PA2 mice 
following treatment with 17β-estradiol. This provided novel results on the ongoing effect of a 
partial loss of Arx early in brain development on the transcriptome of PA mutant mice in early 
postnatal life. We established the deregulated transcriptomic profile in PA1 and PA2 mutant 
mice (untreated) compared to wild-type littermates, and found that despite low Arx expression 
in the brain, genes associated with neurodevelopmental processes were deregulated. We 
determined that 17β-estradiol treatment did not repair the deregulated transcriptome but instead 
recruited alternative gene pathways that we conclude contribute to the reduced seizure 
frequency and severity. 
 
Another important finding of our study was the comprehensive analysis we performed of 
interneuron associated genes at P3 and P10 in untreated PA1 and PA2 mice. This analysis of 
interneuron genes across developmental time points has not been performed in these mutant 
mice, and we determined that many genes with deregulated expression persist from P3 to P10. 
Despite our immunofluorescence analysis at P10 showing no deficits in calbindin or 
neuropeptide-Y positive interneuron populations, we provided evidence for somatostatin, 
parvalbumin, neuropeptide-Y and cholinergic interneurons being deregulated in PA mutant 
mice early in postnatal day life. This analysis provides insight into specific subtypes of 
inhibitory cells that might be affected by the expanded polyalanine tract mutations in Arx, and 
provide evidence for mechanisms of disease.  
 
We demonstrate neuromuscular deficits are present in both PA mutant mice for the first time. 
Patients with expansion mutations, particularly of the second polyalanine tract, feature dystonia 
of the hands as a significant part of their phenotype (Stromme et al., 2002, Shoubridge et al., 
2010). This phenotype is referred to as Partington Syndrome with 63% of patients with 
expansions of PA2 having dystonic movements of the hands (Partington et al., 2004). This 
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aspect of the phenotype was further characterised by Dubos et al. with impaired grasping 
movements of the hands in PA2 patients (Partington et al., 2004, Dubos et al., 2018). 
Generalised dystonia has been reported in patients with expansions of the first polyalanine tract. 
A report by Guerrini et al. reported six male patients with generalised dystonia that worsened 
to severe quadriplegic dyskinesia by two years of age (Guerrini et al., 2007). My study found 
that PA2 mice had decreased grip strength in the inverted grid test compared to their wild-type 
littermates, perhaps not surprising as this is such a prominent feature in PA2 patients. 
Interestingly, PA1 mice also had reduced grip strength at two months of age (trending at one 
month but non-significant). The Price et al. PA1 mouse model presents with better performance 
in the rotarod test than their wild-type littermates, indicative of increased locomotor 
coordination (Price et al., 2009). A different PA2 mouse model that has since been developed 
since the beginning of my project, has been reported to have a deficit in reaching and grasping 
(Dubos et al., 2018). However, these two studies are the only reported information of 
neuromuscular strength deficits in any PA mouse models. My study provides novel findings for 
a neuromuscular strength deficit in the Kitamura et al. PA1 and PA2 mouse models. 
Unfortunately, estradiol treatment at the current dosage and timing of treatment did not improve 
this phenotypic outcome.  
 
6.2 Reproducibility of pre-clinical trials  
Reproducibility between preclinical trials is vital to the process of eventually getting novel 
therapies to human clinical trials. The rate of translation from preclinical trials to human clinical 
application is approximately 8% (Mak et al., 2014). This low translation level is partially due 
to treatment and clinical studies from mice and humans often having quite different outcomes. 
However, increased understanding of molecular mechanisms behind inherited disorders has led 
to more relevant mouse models for treatment trials being established (Berry-Kravis et al., 2018). 
The Kitamura and Price PA1 mouse models differ slightly in their seizure, behavioural and 
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cellular phenotypes, but both mice strongly recapitulate many aspects of the human phenotype 
in patients with PA1 expansion mutations in ARX. 
 
Estradiol treatment early in postnatal life modelled in our study, based on the previous study by 
our collaborators (Olivetti et al., 2014), shows vast effectiveness in reducing aspects of the 
seizure burden in PA1 mice, as well as PA2 mice. Moreover, treatment given very early in 
postnatal life provided lasting impact on reductions in seizures for up to 2 months of age (study 
end point) which spans the normal peak of seizures in these models. However, this regime of 
estradiol treatment failed to improve cognitive and behavioural outcomes in either mouse 
model. Reproducibility of behavioural testing can be difficult to measure in mice, using the 
Fmr1-KO mouse model of Fragile X Syndrome as an example, we can begin to understand why 
preclinical trials in intellectual disability models are challenging. Fragile X Syndrome is the 
most common genetic form of intellectual disability and autism in humans (Berry-Kravis et al., 
2018). The Fmr1-KO mouse model shows variability and small effect size in cognitive deficits, 
displaying differing results in standard behaviour tests in different laboratories and on different 
genetic backgrounds (Kazdoba et al., 2014, Gross et al., 2015, Leach et al., 2016).   
 
The effects of this early intervention with estradiol treatment on seizure outcomes in PA1 and 
PA2 mice is striking. This is the first study reporting the effects (or lack thereof) of estradiol on 
behaviour in the PA1 and PA2 mouse models. While intellectual disability is a cardinal feature 
of ARX mutations, inconsistent or small deficits in cognition and behaviour in a mouse model 
have the potential to limit the value of these particular mouse models for evaluating the effects 
of early estradiol treatment on behaviour. Future studies investigating the effects of a treatment 
outcome on intellectual disability models may benefit from using a touchscreen platform to 
investigate subtle changes to cognitive outcomes, with high translation of the behavioural 
phenotype to human cognitive outcomes (Horner et al., 2013). Touchscreen testing in rodents 
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requires several months of training prior to testing. As such, the high and early mortality rate 
in the Arx mutant mice means this platform was not a viable option for us to consider.  
 
6.3 Separating behaviour and seizures in PA mice 
Separating behaviour from seizures is notoriously difficult, particularly when many 
neurodevelopmental disorders feature seizures as a co-morbidity, and many patients with 
epilepsy are known to have cognitive disabilities. As many as 30% of autistic children have 
epilepsy (Chow et al. 2019). There is a high number of genes that when mutated lead to not 
only intellectual disability but also present with autism and epilepsy. This suggests that 
convergent molecular processes are being impacted by a variety of genetic insults early in 
development.  Epileptic encephalopathies are defined as disorders in which early, severe 
seizures contribute to cognitive and behavioural impairments (Nickels and Wirrell, 2017). 
While the exact mechanisms are yet to be determined, seizures early in development are thought 
to impair neurogenesis, synaptic reorganisation, and spinal loss in hippocampal neurons 
(Nickels and Wirrell, 2017). Individuals predisposed to epileptic syndromes are highly 
correlated with intellectual disability, even in the absence of seizures (Nickels and Wirrell, 
2017).  All patients with mutations in ARX have intellectual disability, but the extent to which 
seizures contribute to the cognitive impairment is not clear. 
 
Analysing the behavioural comorbidities in children with severe epilepsy can be challenging. 
In humans, it can be difficult to interpret whether behavioural abnormalities and cognitive 
regression are primary or secondary conditions, occurring before or after the onset of seizures, 
and if these phenotypic aspects worsen with seizures. This can be further complicated by the 
effects that anti-epileptic drugs may have on cognition and behaviour (Thompson et al., 2000, 
Mazarati, 2019). Animal models like the PA mutant mice provide the capacity to test if the 
primary cognitive deficits are present (and at what level) before the onset of seizures. For the 
first time in an Arx mutant mouse model, we have demonstrated that behavioural deficits in 
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sociability, anxiety, neuromuscular strength and hyperactivity, are all present prior to the major 
peak of seizure onset compared to wild-type littermates. Furthermore, we have shown that these 
traits do not change between one and two months of age despite the frequency and severity of 
seizures that PA1 and PA2 mice present with (with or without estradiol treatment). This leads 
us to suggest that expanded PA mutations in ARX may not cause traditional epileptic 
encephalopathies in humans. This is supported by the lack of cognitive regression observed in 
the mouse models, and limited evidence of regression of cognitive or behavioural deficits in 
patients. This is a cardinal finding for novel therapeutic development for these disorders, as a 
drug that targets seizures may not necessarily be effective for the intellectual disability in these 
patients, as observed in our study. Hence, treating intellectual disability in ARX patients 
remains problematic to address, particularly with such an early onset of phenotype, and the 
embryonic expression of the gene. 
 
The timing of treatment remains one of the most significant challenges in treating children with 
genetic mutations that cause neurodevelopmental disorders, such as ARX. The timing of key 
neurodevelopmental events, particularly interneuron development, takes part in mostly prenatal 
period in humans. In contrast, this process is still being completed in early postnatal life in mice. 
Hence, this time is available to target in the Arx mutant mice used in my PhD project with the 
period of estradiol treatment from postnatal days 3 to 10 but is equivalent to prenatal 
development of the brain in humans. In addition, the initial genetic insult we are modelling 
reflects ARX expression that is largely restricted to embryonic life. This undoubtedly presents 
a limitation of my study. However, given estradiol treatment during early postnatal period is 
effective at treating seizure frequency and severity in the PA mouse models, it provides 
important results for how exogenous steroids may impact the transcriptome of the brain, and 





6.4 Understanding the transcriptome of the developing PA brain in early postnatal life 
Despite low levels of Arx expression in the postnatal brain we wanted to establish the impact 
of PA mutations in Arx on the transcriptome in PA1 and PA2 mutant mice during early postnatal 
development. The genes that were deregulated in the PA1 and PA2 mutant mice at P10 were 
enriched for those involved with neurodevelopment, especially interneuron function. It is 
attractive to speculate that these deregulated interneuron genes contribute to the sustained 
seizures and behavioural phenotype reported in these PA mouse models. Arx is a transcriptional 
regulator and activator in embryonic brain development, so it was fascinating to see how the 
effects of a partial loss of function of this gene early in embryonic life impacts the brains of 
these mice, still at postnatal day 10. Many Arx target and responsive genes remain deregulated 
in our P10 data. This is interesting given that Arx expression is normally very low in the 
postnatal brain. Hence, I hypothesise that the loss of Arx during early development causes a 
“ripple” effect, with these genes and downstream targets being dysregulated even when Arx 
expression (and function) would normally be minimal.   
 
My original hypothesis was that estradiol treatment would improve seizure frequency and 
severity by rescuing the interneuron deficits present in the brain of PA mutant mice. This is the 
mechanism of action proposed by our collaborators when estradiol proved effective in the 
alternate Price et al. PA1 mouse model (Olivetti et al., 2014). However, while interneuron 
associated genes were deregulated without estradiol treatment, the majority of the deregulated 
transcriptome was unchanged by estradiol treatment. There was only a small overlap in genes 
deregulated by disease alone and the subsequent response to estradiol treatment. Furthermore, 
our immunofluorescence analysis of the brain did not indicate any increase to interneurons 
positive for calbindin or neuropeptide-Y with estradiol treatment. My analysis of the 
transcriptome following estradiol treatment indicates different pathways and processes are 
impacted compared to those initially disrupted. This is a potentially exciting finding as the 
beneficial effect of estradiol treatment may be useful for diminishing the severity of seizures 
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across a number of genetic causes of neurodevelopmental disorders where interneuron 
deficiency is not the mechanism of pathogenesis, such as epilepsies caused by disturbed 
excitatory neuron output. Instead our data leads us to propose that estradiol treatment acts via 
direct and non-direct estrogen signalling to change gene expression in pathways involved in 
transcriptional regulation, synaptic activity, neuronal development and other key brain related 
processes, to activate and repress genes outside of the disturbed PA transcriptome. The fact that 
estradiol did not act upon the same inhibitory neuron processes disrupted by the PA mutations 
may provide some explanation as to why treatment did not improve the cognitive phenotype in 
these mice.  
 
6.5 Future directions 
We have shown a reproducible effect of estradiol on the seizure phenotype of the PA1 and PA2 
mice in my study compared to an independent PA mouse model. However, my findings are in 
contrast when compared to induced models of seizures in mice. In an induced rat model of 
infantile spasms, the same dose (40ng/g) of estradiol did not reduce spasms, even while 
increasing the number of GABAergic cells in the neocortex (Chachua et al., 2016). The 
investigators concluded that estradiol treatment may only be effective in genetic models of 
interneuronopathies, and not in artificially induced seizure models, in this case, by using 
betamethasone and N-methyl-D-aspartic acid (NMDA). Genetic models of epilepsy and 
seizures have an advantage in regards to induced seizures models of implementing treatments 
early in development, prior to seizure onset. This is the case with the Olivetti et al. (2014) study, 
where early postnatal (P3-10) but not late (P33-40) estradiol treatment produced prolonged 
activation of estrogen receptors and gave an extended anti-epileptogenic effect. These anti-
epileptogenic effects of estradiol remain relatively unexplored. Much of the field has focused 
on the pro-epileptogenic effects of estradiol in female rodents, with oral contraceptives 
facilitating increased seizure activity and accelerating the rate of seizure onset in female mice 
(Younus and Reddy, 2016). Further investigation into the effects of estradiol in 
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neurodevelopmental models exhibiting seizures, even if not associated with interneuron 
deficits, would be particularly useful to further understand the anti-epileptogenic effects of low 
dose estradiol treatment.  
 
Fortunately, we found no adverse effects of 40ng/g 17β-estradiol for the seven-day period mice 
were treated in our study. Selective estrogen receptor modulators (SERMs) may be a potential 
treatment for epilepsy, without side effects that may come with higher doses of estradiol. While 
the research is still in early stages, raloxifene, a SERM currently authorised for treatment of 
osteoporosis, has shown promising results for treating epilepsy in post-menopausal women, for 
whom estradiol treatment is inadvisable (Pottoo et al., 2014). However, these preliminary 
studies have been in post-menopausal women (as with many studies into estradiol and epilepsy). 
In contrast, my project provides insight into low dose estradiol treatment in young, male mice. 
Interestingly, adjunct treatment of raloxifene may improve cognitive functioning, something 
we did not find estradiol treatment improved. A pilot study in schizophrenia patients using 
raloxifene with a calcium channel blocker, found that cognitive tests assessing memory were 
significantly improved with treatment (Pottoo et al., 2020). SERMs may provide a potential 
therapeutic target for neurodevelopmental disorders with both epilepsy and intellectual 
disability as key components of the clinical phenotype.  
 
My project utilised a bulk RNA sequencing technique to investigate the broad effects of Arx 
PA expansion mutations on the cortex of the brain. This approach has several limitations, 
including that gene expression levels are impacted by the proportion of individual cell types 
within the tissue, and the relative abundance of these cells, which in this case include excitatory 
and inhibitory neurons, as well as other cell lineages of the brain, such as abundant astrocytes 
(Sutton and Voineagu, 2020). With the advances in the techniques (including availability and 
cost) future experiments in these PA mice would benefit from using single cell RNA sequencing 
approaches to study the gene expression profiles deregulated by Arx mutations. The increased 
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resolution would have the capacity to determine the small but direct effects of a partial loss of 
Arx in subsets of cells and cell types. This approach could potentially determine the impact of 
these mutations and subsequent treatment on interneurons within the cortex specifically. Whilst 
potentially very powerful, this technology still has limitations.  Due to the lower input of single 
cell RNA sequencing, there is often higher levels of “noise” within the sample which requires 
additional analysis power. This method provides a sparse data set, with only a small subset of 
genes detected per cell (Sutton and Voineagu, 2020). To overcome these challenges a process 
of deconvolution could be utilised to enhance the usefulness of the pre-existing bulk RNA 
sequencing data obtained in my study. Deconvolution estimates the cellular composition of a 
tissue sample from its gene expression profile. This then allows approximate separation of gene 
expression patterns of each individual cell type within the tissue (Sutton and Voineagu, 2020). 
This method could allow separation of inhibitory interneuron gene expression from our data set 
of the postnatal day 10 cortex. Colleagues within my collaborator’s laboratory (Prof. Jozef 
Gecz, University of Adelaide, Australia) are currently building upon the limited methods for 
deconvolution of bulk RNA sequencing brain data, developing expertise in this growing field. 
Application of this analysis to gene expression studies in neurodevelopmental mouse models, 
including the Arx PA1 and PA2 mice would be of great interest to discovery and translational 
scientists alike.   
 
Currently there are only 34 clinical trials underway for infantile spasms in North America 
(www.clinicaltrials.gov). The discovery of new anti-epileptic drugs has been limited in recent 
times, and newer drugs have not yet shown increased efficacy over traditional therapies to date 
(Rho and White, 2018). The traditional anti-epileptic drugs are often of limited use against the 
refractory seizures in infantile spasms patients, including those with PA expansion mutations. 
While estradiol may provide a unique therapeutic approach to treating infantile spasms, the 
research is currently still limited, and treating male patients with high doses may prove 
problematic. Cannabidiol is currently being used in five clinical trials in North America 
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(www.clinicaltrials.gov). Cannabidiol is the non-hallucinogenic component of cannabis, and 
while its direct anti-epileptic mechanism of action is unknown, there are promising studies 
emerging. The endocannabinoid system is being increasingly associated with seizure activity, 
and uses endocannabinoid receptors CB1 and CB2 (Gaston and Szaflarski, 2018). Cannabidiol 
may have antagonist activity for these receptors, as well as blocking amandamide uptake, 
increasing its availability to activate CB1 and CB2 (Wallace et al., 2001, Thomas et al., 2007). 
Interestingly in terms of my study, there are now overlapping molecular pathways associated 
with CB1 and CB2 and estrogens (Dobovišek et al., 2016). 17β-estradiol has been shown to 
regulate the expression of CB1 in the brain in particular, and can increase the expression of both 
CB1 and CB2 in osteoblasts (Riebe et al., 2010, Rossi et al., 2013). Estrogen and cannabinoid 
receptors both activate the protein kinase A, cAMP, MAPK and PI3K pathways, and selective 
estrogen receptor modulating drugs have been shown to also act as agonists to CB1 and CB2 
(Dobovišek et al., 2016, Dobovišek et al., 2020).  Cannabidiol has recently been shown to be 
effective in treating refractory seizures (with sustained results) in Dravet syndrome patients, 
providing promising results for neurodevelopmental disorders with refractory epilepsy as a 
comorbidity (Moore and Robinson, 2018, Devinsky et al., 2019). With the interactions between 
estradiol and Cannabidiol becoming increasingly known, it is possible that the two drugs could 
act as adjunct therapies in treating these refractory seizures in neurodevelopmental patients.  
 
6.6 Concluding remarks 
Throughout my PhD project, I have investigated the effects of daily, short-term estradiol 
treatment given for 7 days in early postnatal life, to mice with expansion mutations in the first 
and second polyalanine tracts of Arx. I have documented the impact of estradiol treatment on 
seizures, cognition and behaviour, and investigated the transcriptomic profile of the brain in 
these mice. Estradiol treatment significantly reduced both the frequency and severity of seizures 
in the PA1 mouse model, and a model of the most common ARX mutation, PA2, in agreement 
with previous studies in an alternate PA1 mouse model. This provides reproducibility in pre-
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clinical animal studies, an important outcome of my project. Animal studies involving 
therapeutic targets for neurodevelopmental disorders are notoriously difficult to reproduce, but 
with the remarkable recapitulation of the patient phenotype in both of these PA mouse model, 
this reproducibility is promising in a field where new therapies for spasms and seizures have 
been lacking. However, the challenge remains in treating a disorder which impacts the brain in 
embryonic life, and we have still yet to show improvement to the debilitating intellectual 
disability aspect of ARX PA mutations. Importantly, we continue to uncover novel insights into 
the pathogenesis of PA mutations, showing the ongoing effects of a partial loss of Arx to the 
transcriptome at postnatal day 10, even with limited expression of Arx at this age. The 
association of interneurons of the cortex uncovered in my studies provides new insights into 
the cortex of these mice, and how different gene pathways contribute to the dramatic seizure 
phenotype of these mice, as well as the persistent anxiety and autistic-like behaviour. Although 
estradiol may not represent a clinical therapy for PA patients currently, by bettering our 
understanding of the mechanisms of disease and the impacts of estradiol treatment and 
outcomes on phenotype may provide critical insights to develop this as a potential adjunct 
therapy with other novel anti-epileptic drugs. Taken together, my data indicates strongly that 
estradiol treatment recruits processes and pathways reducing the frequency and severity of 
seizures in the Arx PA mutant mice, without precisely correcting the deregulated transcriptome, 
nor improving mortality or cognitive deficits. It is my firm belief that future studies will find 
my investigation into estradiol treatment for PA mutant mice valuable. It is my sincere hope 
that my studies may contribute to development of an effective therapy for infantile spasms and 
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Children with severe intellectual disability have an increased prevalence of refractory seizures. 
Steroid treatment may improve seizure outcomes, but the mechanism remains unknown. Here 
we demonstrate that short term, daily delivery of an exogenous steroid 17β-estradiol (40 ng/g) 
in early postnatal life significantly reduced the number and severity of seizures, but did not 
improve behavioural deficits, in mice modelling mutations in the Aristaless-related homeobox 
gene (ARX), expanding the first (PA1) or second (PA2) polyalanine tract. Frequency of 
observed seizures on handling (n=14/treatment/genotype) were significantly reduced in PA1 
(32% reduction) and more modestly reduced in PA2 mice (14% reduction) with steroid 
treatment compared to vehicle. Spontaneous seizures were assessed (n=7/treatment/genotype) 
at 7 weeks of age coinciding with a peak of seizure activity in untreated mice. PA1 mice treated 
with steroids no longer present with the most severe category of prolonged myoclonic seizures, 
while treated PA2 mice had a complete absence of any seizures during this analysis. Despite 
the reduction in seizures, 17β-estradiol treated mice showed no improvement in behavioural or 
cognitive outcomes in adulthood. For the first time we show that these deficits due to mutations 
in Arx are already present before seizure onset and do not worsen with seizures. ARX is a 
transcription factor and Arx PA mutant mice have deregulated transcriptome profiles in the 
developing embryonic brain. At postnatal day 10, treatment completion, RNAseq identified 
129 genes significantly deregulated (Log2FC >± 0.5, P-value<0.05) in the frontal cortex of 
mutant compared to wild-type mice. This list reflects genes deregulated in disease and was 
particularly enriched for known genes in neurodevelopmental disorders and those involved in 
signalling and developmental pathways. 17β-estradiol treatment of mutant mice significantly 
deregulated 295 genes, with only 23 deregulated genes overlapping between vehicle and steroid 
treated mutant mice. We conclude that 17β-estradiol treatment recruits processes and pathways 
to reduce the frequency and severity of seizures in the Arx PA mutant mice but does not 
precisely correct the deregulated transcriptome nor improve mortality or behavioural and 






 Mice with PA expansions in Arx present with severe seizures and behavioural deficits. 
 17β-estradiol treatment in early postnatal life reduced seizure frequency and severity. 
 Treatment with 17β-estradiol did not improve abnormal behaviour or mortality. 
 Behavioural deficits were present prior to and did not worsen with seizures.  
 17β-estradiol treatment activated alternate gene pathways to those disturbed due to 
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Epilepsy is a devastating disorder that affects more than 50 million people worldwide (WHO, 
2019), with recent estimates of active epilepsy as high as 1.2% in developed western countries 
(Zack and Kobau, 2015). This disorder is characterised by involuntary seizures, due to an 
imbalance of excitatory and inhibitory neuronal activity in the brain. One form of epilepsy in 
infancy is epileptic spasms, including X-linked infantile spasms syndrome (ISSX; MIM# 
308350). This disorder has a prognosis of severe epilepsy coupled with intellectual disability 
persisting throughout childhood and adolescence (Olivetti and Noebels, 2012, Hrachovy and 
Frost, 2013). Children with neurodevelopmental disorders often have complex overlapping 
phenotypes. For example, patients with severe intellectual disability have a 15-20% incidence 
higher than the general population of co-morbid features including recurrent seizures and 
autism spectrum disorder (ASD). As many as half of intellectual disability cases and epileptic 
syndromes are believed to be caused by genetic mutations, with an increasing list of genes 
responsible (Willemsen and Kleefstra, 2014, Chiurazzi and Pirozzi, 2016, Ellis et al., 2020), 
with genes involved in various pathways including development and maintenance of the brain 
function and architecture, and neuronal functioning often mutated (Paciorkowski et al., 2011, 
Olivetti and Noebels, 2012). 
The Aristaless-related homeobox gene (ARX) [NM_139058.2] (MIM#300382) is known to 
play a pivotal role in the development of the brain, specifically the migration and differentiation 
of interneurons (Miura et al., 1997, Kitamura et al., 2002, Kitamura et al., 2009, Lee et al., 
2014). Interneurons are small, locally projecting neurons that use the neurotransmitters γ-
aminobutyric acid (GABA), acetylcholine and neuropeptides, to modulate excitation within 
neural networks. It is not surprising that dysfunction of GABA interneurons in the cerebral 
cortex is involved in neuropathology including epilepsy, schizophrenia, autism and intellectual 
disability syndromes (Le Magueresse and Monyer, 2013, Smith-Hicks, 2013). Mutations in 




comorbidities, including autism, dystonia, and epilepsy (Kitamura et al., 2002, Shoubridge et 
al., 2010). Over half of all inherited mutations in ARX patients leads to expansion of the first 
or second polyalanine tracts. Clinical presentation of families with expansion mutations in the 
first tract (PA1) generally present with phenotypes of infantile spasms and seizures (81%) 
(Shoubridge et al., 2010, Marques et al., 2015), while patients with mutations in the second 
tract (PA2) present with non-syndromic intellectual disability (68%), with dysarthria, dystonic 
hand movements (20%) and infantile spasms (26%) (Partington et al., 2004, Shoubridge et al., 
2010, Marques et al., 2015, Jackson et al., 2017). The mechanisms underpinning this clinical 
variability remain unclear. 
Children with infantile spasms associated with severe intellectual disabilities respond poorly 
to anti-convulsant medication. Adrenocorticotrophic hormone (ACTH) therapy known to 
stimulate production and release of corticosteroids is a frontline treatment for these disorders 
but often has low efficacy, high relapse rates and severe side effects that alongside early-onset 
seizures, are thought to further exacerbate the behavioural and cognitive deficits in affected 
children (Hrachovy and Frost, 2013). A preclinical trial in the Arx PA1 mouse (Price et al., 
2009) model found that short-term 17β-estradiol (E2) given daily in the first postnatal week 
alleviated the severe seizure phenotype in adult male mice (Price et al., 2009, Olivetti et al., 
2014). Estradiol is a neurosteroid produced in the nervous system which plays important roles 
in the developing brain in synaptogenesis and morphometry of neurons and glial cells and can 
induce long-term changes in gene expression in the brain via activation of estrogen receptors 
and non-receptor pathways. 17β-estradiol treatment of PA1 mice partially restored the 
interneuron migration deficits in the neocortex, increased populations of neuropeptide-Y and 
calbindin positive interneurons, and changed the expression of several genes normally 
regulated by Arx (Olivetti et al., 2014).  
The migration of these inhibitory cells and other stages of cortical laminar positioning occurs 




there is a surge of intrinsic estradiol and conversion of testicular testosterone into estradiol 
during this period of brain development (McCarthy, 2008). While much research into 
estradiol’s effects on the epileptic brain has been focused on the pro-epileptic activity of the 
hormone in the adult brain, its neuroprotective effects in the developing nervous system are 
still being explored. Estradiol has long-lasting transcriptional actions via estrogen receptors α 
and β, with genes regulated by estradiol being involved in cell proliferation, neuronal 
migration, synaptogenesis and cell survival. Estradiol also regulates of GABAergic neuronal 
populations and increases the numbers of inhibitory neurons in the pyramidal layers of the 
cortex (Nakamura and McEwen, 2005, Velíšková, 2006).  
Here we investigate the role of early estradiol treatment in mice modelling both the common 
PA1 and the more frequent PA2 ARX mutations (originally reported by Kitamura et al. 2009). 
Our study explores the effect of estradiol on the seizure phenotype in Arx mutant mice and 
extends the investigation to the impact of this treatment on cognitive outcomes before and after 
the peak onset of seizures. We also analysed genome wide transcriptomic changes in the 
postnatal neocortex in PA1 and PA2 mutant mice with and without estradiol treatment to 
elucidate molecular mechanisms driving infantile spasms, seizures and intellectual disability 











Materials and Methods 
Animals. All animal procedures were approved by the Animal Ethics Committee of The 
University of Adelaide, Adelaide. ArxGCG7/+ (RBRC03654) and Arx432-455dup/+ (RBRC03653) 
heterozygous females, called PA1 and PA2 mice respectively, originally imported from 
RIKEN Bioresource Centre, Japan were maintained on the C57BL/6N-Hsd background 
(Kitamura et al., 2009). Animals were housed in individually ventilated cages under constant 
temperature and humidity with an 8:00 to 20:00 light/dark cycle. Animals were given a diet of 
10% fat food and water available ad libitum, as well as crushed standard chow soaked in sterile 
water in an accessible feeding dish, refreshed daily. PA1 and PA2 heterozygous females were 
bred as trios with wild-type C57BL/6N-Hsd stud males to produce wild-type and hemizygous 
mutant males. There were no abnormal parenting behaviours in our heterozygous female 
mothers to report.  Five rounds of staggered breeding were performed to generate experimental 
cohorts. Litters of male mice were weaned from their mothers at approximately postnatal day 
21 to day 23 (P21-P23) upon the smallest pup reaching 8 grams of body weight as a minimum. 
All pups were weighed from P3 and monitored and scored daily for general health and welfare, 
appearance, and any observed seizure activity.  
Genotyping.  A small piece of toe tissue was removed by sterile technique at postnatal day 5 
or 6 for genotyping and to provide an individual identification mark.  Genomic DNA was 
extracted as per manufacturers’ instructions for the High Pure PCR Template Preparation Kit 
(Roche) or the Maxwell® RSC Tissue DNA kit (Promega). Genotyping PCR was performed 
as described in (Lee et al., 2014).  
Drug preparation and injections. In all cases, male mice were studied. 17β-estradiol (E2) 
(Sigma) was diluted in sterile sesame oil (Sigma) containing 0.75% (v/v) dimethyl sulfoxide 
(DMSO) (Sigma). Vehicle comprised sesame oil with 0.75% (v/v) DMSO. Estradiol and 




P3 and all males from one litter were injected subcutaneously with either estradiol or vehicle 
daily from P3 until P10 inclusive, alternating injection site daily between the neck and left and 
right hips of the pup. The estradiol dose used was 40ng/g, therefore mice weighing 1.5g 
received 60ng of estradiol (Olivetti et al., 2014).  
Treatment groups. All male mice in each litter were injected with either estradiol or vehicle 
treatment (Drug 1 or Drug 2 as these were blinded for the duration of the study). Genotypes 
and drugs were unblinded at the end of the study. This resulted in six different treatment groups 
for subsequent analysis: wild-type mice treated with either vehicle or estradiol, PA1 mice 
treated with either vehicle or estradiol, and PA2 mice treated with either vehicle or estradiol. 
Behavioural analyses. Repeat behavioural testing was performed at approximately one and 
two months of age. Tests were conducted in the light phase of the cycle, always beginning by 
9:00 and ending by 13:00. Testing at one month of age ran for one week and were performed 
in the following order: open field and inverted grid; sociability and social novelty. Testing at 
two months of age ran for two weeks and were performed in the same order in the first week, 
followed by Barnes maze in the second week. All testing was analysed using ANYmaze video 
tracking software (Stoelting). Behavioural apparatuses were thoroughly cleaned with F10 
Veterinary Detergent between mice to remove olfactory traces. The behavioural testing 
protocols were previously described (Jackson et al., 2017). A more detailed description of the 
behaviour testing protocols used for this study is outlined in Supplementary File 1.  
Seizure monitoring and analysis. Mice received daily injections between day 3 and day 10 
and remained with their mothers until weaning. From the start of treatment (postnatal day 3) 
until postnatal day 70, all mice for behavioural testing and seizure monitoring were handled 
and weighed daily. Any observed seizures occurring during this daily handling were recorded. 
Spontaneous seizures were assessed during non-invasive video monitoring (with offline 
analysis) across the peak period of seizures (previously determined in untreated mice to occur 




was conducted three times a week in four hour blocks from 11:00 until 15:00 during light cycle, 
on PA1 and PA2 hemizygous males and age matched control wild-type littermates, between 
the ages of P38 and P56. Cage mates were placed in a Perspex covered 17.5cm by 31cm cage, 
with a small piece of Nectragel (Able Scientific) and food available ad libitum during the 
filming period. Natural behaviour was captured and automatically saved in 50-minute video 
files by a Sony FDR-AXP35 4K Handycam or a Panasonic HC-VX980M 4K Video Camera. 
Activity levels and seizure activity were viewed offline using VLC Media Player (version 
2.1.3). Videos were analysed by observers blinded to genotype and treatment.  Seizure activity 
was scored using a defined scoring system based on categorisation of seizures compared 
directly to video-electroencephalography in untreated mutant mice from a previous study 
(Jackson et al., 2017). In brief, seizures in mutant mice were characterised into four categories: 
(1) rapid and jerky movements around the cage and stationary seizures, (2) mild repetitive 
myoclonic jerks (duration less than 10 secs), (3) prolonged myoclonic seizures lasting longer 
than 10 seconds and (4) found dead. Myoclonic seizures were recorded for length of seizure in 
seconds.  
Tissue collection. Animals for RNA sequencing analysis were humanely killed by decapitation 
at P10, and behavioural/seizure monitoring animals were humanely killed at approximately 
P70 by CO2 asphyxiation, if not euthanised for humane reasons prior to endpoint. The brain 
was dissected, and the forebrain separated from the cerebellum and cut in half sagittally along 
the cerebral fissure. The left hemisphere of the brain was minced and snap frozen in liquid 
nitrogen and stored at -80°C.  
RNA isolation and sequencing.  RNA was extracted from the cortex of hemizygous male mice 
from each of the two strains, PA1 and PA2, and matched wild-type littermates, using Trizol 
(Sigma) and RNAeasy Mini Kit (Qiagen). RNA was prepared using Illumina’s TruSeq stranded 
RNA sample preparation protocol and sequenced on an Illumina NextSeq Platform (n = 6 wild-




data was generated using the Illumina bcl2fastq 2.19.1.403 pipeline. The per base sequence 
quality was >95% bases above Q30 across all samples. The reads were also screened for the 
presence of any Illumina adaptor/overrepresented sequences and cross-species contamination. 
The cleaned sequence reads were then aligned against the Mus musculus genome (Build version 
mm10). The Tophat aligner (v2.1.1) was used to map read to the genomic sequences. The 
counts of reads mapping to each known gene were summarised and used for computing 
differential gene expression with ‘edgeR’ version 3.12.1 to assess differential expression. Low 
counts were filtered out (cpm<1) and the default TMM normalisation method of edgeR was 
used to normalise the counts between samples. A generalised linear model was then used to 
quantify the differential expression between the groups. Transcripts that were significantly 
different within genotype and treatment group comparisons were selected by applying a p-
value cut off <0.05 and a log2 fold-change of ±0.5.  
RT-qPCR for RNAseq validation.  RNAseq results were validated using Taqman RT-qPCR 
on two groups of RNA; a technical validation cohort on the samples used for RNAseq, and a 
biological validation cohort, using RNA from mouse samples (n = 6 wild-type samples and n 
= 4 PA1 and PA2 samples for each treatment group). RNA was extracted as described above. 
cDNA was prepared and RT-qPCR was performed as previously described (Mattiske et al., 
2016). Expression of genes was determined using Taqman probes labelled with FAM with 
expression normalised to the reference gene, Beta-Actin assayed within the same sample using 
a Taqman probe labelled with VIC. Taqman probes used in this study are listed in 
Supplementary Table 1. 
Gene enrichment analysis.  Venn diagrams for gene expression data analysis were created 
using http://bioinformatics.psb.ugent.be/webtools/Venn. Statistical analysis of the enrichment 
of gene expression data was performed using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) Functional Annotation Bioinformatics Microarray Analysis. 




et al., 2009). These clusters were given overarching theme names and ranked. To rank the 
enrichment results we used enrichment scores calculated by DAVID.  
Interneuron quantification - Tissue sectioning. Cortex from mice was coronally embedded in 
OCT and stored at -80°C until sectioning. Coronal sections of 10µm thickness (~2-3 cells thick) 
at 100µM apart were taken serially using a Leica Crytostat (Leica Biosystems) at -24°C. 
Sections were fixed to SuperfrostTM Plus microscope slides (ThermoFisher). Frozen cortical 
sections were stored at -20°C until analysis. Sections analysed align to sections 100-124 of the 
Nissl stained postnatal day 7 coronal brain of the Allan Brain Atlas reference guide. 
Staining and microscopy. Immunofluorescence staining was performed as described in Lee et 
al. 2017. Primary antibodies: rabbit anti-calbindin (1:1000, Merck PC252L) and sheep anti-
neuropeptide Y (1:1000, Sigma T2200). Secondary antibodies: goat anti-rabbit (1:500, Alexa 
555, Thermo Fisher A27039) and donkey anti-sheep (1:500, Alexa 488, Thermo Fisher 
A11015). Immunofluorescent images were captured using a Zeiss AxioCam mRM camera 
attached to a Zeiss Axio Imager.M2 microscope equipped with Axio Vision software (version 
5.1). All comparative images were captured with the same exposure times.  
Interneuron analysis. At least four sections across the right hemisphere were analysed. Images 
were stitched together using Microsoft Image Compositor (Microsoft, version X) and imported 
into Image J (FIJI, version X) for processing and analysis. Manual cell counts were performed 
using the Cell Counter plugin for Image J, using method described in Lee et al. 2017. Calbindin 
positive cells had a circular-like cell body with neuropeptide-Y cells displaying cytoplasmic 
and/or nuclear staining with clear boundaries of the structure, correlating to a clear nucleus 
DAPI stained. Counts were exported into Excel and a cell density of number of cells/mm2 were 





Statistical analysis. Data analysis was performed using GraphPad Prism version 7.0 (GraphPad 
Software Inc.). Data normality was confirmed using a D’Agostino and Pearson normality test. 
Statistical significance of the difference between means of each genotype (PA1 or PA2), 
treatment groups (estradiol or vehicle) and wild-type littermates was determined using a one-
way analysis of variance (ANOVA) followed by a Tukey’s HSD post-hoc test. When 
comparisons were made between two treatment groups of the same genotype (PA1 or PA2), 
without wild-type littermates included in the comparisons (seizure data), a two-tailed, unpaired 
t-test was performed to determine statistical significance. The statistical significance of the 
overlap of genes between two groups was calculated using exact hypergeometric probability 
(http://nemates.org/MA/progs/overlap_stats.html; date last accessed April 19, 2020). For 
statistical analysis of interneuron cell counts, PA1 and PA2 mice were pooled. A one-way 
ANOVA was performed to determine statistical significance between PApool mice treated with 















Estradiol treatment reduces seizure frequency and severity but does not improve 
mortality in PA mutant mice.  
PA1 and PA2 mutant males and wild-type (WT) male littermates were treated with daily 
subcutaneous injections of estradiol (40ng/g) for seven days between P3 and P10 (Figure 1A). 
Estradiol treatment significantly reduced the overall proportion of adult PA1 mutant mice 
experiencing seizures on daily handling, with a 32% reduction compared to vehicle treated 
mice (14% and 46% respectively, Figure 1B). Within the PA2 cohort, a 14% reduction was 
noted with estradiol treatment (44% versus 58%, respectively) but this did not reach 
significance (p = 0.4243). In PA1 mice, both the total number of observed seizure events and 
the number of severe seizures (scores of 2 or 3) were significantly reduced in estradiol treated 
animals compared to vehicle treated mutant mice (Figure 1C).  
However, the effect of estradiol on the age of seizure onset differed between the two mutations. 
Estradiol actually accelerated the onset of seizures in PA2 mice, with estradiol-treated mice 
having their first seizure at postnatal day 26 ± 2.5 (mean ± SEM) (Figure 1D), while treatment 
had no effect on PA1 mutants (45 ± 1.5) and vehicle treatment (43± 2.6) (Figure 1D). These 
data demonstrate that observed seizures on handling the Arx mutant mice are reduced in both 
severity and frequency with estradiol treatment, however, the specific intragenic mutation 
produced a differential response with estradiol, with accelerated epileptogenesis in PA2 mice 
compared to PA1. Mice observed having a seizure upon daily handling that subsequently went 
on to die from a presumed seizure (found dead in their cage) within 2-4 days of having seizure 
are shown as stars on Figure 1D. Interestingly, 2 of the 3 PA2 mice treated with estradiol in 
this category died during this early time point (Supplementary Figure 1), whilst the third mouse 
died after a subsequent seizure at a later time point (postnatal day 56). Within the PA2 vehicle 




recorded as having an observed seizure on handling during this period.  However, we cannot 
rule out that seizures may have occurred outside of the times we were handling and observing 
the animals as part of daily health checks (P3 to P70) or outside the times captured by video 
seizure monitoring during P35 to P60.  
In untreated mutant mice the peak of observed seizures was clustered between P35 and P60 
(Jackson et al., 2017). To exclude any influence of induced stress due to handling of the mice, 
we investigated seizures in a spontaneous setting via non-invasive video monitoring (12 hours 
per mouse over a period of four days) during this peak period. At P45 to P48, 36% (4/11) of 
PA1 mice treated with vehicle displayed a large number of clusters of individual seizure events 
ranging from rapid, jerky movement around the cage (score 1) through to increasingly severe 
myoclonic seizures (score 2 and 3) (Figure 2). Video clips of seizures in these mice are 
available (Jackson et al., 2017). Although 30% (3/10) of the estradiol treated PA1 mice 
displayed seizures across this same period of time, both the number and severity of seizure 
events were significantly reduced (Figure 2). This trend is even more striking in the PA2 
cohort; 33% (4/12) of vehicle treated mice displaying a total of 28 seizure events across all 
scoring categories, compared to seizures being completely absent in the estradiol treated mice 
(0/7) during this same monitoring period (Figure 2). Further, when looking at the observed 
seizures on handling that PA2 mice experienced during this time, only one mutant mouse 
treated with estradiol experienced seizures during this same period of time. We observed that 
there were no seizures in vehicle or estradiol treated wild-type mice by either the observed 
seizures on handling or non-invasive video seizure monitoring analysis.  
Despite the significant improvements in frequency and severity of seizures in both the PA1 and 
PA2 mutant mice treated with estradiol, the median survival rates of these animals were not 
significantly extended compared to vehicle treated animals (Figure 3). Survival was recorded 
from P0 to P70. These data excluded mice that were cannibalised by their mother prior to P10 




phenotype. Mice still alive at the completion of the experimental period were culled at P70. 
Considering the animals that died before the experimental end point at P70, 62% of PA1 mice 
treated with vehicle died compared to 64% treated with estradiol (Figure 3). Similarly, 37% of 
PA2 mice treated with vehicle died before the experimental end point at P70, compared to 31% 
treated with estradiol (Figure 3). The mean age of death (excluding survival to end point cull) 
in vehicle treated compared to estradiol treated mutant mice was not significantly different for 
either PA1 or PA2 mice; PA1 vehicle treated mice 53 ± 5.1 (mean ± SEM) compared to 52 ± 
5.5 in PA1 estradiol treated mice, with PA2 vehicle treated mice was 45 ± 4.6, compared to 37 
± 5.2 in PA2 estradiol treated mice (Supplementary Figure 1). There were no deaths among the 
WT group (vehicle or estradiol) other than animals culled to provide age matched littermate 
samples for mutant mice where required.  
Further to our seizure and mortality findings, we confirm in this study that compared to WT 
littermates the PA mutant mice have reduced testes weight and reduced body weight, consistent 
with previous reports (Kitamura et al., 2009, Jackson et al., 2017). Here we demonstrate that 
there was no change to the weight of the testes or brain in WT, PA1 or PA2 mice following 
estradiol treatment (Supplementary Figure 2). Similarly, there were no improvements to the 
reduced body weight of mutant mice compared to WT littermates with estradiol treatment 
(Supplementary Figure 3). 
 
Behavioural deficits are present in PA mice prior to seizure onset, and do not improve 
with estradiol treatment.  
Both PA1 and PA2 mutant mice exhibit increased locomotor activity, abnormal anxiety traits 
and reduced sociability and autistic-like behaviour at two months of age (Kitamura et al., 2009, 
Jackson et al., 2017). To examine disease progression in relation to seizure onset, we tested 




and again at P56 to P70 (two months of age – after peak seizure onset) with and without 
estradiol treatment. We did not observe any significant difference in the total distance travelled, 
nor time spent immobile by PA mutant mice compared to wild-type littermates (Supplementary 
Figure 4). In contrast, we demonstrated that the anxiety-response in PA mutant mice was 
different compared to WT littermates and did not regress over the duration of the study. At 2 
months of age, WT littermates displayed normal exploratory behaviour with an average of 84% 
(vehicle) and 80% (estradiol) of the total distance travelled in the open field periphery. Contrary 
to this, PA1 mutant mice spent significantly more time in the periphery versus the central field 
of the open field apparatus, with an average of 91% (vehicle) and 96% (estradiol) (Figure 4A). 
This was also observed in the PA2 cohort, in both treatment groups with an average of 95% 
(vehicle) and 93% (estradiol) (Figure 4A). These results are indicative of decreased exploratory 
behaviour in both PA mutant mice compared to WT littermates, with increased anxiety-like 
behaviour (increased fear of venturing into the central field, choosing to stay in the safety of 
the periphery). These differences are shown in the tracking maps from the respective genotypes 
in the open field test (Figure 4B). There were no significant differences observed between the 
two ages sampled in either PA mutant cohort, indicating there was little change due to disease 
progression or age of the mice in either genotype. This data indicates that early estradiol 
treatment did not improve anxiety or fear behaviour in adult PA mutant mice. 
Sociability testing measures several behavioural traits seen in mouse autism models. As 
expected, WT littermates chose to interact with another mouse over an inanimate object (empty 
chamber) (sociability phase: Figure 4C), and then chose to interact with novel (or stranger) 
animal over the familiar (or known) animal (social novelty phase: Figure 4D). This pattern of 
behaviour is indicative of normal social interaction and memory recall. Combining the mutant 
PA1 and PA2 data to create a PApool group compared to wild-type littermates, we demonstrate 
the PApool mutant mice of both vehicle and estradiol treatment groups showed significantly 




(individual PA graphs are supplied in Supplementary Figure 5).  The interaction times with 
other mice in the test chambers were reduced, regardless of whether the mouse occupant was 
novel or familiar. There was no significant difference between the two time points in the PApool 
cohort, indicating reduced sociability was already present at one month of age and did not 
change with disease progression or age.  
Next we determined the impact of genotype and treatment on the neuromuscular strength in 
PA mice at two months of age using the inverted grid test. WT littermates decreased latency to 
fall from the grid averaged 76 seconds (vehicle) and 90 seconds (estradiol) compared to PA1 
mice with 25 seconds (vehicle) and PA2 mice for 23 seconds (estradiol) (Figure 4E). Pooling 
the data for the mutant mice (PApool group) to increase the sample size, both vehicle and 
estradiol had significantly decreased latency to fall from the grid compared to their respective 
WT groups (Figure 4E). 
To assess the impact of treatment on cognition and learning, the Barnes maze tested the amount 
of time each mouse required to locate an escape hole (in relation to false holes) in the testing 
apparatus, with improving or shorter times gained during subsequent testing. This test is 
conducted at two months of age. All groups tested showed normal adaptive function and 
memory, demonstrating shorter times to find the escape hole over a progressive four-day 
testing period (Supplementary Figure 6). Although we have previously demonstrated a memory 
deficit when testing via the Barnes maze in untreated PA mutant mice (Jackson et al., 2017), 
in the current trial we did not detect a significant difference between the PA mutant mice of 
either treatment group and their WT littermates. This difference is likely due to the limited 
numbers of animals achieving the age required to perform this test. Of note, there was no 
difference in the performance of WT or mutant animals when vehicle treated animals were 





PA1 and PA2 mutant mice have a deregulated cortical transcriptome at postnatal day 10. 
Since Arx is a transcription factor, our next aim was to generate an unbiased map of RNAseq 
mRNA copy number changes in the cortical transcriptome at P10 due to Arx PA mutations. 
Compared to age-matched, vehicle treated WT mice analysis of PA1 mice revealed 63 genes 
deregulated by Log2 fold change greater than ± 0.5 with a P-value of less than 0.05 
(Supplementary Table 2). The majority (65%) of genes were found at a decreased level of 
expression compared to WT (Figure 5A). PA2 mice demonstrated 80 genes deregulated using 
the same fold cut-off (Supplementary Table 2), with 46% of genes having decreased expression 
when compared to WT mice (Figure 5A). Of the twelve genes chosen for biological validation 
by quantitative PCR, 100% (12/12) validated in PA1 mice and 60% (7/12) validated in PA2 
mice (Supplementary Figure 7). There were fourteen genes deregulated in both PA1 (22%) and 
PA2 (18%) mice (Figure 5B). Of this core overlap group, 57% (8/14) of genes were 
downregulated in their expression and included genes important in neuronal development and 
associated with neurodevelopmental disorders (Figure 5C). Given the highly similar 
neurological phenotypes between the PA1 and PA2 mice coupled with similar responses to 
estradiol treatment observed in this study we chose to combine the data of the four males from 
each of the PA1 and PA2 mice as a single mutant group (PApool). This analysis showed 58 
genes deregulated using the same fold cut-off, with 62% demonstrating a decreased level of 
expression compared to the pooled WT controls (Figure 5A).  
Arx target genes (identified in Mattiske et al. 2016) were significantly enriched in the list of 
deregulated genes in the PApool group (10/58, 17%, p<1.288e-5) and in each of the PA1 (13/63, 
21%, p<7.366e-8) and PA2 groups (9/80, 11%, p<9.641e-4). Known epilepsy genes (in house 
curated reference list) were not significantly enriched in any group of genes deregulated by 
disease (PA1; 2/63, 3%, p<0.100: PA2; 2/80, 2%, p<0.343: PApool; 3/58, 5%, p<0.058). Genes 
associated with autism and ID (Gene Dx Xpanded Panel, (GeneDx, 2020)) were significantly 




neuron regulation or development (in house curated reference list) (10/58, 17%, p<6.957e-16) 
compared to WT mice (Figure 5D). Interestingly, the majority of these enriched interneuron 
genes were downregulated in their expression for all three genotypes (PA1, PA2 and PApool) 
(11/13, 84.6%) (Figure 5E).  
Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) we 
analysed pathways and ontology terms enriched within the disease-deregulated transcriptomes 
of PA mutant mice (Supplementary Figure 8). These clusters were ranked by enrichment score, 
with two clusters overlapping between PA1 and PA2; glycoproteins and glycoprotein 
receptors. Other enriched functions of note were PI3K-Akt signalling, neurotransmitter 
biosynthesis, and synaptic processes (Supplementary Figure 8). Many of the clusters are 
associated with brain and neuron development or signalling that when disrupted may be 
predicted to contribute to the phenotypic features of the PA mutant mice.  
 
Estradiol targets genes outside of the deregulated transcriptome of PA mutant mice. 
To investigate the impact of estradiol treatment at the transcriptome level, we first analysed 
WT mice treated with vehicle compared to estradiol. There were 56 genes deregulated by Log2 
fold change greater than ± 0.5 with a P-value of less than 0.05 in the WT cohort when treated 
with estradiol. Genes deregulated in the WT mice estradiol treatment group that overlapped 
with the PA mutant groups were removed from subsequent analysis of PA1, PA2 and PApool 
(Supplementary Table 3).  
Analysis of PA1 mice with estradiol treatment compared to vehicle resulted in 124 genes 
deregulated by Log2 fold change greater than ±0.5 with a p-value of less than 0.05 
(Supplementary Table 4). The majority (75%) of genes were found with an increased level of 
expression compared to vehicle treated PA1 mice. This was in contrast to the smaller response 




mice with estradiol treatment compared to vehicle resulted in 158 genes deregulated at the 
same cut-off (Figure 6A).  
In contrast to the PA1 mice, in the estradiol treated PA2 mice had 77% of genes with a 
decreased level of expression (Figure 6A). This is compared to the similar numbers of disease 
changed genes (PA2 vs WT) having increased or decreased expression (54% vs 46%, 
respectively). In the estradiol treated PApool mice there were 55 genes deregulated by the same 
cut-off, with 62% having increased expression (Figure 6A). We randomly chose nine genes for 
biological validation by quantitative PCR, with 44% (4/9), 22% (2/9) and 56% (5/9) validating 
in PA1, PA2 and PApool mice respectively (Supplementary Figure 9).  
We next determined if genes deregulated by estradiol were enriched for genes containing 
estrogen response elements by comparing to a list of mouse genes containing high-affinity 
estrogen response elements (EREs) (Bourdeau et al., 2004). ERE-containing genes were 
significantly enriched in WT (12/56, 21%, p<0.012) and in PA1 mice treated with estradiol 
(22/124, 18%, p<0.010) but not in PApool (8/53, 15%, p<0.190) or PA2 mice (22/158, 15%, 
p<0.106) (Figure 6A). 
The size of the gene expression response to estradiol treatment in PA1 and PA2 mice was larger 
in comparison to genes deregulated by the Arx mutation alone and with little overlap (Figure 
6B). Genes deregulated by estradiol treatment were quite different between genotypes, with 
only small numbers of overlapping genes (8 genes in PA1 mice, 12 genes in PA2 mice and 3 
in PApool) (Figure 6C). Interestingly, all of the genes deregulated by disease that were also 
changed with estradiol treatment were deregulated in the opposite direction with treatment 
(Figure 6C). When we analysed the proportion of genes deregulated by estradiol in all three 
mutant groups (PA1, PA2 and PApool) the response to estradiol treatment between these three 
groups is strikingly different (Figure 6D). Only 11 genes overlapped between the PA1 and PA2 
estradiol response (Figure 6D). When we consider the functionality or pathways responding to 




three of the mutant groups, including transcription regulation and glycoproteins 
(Supplementary Figure 10). Of note, genes involved in transcription regulation included Shox2 
and Ebf3. Both of these genes were significantly downregulated with treatment (Olivetti et al., 
2014). We see this in PA2 mice in our study, however not in the PA1 mice, largely due to the 
variation between samples. 
Extending the data from genes deregulated by Arx mutation (Figure 5D), both 
neurodevelopmental disorder and inhibitory neuron associated genes were enriched in 
estradiol-treated mice (Figure 6E). However, in comparison to disease changed genes, 
interneuron associated genes were not trending in a particular direction with estradiol, with 
approximately equal proportions being increased or decreased in expression with treatment in 
the PA mutant mice (data not shown). Genes associated with autism and intellectual disability 
were significantly enriched in all groups treated with estradiol (PApool: 9/53, 13%, p<2.083e-5: 
PA1; 15/124, 10%, p<0.000003: PA2; 10/158, 6%, p<0.016). Epilepsy associated genes were 
enriched to a very low level, and variably depending upon the mutant group considered (PA1; 
6/124, 5%, P<0.014: PApool; 1/53, 2%, p<0.431: PA2; 3/158, 2%, P<0.442) (Figure 6E). Genes 
associated with inhibitory neurons were significantly enriched in the list of genes deregulated 
with estradiol treatment (PApool; 6/55, 11%, p<8.962e-9: PA1; 7/128, 6%, p<6.424e-8; PA2; 
9/161, 6%, p<6.609e-10) (Figure 6E).  
Next we performed immunofluorescent microscopy to determine the abundance of calbindin 
(Cb) and neuropeptide-Y (Npy) positive interneurons in the prefrontal cortex of mutant and 
WT mice at postnatal day 10. There were no significant deficits in the density of Cb or Npy 
positive interneurons in PApool mice compared to WT at postnatal day 10 across all layer of 
the cortex (Figure 7A-B).  Nor did we see any difference to cell density of either of these 







Here we present a comprehensive behavioural and transcriptomic assessment of the impact of 
early postnatal steroid treatment on the development of seizures in mice modelling the two 
most common ARX polyalanine expansion mutations. Our data demonstrates that despite the 
sustained benefit of short term 17β- estradiol treatment early in postnatal life on the frequency 
and severity of seizures in both PA1 and PA2 mutant mouse models, there were no significant 
improvements to survival, anxiety, sociability, cognitive or neuromuscular deficits in treated 
mice in adult life. Importantly, our data provides support for reproducible anti-epileptogenic 
outcomes previously reported in a comparable Arx PA1 mutant mouse, studied on a different 
genetic background (Olivetti et al., 2014). We have characterised the reduction in seizure 
frequency and severity in both PA mutant mice using a scoring matrix via video monitoring 
correlated to video-EEG (Jackson et al., 2017). Here we expand these findings to indicate that 
short term, early 17β-estradiol administration also reduced seizures in the PA2 mutant mouse 
that models the most frequently reported polyalanine tract expansion mutation in ARX patients. 
 In contrast to the reproducible effect of estradiol on the seizure phenotype of the PA1 and PA2 
mice, the same dose (40ng/g) of estradiol in an induced rat model of infantile spasms (via 
betamethasone and N-methyl-D-aspartic acid) did not improve spasms, even while increasing 
the number of GABAergic cells in the neocortex (Chachua et al., 2016). Similarly, estradiol 
treatment was demonstrated to have no effect in an induced infantile spasms rat model 
(Galanopoulou and Moshé, 2015). The anti-epileptogenic effects of estradiol remain relatively 
unexplored with much of the field focused on the pro-epileptogenic effects of estradiol in 
female rodents (Younus and Reddy, 2016). Investigation into the effects of estradiol in other 
neurodevelopmental models exhibiting seizures, with and without associated interneuron 





Despite the reduction in the frequency and severity of seizures there was no reduction in 
mortality of either PA1 or PA2 mice with steroid treatment. This was a novel finding. The 
cause of death could not be confirmed by post-mortem due to the timing of death occurring 
overnight. On examination in the mornings, we could not contribute death to any obvious 
cause. While the immediate cause of death in PA mutant mice is unclear, the lack of progressive 
deterioration and presence of convulsive seizures suggests that sudden unexpected death in 
epilepsy (SUDEP), or prolonged status epilepticus, as a possible diagnosis. Although 17β-
estradiol treatment decreased the frequency and severity seizures in mutant PA Arx mouse 
models, the residual amount of seizures still present particularly evident upon handling, could 
account for the premature mortality in these mice. 
An epileptic encephalopathy is defined as a condition where seizures or frequent interictal 
discharges exacerbate neurocognitive dysfunction beyond what would be expected on the basis 
of underlying aetiology (Nickels and Wirrell, 2017). This occurs in intractable epileptic 
disorders that start early in life, such as Ohtahara syndrome (OS), or Early Infantile Epileptic 
Encephalopathy (EIEE). Infants with these severe epileptic encephalopathies generally present 
with poor cognitive outcomes, with profound intellectual disability in 50% of patients if they 
survive severe spasms and seizures in infancy. Although these disorders have many different 
genetic aetiologies, both of these conditions are reported in patients with expanded polyalanine 
tract mutations in ARX (Shoubridge et al., 2010, Marques et al., 2015). Closer examination of 
the clinical spectrum in patients with ARX mutations in the first polyalanine tract (100% of who 
had seizures), indicates that developmental delay is reported in 25% of cases. The onset of 
seizures spanning from 0 to 18 months of age (median 4 months). Furthermore, only 26% of 
individuals with expansions of the second polyalanine tract exhibit seizures, despite 100% of 
these patients having intellectual disability (Jackson et al., 2017).  
The distribution of IQ scores in children with epilepsy and infantile spasms are often skewed 




development (Farwell et al., 1985, Neyens et al., 1999, Prasad et al., 2014). However, it can 
often be difficult to elucidate how much of a child’s intellectual disability was pre-existing and 
how much was caused by epilepsy early in key points of brain development (Nabbout and 
Dulac, 2003). A cardinal finding of our study is the relative differential response of seizure 
severity compared to behavioural and cognitive deficits following estradiol treatment. We 
predicted that seizure onset would lead to a worsening of cognitive and behavioural 
impairments in the PA1 and PA2 mutant mice. An extension of this prediction would be that 
17β-estradiol treatment alleviating seizures might improve cognitive and behavioural deficits. 
In contrast to our predictions, we demonstrate that behaviour did not improve with alleviation 
of seizures and that the deficits were already present before and did not decline further after 
the point of seizure onset. This provides important evidence separating the impact of seizures 
upon behavioural deficits in PA1 and PA2 mice. 
Arx is highly expressed in the developing (embryonic) brain during cellular proliferation and 
the first wave of neuron migration from the ganglionic eminence to the developing cortex 
(Colombo et al., 2007, Friocourt et al., 2008, Colasante et al., 2009, Lee et al., 2014). The 
transcriptome in forebrain of PA mutant mice at embryonic day 12.5 demonstrated that 
interneuron associated genes were enriched in this data, with the majority having decreased 
expression (Mattiske et al., 2016). In the newborn period, there is a delayed migration of 
calbindin-positive interneurons in the cortex of PA mutant mice (Lee et al., 2017). From these 
studies we contend that the initial disruption to the transcriptome and subsequent impaired 
interneuron migration caused by these mutations in Arx drive the seizures and behavioural 
deficits measured in the PA mutant mice.  In the current study we demonstrate a modest number 
of deregulated genes from the cortex at P10. This is in comparison to the larger number of 
deregulated genes detected at embryonic day 12.5 in wildtype compared to Arx PA mutant 
mice (vehicle treated mice only) (Mattiske et al., 2016). Genes included Tnn and Ngfr, 




2007, Lin et al., 2015), while Tacr1 is part of the family of G coupled-protein receptors, highly 
concentrated in the central nervous system (UniProt, 2020). Consistent with clinical 
phenotypes known to present in patients with ARX expansion mutations, Cpz is associated with 
autism spectrum disorders and/or intellectual disability (Loch et al., 2018). Despite the reduced 
expression of Arx within the brain at P10, the genes deregulated in mutant mice were enriched 
for Arx target genes and genes known to be associated with autism and intellectual disability. 
The genes overlapping in mutant animals at P10 are important in brain development, including 
metal ion binding, known to be involved in cognitive decline in Down syndrome (Malakooti 
et al., 2014) and Alzheimer’s disease (Cristóvão et al., 2016), as well as signal transduction 
and glycoproteins, both heavily involved in neurotransmitter release and modifying neuronal 
functioning (as shown in KEGG pathway analysis) (Kanehisa and Goto, 2000, Kanehisa, 2019, 
Kanehisa et al., 2019). Although epilepsy associated genes were not significantly enriched in 
the mutant mice at P10, genes associated with inhibitory neurons were enriched. 
Of the interneuron genes overlapping between PA1 and PA2 mutant mice, Th and Tacr1 are 
associated with somatostatin positive interneurons, Akr1c18 is associated with parvalbumin 
positive interneurons and Chat is known to play key roles in cholinergic interneurons. Neither 
of these subtypes have been previously shown to be disturbed in the PA1 and PA2 models at 
P10. Th is a gene of particular interest. Downregulation of Th was validated in both PA1 and 
PA2 vehicle-treated mice compared to WT and is an enzyme that assists in the formation of 
dopamine, a neurotransmitter, as well as having an association with interneurons. Th was 
unaltered with estradiol treatment, as well as other interneuron genes downregulated with 
disease. This supports the notion that disturbed function of these inhibitory cells are likely to 
play a critical role in the seizure phenotype due to mutations in Arx, and that the lack of 
“rescuing” of these genes might be associated with the remaining seizures we see with 
treatment in mutant mice, as well as the unaltered cognitive and behavioural phenotype. Many 




mutant phenotype and in Arx function more generally, single cell RNA sequencing would be 
a useful future strategy to determine the impact of disease and treatment on specific subtypes 
of inhibitory neurons.  
We were somewhat surprised by the difference in gene expression in PA1 and PA2 mice, given 
their strikingly similar behavioural and seizure phenotypes, both in disease changed genes, and 
in their response to estradiol treatment. In terms of log2 fold change and counts per million 
(gene expression level) we saw that PA2 had a greater number of genes with reduced 
expression compared to PA1 (Supplementary Figure 11). It was also unclear if 17β-estradiol 
treatment would “rescue” the deregulated transcriptome of the PA mutant mice at P10, or if 
this treatment would target alternative pathways to reduce seizure frequency and severity. In 
the previous study in an alternate PA1 mutant mouse model the same strategy of 17β-estradiol 
treatment altered expression of three downstream targets of Arx, namely Shox2, Ebf3 and Lgi1 
(Olivetti et al., 2014). In the current study, we demonstrated only minimal overlap in the genes 
deregulated by disease (PA mutant mice compared to WT mice – vehicle treated only) 
compared to genes deregulated by 17β-estradiol treatment (vehicle treated mice compared to 
estradiol treated mice – PA mutant mice only). Despite these small numbers of genes that 
overlapped between these two comparisons, the genes that did overlap in PA1 and PA2, were 
deregulated in the opposite direction when treated with estradiol. In the PA1 gene list, there 
were some key genes of note, including Ptgs2 (involved in schizophrenia, another 
neurodevelopmental disorder) and Slc17a8 (highly involved in synaptic vesicle function in 
excitatory neurons) (Wei and Hemmings, 2004, UniProt, 2020). In PA2, these genes included 
Arc (a master regulator of synaptic plasticity, and associated with epilepsy and schizophrenia), 
and Nppa (a regulator of neuropeptide hormone activity) (Haug et al., 2000, Huentelman et al., 
2015). Though these genes may play a role in the alleviation of the seizure phenotype of PA 
mutant mice, these modest number of disease genes deregulated when treated with estradiol 




pathways deregulated by the PA mutant genotype and more likely recruiting new pathways to 
affect the reduction in seizures.  
Genes containing known conserved estrogen response elements (ERE) were only enriched to 
very low levels in PA mutant mice with estrogen treatment (Figure 6A, Supplementary Figure 
5). Estradiol signalling can occur by direct genomic signalling where there is estrogen receptor 
dimerization and binding to EREs, as well as via indirect signalling, where estradiol can 
influence the expression of genes without EREs. As many as one third of estrogen responsive 
genes lack ERE-like elements (Vrtačnik et al., 2014). Hence, using DAVID, we analysed 
pathways and ontology terms enriched within the data that were known effects of 17β-estradiol 
signalling. Many of our enriched clusters were known to be direct responses to the estrogen 
receptor pathway according to KEGG  or indirect effects of the estradiol pathway (Kanehisa 
and Goto, 2000, Kanehisa, 2019, Kanehisa et al., 2019).  Our data demonstrates that 17β-
estradiol treatment in early postnatal life recruits pathways impacting synaptic function, signal 
transduction, transcriptional regulation, and hormone activity responsible in reducing the 
frequency and severity of seizures in PA mutant mice.  
We have previously reported specific spatial differences in the density of Cb interneurons at 
postnatal day 0 in PA1 and PA2 mutant mice, suggestive of a lag in migration at this 
developmental period compared to WT mice (Lee et al. 2017). At the cessation of estradiol 
treatment at postnatal day 10, we did not detect any significant differences between WT and 
mutant animals, with or without treatment, in the gene expression of markers for Cb 
interneurons, nor in the density of these neurons within the cortical layers of the brain. In the 
case of Npy positive interneurons, the alternative PA1 mouse displayed a reduced density of 
these cells in adult brain, which was ameliorated with early postnatal E2 treatment (Olivetti et 
al., 2014). In agreement, we determined a modest reduction in the expression of the Npy gene 
expression in PA1 mutant mice compared to WT animals at the earlier time point of P10. 




cortex at this time point, with or without estradiol treatment. The expression of Npy2r is known 
to increase in the brain from approximately P14 (Allen brain atlas), meaning we cannot rule 
out that changes to the density of Npy positive interneurons at later stages of development may 
occur and contribute to the sustained reduction in seizures observed in estradiol treated mice. 
Although we detect differences in gene expression of multiple interneuron associated genes at 
P10 of development, our data indicates to us that the many other genes (and pathways) 
regulated by estradiol treatment are likely to be participating in the alleviation of seizures, as 
opposed to increased inhibition in the brain as the sole mechanism.  
Conclusion 
Here we provide evidence to begin separating the relationship between seizures and cognitive 
and behavioural deficits in a genetic model of a neurodevelopmental disorder. We demonstrate 
that behaviour and cognitive outcomes did not improve in the Arx PA mutant mice despite 
significant reductions to the frequency and severity of seizures achieved with early postnatal 
steroid treatment. Indeed, behavioural deficits were already present prior to peak of seizure 
onset and do not decline with seizures. Our findings on the broader behavioural phenotypes of 
PA1 and PA2 mice support the idea that the mechanisms underlying the cognitive deficits in 
PA patients are complex. The 17-β estradiol treatment early in postnatal life recruited 
molecular and cellular pathways to reduce the frequency and severity of seizures rather than 
restoring pathways initially deregulated in Arx PA mutant mice driving pathogenesis. Taken 
together, our data strongly indicates that reduced expression of the inhibitory neuron genes, as 
well as the genes associated with autism/ID contribute to the seizure and cognitive phenotype 
of the PA mice. The lack of effective treatments for intellectual disability and neuropsychiatric 
disturbances, let alone associated early onset seizures, remains a significant challenge and 
highlights the continued need to elucidate the molecular and cellular drivers of the intellectual 
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Figure 1: Early estradiol treatment diminishes observed seizure severity and frequency 
in PA mutant mice. Timeline showing the experimental course of the mouse treatment study 
(A). PA1 and PA2 mutant mice exhibit reduced seizure frequency (B) and seizure severity (C) 
when treated with estradiol compared to their vehicle treated counterparts (percentage seizure 
occurrence – percentages do not include repeated seizures from the same mouse). (PA1: (B) 
two-tailed t-test, p<0.0001, df = 70; (C) Chi square test, p = 0.0036, df = 11.26, 2)). Estradiol 
treatment did not delay the age of first seizure (D) in either mutant strain (PA2: two-tailed t-
test, p = 0.0002, F = 1.463 (10,7), df = 17). Mice marked with a star died of a seizure (found 
dead in cage) within 2-4 days of having an observed seizure on handling. Median ± min/max 
is presented for PA1 and PA2 mice from vehicle and estradiol treatment groups. Each dot 
represents an individual animal at the age of their first seizure. Analysis across five separate 
breeding rounds each for PA1 mice (Estradiol; n = 14; dark orange (dashed line/square dots) 
vs vehicle; n = 13 light orange (solid line/circles)) and PA2 mice (Estradiol; n = 16; dark blue 
(dashed line/square dots) vs vehicle; n = 19; light blue (solid line/circles)). # p<0.05 indicates 
significant difference between estradiol and vehicle treated animals across the duration of the 
study. 
 
Figure 2: Seizure severity and frequency during video seizure monitoring are reduced in 
PA mutant mice treated with estradiol. PA1 and PA2 mice exhibit reduced seizure frequency 
and severity when treated with estradiol (PA1; n = 10; dark orange) (PA2; n = 7; dark blue) 
compared to their vehicle treated counterparts (PA1; n = 11 light orange) and (PA2; n = 12; 
light blue). Each dot represents an individual seizure event measured during 12 hours of video 
footage per mouse across multiple days. Seizure scores increase with severity from “no 




between estradiol and vehicle treated PA mice (one-way ANOVA, Tukey’s HSD post hoc 
analysis, F (3, 135) = 11.28, p<0.0001). 
 
 
Figure 3: Early estradiol does not improve survival in PA mutant mice. Estradiol did not 
improve mortality in either PA1 or PA2 mice. Analysis across five separate breeding rounds 
each for PA1 mice (Estradiol; n = 14; dark orange (dashed line) vs vehicle; n = 13 light orange 
(solid line)) and PA2 mice (Estradiol; n = 16; dark blue (dashed line) vs vehicle; n = 19; light 
blue (solid line)). There were no WT mice treated with vehicle and estradiol that died during 
the trial with data pooled into one group (grey line). 
 
Figure 4: Early estradiol does not improve behavioural deficits in PA mutant mice. 
Anxiety-like behaviour was measured using the open field test. (A) The distance the mice 
travelled in the periphery versus the central field of the open field was measured in metres (m) 
is shown at one month and two months of age. WT mice treated with vehicle (n = 17/12; light 
grey) and estradiol (n = 8/8; dark grey); PA1 mice treated with vehicle (n = 6/5; light orange) 
and estradiol (n = 4/3; dark orange); PA2 mice treated with vehicle (n = 11/6; light blue) and 
estradiol (n = 5/5; dark blue) (Two months ~one-way ANOVA, F (5,33) = 12.25, P<0.0001). 
(B) Representative tracking maps from WT (n = 2; grey), PA1 (n = 1; orange) and PA2 (n = 1; 
blue). (C) Autistic-like behaviour was measured at one and two months of age by the time in 
seconds (s) the mice spent interacting with a new mouse in the sociability test (Two months~ 
one-way ANOVA, F (3,26) = 21.85, P<0.0001), (D) or the familiar (white bars) or stranger 
(coloured bars) mouse in the social novelty test. WT mice treated with vehicle (n = 15/9; light 
grey) and estradiol (n = 8/6; dark grey); PApool mice treated with vehicle (n = 15/9; light green) 




grid test at two months of age (one-way ANOVA, F (3,31) = 7.920, P=0.0005). The latency 
for mice to fall from the inverted grid was measured in seconds (s). WT mice treated with 
vehicle (n = 11; light grey) and estradiol (n = 7; dark grey); PA1 mice treated with vehicle (n 
= 6; light orange) and estradiol (n = 3; dark orange); PA2 mice treated with vehicle (n = 4; light 
blue) and estradiol (n = 4; dark blue). In the second graph, PA1 and PA2 mice were combined 
as a PApool group. WT mice treated with vehicle (n = 11; light grey) and estradiol (n = 7; dark 
grey); PApool mice treated with vehicle (n = 10; light green) and estradiol (n = 7; dark green).  
* indicates significant difference between PA mutant mice and WT control littermates across 
the duration of the study, p<0.05, Tukey’s HSD post hoc analysis.  
 
Figure 5: Transcriptome is deregulated by disease in PA mutant mice. Transcriptomic 
analysis of postnatal day (P) 10 brains of PA mutant mice. Differential expression of genes 
from P10 mice was determined using EdgeR and selected based on a Log2 fold change greater 
than ±0.5 with a p-value < 0.05. (A) Total number of deregulated genes and the percentage of 
either upregulated or downregulated genes from our analysis of vehicle treated PA1, PA2 and 
PApool mice compared to vehicle treated WT littermates. (B) Venn diagram displaying overlap 
of deregulated genes in PA1 (orange), PA2 (blue) and PApool (dotted circle) groups, as well as 
core overlapping genes (green with list of genes).  (C) Graph showing log fold change values 
of genes from the core overlap lists in (B). Interneuron genes are highlighted in the grey dashed 
box. (D) Table showing overlap of deregulated genes from vehicle treated PA1, PA2 and PApool 
mice with known neurodevelopmental disorder (NDD), inhibitory cell and ARX target genes. 
(E) Graph showing log fold change values of genes from enriched interneuron genes in (D). 
Genes from core overlap are in the grey dashed box. * indicates significant overlap with 





Figure 6: Estradiol alters the transcriptome of PA mutant mice. Transcriptomic analysis 
of postnatal day (P) 10 brains of PA mutant mice. Differential expression of genes from P10 
mice was determined using EdgeR and selected based on a Log2 fold change greater than ±0.5 
with a p-value < 0.05. (A) Total number of deregulated genes and the percentage of either 
upregulated or downregulated genes from our analysis of estradiol treated PA1, PA2 and PApool 
mice compared to vehicle treated PA mutant mice. Table also shows number and percentage 
of genes known to contain a high-affinity mouse estrogen-response element (ERE). * indicates 
significant overlap between genes deregulated by estradiol and ERE-containing mouse genes 
(p < 0.05). (B) Venn diagram showing overlapping between the disease-deregulated 
transcriptome and the estradiol-treated transcriptome of PA1, PA2 and PApool mice. (C) Graphs 
showing the opposite deregulation direction between genes overlapping between disease and 
estradiol changed genes in PA1 and PA2. (D) Venn diagram displaying overlapping genes 
between the estradiol-treated transcriptomes of PA1 (orange), PA2 (blue) and PApool (green) 
mice. (E) Overlap of deregulated genes from estradiol treated PA1, PA2 and PApool mice with 
known neurodevelopmental disorder (NDD) and inhibitory cell genes. * indicates significant 
overlap with reference gene lists (p < 0.05). 
 
Figure 7: Abundance of calbindin (Cb) and neuropeptide-Y (Npy) positive cells in the 
prefrontal cortex. (A) Representative DAPI stained image of the brain in a WT mouse 
illustrating the region of the brain analysed (within dashed lines). Scale bar 200µM. (B) 
Pictomicrographs of brain sections with arrows indicating positive cells corresponding to Cb 
and Npy interneurons. Scale bar 50µM. (C) Density of Cb and Npy positive cells/mm2 in WT 
(Veh and E2 combined) (circles) and PApool mice (PA1; squares and PA2; triangles). treated 
with vehicle or estradiol. Cb: WT mice (n = 5; white), PApool mice treated with vehicle (n = 6; 
light grey) and estradiol (n = 5; dark grey). Npy: WT mice (n = 7; white); PApool mice treated 











Supplementary Figure Legends 
Supplementary File 1: Detailed behaviour testing protocols. 
 
Supplementary Table 1: Taqman assay details. RNA sequencing validation experiments 
were prepared as described in the Taqman PreAmp Master Mix Kit user guide (Applied 
Biosystems). Expression values were normalised to reference gene β-Actin.  
 
Supplementary Figure 1: Ages of death in PA mutant mice treated with vehicle or 
estradiol. PA1 and PA2 mice treated with estradiol (PA1; n = 13; dark orange) (PA2; n = 18; 
dark blue) do not exhibit improved survival when compared to their vehicle treated 
counterparts (PA1; n = 14; light orange) (PA2; n = 21; light blue). Individual circles represent 
individual mice throughout the duration of the study (up to 70 days postnatal). Data is shown 





Supplementary Figure 2: Testes and brain weights of PA mutant mice treated with 
vehicle or estradiol. Testes (left and right combined) and cerebral hemispheres (left and right 
combined) were weighed at postnatal day 70. WT mice, vehicle-treated (light grey) testes 
(n=27) and brain (n=26) and estradiol-treated (dark grey) testes and brain (n=18). PA1 mice, 
vehicle-treated (light orange) testes and brain (n=5) and estradiol treated (dark orange) testes 
(n=2) and brain (n=3). PA2 mice, vehicle-treated (light blue) testes (n=6) brain (n=7) estradiol-
treated (dark blue) testes and brain (n=4). * indicates significant difference between PA mutant 
mice and WT littermates, p<0.05, one-way ANOVA with Tukey’s HSD. 
 
Supplementary Figure 3: Body weights of PA mutant mice treated with vehicle or 
estradiol. PA1 and PA2 mice treated with estradiol (PA1; n = 13; dark orange) (PA2; n = 18; 
dark blue) or vehicle (PA1; n = 14; light orange) (PA2; n = 21; light blue) do not exhibit any 
improvement to body weight through the duration of the study (postnatal day 0 to postnatal day 
70), compared to their WT littermates, treated with either estradiol (WT; n = 30; dark grey) or 
vehicle (WT; n = 23; light grey). Data is shown at mean weight on each day of the study ± 
SEM. * indicates significant difference at postnatal days 10, 21, 45 and 60 between PA mutant 
mice and WT littermates, p<0.05, one-way ANOVA with Tukey’s HSD. 
 
Supplementary Figure 4: PA mutant mice do not display hyperactivity as measured by 
total distance in the open field test. Anxiety-like and fear response behaviour was measured 
using the open field test. (A) The total distance the mice travelled in the open field apparatus 
during the duration of the test at one month and two months of age. Wild-type mice treated 
with vehicle (n = 17/12; light grey) and estradiol (n = 8/8; dark grey); PA1 mice treated with 
vehicle (n = 6/5; light orange) and estradiol (n = 4/3; dark orange); PA2 mice treated with 





Supplementary Figure 5: PA1 and PA2 mutant mice display autistic-like behaviour as 
measured by sociability and social novelty tests. (A) Autistic-like behaviour was measured 
at one and two months of age by the time in seconds (s) the mice spent interacting with a new 
mouse in the sociability test, (B) or the familiar (white) or stranger (black) mouse in the social 
novelty test. WT mice treated with vehicle (n = 15/9; light grey) and estradiol (n = 8/6; dark 
grey); PA1 mice treated with vehicle (n = 6/4; light orange) and estradiol (n = 3/2; dark orange); 
PA2 mice treated with vehicle (n = 9/5; light blue) and estradiol (n = 5/4; dark blue). * indicates 
significant difference between PA mutant mice and WT control littermates across the duration 
of the study, p<0.05, one-way ANOVA with Tukey’s HSD. # indicates significant difference 
between estradiol and vehicle treated mutant animals across the duration of the study, p<0.05, 
one-way ANOVA with Tukey’s HSD. 
Supplementary Figure 6: PA mutant mice do not display learning and memory deficits 
in the Barnes maze. Learning and memory was measured using the Barnes maze at two 
months of age only. The latency to find the escape hole was measured in seconds (s) across a 
four-day testing period. Mice were measured from WT treated with estradiol (n = 10; dark 
grey) or vehicle (n = 8; light grey) with A) PA1 and PA2 mice were combined as a PApool group 
and PApool treated with estradiol (n = 6; dark green) or vehicle (n = 6; light green). B) PA1 mice 
treated with estradiol (n = 4; dark orange) and vehicle (n = 2; light orange). C)  PA2 mice 
treated with estradiol (n = 4; dark blue) and vehicle (n = 4; light blue).  
 
Supplementary Figure 7: Biological validation of genes deregulated by disease in PA 
mutant mice by quantitative PCR (qPCR) analysis. Samples tested were RNA samples 
prepared from the cortex of vehicle-treated mice at postnatal day 10 across each genotype (WT; 
n = 6; PA1; n = 4; PA2; n = 4; PApool; n = 4 PA1 + 4 PA2 samples combined). Expression 




counts per million from our RNAseq data, where qPCR results agreed with RNAseq results. 
(B) Represents control genes that were non-significant in both RNAseq and qPCR analysis. 
(C) Represents genes where the breadth of signal was variable across the three genotype groups 
between the RNAseq and qPCR analysis. Summary tables show results of these genes in 
RNAseq and qPCR data, with final column showing whether the qPCR results agreed with the 
RNAseq data. Grayscale colours in significance tables represent significance of result (lightest 
grey p<0.05, medium grey p<0.005 and darkest grey p<0.0001). Individual graphs show 
relative quantity for each gene for WT (grey), PA1 (orange), PA2 (blue) and PApool (green). 
*p<0.05, **p<0.005, ***p<0.0001 (one-tailed t-test of PA1, PA2 or PApool compared to WT).  
 
Supplementary Figure 8: Enrichment analysis of genes deregulated by disease in PA 
mutant mice. Table showing significant gene enrichment terms in deregulated genes in PA1, 
PA2 and PApool groups from DAVID cluster annotation analysis. Clusters with enrichment 
scores of <0.9 are not shown. Heat map is based on maximum, minimum and 50th percentile 
score in data set (legend in figure).  
 
Supplementary Figure 9: Biological validation of genes deregulated by estradiol in PA 
mutant mice by quantitative PCR analysis. Samples tested were pooled RNA samples 
prepared form the cortex of vehicle and estradiol treated mice at postnatal day 10 across each 
genotype. WT pooled samples contained RNA from n = 6 cortex samples for each treatment 
group. PA1 and PA2 pooled samples contained RNA from n = 4 cortex samples for each 
treatment group. Expression values were normalised to the reference gene, β-Actin. (A) 
Summary table shows results of these genes in RNAseq and qPCR data, with final column 
showing whether the qPCR results agreed with the RNAseq data. Grayscale colours in 




and darkest grey p<0.0001). (B) Individual graphs of relative quantity for each gene for WT 
(vehicle = light grey; estradiol = dark grey), PA1 (vehicle = light orange; estradiol = dark 
orange), and PA2 (vehicle = light blue; estradiol = dark blue). Significance indicated by 
*p<0.05, **p<0.005, ***p<0.0001, one-tailed t-test of vehicle treated WT, PA1 and PA2 
compared to estradiol treated WT, PA1 and PA2). 
 
Supplementary Figure 10: Enrichment analysis of genes deregulated by estradiol in PA 
mutant mice. Significant gene enrichment terms in genes deregulated by estradiol in PA1, 
PA2 and PApool groups from DAVID cluster annotation analysis. Heat map is based on 
maximum, minimum and 50th percentile score in data set (legend in figure). No clusters with 
enrichment scores of <1.0 are shown. Clusters with # are pathways and functions known to be 
regulated by the estrogen receptor pathway. 
 
Supplementary Figure 11: Technical validation of genes deregulated by disease in PA 
mutant mice by quantitative PCR analysis. Scatter plots showing relationship between 
log2fold change and average log count per million (CPM) of genes changed with estradiol 
treatment in PA1 (A) and PA2 (B) mice. Orange lines show log2fold change ±1 and black lines 
show log2fold change ±0.5. (C) shows individual quantitative PCR results, from untreated 
pooled samples of those used for RNAseq analysis (WT; n = 6; PA1; n = 4; PA2; n = 4). 
Expression values were normalised to the reference gene, β-Actin. Frmd7 was significantly 
decreased in PA1 in our RNAseq analysis and this was validated by qPCR. Shox2 was 
significantly decreased compared to their WT littermates in PA2 in our RNAseq analysis, 
however, this was not validated by qPCR. Th was significantly decreased in PA1 and PA2 in 
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Genes deregulated by E2 treatment
WT PA1 PA2 PApool
vs VEH 56 124 158 53
↑ 27 (48%) 93 (75%) 36 (23%) 33 (62%)
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Heterozygous loss of function of IQSEC2/Iqsec2 leads to
increased activated Arf6 and severe neurocognitive
seizure phenotype in females
Matilda R Jackson1,2, Karagh E Loring1,2, Claire C Homan2, Monica HN Thai1, Laura Määttänen3, Maria Arvio3,4,5 ,
Irma Jarvela6, Marie Shaw2, Alison Gardner2, Jozef Gecz2,7 , Cheryl Shoubridge1,2
Clinical presentations of mutations in the IQSEC2 gene on the
X-chromosome initially implicated to cause non-syndromic
intellectual disability (ID) in males have expanded to include
early onset seizures in males as well as in females. The mo-
lecular pathogenesis is not well understood, nor the mecha-
nisms driving disease expression in heterozygous females.
Using a CRISPR/Cas9–edited Iqsec2 KO mouse model, we
confirm the loss of Iqsec2 mRNA expression and lack of Iqsec2
protein within the brain of both founder and progeny mice.
Both male (52%) and female (46%) Iqsec2 KO mice present with
frequent and recurrent seizures. Focusing on Iqsec2 KO het-
erozygous female mice, we demonstrate increased hyperac-
tivity, altered anxiety and fear responses, decreased social
interactions, delayed learning capacity and decreased memory
retention/novel recognition, recapitulating psychiatric issues,
autistic-like features, and cognitive deficits present in female
patients with loss-of-function IQSEC2 variants. Despite Iqsec2
normally acting to activate Arf6 substrate, we demonstrate that
mice modelling the loss of Iqsec2 function present with in-
creased levels of activated Arf6. We contend that loss of Iqsec2
function leads to altered regulation of activated Arf6-mediated
responses to synaptic signalling and immature synaptic net-
works. We highlight the importance of IQSEC2 function for
females by reporting a novel nonsense variant c.566C > A,
p.(S189*) in an elderly female patient with profound in-
tellectual disability, generalised seizures, and behavioural
disturbances. Our human and mouse data reaffirm IQSEC2 as
another disease gene with an unexpected X-chromosome
heterozygous female phenotype. Our Iqsec2 mouse model re-
capitulates the phenotypes observed in human patients de-
spite the differences in the IQSEC2/Iqsec2 gene X-chromosome
inactivation between the species.
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Introduction
X-linked intellectual disability is a common, clinically complex
disease arising from mutations in more than 140 genes on the
X-chromosome (1), affecting between 1/600 and 1/1,000 males and
a substantial number of females (2). X-linked inheritance is more
complex than simply X-linked recessive or dominant (3) with both
X-inactivation (including associated tissue specific selection) and
the impact of individual mutations contributing to this complexity.
In mammals, the sex determination system used is XX/XY, with
dosage compensation in females as a result of random inactivation
of one of the two X chromosomes in every cell. As a consequence,
heterozygous females typically have a milder disease phenotype or
are not affected. Despite this, there is a growing list of X-chro-
mosome genes which are subject to X-inactivation or escape
X-inactivation, including, for example, PHF6, CLCN4, ALG13, ARX, or
USP9X, DDX3X, which display distinct phenotypes in males and
females depending on the functional severity of the variant, as well
as manifesting in a more severe female phenotype than the het-
erozygous state would predict (4, 5, 6, 7, 8, 9, 10). We contend that the
IQ motif and Sec7 domain 2 protein (IQSEC2) (NM_001111125) (MIM
300522) is another X-chromosome disease gene in which we see a
severe female phenotype because of heterozygous loss-of-function
mutation.
We previously implicated IQSEC2 as an X-linked intellectual
disability (XLID) gene through identification of variants in affected
males in four separate families (11). These missense variants were
clustered around the Sec7 and IQ-like domains and resulted in
reduced enzymatic activity (11). Clinical features within these non-
syndromic XLID families included moderate to severe intellectual
disability (ID) in all affected males, with variable seizures, autistic
traits, and psychiatric problems (11). Since then, unbiased, high-
throughput sequencing in ID and epilepsy cohorts have identified
familial and increasingly de novo loss-of-function IQSEC2 variants,
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typically leading to phenotypic outcomes, including severe ID with
epileptic encephalopathy, and a high prevalence of speech de-
velopment deficits and psychiatric features, including autistic
spectrum disorder. Interestingly, these severe phenotypes are
noted not only in affected males but also in affected, heterozygous
females (12). The mechanisms contributing to the disease severity,
particularly in heterozygous females is unknown and perplexing.
IQSEC2 is a guanine nucleotide exchange factor, which catalyzes
exchange of GDP for GTP in a number of ARF superfamily of proteins.
IQSEC2 is highly expressed in the forebrain, specifically localized to
excitatory synapses as part of the N-methyl-D-aspartate receptor
(NMDAR) complex (13, 14). The exact role IQSEC2 plays at excitatory
synapses remains unclear. Limited studies indicate a role in the
activity-dependent removal of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPAR) and activity-dependent
synaptic plasticity (15, 16). Our own studies have shown that IQSEC2
also has a fundamental role in controlling neuronal morphology (17).
However, there is currently no published research investigating the
impact of loss or altered Iqsec2 function on the development and
resulting cognitive outcomes in any animal model. It is not certain if
severe loss-of-function mutations in IQSEC2 can be transmitted in the
human setting, with only missense variants giving rise to milder non-
syndromic features beingmaternally inherited. Hence, it was unclear if
the loss of Iqsec2 function modelled in mice would survive into
postnatal life, be reproductively viable or useful to model disease
pathogenicity observed in humans. Here, we show that mice with the
complete loss of function of Iqsec2 by successfully targeting exon 3
using CRISPR/Cas9 technology survive into postnatal life and are vi-
able. In this study, we investigate the effect of severe loss-of-function
mutations driving the phenotype in patients, including the emerging
female-specific phenotype using a mouse modelling the KO of Iqsec2.
We present an elderly female patient with profound ID and gen-
eralised seizures with a novel loss-of-function IQSEC2 variant, pro-
viding important life span information for other patients diagnosed
with this typically early onset neurodevelopmental disorder. We re-
view the present literature of the growing number of females with
loss-of-function variants in IQSEC2, who have a more severe phe-
notype than the heterozygous state would predict. In humans, the
prevailing evidence suggests that IQSEC2 escapes X-inactivation (18,
19); however, inmice, Iqsec2 is subject to X-inactivation (20). Hence, the
mouse modelling heterozygous KO of Iqsec2 provides an opportunity
to assess the impact of X-inactivation and altered Iqsec2 gene dosage
in females. Here, we show that the loss of Iqsec2 function in mice
recapitulates key aspects of the human phenotype, irrespective of the
X-inactivation status of the gene in the two species, highlighting that
our understanding of the traditional X-chromosome inheritance with
heterozygous female sparing needs to be revisited.
Materials and Methods
Animal generation
All animal procedureswere approved by the Animal Ethics Committee
of The University of Adelaide, Adelaide, Australia, and undertaken in
accordance with their regulatory guidelines. Founding Iqsec2 KOmice
were generated by CRISPR/Cas9 by the South Australian Genome
Editing facility (SAGE), University of Adelaide, Adelaide; details given
below. Mice were maintained in the C57Bl/6N-Hsd background. An-
imals were of same sex and housed in individually ventilated cages,
with sterile food and water available ad libitum. Iqsec2 KO hemi-
zygous male founder A was bred with a wild-type female to generate
Iqsec2 KO heterozygous progeny, which were subsequently bred with
a wild-type stud male to generate Iqsec2 KO hemizygous, Iqsec2 KO
heterozygous, and wild-type littermates. Iqsec2 KO hemizygousmales
(n = 46) and Iqsec2 KOheterozygous females (n = 153) weremonitored
and scored daily (from postnatal day [P] 14) for general health and
welfare, appearance, weight, and the presence of seizure activity. In
addition to standard food available ad libitum, crushed chow was
soaked in sterile water and placed in an easily accessible feeding
dish, which was refreshed daily.
CRISPR/Cas9 guide design
Guides were designed by the SAGE facility, University of Adelaide,
under the guidance of Professor Paul Q Thomas as part of a fee for
service for the generation of CRISPR/Cas9 Iqsec2 KO mice. The
online tool (http://crispr.mit.edu/) was used to search for ap-
propriate CRISPR guide sites targeting the removal of Iqsec2 exon 3.
The most appropriate guide was determined by total score, cut site
in target gene, and number of off-target mismatches. Guides’
sequences determined most suitable were upstream CRISPR guide
59-TCTAGTGTACTCACTCAGTT-39 and downstream CRISPR guide 59-
AGGCTGGAACTGGCGAAAAC-39. The CRISPR/Cas9 complex will cause
double strand breaks in intron 2–3 of Iqsec2 and intron 3–4, causing
exon 3 to be deleted by a process of non-homologous end joining.
CRISPR gRNA generation, microinjections of zygotes, and transfer to
pseudopregnant recipients were performed by the SAGE facility as
previously described (21, 22, 23).
Genotyping
A small segment of toe tissue was removed by sterile technique at P5
from all pups for genotyping and identification purposes. Genomic
DNA was extracted as per the manufacturer’s instructions for Phire
Hot Start II DNA polymerase (Thermo Fisher Scientific). Genotyping
PCR was performed using 10 μM forward and reverse primer pairs
(Table S1), 2x Phire Tissue Direct PCRMaster Mix, andmade up to 20 μl
with MilliQ water. Reactions were placed in a thermocycler for one
cycle at 98°C for 5min, 32 cycles at 98°C for 30 s, 62°C for 30 s, 72°C for
1 min, and one cycle at 72°C for 1 min. PCR products were held at 4°C
before visualising on a 1.5% (wt/vol) agarose gel with 0.2 μg/ml
ethidium bromide in TBE buffer (1.1 M Tris, 900mM borate, and 25 mM
EDTA, pH 8.3) alongside 1 kb+ molecular weight marker. Images were
captured on a SynGene UV dock at 400 ms exposure on GeneSnap
v7.05 for SynGene. DNA sequencing analysis was performed using
SeqMan Pro version 10.1.2 (DNASTAR, Inc) against Iqsec2 cDNA ref-
erence sequence NM_001114664.
Analysis of Iqsec2 mRNA and Iqsec2 protein
Animals were humanely killed by cervical dislocation. Brain was
dissected from the skull and cut into two halves sagittally along the
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cerebral fissure. The right-hand side brain was separated and
minced into cortex (n = 2, one each for protein and RNA) and
cerebellum, snap-frozen in liquid nitrogen, and stored at −80°C
pending analysis. RNA was extracted from 40 mg homogenised
brain cortical tissue in TRIzol reagent and converted to cDNA using
SuperScript RT (Thermo Fisher Scientific) as described previously
(24). Iqsec2 gene expression was performed using both RT-PCR and
qPCR. RT-PCR was performed using 50 pmol forward and reverse
primer pairs (Table S1), 20U Roche Taq DNA polymerase, FailSafe
PCR 2X PreMix J (Epicentre), and made up to 50 μl with MilliQ water.
Reactions were placed in a thermocycler for one cycle at 94°C for 2
min, 35 cycles at 94°C for 30 s, 57–60°C for 30 s, 72°C for 30 s, and one
cycle at 72°C for 5 min. Images were captured as described above.
qPCR was performed using TaqMan gene expression assay probes
(Thermo Fisher Scientific) spanning exon 3–4 boundary
(Mm02344188_m1), exon 11–12 boundary (Mm02344183_m1), and
exon 13–14 boundary (Mm02344185_m1) with gapdh used as a
housekeeper (Mm99999915_g1). Wild types were pooled and av-
eraged based on sex (n = 4 female wild type, n = 5 male wild type).
Each individual Iqsec2 KO hemizygous male or heterozygous female
sample was normalised to the averaged wild-type data for their
respective sex, with resulting data displayed as relative Iqsec2
expression to their respective sexed wild-type controls. Protein
extraction, SDS–PAGE, and Western blot analysis of protein levels
were performed as described previously (17). The primary anti-
bodies were rabbit anti-IQSEC2 (1:2,000) as previously described
(17), rabbit anti-IQSEC1 and rabbit anti-IQSEC3, both used at 1:1,000
(Invitrogen), and mouse β-actin (AC-74; 1:20,000; Sigma-Aldrich
A2228). Secondary antibodies from DAKO (Santa Clara) were goat
antimouse HRP (1:2,000 P0447) and goat antirabbit HRP (1:2,000
P0448). Images were imported into Image Studio (Li-Cor Bio-
sciences), and band intensities of Iqsec proteins were normalised
to their respective β-actin loading control, and where required were
harmonized across multiple immunoblots using a consistent
control sample. Each individual Iqsec2 KO hemizygous or hetero-
zygous sample was normalised to the averaged pooled wild-type
data for their respective sex, with relative intensities presented (n
for each as described in figure legends).
Behavioural assessment
Iqsec2 KO heterozygous and wild-type females underwent monthly
behavioural testing from one to 6 mo of age (n = 4 Iqsec2 KO
heterozygous and n = 3 wild-type controls at 1 mo, n = 8 Iqsec2 KO
heterozygous, and n = 6 wild-type controls at all other time points)
as previously described (25).
Neuroanatomy
The left-hand side brain, separated along the cerebral fissure, was
fixed at 4 degrees in 10% neutral buffered formalin overnight,
before being washed three times in cold PBS, and stored in 70%
ethanol at 4 degrees. The samples were processed and paraffin-
embedded by the Adelaide University Histology Department. Semi-
serial sections, measuring 10 μm thick, were collected using a
strategy of mounting every fifth serial section across five slides
(series 1–5) with up to five replicates of this strategy per sample
(A–E) to span the breadth of the mouse brain in sagittal or coronal
orientation. The sections were stained by haematoxylin and eosin
or Nissl and scanned using a Hamamatsu NanoZoomer 2.0-HT
whole slide imager (Meyer Instruments). Images were imported into
ImageJ (Fiji; version 2.0.0-rc-59/1.51k, build fab6e1a004) for pro-
cessing and measurement.
Multielectrode array
Cortical neuronal were isolated from embryonic day (E) 17.5 Iqsec2
KO heterozygous female (n = 12) and wild-type littermates (n = 7
female) as per Hinze et al (17). Neuronal suspensions were plated at
2.97 × 105 cells/well on 0.1% polyethyleneimine/20 μg/ml laminin-
coated 24-well glass bottomed multielectorde array (MEA) plate
(product: 24W300/30G-288; MultiChannel Systems). After 21 d in
culture, 15-min recordings were captured using MultiScreen (version
1.5.9.0; MultiChannel Systems) at a sampling rate of 20,000Hz and 1,000
ms baseline duration. Spike binning was performed at 100-ms in-
tervals, with minimum burst duration set at 50 ms, with a minimum
spike count in burst set at four spikes. Captured data were uploaded
and exported using MultiAnalyser (version 1.2.90; MultiChannel Sys-
tems). Data obtained fromeach individual Iqsec2 heterozygous female
embryo was normalised to the averaged wild-type data.
G-LISA Arf6 activation assay
Protein was extracted from snap-frozen cortical tissue of wild-type
malemice (n = 4), KOmale mice (n = 6), wild-type femalemice (n = 5)
and HetKO female mice (n = 9) following the manufacturer’s in-
structions for use in a G-LISA Arf6 Activation assay Biochem Kit
(absorbance based) (Cytoskeleton). The levels of activated Arf6
measured in the cortical tissue were from mice ranging in age from
2 to 9 mo. Each sample was measured with an n = 4 replicates.
Within each assay, the levels of activated Arf6 measured in the wild-
type animals for each sex was set to 1, and values for each of the KO
or HetKO samples were determined relative to these age and sex-
matched wild-type controls. The relative levels of activated Arf6 for
all WT animals measured in a single assay were used to normalise
activated Arf6 levels across multiple assays. An aliquot of protein
from each cortical sample analysed in the GLISA assays was also
prepared for SDS–PAGE and Western blot analysis and probed for
Iqsec2 as described (17) and Arf6 protein abundance using poly-
clonal Arf6 antibody (PA1-093; Thermo Fisher Scientific) and
quantitated as indicated above for Iqsec2 protein abundance.
Molecular analysis of IQSEC2 variant
The screening protocols were approved by the Women’s and
Children’s Health Network Human Research Ethics Committee and
the Human Ethics Committee of The University of Adelaide, Ade-
laide, Australia (approval number REC2361/03/2020) and conforms
with the principles set out in the WMA Declaration of Helsinki and
Australian National Statement on Ethical Conduct in Human Re-
search (2018). Informed consent was obtained from carers of the
patient, including consent to publish images. DNA from the affected
female was whole-exome sequenced on an Illumina HiSeq2500 by
the Australian Genome Research Facility. Reads were mapped to
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Figure 1. CRISPR/Cas9 targeting of Iqsec2 resulted in absent (KO males) or reduced (KO HET females) Iqsec2/Iqsec2 expression.
(A) Schematic of the exon–intron structure of Iqsec2 long (NM_001114664) and short (NM_001005475) isoforms, with the dashed box indicating consensus sequence.
Zoomed-in schematic of Iqsec2 exon 2–4 (exon 2 long = 2L and exon 2 short = 2S) with CRISPR guides (arrows) flanking exon 3 (diagonal line fill), resulting in a predicted
445-bp deletion. Actual deletion size (highlighted by an orange box) shown flanking CRISPR guide putative cut sites in Founder A, with sex and total deletion size shown on
left-hand side. (B) RT-PCR amplification of exon 2/3 boundary, exon 1 (short isoform), and exon 1 (long isoform) to exon 4 of 3 male founders, and subsequent progeny
from founder A. (C) qPCR of three founder males (grouped) and subsequent progeny from founder A. Results are expressed as mean relative expression (±SEM; n = 3
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the human genome (hg19) using BWA-MEM (26) and mapping re-
fined using Genome Analysis Toolkit version 3.5 (27). Mapping
achieved a minimum median target coverage depth of 49 reads/
sample and covered 87.67% of intended targets with at least 20
reads. Single-nucleotide variants and small insertions and de-
letions were called by the genome analysis toolkit haplotype caller
version 3.5 (27). Whole-exome sequencing data are available upon
request.
All variants were annotated for allele frequency, clinical signifi-
cance, locus identity, and likely pathogenicity using ANNOVAR (28).
Statistical analysis
The statistical significance (P < 0.05) of the difference between
means of each strain, namely, Iqsec2 KO hemizygous males, Iqsec2
KO heterozygous females, and their respective age-matched con-
trol littermates, was determined using multiple statistical means. A
one-way ANOVA followed by Tukey’s HSD post hoc test was used for
qPCR and MEA analysis, whereas a two-way ANOVA followed by
Tukey’s HSD was used to assess behavioural differences across
time. A two-tailed, unpaired t test was used to compute statistical
significance of the difference between means for the GLISA anal-
ysis, and when wild-type littermates were omitted from statistical
analysis (seizure propensity). All data analyses were performed
using GraphPad Prism version 7 (GraphPad Software Inc.).
Results
Generation of loss-of-function Iqsec2 KO mice by CRISPR/Cas9
deletion of exon 3
Generation of a knockout (KO) mouse line to model the loss of
Iqsec2 function was achieved by targeting exon 3 of Iqsec2 for
deletion by CRISPR/Cas9 editing (17). The sequence and targeting of
CRISPR guides to remove exon 3 in both isoforms are detailed in Fig
S1. Exon 3 is invariable between the two main isoforms of Iqsec2,
with exons 3–13 comprising consensus sequence (Fig 1A). Injection
of the CRISPR/Cas9 guides was performed as a fee for service
(South Australian Genome Editing facility, University of Adelaide,
Adelaide) (21). PCR amplification of genomic DNA (Fig S2A) and
subsequent breakpoint mapping and sequencing of amplicons
demonstrate that Founder A (male) had exon 3 removed with
neighbouring exon 2 (short and long isoforms), exon 4, and exon 5
unaffected by the deletion, demonstrating successful targeted
deletion of exon 3 (Fig 1A). Although exon 3 did not amplify in any of
the four founders generated (Fig S2B), founders B and C (males) had
larger deletions than expected (Fig S2A), both impacting exon 4, and
founder D (female) had a homozygous deletion of exon 3 (Fig S2C).
The homozygous loss of IQSEC2 has not been reported in the human
population. Given the increasing incidence of mutations in girls
(heterozygous) with early-onset seizure phenotypes, it was not
unexpected that this female homozygous KO mouse was found
dead early in postnatal life, negating the opportunity to collect
samples for expression analysis, or attempt breeding. This animal
was not included in any further analysis. Overall, the editing of all
founders extended past the recognised CRISPR/Cas9 guide cut sites
in both directions by nonstandard amounts, with larger deletion
sizes of this X-chromosome region noted in males. This finding
demonstrates that CRISPR/Cas9, although an effective genome
editing tool, requires careful validation.
To confirm that deletion of exon 3 by CRIPSR/Cas9 editing
resulted in loss of Iqsec2/Iqsec2, we analysed the gene expression
and protein level from cortical brain tissue in which Iqsec2 is highly
expressed during postnatal life. We demonstrate in the three
founder males and progeny of founder A that Iqsec2 expression was
reduced or absent when detected by RT-PCR (Fig 1B) and signifi-
cantly reduced compared with sex-matched wild-type progeny
when analysed by qPCR (Fig 1C). Founder A and founder B had no
detectable Iqsec2 expression by either analysis. The negligible
expression levels of Iqsec2 short isoform detected for founder C in
the RT-PCR analysis was not replicated by qPCR. Iqsec2 KO hemi-
zygous male progeny from founder A also had no detectable Iqsec2
expression by RT-PCR (Fig 1B) but demonstrated minimal Iqsec2
expression by qPCR with the probe spanning across the exon 11–12
boundary Fig 1C. (ii) This result is consistent with very low levels of
transcript (~5% of normal) being present before nonsense-
mediated mRNA decay. Iqsec2 KO heterozygous female progeny
showed that Iqsec2 expression by RT-PCR for both the short and
long isoforms were reduced to less than half the levels of wild-type
female controls (Fig 1B). Similarly, reduced Iqsec2 expression in
these females was also noted by qPCR, with expression levels
dependent on the probe used (range 0–79%, mean 35%), but were
still significantly elevated above both founder males and Iqsec2 KO
hemizygous male progeny (Fig 1C). We note that expression levels
were quite varied between individual heterozygous females and
cannot discount differences due to levels of X-inactivation in these
animals. The threemale founders had no discernible Iqsec2 protein
in the cortex (Fig 1D). Similarly, there was no discernible Iqsec2
protein in KO hemizygous male progeny and reduced levels of
Iqsec2 protein (~half of the wild-type control levels) in KO het-
erozygous female progeny (Fig 1D). Off-target analysis of CRISPR/
Cas9 editing using computational tools (CRISPR design tool by MIT:
http://crispr.mit.edu/ and COSMID: https://crispr.bme.gatech.edu)
identified that the majority (92%) of predicted off-targets were
located in regions that did not harbour genes or impacted intronic
regions within genes and were unlikely to effect the coding region
founders, n = 6 Iqsec2 KO hemizygous males (KO), n = 6 Iqsec2 KO heterozygous females [HET]) normalised to wild types, which were pooled and averaged dependent on
sex (n = 4 female wild type, n = 5 male wild type). (C) TaqMan gene expression assay probes spanning (i) exon 3–4 boundary, (ii) exon 11–12 boundary, and (iii) exon 13–14
boundary with gapdh used as a housekeeper. (D)Western blot analysis of Iqsec2 and Iqsec3 expression in three founder males and subsequent progeny from founder A.
Blots were imported into Image Studio (Li-Cor Biosciences) and band intensities normalised to their respective beta-actin (Actb) loading control. Wild types were
pooled and averaged dependent on sex (n = 2 female wild type, n = 2male wild type). White spaces indicate a cropped image. # indicates significant difference between HET
and founder, P < 0.0001 one-way ANOVA, Tukey’s HSD, ^ indicates significant difference between HET and KO, P < 0.0001; one-way ANOVA, Tukey’s HSD.
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of the genome (Table S2). For the 31 genes identified to potentially
be impacted by off-target effects, 28 were reported with high
numbers of mismatch (n = 4). In contrast, Iqsec3 was the only gene
predicted to be impacted by either CRISPR guide that was identified
by both computational tools (Table S2). IQSEC3 is highly expressed
within multiple regions of the brain, including the cortex. Our
analysis of the three founder males demonstrates that Iqsec3
protein levels in the cortex were reduced (27%, 14%, and 36% of
wild-type, respectively) but were normalised to wild-type levels in
subsequent founder A progeny (Fig 1D). Taken together, these data
suggest successful outbreeding of the potential off-target effects.
To investigate if the loss (or partial loss) of Iqsec2 protein in the
Iqsec2 KO mice elicited a compensatory effect by other members of
the Iqsec protein family, we measured the protein abundance of
Iqsec1 and Iqsec3 in cortical samples of the wild-type and Iqsec2 KO
mice by immunoblot. The levels of Iqsec1 protein were very low
compared with the ready detection of Iqsec3 protein in the same
samples and were not robust enough for semiquantitative analysis.
Despite this, we did not see any empirical evidence of a consistent
or stronger signal in the Iqsec2 KO animals. In the case of Iqsec3,
there was no significant increase in protein abundance in the
brains of Iqsec2 KO hemizygous male or KO heterozygous female
mice compared with wild-type sex-matched mice (Fig S3). Hence,
we demonstrate that Iqsec protein family members are unlikely to
provide a compensatory role to ameliorate the loss or partial loss of
Iqsec2.
Iqsec2 KO male and female mice present with spontaneous
seizures
We observed severe spontaneous seizures in both Iqsec2 KO
hemizygous male and heterozygous female mice modelling loss of
Iqsec2 function. We saw a combination of four seizure subtypes that
although distinctive in appearance, were often observed in a single
seizure episode in both sexes. The seizures included (i) sudden
onset of irregular generalised clonic jerks, where the mouse
demonstrated involuntary, uncontrolled, unilateral head move-
ments (Video 1); (ii) repetitive forelimb clonus that commenced with
intermittent clonic jerking of the head and forelimbs, which then
became rhythmic, associated with tonic posturing of the forelimbs,
evolving to rearing and generalised tonic–clonic activity lasting ~60 s
(Video 2); (iii) uncontrolled convulsions with bilateral forelimb
Figure 2. Iqsec2 KO hemizygous males and
heterozygous females exhibit spontaneous
seizures and reduced survival, which was not
observed in their wild-type control littermates.
The total number of animals phenotyped include KO;
n = 46 (blue) and HET; n = 153 (pink). (A, B, C, D, E)
Percentage seizure occurrence and (B) survival
presented at daily intervals from birth, with both
further subclassified as (C) age at observed first
seizure, (D) age at unexpected death, and (E) occurrence
of repeat seizures presented as median (±min/max),
where each dot represents an individual animal.
Unexpected death was classified as humane euthanasia
or found dead presumed because of seizure or status
epilepticus and does not include those individuals
taken for experimental end point. These data do not
include any movement phenotypes observed. (F)
Iqsec2 heterozygous females (Het/pink; n = 13) have
reduced levels of Iqsec2 protein compared with female
wild-type animals (WT/grey; n = 11). Mean (±SEM) data
presented. The animals with observed seizures are
denoted as stars. There were no significant differences
in Iqsec2 protein abundance between male (WT/
Black; n = 10) and female wild-type animals (WT/grey; n =
11). * indicates significant difference between KO males
and HET females, P < 0.05, two-tailed, unpaired t test,
# indicates P < 0.0001, two-tailed, paired t test, ^
indicates P < 0.05 between HET/KO and female WT
controls, two-tailed, unpaired t test.
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outward stretching were also noted which commenced with the
sudden onset of irregular generalised clonic jerks followed by
hypermotor activity, which lasted ~5 s before ceasing (and often
reinitiating; Video 3); and (iv) and full body tonic–clonic seizures
that started with symmetrical tonic extension of both forelimbs and
hindlimbs, which develop into rhythmic generalised clonic activity
after ~15 s, continuing for an additional 30 s before ceasing (Video
4). Seizure episodes were frequently accompanied by twitching
ears, a straight tail, and an increase in facial grooming/washing
pre- and post-seizure occurrence. Iqsec2 KO mice that were found
dead in their cage were classified as having died because of either a
seizure or status epilepticus, as no wild-type control littermates
were found dead in this study.
In concordance with the clinical variability noted in both male
and female human patients with loss-of-function mutations, we
measured large variations in age of onset, seizure severity, and
progression amongst individual Iqsec2 KO mice. The proportion of
Iqsec2 KO hemizygous males exhibiting seizures (all sub-types
combined) from birth to 4 mo of age (7–54%, respectively) was
significantly increased when compared with heterozygous females
(2–37%, respectively; Fig 2A). However, after 5 mo of age, the pro-
portion of Iqsec2 KO mice exhibiting seizures plateaued, with males
ranging from 57 up to 65% at the study end point (~300 d of
postnatal life) and females ranging from 54 to 60% across the same
time period. The survival from birth to 3 mo of age in Iqsec2 KO
hemizygous males (87%) was significantly decreased compared
with heterozygous females (91%; Fig 2B). From 4mo of age, Iqsec2 KO
males reached a plateau (80%), whereas survival of heterozygous
females continued to significantly decline until 8 mo of age (69%).
The first observed seizure occurred with similar timing in both
Iqsec2 KO male and female mice, at postnatal day (P) 29 and P23,
respectively (Fig 2C), with the first unexplained death occurring at
P16 and P7, respectively (Fig 2D). The majority of male (52%) and
female (46%) Iqsec2 KO mice were observed to have only one
seizure. The proportion of mice observed to have two or more
seizures spanning their postnatal life were similar between male
and female KO mice (13% and 2% versus 12% and 3%, respectively;
Fig 2E). The levels of Iqsec2 protein abundance in cortical tissue
Figure 3. Iqsec2 KO heterozygous females display
altered anxiety, increased locomotor activity and
reduced spatial learning and memory.
(A, B, C, D, E, F, G) Behavioural tests undertaken at
monthly intervals between 1 and 6 mo of age show
that Iqsec2 KO heterozygous females (HET/pink) (n = 4
at 1 mo; n = 8 at 2–3 mo, n = 7 at 4–6 mo) compared with
their wild-type female controls (WT/grey) (n = 3 at
1 mo; n = 6 at 2–6 mo) demonstrate (A) increased speed
across multiple apparatus (sociability apparatus
shown), (B) increased exploratory behaviour in the
open field test, (C) increased anxiety in open field test,
(D) decreased fear response in the elevated zero maze,
(E) reduced total interaction time in the sociability
apparatus regardless of familiar or novel cage
occupant, (F) decreased novel recognition in the
Y-maze, (G) and reduced spatial learning in the
Barnes maze (conducted at 6 mo of age). Mean (±SEM)
data presented, where * indicates significance between
HET/KOandWT controls, # indicates significant between
HET time points, two-way ANOVA with Tukey’s HSD.
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were reduced in heterozygous female mice compared with wild-
type female littermates (1.8 fold, P = 0.0264) as measured by
semiquantitative immunoblot (Fig 2F). Iqsec2 protein abundance
was not impacted by the presence of an observed seizure (in-
dicated by stars instead of circles).
Iqsec2 KO heterozygous female mice demonstrate altered
behavioural phenotyping
Given the striking similarity in the seizure phenotype displayed by
the Iqsec2 KO hemizygous male and heterozygous female mice,
coupled with the marked overlap in phenotypic outcomes in loss-
of-function male and females patients in the human setting, we
contend that the Iqsec2 KO heterozygous females provide a rep-
resentative model for this disorder. Interestingly, the male KO
progeny were able to breed and transmit the loss-of-function
Iqsec2 mutation with minimal difficulty. In contrast, the Iqsec2
KO heterozygous females displayed reduced breeding success (Fig
S4). However limited, this indicates that a loss-of-functionmutation
in Iqsec2 is able to be transmitted, at least in mice. Due largely to
the limited breeding success of our Iqsec2 KO heterozygous fe-
males, generating the required number of age appropriate KO
males for behavioural testing was challenging and precluded
testing in hemizygous males. Hence, we undertook a battery of
behavioural tests at monthly intervals up to 6 mo of age in the
Iqsec2 KO heterozygous females compared with female wild-type
controls.
Iqsec2 KO heterozygous females demonstrate an increased lo-
comotor activity and exploratory behaviour. Iqsec2 KO heterozy-
gous females exhibit reduced neuromuscular strength at 3, 5, and 6
mo of age using the inverted grid test (Fig S5A). Although the
difference in overall performance by each genotype on the ap-
paratus was significant (P = 0.0031), the variability amongst in-
dividuals meant that significance was not reached at any individual
time point. Hyperactivity was indicated by a significant (P < 0.0001)
increase in the overall average speed (Fig 3A; sociability apparatus
shown), and overall total distance travelled (Fig 3B; open field test
shown) compared with wild-type littermates onmultiple apparatus.
Figure 4. Neuroanatomy changes in Iqsec2 KO mouse brains.
(A, B) Nissl staining of brain sections in both (A) coronal and (B) sagittal orientations from adult wild-type and heterozygous KO females demonstrate there is no gross
disturbance to brain morphology. Scale bars shown for each set of pictomicrographs. (C) The thickness of the corpus callosum (CC) measured where the (1) start and (2)
end of the cingulum intercepts the CC in three coronal sections for each of n = 4 animals per genotype is significantly thinner in heterozygous female (HET/pink) mice
compared with wild-type female (WT/Grey) mice. (D) Heterozygous females have increased total hippocampal and dentate gyrus volume compared with wild-type
littermates (n = 4 each). (E) The area of the brain was measured in animals from 60 to 155 d postnatal age in sagittal sections in HET/pink and WT/grey females (a total 36
sectionsmeasured per genotype: nine sections each for n = 4 animals). The Iqsec2HetKO animals with observed seizures are denoted by stars. Mean (±SEM) data presented
where # indicates P < 0.001, and # # indicates P < 0.0001, two-tailed, unpaired t test between wild-type and heterozygous females.
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Altered anxiety and fear response was also noted in Iqsec2 KO
femalemice, with a significant increase in percentage total distance
travelled in the inner third of the open-field apparatus (Fig 3C and P
= 0.0006), increased number of head dips on the elevated zeromaze
(Fig 3D and P < 0.0001), and an initial increase in percentage total
distance travelled in the open arms of the elevated zero maze (Fig
S5B and P = 0.0007). This is in comparison with wild-type females,
which from 4 mo of age travelled a greater percentage of total
distance on the open arms of the elevated zero maze, suggesting
habituation (Fig S5B).
Normal social interaction and memory recall is demonstrated by
mice choosing to interact with a mouse rather than an empty cage
and a preference to interact with a novel mouse over a familiar
mouse when tested in a three-chamber sociability apparatus. The
Iqsec2 KO heterozygous females displayed autistic-like behaviour
evident by a significant decrease in the total overall time of in-
teraction, regardless of the other cage occupant (Fig 3E and P <
0.03). In addition, the behaviour of the Iqsec2 KO heterozygous
females suggests reduced learning capacity and spatial memory
retention in contrast to wild-type females. Iqsec2 KO heterozygous
females had a significant preference toward exploring the familiar
arm of the Y-maze increasing over time (Fig 3F and P = 0.0261) and
took significantly longer and travelled further distance to find the
escape hole in the Barnes maze (Fig 3G and P < 0.0265).
Altered neuroanatomy in Iqsec2 KO heterozygous female mice
Nissl stain of both the coronal (Fig 4A) and sagittal (Fig 4B) ori-
entations demonstrate there is no gross disturbance to the overall
anatomical structure of the brain in heterozygous female compared
with wild-type mice. Emerging evidence suggests that severely
affected patients with IQSEC2 loss-of-function mutations display a
phenotype that includes thinning of the corpus callosum. We ex-
amined the thickness of the corpus callosum at two distinct points,
each in three semi-serial coronal sections from an n = 4 animals per
genotype (sections relative to the reference Allen Brain Atlas,
Mouse, P56, and coronal images 44–46 of 132). Using this approach,
we demonstrate that the thickness of these regions was signifi-
cantly diminished in the heterozygous female mice compared with
the wild-type female mice (Fig 4C). In line with the increase in
Figure 5. Embryonic (E)17.5 cultured cortical neurons
from Iqsec2 heterozygous females (HET/pink; n =
449 electrodes from n = 12 embryos) exhibit hallmarks
of immature synaptic networks when compared with
their respective wild-type (WT) control littermates
(WT female/grey n = 256 electrodes from n = 7
embryos).
(A, B, C, D) Representative raster plots for (A.i) WT
female and (A.ii) HET female after 21 d in culture.
Quantitatively, HET cultures showed an increased (B)
spike count, (C) burst count, and (D) mean burst
duration compared with wild-type control littermates.
Mean (±SEM) data presented, where * indicates
significance between HET and WT control, two-tailed,
unpaired t test , where P < 0.05.
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hyperactivity and anxiety noted in our Iqsec2 KO heterozygous
females, we observed an increase in total hippocampal volume in
heterozygous KO female mice (34%, P = 0.0008 HET versus WT fe-
males) and an increase in the volume of the dentate gyrus (48%, P =
0.0006 for HET females) shown in Fig 4D (sections relative to the
reference Allen Brain Atlas, Mouse, P56, sagittal images 9–10 of 21).
Despite these discreet changes to specific neuroanatomical regions
of the brain, our analysis indicates there were no significant dif-
ferences in the area of the brain sections measured between wild-
type females and the heterozygous KO females (Fig 4E) (sections
relative to the reference Allen Brain Atlas, Mouse, P56, sagittal
images 11–12 of 21).
Iqsec2 female mice display hallmarks of immature synaptic
networks ex vivo
To investigate the impact of Iqsec2 on the activity of synaptic
networks, we analysed cultured cortical neurons using a multi-
electrode array. Neurons isolated from individual Iqsec2 KO het-
erozygous female embryos grown for 21 d in culture display
hallmarks of immature synaptic networks when compared with
neurons from wild-type littermates (Fig 5). Burst activity and
bursting behaviour is considered one of the most important
properties for analysing synaptic plasticity and information pro-
cessing within the central nervous system. Wild-type cultures
demonstrated consistent, evenly spaced bursts of closely clustered
action potentials, suggestive of a highly synchronised culture (Fig
5A.i). In contrast, Iqsec2 KO heterozygous cultures showed aberrant
synchronicity; with action potentials not consistently clustered in
large bursts, but included smaller, randomly spaced events (Fig
5A.ii). In line with this observation, cultures from heterozygous
females exhibited significantly elevated spike count (121%; Fig 5B
and P < 0.0001), burst count (113%; Fig 5C and P = 0.0002), andmean
burst duration (114%; Fig 5D and P = 0.003), but no difference in
mean burst interval (Fig 5E) when compared with sex-matched
wild-type controls. It must be noted that large variations existed
in Iqsec2 KO heterozygous cultures, with some embryos dem-
onstrating burst patterning similar to that of their wild-type
counterparts.
Loss of Iqsec2 function leads to an increased level of activated
Arf6 in cortical tissues
There are multiple ArfGEFs, each with a conserved Sec7 domain
responsible for catalysing nucleotide exchange and activating
members of the small G protein Arfs. Hence, it was not clear what
impact the loss-of-function of a single ArfGEF would have on
regulating activated Arf-mediated responses to synaptic signalling
in vivo. As Iqsec2 is an ArfGEF particularly for the small GTPase Arf6,
we analysed the levels of activated (or GTP bound) Arf6 in cortical
tissues from individual mice of each genotype. There was no change
in the level of Arf6 activation with increasing postnatal age (range
2–9 mo), and although the levels of activated Arf6 were higher in
wild-type females relative to wild-type males, this difference was
not significant (1.5 fold; Fig 6A). In contrast, cortical tissues from
heterozygous females exhibited significantly elevated levels of
activated Arf6 (2.6 fold; P = 0.0186) when compared with sex-
matched and age-matched wild-type controls (Fig 6B). A similar
outcome was observed in cortical tissues from hemizygous males
with an elevated, although not statistically significant, level of
activated Arf6 (2.45 fold; P = 0.0536) (Fig 6B). The increases in ac-
tivated Arf6 levels in Iqsec2 KO hemizygous and heterozygous mice
were not reflected by a significant increase in Arf6 protein abun-
dance relative to wild-type for either sex (detected in the same [and
additional] cortical tissue) (Fig 6C). Nor was Arf6 protein abundance
impacted by the presence of an observed seizure (indicated by
stars instead of circles; P = 0.1009).
Heterozygous loss-of-function variant in IQSEC2 in a female with a
neurocognitive seizure phenotype
Here, we report an elderly, 68-yr-old female (II-2) (Fig 7A) with
severe-to-profound ID, early onset of seizures who is nonverbal,
Figure 6. The levels of activated Arf6 in cortical tissue are elevated because of
Iqsec2 KO.
(A) Biochemical assays to measure the levels of activated Arf6 (G-LISA)
undertaken in cortical tissues of animals across postnatal development between
2 and 9 mo of age show that (A) the levels of activated Arf6 in wild-type male
mice (WT/black) (n = 4) are elevated in age-matched wild-type female mice (WT/
grey) (n = 5). (B) Iqsec2 KO hemizygous males (KO/blue, n = 6) and heterozygous KO
females (Het/pink; n = 9) both display increased levels of activated Arf6
compared with the sex-matched wild-type controls listed above. (C) The
abundance of Arf6 protein measured by immunoblot was not significantly
different between any genotype groups. The Iqsec2 KO animals with observed
seizures are denoted by stars. Mean (±SEM) data presented, where * indicates
significance between WT female control and HET/KO, P < 0.05, 2-tailed, unpaired
t test.
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and communicates primarily using sounds and gestures. She has a
history of normal early development, learning to sit at 8–10 mo and
walk at age 18 mo. After seizure onset at 17 mo, she developed
repeated, generalised seizures during the daytime and regression
was observed. She later developed additional atypical absence and
atonic seizure types. Since the age of 11, she has been living in
residential care. Her daily functioning skills are poor, and she needs
assistance in every-day life. Facial features include low-set, large
ears, and asymmetric facial features with prominent angle of the
jaw, thick upper lip with mild hypertrichosis over the upper lip and
deep-set eyes (Fig 7B). No brain MRI has been performed because of
the requirement of general anaesthesia. A detailed clinical de-
scription of the proband is described in Supplemental Data 1.
Whole-exome analysis of four Finnish families identified a novel,
heterozygous single-nucleotide polymorphism at genomic position
ChrX:g.53,349,756 (GRCh37/19) in the female proband of one family.
The variant has been submitted to the gene variant database at
https://databases.lovd.nl/shared/genes/IQSEC2 (patient ID 00174867;
DB-ID #0000398628). Sanger sequencing confirmed the presence of
this variant in the proband (Fig 7C). Samples were not available for
the twin brother or parents of the affected female proband to
confirm the inheritance status of this variant. This variant in exon 1
of the NM_001111125.2 long isoform substitutes a single nucleotide
at c.566C>A, generating a predicted premature stop codon, p.(S189*)
(NP_001104595) in IQSEC2 (Fig 7D). This variant was not found in ExAC,
GnomAD, or dbSNP150 project databases. This predicted premature
stop codon is located 141 nucleotides from the exon 1–2 junction, with
the transcript predicted to be degraded via the nonsense-mediated
mRNA decay pathway, resulting in loss of the IQSEC2 protein.
Review of the literature shows that the affected female proband
adds to the growing number of affected females with loss-of-function
variants in IQSEC2 gene presenting with severe ID and early-onset
seizures (Table 1) (29–42) recently reviewed (12). Table 1 details 31
different variants in IQSEC2 in 38 separate cases of affected female(s)
predicted to cause pathogenic loss of IQSEC2 function. Of these 31
variants, 28 are known to have arisen de novo, one case of gonadal
mosaicism in a family of four affected girls, and one case of
monozygotic twins, with discordant phenotypes. The inheritance in
the proband of the current report was unable to be determined.
Although not all cases were accompanied by complete clinical de-
scriptions, 33 of the 38 cases report developmental delay or ID ranging
from mild-to-severe or profound and present with a range of
comorbid behavioural and psychiatric features (Table 1). Interestingly,
28 of the 38 cases reported a range of seizure types in the affected
females, including epileptic encephalopathies (Table 1). In a recent
review of the phenotypic spectrum of epileptic encephalopathies in
male and female patients with pathogenic IQSEC2 variants, it was
noted that there was no specific electroclinical syndrome that could
Figure 7. Identification of a c.556C > A
(NM_001111125.2) variant resulting in a premature
stop codon at p.(S189*) (NP_001104595) in IQSEC2.
(A) Pedigree of family. Open symbols represent
unaffected individuals and filled black circle
represents female with profound-to-severe
intellectual disability and epilepsy. Normal (N) and
mutant (M) alleles shown for proband. (B)
Asymmetrical facial features, prominent angle of the
jaw and low-set, large ears of II-2 (front and side).
(C) DNA sequence electropherograms for the chrX:
g.53349756 (GRCh37/hg19 assembly); c.556C>A mutation
in exon 1 of 15 of IQSEC2 in II-2 affected female.
(D) Predicted impact of novel variant in IQSEC2. The
exon–intron structure of the longest isoform of the
IQSEC2 gene (NM_001111125.2) with 15 exons, the ATG and
open reading frame and stop codon position in black
and 59 and -39 untranslated regions in light grey. The
predicted protein structures (NP_001104595) with
known functional domains highlighted; coiled–coiled
(CC-red), IQ-like (orange) Sec7 enzyme domain (Green),
PH domain (purple), and PDZ-binding motif (Blue),
corresponding amino acids listed below each
domain. The variant c.566C>A replaces the codon for
Serine (p.189) for a stop codon and is predicted to result
in nonsense-mediated mRNA decay and loss of the
protein from the mutant allele.
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Table 1. Pathogenic loss-of-function variants in IQSEC2 in females with intellectual disability and other comorbidities.
cDNA Ex Protein Dom Family DD/ID Seizures Behavioural/Psychiatric/Physical features Ref
c.55_151delinsAT 1 p.Ala19Ilefs*32 — P1 Mild ID None
Speech
deficits—pronunciation,
syntax issues at 6.5 years.
Tantrums, anxiety
(29)
c.83_85del 1 p.Asp28del CC 108286 Rett like None









screaming spells. Partial or
loss of spoken language.
(31)









c.804delC 3 p.Tyr269Thrfs*3 — 48 Seizures Limited phenotype reported. (32)
c.854del 3 p.Pro285Leufs*21 — P11 Severe ID Seizures (12 mo) tonic–clonic Says words at 16 years. Limbrigidity, walking instability. (29)
c.928G>T 3 p.Glu310* — P16 Mild-mod DD FE No ASD or other features.Nonverbal at 3 years. (33)
c.1556_1599delACCT 5 p.Tyr519Trpfs*87 — P10 DD, Severe toprofound ID None




c.1591C>T 5 p.Arg531* — P3 DD, Severe toprofound ID Tonic–clonic, absence




c.1744_1763del 5 p.Arg582Cysfs*9 — P16 Mild DD Focal epilepsy (17 mo)




c.1983_1999del 5 p.Leu662Glnfs*25 — P17 Global DD Focal epilepsy (11 mo) Babbling at 16 moHypertonia. (29)
c.2052_2053delCG 5 p.Cys684* — 47 Seizures Limited phenotype reported. (32)
c.2078delG 5 p.Gly693Valfs*29 P18 Mod globalDD None




c.2203C>T 5 p.Gln735* — T17563 Mild ID
SGE (5 years)—regression
with nonconvulsive SE.
Absence to tonic–clonic and
myoclonic seizures, drop
attacks. Offset at 38 years.
(35)
c.2272C>T 5 p.Arg758* — P19 Severe ID Multifocal epilepsy (23 mo) 3 words at 11.3 years. Self-injurious behaviours. (29)
P20 Mod ID Seizures (9 years 4 mo) GTCS,focal, atypical absences
Speaks sentences,
reasoning difficulties
c.2317C>T 6 p.Gln773* Sec7 P6 Global DD Seizures (18 mo) Hypotonic, strabismus,dysmorphic face (36)
P23 Mod ID Seizures (14 years), GTCS,absences
Few words at 43 years. ASD
(13 years) aggressive. (29)
c.2317_2332del 6 p.Gln773Glyfs*25 Sec7 P24 Seizures (6 years) Sentences at 11.3 years (29)
(Continued on following page)
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Table 1. Continued
cDNA Ex Protein Dom Family DD/ID Seizures Behavioural/Psychiatric/Physical features Ref
c.2679_2680insA 8 p.Asp894fs*10 Sec7 K2 DD, Mod-severe ID Epilepsy
4 affected sisters, nonverbal
(2), language delay (1),
aggressive when young and
ASD traits (2)
(37)
c.2776C>T 9 p.Arg926* Sec7 P3 Severe IDRett like EE
ASD (balance & hand
stereotypies), pain
sensitivity & aggressive.
Speech delay, regression at 2
years. Now nonverbal
(38)
P26 Profound ID LGS (23 mo)









delay, nonverbal at 14 years.
(39)
c.2854C>T 9 p.Gln952* PH P27 Severe ID EE (12 years), absences, GTCS




c.2911C>T 10 p.Arg971* PH P8 DD, Severe toprofound ID Seizures
No ASD. Stereotypies and
dysmorphic features. (34)
P11 DD, Severe toprofound ID Seizures





c.3079delC 11 p.Leu1027Serfs*75 PH P29 Mod-severeID None 10 words at 8 years (29)
c.3163C>T 12 p.Arg1055* PH Pat19 Severe ID Epilepsy Borderline macrocephaly,skewed X-inactivation (97:3) (40)
P31 Mod-severeID
Seizures (5 years 8 mo) GTCS,
focal dyscognitive
3 word sentences, and 20





c.3278C>A 13 p.Ser1093* — P36 Severe ID None Few words, rare sentences at13 years. (29)
c.3322C>T 13 p.Gln1108* — KO EE (41)
c.3433C>T 13 p.Arg1145* — P39 Severe ID Focal epilepsy (11 mo) focal,tonic, tonic–clonic
Nonverbal at 11 years.
Autistic behaviour. (29)
c.3457del 14 p.Arg1153Glyfs*244 — P40 Severe ID
IS (7 mo) spasms, focal,
absence, tonic, myoclonic
jerks
Nonverbal at 20 years.
Autistic behaviour, truncal
hypotonia. MRI mild atrophy
and cerebral white matter
hyperintensities.
(29)
c.4039dupG 15 p.Ala1347Glyfs*40 — 1098 M EE (19 mo) ASD, macrocephaly (42)
P41 Mild-mod ID Seizures (3 years) absenceand falls
Speaks sentences, writes




c.4401del 15 p.Gly1468Alafs*27 — P42 Mod-severeID None




(Continued on following page)
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be defined, with all patients displaying multiple seizure types con-
sisting mainly of atonic, myoclonic, or epileptic spasms. The seizure
phenotypes were accompanied with a variety of electroencephalo-
gram (EEG) patterning, including hypsarrhythmia, polyspikes and
waves, generalised spikes and waves, slow spikes and waves, as well
as background slowing (33). The advanced age of the female proband
(68 yr old) we identify and present as part of this study underscores
the importance of considering IQSEC2 as an explanation of ID and,
particularly, seizures in females across their life span. Furthermore,
this finding reinforces the fact that a female IQSEC2 phenotype may
still be under-ascertained.
Discussion
The cellular andmolecular pathogenesis of IQSEC2mutations is not
well understood. To address this, we used CRISPR/Cas9–targeted
editing to generate an Iqsec2 KO mouse model with no (Iqsec2 KO
hemizygous males) or reduced (Iqsec2 KO heterozygous females)
Iqsec2 mRNA and protein. We validated both successful genome
editing and germline transmission. To date, there have beenno reports
of transmission of loss-of-function mutations in IQSEC2 in the human
setting, with the exception of gonadal mosaicism in a family of four
affected female siblings (37). We demonstrate that hemizygous KO
males were viable and able to breed and generate healthy female
heterozygous KO offspring. This suggests a potential difference in
mouse to human phenotypic outcomes related to brain and sexual
development (43, 44). Despite some difficulties, the successful
breeding of the Iqsec2 KO heterozygous femalemice shows that a loss-
of-function mutation in Iqsec2 can be transmitted, at least in mice.
In agreement with the expanding phenotypic spectrum and the
67% penetrance of seizures in patients with de novo pathogenic
variants in IQSEC2 (33), we demonstrate that severe spontaneous
seizures are observed in approximately half of all the Iqsec2 KO
mice. In these mice, we observed four distinct seizure types: (i)
involuntary, uncontrolled, unilateral head movements, (ii) re-
petitive forelimb clonus, (iii) uncontrolled convulsions with bi-
lateral forelimb outward stretching, and (iv) full body tonic–clonic
seizures. Using the (human) International League Against Epilepsy
classification system, these seizures can be considered equivalent
to a (i) generalised clonic seizure, (ii) focal seizure evolving to
bilateral tonic–clonic seizure, (iii) focal motor seizure (likely frontal
lobe onset), and (iv) generalised tonic–clonic seizure (Personal
communication: A/Prof Nigel C Jones, Department of Neuroscience,
Central Clinical School, Monash University, Melbourne, Victoria,
Australia). Although EEG analysis was not undertaken in this study,
aberrant firing and abnormal burst activity was noted in neuronal
cultures of Iqsec2 KO affected embryos. This abnormal activity is
consistent with immature synaptic networks, previously associated
with neurodevelopmental disorders (45, 46, 47).
Ionotropic glutamate receptors are ligand-gated cation
channels that mediate most of the excitatory neurotransmission
in the brain and are classified based on pharmacological se-
lectivity to AMPA, kainic acid, and N-methyl-D-aspartic acid
(NMDA). Activation of these receptors couples the electrical signal
at the synapse to downstream biochemical signalling pathways.
Selected NMDAR subunit genes have been implicated in the
pathogenesis of ID (48, 49, 50). Synaptic plasticity associated with
changes to spine morphology has been shown to be dependent
on activation of these receptors (51, 52, 53, 54). IQSEC2 is localized
to excitatory synapses as part of the protein scaffold downstream
of the NMDA receptor complex. Through enzyme activity, IQSEC2
activates ARF6, a member of the Ras superfamily (55) to facilitate
downstream remodelling of actin cytoskeleton, a site of con-
vergence with other ID and autism genes. In the present study, we
demonstrate that neurons in culture isolated from individual
heterozygous female embryos display hallmarks of immature
synaptic networks. Investigating which critical components of
synaptic signalling are altered in response to Iqsec2 dosage, we
show surprisingly the loss of Iqsec2 leads to an increase in the
levels of activated Arf6 in cortical tissue during postnatal life. The
increase in the active form of Arf6 is independent of changes to
the overall abundance of Arf6 protein. Taken together, these data
indicate that increased levels of activated Arf6 in the presence of
Iqsec2 loss of function are likely to be at the local, dendritic
environment in response to neuron signalling. Using the novel
and powerful Iqsec2 KO hemizygous male and heterozygous fe-
male mouse models will enable further investigations into the
critical components altered in response to reduced Iqsec2 dosage
and the downstream events contributing to disease outcomes.
Review of the female patients with complete loss-of-function
mutations in IQSEC2 shows that comorbid behavioural and
Table 1. Continued
cDNA Ex Protein Dom Family DD/ID Seizures Behavioural/Psychiatric/Physical features Ref
c.4419_4420insC 15 p.Ser1474Glnfs* — P6 DD, Severe toprofound ID Absence, complex
Autism, hypotonia. First





Twin sister of P6 P7 DD, Mild ID No Autism, first words 11.5 mo.Ataxic gait
ASD, autistic spectrum disorder; DD, developmental delay; EE, epileptic encephalopathy; GTCS, generalised tonic–clonic seizures; IS, infantile spasms; SGE,
symptomatic generalised epilepsy.
Del, deletion; dup, duplication. Numbers (alone) in brackets indicate number of affected individuals.
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence for IQSEC2
(GenBank: NM_001111125.2).
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psychiatric features are frequently present in addition to ID (Table
1). Hence, it was not surprising that mice modelling Iqsec2 KO in the
heterozygous female state displayed a range of phenotypic traits
across a series of behavioural tests corresponding to these ad-
ditional features (Table 2). Notably, the Iqsec2 KO heterozygous
females recapitulated a reduction in intellectual functioning and
autistic-like behaviours, demonstrated through a loss of novel
recognition on the Y-maze, a reduction in learning and memory
during the Barnesmaze trial, and an overall reduction in interaction
time during the sociability test. Altered anxiety-like/fear responses
and hyperactivity in the Iqsec2 KO heterozygous female mice on
multiple apparatus correlate with an increase in hippocampal
volume, which has been associated with mental retardation and
psychiatric issues such as autism, attention-deficit disorder, and
schizophrenia (56, 57). We also observe a thinning of the corpus
callosum in the Iqsec2 KO heterozygous female mice, a phenotype
emerging in several cases (29). Taken together, these findings
highlight that our Iqsec2 KO mouse model recapitulates the
complex phenotypic spectrum observed in female patients with
loss-of function IQSEC2 variants (31, 32, 33, 35, 36, 37, 38, 39, 40, 41).
Interestingly, the emergence of a speech phenotype is noted in
the proband reported in this study and 26 of the 38 published
female cases with loss-of-function variants (Table 1). Although we
have not yet addressed this clinical feature in mice, it would be
interesting to investigate it, particularly in view of the observa-
tions of reduced mothering skills of the breeding heterozygous
females.
Female patients with de novo loss-of-function mutations in
IQSEC2 often have a more severe phenotype than the heterozygous
state would traditionally predict, particularly if IQSEC2 is thought to
escape X-inactivation. The capacity of genes on the X-chromosome
to be silenced, or to escape to some degree X-inactivation is not
fully understood. Escape from X-inactivation for IQSEC2 in humans
has long been the prevailing view, as demonstrated by evidence
measuring DNA methylation as a predictor of inactivation status
across a panel of 27 tissues from 1,875 females (58). In contrast,
recent large-scale expression studies from the GTEX consortium
demonstrate that the expression of IQSEC2 is similar in males and
females across a broad range of tissues, including regions of the
brain (19). This would suggest either dosage compensation in males
(up-regulation) or females (down-regulation) or X-chromsome
inactivation (XCI) in females. The degree by which incomplete XCI
manifests as detectable sex differences in gene expression and
phenotypic traits remains poorly understood (58, 59). The Iqsec2 KO
mouse model studied here shows severe phenotypic presentation
in the heterozygous state. This fact would suggest that the severity
of the phenotype in heterozygous females with loss-of-function
IQSEC2/Iqsec2 allele is generally independent of X-chromosome
inactivation. Given that X-inactivation leads to cellular mosaicism in
heterozygous females one may speculate that the function and
impact of IQSEC2/Iqsec2 is cell nonautonomous, that is, loss of
IQSEC2/Iqsec2 impacts wild-type (i.e., where the mutant X is
inactivated) as well as mutant (i.e., cells where the wild-type X is
inactivated) cells. As such, this genetic KO model will provide an
excellent tool to investigate the molecular mechanisms of X-linked
inheritance underpinning the male and female phenotypes, pro-
viding valuable information not only for Iqsec2, but other X-linked
genes with an emerging female phenotype (4, 5, 6, 37).
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Colony ID Genotype DOB Drug
Breeding 
Round
Date of death Reason for death
PA1 2208G PA1 hemizygous male 17/07/2017 Vehicle 2 26/09/2017 End point
PA1 2209G PA1 hemizygous male 17/07/2017 Vehicle 2 1/09/2017 Found dead in cage
PA1 2258G PA1 hemizygous male 21/07/2017 Vehicle 2 26/09/2017 End point
PA1 2302G PA1 hemizygous male 3/08/2017 Vehicle 3 6/10/2017 End point
PA1 2327G PA1 hemizygous male 8/09/2017 Vehicle 4 1/10/2017 Found dead in cage
PA1 2330G PA1 hemizygous male 8/09/2017 Vehicle 4 6/11/2017 End point
PA1 2352G PA1 hemizygous male 9/09/2017 Vehicle 4 8/11/2017 End point
PA1 2205G Wild-type male 17/07/2017 Vehicle 2 26/09/2017 End point
PA1 2206G Wild-type male 17/07/2017 Vehicle 2 26/09/2017 End point
PA1 2207G Wild-type male 17/07/2017 Vehicle 2 26/09/2017 End point
PA1 2259G Wild-type male 21/07/2017 Vehicle 2 26/09/2017 End point
PA1 2260G Wild-type male 21/07/2017 Vehicle 2 26/09/2017 End point
PA1 2300G Wild-type male 3/08/2017 Vehicle 3 6/10/2017 End point
PA1 2301G Wild-type male 3/08/2017 Vehicle 3 6/10/2017 End point
PA1 2303G Wild-type male 3/08/2017 Vehicle 3 6/10/2017 End point
PA1 2304G Wild-type male 3/08/2017 Vehicle 3 6/10/2017 End point
PA1 2305G Wild-type male 3/08/2017 Vehicle 3 6/10/2017 End point
PA1 2328G Wild-type male 8/09/2017 Vehicle 4 8/11/2017 End point
PA1 2329G Wild-type male 8/09/2017 Vehicle 4 6/11/2017 End point
PA1 2351G Wild-type male 9/09/2017 Vehicle 4 8/11/2017 End point
PA1 2353G Wild-type male 9/09/2017 Vehicle 4 8/11/2017 End point
PA1 2354G Wild-type male 9/09/2017 Vehicle 4 8/11/2017 End point
PA1 2188G PA1 hemizygous male 29/06/2017 E2 1 7/09/2017 End point
PA1 2217G PA1 hemizygous male 18/07/2017 E2 2 11/08/2017 Found dead in cage
PA1 2219G PA1 hemizygous male 18/07/2017 E2 2 3/08/2017 Cannibalised
PA1 2220G PA1 hemizygous male 18/07/2017 E2 2 4/08/2017 Cannibalised
PA1 2332G PA1 hemizygous male 8/09/2017 E2 4 8/11/2017 End point
PA1 2337G PA1 hemizygous male 8/09/2017 E2 4 6/11/2017 End point
PA1 2340G PA1 hemizygous male 8/09/2017 E2 4 8/11/2017 End point
PA1 2185G Wild-type male 29/06/2017 E2 1 7/09/2017 End point
PA1 2186G Wild-type male 29/06/2017 E2 1 7/09/2017 End point
PA1 2187G Wild-type male 29/06/2017 E2 1 7/09/2017 End point
PA1 2218G Wild-type male 18/07/2017 E2 2 11/08/2017 Wild-type control
PA1 2333G Wild-type male 8/09/2017 E2 4 8/11/2017 End point
PA1 2334G Wild-type male 8/09/2017 E2 4 6/11/2017 End point
PA1 2338G Wild-type male 8/09/2017 E2 4 27/09/2017 Humane - runt
PA1 2339G Wild-type male 8/09/2017 E2 4 8/11/2017 End point
Colony ID Genotype DOB Drug
Breeding 
Round
Date of death Reason for death
PA2 2149D PA2 hemizygous male 28/06/2017 Vehicle 1 7/09/2017 End point
PA2 2151D PA2 hemizygous male 28/06/2017 Vehicle 1 24/08/2017 Found dead in cage
PA2 2152D PA2 hemizygous male 28/06/2017 Vehicle 1 18/07/2017 Found dead in cage
PA2 2170D PA2 hemizygous male 29/06/2017 Vehicle 1 7/09/2017 End point
PA2 2178D PA2 hemizygous male 29/06/2017 Vehicle 1 11/08/2017 Humane - seizures
PA2 2180D PA2 hemizygous male 29/06/2017 Vehicle 1 11/08/2017 Humane - seizures
PA2 2181D PA2 hemizygous male 29/06/2017 Vehicle 1 20/07/2017 Humane - runt
PA2 2232D PA2 hemizygous male 21/07/2017 Vehicle 2 26/09/2017 End point
PA2 2234D PA2 hemizygous male 21/07/2017 Vehicle 2 27/07/2017 Cannibalised
PA2 2235D PA2 hemizygous male 21/07/2017 Vehicle 2 26/09/2017 End point
PA2 2238D PA2 hemizygous male 21/07/2017 Vehicle 2 26/09/2017 End point
PA2 2280D PA2 hemizygous male 30/07/2017 Vehicle 3 21/08/2017 Found dead in cage
PA2 2281D PA2 hemizygous male 30/07/2017 Vehicle 3 24/08/2017 Found dead in cage
PA2 2282D PA2 hemizygous male 30/07/2017 Vehicle 3 22/08/2017 Found dead in cage
PA2 2283D PA2 hemizygous male 30/07/2017 Vehicle 3 11/08/2017 Found dead in cage
PA2 2361D PA2 hemizygous male 10/09/2017 Vehicle 4 6/11/2017 End point
PA2 2362D PA2 hemizygous male 10/09/2017 Vehicle 4 6/11/2017 End point
PA2 2364D PA2 hemizygous male 10/09/2017 Vehicle 4 31/10/2017 Found dead in cage
PA2 2150D Wild-type male 28/06/2017 Vehicle 1 7/09/2017 End point
PA2 2169D Wild-type male 29/06/2017 Vehicle 1 7/09/2017 End point
PA2 2171D Wild-type male 29/06/2017 Vehicle 1 7/09/2017 End point
PA2 2177D Wild-type male 29/06/2017 Vehicle 1 7/09/2017 End point
PA2 2179D Wild-type male 29/06/2017 Vehicle 1 7/09/2017 End point
PA2 2231D Wild-type male 21/07/2017 Vehicle 2 26/09/2017 End point
PA2 2233D Wild-type male 21/07/2017 Vehicle 2 26/09/2017 End point
PA2 2236D Wild-type male 21/07/2017 Vehicle 2 26/07/2017 Cannibalised
PA2 2237D Wild-type male 21/07/2017 Vehicle 2 26/09/2017 End point
PA2 2273D Wild-type male 30/07/2017 Vehicle 3 6/10/2017 End point
PA2 2274D Wild-type male 30/07/2017 Vehicle 3 6/10/2017 End point
PA2 2275D Wild-type male 30/07/2017 Vehicle 3 6/10/2017 End point
PA2 2359D Wild-type male 10/09/2017 Vehicle 4 6/11/2017 End point
PA2 2360D Wild-type male 10/09/2017 Vehicle 4 6/11/2017 End point
PA2 2363D Wild-type male 10/09/2017 Vehicle 4 6/11/2017 End point
PA2 2157D PA2 hemizygous male 28/06/2017 E2 1 15/07/2017 Humane - runt
PA2 2158D PA2 hemizygous male 28/06/2017 E2 1 7/09/2017 End point
PA2 2159D PA2 hemizygous male 28/06/2017 E2 1 20/07/2017 Found dead in cage
PA2 2160D PA2 hemizygous male 28/06/2017 E2 1 13/07/2017 Found dead in cage
PA2 2161D PA2 hemizygous male 28/06/2017 E2 1 7/07/2017 Humane - runt
PA2 2162D PA2 hemizygous male 28/06/2017 E2 1 18/07/2017 Found dead in cage
PA2 2210D PA2 hemizygous male 17/07/2017 E2 2 10/08/2017 Found dead in cage
PA2 2213D PA2 hemizygous male 17/07/2017 E2 2 26/09/2017 End point
PA2 2223D PA2 hemizygous male 19/07/2017 E2 2 12/08/2017 Found dead in cage
PA2 2294D PA2 hemizygous male 1/08/2017 E2 3 30/09/2017 Found dead in cage
PA2 2309D PA2 hemizygous male 5/08/2017 E2 3 8/09/2017 Humane - seizures
PA2 2311D PA2 hemizygous male 5/08/2017 E2 3 26/08/2017 Found dead in cage
PA2 2343D PA2 hemizygous male 8/09/2017 E2 4 8/11/2017 End point
PA2 2345D PA2 hemizygous male 8/09/2017 E2 4 2/10/2017 Found dead in cage
PA2 2367D PA2 hemizygous male 10/09/2017 E2 4 8/11/2017 End point
PA2 2155D Wild-type male 28/06/2017 E2 1 7/09/2017 End point
PA2 2156D Wild-type male 28/06/2017 E2 1 7/09/2017 End point
PA2 2211D Wild-type male 17/07/2017 E2 2 26/09/2017 End point
PA2 2212D Wild-type male 17/07/2017 E2 2 26/09/2017 End point
PA2 2224D Wild-type male 19/07/2017 E2 2 26/09/2017 End point
PA2 2225D Wild-type male 19/07/2017 E2 2 26/09/2017 End point
PA2 2286D Wild-type male 1/08/2017 E2 3 6/10/2017 End point
PA2 2287D Wild-type male 1/08/2017 E2 3 6/10/2017 End point
PA2 2288D Wild-type male 1/08/2017 E2 3 6/10/2017 End point
PA2 2293D Wild-type male 1/08/2017 E2 3 6/10/2017 End point
PA2 2310D Wild-type male 5/08/2017 E2 3 8/09/2017 Wild-type control
PA2 2312D Wild-type male 5/08/2017 E2 3 8/09/2017 Wild-type control
PA2 2344D Wild-type male 8/09/2017 E2 4 8/11/2017 End point
PA2 2365D Wild-type male 10/09/2017 E2 4 8/11/2017 End point















GeneID logFC logCPM LR PValue FDR
1700007G11Rik 0.593699697 0.101188128 4.517789545 0.033544144 0.999830311
1700010I14Rik 0.675700367 0.60179567 7.661481133 0.005641217 0.999830311
4930481A15Rik 0.549233248 0.224790427 4.292578945 0.03827906 0.999830311
4933408B17Rik 0.82816721 0.091874136 7.109956592 0.007665697 0.999830311
9430083A17Rik 0.629609892 1.574897233 10.52467324 0.001177912 0.999830311
Acad12 0.527730136 0.560155887 4.57762345 0.032392111 0.999830311
Akr1c18 -1.565972532 0.365068516 7.048213896 0.007934433 0.999830311
Arc -0.622817614 5.388169925 10.09935598 0.001483211 0.999830311
Armc3 0.520583145 0.874715913 5.340100357 0.020840273 0.999830311
B3gnt4 -0.680465861 0.239804633 4.34478577 0.037122437 0.999830311
BC006965 -0.574952206 0.807649024 4.887206363 0.027056432 0.999830311
Bves 0.738581978 0.665178896 8.844287959 0.002940076 0.999830311
Catip 0.514483972 1.150724217 6.117209697 0.013387195 0.999830311
Ccdc60 0.728797038 0.53253956 8.96313191 0.002754822 0.999830311
Ccl17 0.660450468 0.483802352 4.51569288 0.03358528 0.999830311
Cfap52 0.531688623 1.531096669 5.804853128 0.015982003 0.999830311
Chat -1.352475754 0.495423795 8.049329446 0.00455205 0.999830311
Chrna2 -0.977895842 0.397850957 6.413861415 0.011323291 0.999830311
Clca3a1 0.502468008 1.121170823 5.340103599 0.020840235 0.999830311
Col14a1 -0.510081924 1.48612544 4.884867163 0.027093119 0.999830311
Colq -0.610360067 1.022193381 4.31220005 0.037839994 0.999830311
Cpz -0.558674617 0.814003639 5.130996181 0.023502235 0.999830311
Crabp1 -0.705827664 2.84839265 8.218560723 0.004146407 0.999830311
Dmrt2 0.502511095 1.694868683 3.913056025 0.047912397 0.999830311
Ercc6l -0.643148248 0.634568213 6.251646067 0.012407795 0.999830311
Exoc3l4 0.693532137 0.334401455 5.817781335 0.015864945 0.999830311
Fam183b 0.532865749 1.225288501 7.192648545 0.007320285 0.999830311
Fam221a 0.800498427 0.310502229 9.605207641 0.001940263 0.999830311
Fgf16 -0.813595344 0.485286679 9.19519943 0.002426507 0.999830311
Flnc 0.52665066 2.35741235 7.322328686 0.006810311 0.999830311
Gm11992 0.625126263 1.012205227 6.781842578 0.009208978 0.999830311
H2-Q4 0.640163253 1.845653462 4.146921308 0.041710295 0.999830311
Hmga2-ps1 -0.56990098 0.48193279 4.353702546 0.036928579 0.999830311
Hrc -0.548340431 0.296751047 4.169869844 0.041148961 0.999830311
Isg15 -1.39988018 1.002738235 4.26796578 0.038837398 0.999830311
Lgr5 -0.909630825 2.992426639 4.659321254 0.030885398 0.999830311
Lrguk 0.646383874 0.681334626 7.563287537 0.005956923 0.999830311
Lrp2 0.5267983 0.746314771 5.106913395 0.023830681 0.999830311
Lrrc36 0.888871994 0.485750388 12.08455705 0.000508412 0.999830311
Lrrc74b 0.814932142 1.035340038 13.09750257 0.00029569 0.999830311
Mc5r 0.650483735 0.744673761 6.809573715 0.009067041 0.999830311
Meis1 -0.516355843 3.352135448 6.262989208 0.012328601 0.999830311
Mir17hg -0.71102073 0.793262421 4.636487075 0.031299008 0.999830311
Mme -0.54302654 3.66271461 4.364221385 0.036701252 0.999830311
Mybl2 0.669436309 0.777960791 8.84346731 0.002941398 0.999830311
Myh8 0.829062204 1.488904463 14.8318672 0.000117533 0.999830311
Ngfr -0.724033455 2.450204564 5.187995979 0.022743428 0.999830311
Nppa -0.88782949 1.002833453 4.425983199 0.035395715 0.999830311
Ntrk1 -1.683517417 0.166494995 11.15227791 0.000839286 0.999830311
Nxph2 0.747031405 2.524576563 10.95326832 0.000934387 0.999830311
Omp -1.463505316 1.147093552 4.374600031 0.036478391 0.999830311
Ovgp1 0.569559485 2.365067256 4.838094441 0.027837639 0.999830311
Pappa2 -0.537589652 2.478917336 6.015116362 0.014183843 0.999830311
Pcp4l1 -0.571950362 6.909373509 4.082339897 0.043333611 0.999830311
Prima1 -0.858012921 0.76991666 7.049692721 0.007927885 0.999830311
Prlr 0.512276845 2.263934458 5.223087009 0.02228895 0.999830311
Rgs22 0.660191102 0.802873638 5.557171784 0.018405125 0.999830311
Rxfp3 0.549120607 2.596764152 11.15223931 0.000839303 0.999830311
S100a4 0.541616536 2.285095409 4.424180296 0.035433129 0.999830311
Serpina3n 0.544280102 4.211210994 8.467382642 0.003615713 0.999830311
Serpinb1a 0.536163649 0.667529972 5.386037733 0.020298512 0.999830311
Slc18a3 -0.853818879 1.242835005 9.365482772 0.002211098 0.999830311
Slc5a7 -0.58622272 2.648774517 4.089652276 0.043146518 0.999830311
Slc6a4 -1.356413819 1.303224165 4.350837972 0.036990741 0.999830311
Snord22 0.658422054 0.175634165 4.324815012 0.037560497 0.999830311
Socs1 -0.874431233 0.972939037 10.63966541 0.001106877 0.999830311
Sp6 0.504067161 0.63286386 4.649511124 0.031062393 0.999830311
Sp7 -1.460781938 1.499571632 6.532105991 0.010594445 0.999830311
Spata1 -0.597826355 0.919980252 5.988433399 0.014399986 0.999830311
Spata18 0.563877026 0.374753 4.175078205 0.041022669 0.999830311
Spon2 -0.525922724 0.408704717 3.97416775 0.04620328 0.999830311
Sspo 1.333888522 1.221211028 4.641952331 0.03119949 0.999830311
Sytl4 0.681548408 0.475658157 5.983235248 0.014442486 0.999830311
Tacr1 -0.561922395 3.20321107 8.059301766 0.004527063 0.999830311
Th -1.055313381 4.11335111 5.252397762 0.02191655 0.999830311
Tmco5 -0.875754764 -0.0584237 5.785250739 0.016161192 0.999830311
Tnn 0.78929072 0.035977058 7.351152959 0.006701976 0.999830311
Ush1g -1.533398729 0.768563578 7.51051853 0.006133971 0.999830311
Zc2hc1c 0.504126973 1.183312694 5.498768471 0.019029871 0.999830311
Zfp953 0.629094648 0.736161227 7.095231696 0.00772893 0.999830311
P10VWT_1 P10VWT_2 P10VWT_3 P10VWT_4 P10VWT_5 P10VWT_6
0.900221253 0.827733762 0.881080883 0.647081127 0.920424551 0.495140325
1.050258129 1.504970477 0.734234069 1.058860026 1.380636827 0.919546318
0.975239691 1.053479334 0.95450429 0.941208912 0.690318414 0.636608989
1.050258129 0.902982286 0.95450429 0.705906684 0.287632672 0.424405993
1.800442506 2.407952762 2.936936275 1.882417825 2.818800189 2.122029964
1.200295004 1.580219 1.395044731 0.941208912 0.862898017 0.919546318
1.125276566 0.827733762 2.790089462 0.352953342 1.610742965 2.900107617
37.43420044 44.69762315 63.73151718 41.00141324 47.74702361 56.87040303
2.02549782 1.504970477 1.321621324 1.470638925 1.380636827 0.99028065
1.800442506 1.504970477 0.881080883 1.470638925 1.03547762 0.778077653
2.475608446 1.805964572 2.34954902 1.705941153 1.725796034 1.202483646
0.900221253 1.279224905 1.027927696 1.235336697 0.862898017 1.556155307
2.175534695 2.031710143 1.835585172 1.411813368 1.840849103 1.414686643
0.825202815 1.053479334 1.101351103 1.235336697 0.862898017 1.131749314
0.750184378 1.580219 1.395044731 0.705906684 0.977951086 0.778077653
2.475608446 3.386183572 2.34954902 2.294196724 1.553216431 2.051295632
0.600147502 2.784195382 1.982431986 2.941277851 1.03547762 0.848811986
1.500368755 1.655467524 1.909008579 0.764732241 0.632791879 2.617170289
2.175534695 1.128727857 2.202702207 1.823592268 1.725796034 1.414686643
3.600885013 2.031710143 2.863512869 3.882486763 3.106432861 2.687904621
2.100516257 2.407952762 3.377476717 2.470673395 1.093004155 1.909826968
2.475608446 2.106958667 1.615314951 1.529464482 2.128481775 1.414686643
6.37656721 7.901095002 8.884232233 11.3533325 5.004808499 10.75161848
2.925719073 1.655467524 3.891440565 3.058928965 2.818800189 1.556155307
1.950479382 1.881213096 1.835585172 1.529464482 1.265583758 1.626889639
1.200295004 1.429721953 0.660810662 0.411778899 0.862898017 0.919546318
1.650405631 2.031710143 1.688738358 1.705941153 2.070955241 2.051295632
1.050258129 0.902982286 0.807657476 0.941208912 0.575265345 0.848811986
1.35033188 1.730716048 1.762161765 1.529464482 1.553216431 1.34395231
5.476345957 5.11689962 4.47882782 4.117788991 3.566645137 2.758638953
1.35033188 1.881213096 1.395044731 2.17654561 1.03547762 1.414686643
3.525866575 4.289165858 3.230629903 2.058894496 2.18600831 1.768358303
1.800442506 1.429721953 1.17477451 1.470638925 1.553216431 1.34395231
1.35033188 1.429721953 1.027927696 1.17651114 1.265583758 1.34395231
1.275313442 8.503083193 2.643242648 0.647081127 0.805371483 1.485420975
9.602360034 5.417893716 17.91531128 3.176580079 6.730604533 15.20788141
0.975239691 1.429721953 0.881080883 1.058860026 1.265583758 1.556155307
1.725424069 1.354473429 1.101351103 1.294162254 1.265583758 1.131749314
1.050258129 1.504970477 0.587387255 0.823557798 0.862898017 0.848811986
1.875460944 1.730716048 1.321621324 1.470638925 1.610742965 0.778077653
1.35033188 1.128727857 0.95450429 1.470638925 1.553216431 0.99028065
9.752396909 10.61004186 14.46441116 9.235612452 8.11124136 16.76403671
2.625645322 1.881213096 1.027927696 2.000068939 1.323110293 2.617170289
9.902433785 14.97445624 17.0342304 24.70673395 10.06714353 9.266197509
1.050258129 1.504970477 1.027927696 1.17651114 1.265583758 1.626889639
2.175534695 1.95646162 1.688738358 1.470638925 2.761273654 2.122029964
6.076493459 10.53479334 4.625674634 6.235509044 6.788131067 3.819653935
1.35033188 1.655467524 4.258557599 0.882383355 1.898375637 3.890388267
0.525129064 2.633698334 1.615314951 2.058894496 0.460212276 1.061014982
3.825940326 2.182207191 5.727025737 6.176683487 4.774702361 3.678185271
9.002212532 1.354473429 4.038287379 0.470604456 1.150530689 1.202483646
6.076493459 6.019881906 2.643242648 3.411882307 3.394065534 3.748919603
5.476345957 4.063420287 7.268917282 7.706147969 6.327918792 6.436824224
93.54799189 107.0786494 208.1553585 115.533394 80.76725439 224.0863642
2.100516257 2.483201286 2.1292788 2.17654561 0.862898017 1.909826968
3.000737511 5.493142239 2.863512869 5.11782346 3.509118603 3.890388267
1.200295004 1.881213096 1.17477451 1.764766711 0.632791879 1.202483646
4.801180017 4.740657001 4.772521448 4.588393447 6.615551464 4.31479426
4.426087828 5.041651096 3.450900124 2.823626737 3.566645137 4.809934585
14.55357693 21.59632634 10.27927696 12.76514587 17.54559301 16.48109939
1.200295004 1.279224905 1.248197917 0.941208912 1.323110293 1.414686643
2.175534695 3.988171763 3.157206496 2.647150066 1.438163362 3.112310614
5.926456583 10.30904776 6.82837684 8.294403539 3.394065534 7.922245199
7.576862214 2.784195382 0.660810662 0.941208912 1.093004155 5.870949567
1.275313442 0.752485238 0.95450429 0.647081127 0.690318414 0.565874657
2.70066376 2.784195382 2.276125613 2.117720053 1.265583758 2.475701625
1.275313442 1.580219 1.321621324 1.058860026 1.150530689 0.919546318
3.825940326 1.580219 5.800449144 0.941208912 2.761273654 7.073433213
3.000737511 1.805964572 2.055855393 2.058894496 1.898375637 1.485420975
0.750184378 1.128727857 1.101351103 1.17651114 1.208057224 0.424405993
1.875460944 1.128727857 1.395044731 1.117685583 1.438163362 1.273217978
2.250553133 2.182207191 0.734234069 0.58825557 1.208057224 1.273217978
1.050258129 1.504970477 1.027927696 0.941208912 0.862898017 0.707343321
7.576862214 10.53479334 11.67432169 14.58873814 8.744033239 9.407666173
18.15446194 31.67962853 32.08602881 5.470776803 11.6778865 31.40604347
1.35033188 0.225745571 1.321621324 0.941208912 1.265583758 0.99028065
0.375092189 0.601988191 0.807657476 0.58825557 0.747844948 0.99028065
2.02549782 1.279224905 4.405404413 0.705906684 1.495689896 3.112310614
1.575387193 2.55844981 1.541891545 1.764766711 1.840849103 1.697623971
0.900221253 1.504970477 1.101351103 1.000034469 1.323110293 1.697623971
P10VDP24_1 P10VDP24_2 P10VDP24_3 P10VDP24_4
1.199913934 1.417322473 0.994715813 1.087346529
1.976328833 1.700786967 1.521330067 1.970815583
1.270497107 1.247243776 1.111741202 1.495101477
1.482246625 1.133857978 1.345791982 1.087346529
3.176242767 4.025195822 3.276710913 3.941631167
1.90574566 1.53070827 1.638355456 1.495101477
0.141166345 1.133857978 0.292563474 0.543673264
21.45728447 44.44723274 26.79881425 33.3679466
2.117495178 1.814172765 2.39902049 1.970815583
0.494082208 0.793700585 0.585126949 1.223264845
1.482246625 1.02047218 0.994715813 1.563060635
2.399827868 1.587401169 2.106457015 1.563060635
3.105659594 2.551180451 2.223482405 2.310611374
1.270497107 1.984251462 1.755380846 1.834897267
2.258661523 1.984251462 1.228766592 1.019387371
3.458575457 3.685038429 3.803325166 2.514488848
0.846998071 0.396850292 0.994715813 0.407754948
0.635248553 0.737007686 0.702152338 0.951428213
2.682160559 2.494487552 2.04794432 2.718366322
1.90574566 2.551180451 2.516045879 1.495101477
1.199913934 1.870865664 1.521330067 1.155305687
0.988164416 1.53070827 1.170253897 1.359183161
3.387992285 5.215746699 6.37788374 5.504691802
3.952657666 2.834644945 4.622502894 3.669794535
0.776414899 0.963779281 1.521330067 0.951428213
1.270497107 1.474015372 1.579842761 1.495101477
2.682160559 3.004723642 3.042660133 2.038774742
1.62341297 1.247243776 1.521330067 1.563060635
0.846998071 1.133857978 1.053228508 0.407754948
5.858403326 6.292911778 7.255574163 4.961018538
2.893910077 2.494487552 1.872406236 2.310611374
7.411233123 3.174802339 4.32993942 2.78632548
0.846998071 1.53070827 0.819177728 0.679591581
0.564665381 1.077165079 0.936203118 0.815509897
0.494082208 0.850393484 1.872406236 0.611632422
3.176242767 7.653541352 4.271426725 5.436732644
1.835162488 1.927558563 1.579842761 2.174693058
1.693996142 1.474015372 2.223482405 2.174693058
1.835162488 1.927558563 1.579842761 1.631019793
2.117495178 2.834644945 2.750096659 2.582448006
2.258661523 2.154330158 2.223482405 1.223264845
6.705401397 7.993698746 8.308802671 9.038568021
0.564665381 1.190550877 1.755380846 1.087346529
8.68173023 9.014170926 10.2397216 11.41713855
1.835162488 1.927558563 1.930918931 2.44652969
3.387992285 3.855117126 4.388452115 2.78632548
1.693996142 3.968502923 5.558706012 4.077549483
0.776414899 1.474015372 1.228766592 1.495101477
0.494082208 0.226771596 0.585126949 0.407754948
7.05831726 7.029919464 7.957726502 7.611425702
0.494082208 1.757479866 0.643639644 1.223264845
8.540563885 6.74645497 4.798040979 4.89305938
4.164407183 3.911810024 5.968294876 3.058162112
65.14826831 104.0314695 85.66258528 116.957711
0.917581244 1.644094068 0.643639644 1.019387371
4.234990356 6.689762071 6.845985299 4.89305938
1.62341297 1.814172765 2.106457015 2.718366322
7.834732159 7.086612363 8.367315366 5.91244675
9.316978783 5.952754385 3.920350556 4.213467799
26.39810655 26.41889089 19.25067661 18.55285015
1.835162488 1.927558563 1.989431625 1.359183161
1.764579315 1.474015372 1.579842761 1.223264845
3.740908148 3.741731328 7.314086858 4.077549483
0.776414899 0.623621888 1.930918931 1.563060635
1.693996142 1.02047218 0.760665033 1.698978951
1.199913934 1.02047218 1.638355456 1.019387371
2.046912005 1.644094068 1.579842761 1.631019793
0.28233269 2.097637259 0.994715813 1.902856425
1.341080279 1.644094068 1.228766592 1.155305687
1.129330762 1.360629574 1.579842761 1.698978951
1.058747589 0.793700585 0.877690423 1.087346529
0.917581244 3.11810944 0.585126949 9.242445495
0.917581244 2.040944361 1.638355456 1.834897267
5.999569671 5.782675688 7.665163027 8.834690547
4.940822082 16.78109808 7.021523384 13.04815835
0.635248553 0.51023609 0.468101559 0.611632422
1.199913934 1.077165079 1.462817372 1.019387371
0.141166345 1.587401169 0.526614254 0.679591581
2.823326904 2.154330158 3.159685523 2.242652216
2.117495178 1.587401169 1.989431625 2.1067339
GeneID logFC logCPM LR PValue FDR P10VWT_1
2410018L13Rik 0.569725479 1.368331647 4.157618842 0.041447633 0.999950496 3.208763614
4932411E22Rik -0.584489418 1.886244206 4.214961994 0.040068964 0.999950496 3.059518795
9430065F17Rik 0.674140549 0.220405825 4.056751342 0.043995061 0.999950496 0.373112048
Akr1c18 -1.086824274 0.450216638 4.752258041 0.029259875 0.999950496 1.119336145
Ankfn1 -0.794999238 1.337453417 4.283619606 0.038481318 0.999950496 1.641693012
Atf3 1.026767858 0.561814485 6.108430848 0.013453852 0.999950496 1.492448193
Bves 0.72333052 0.652708874 4.494131865 0.034011379 0.999950496 0.895468916
Car12 -0.618329863 3.187336041 4.014046777 0.045122724 0.999950496 11.6410959
Ccdc125 -0.778216653 0.114336848 6.35031117 0.011736071 0.999950496 1.193958554
Ccdc33 -0.625819082 0.253872364 4.046787543 0.044255486 0.999950496 1.343203373
Ccl17 0.65318629 0.473255755 4.029994408 0.044698089 0.999950496 0.746224096
Cdc42ep5 0.517484528 1.144708651 4.532932748 0.033248592 0.999950496 2.01480506
Chrdl1 -0.579294139 4.327482335 8.472064888 0.003606418 0.999950496 29.92358626
Col3a1 -0.671763689 5.597464858 4.274630124 0.038685383 0.999950496 79.24899903
Cpz -1.270908824 0.629546401 13.92444283 0.000190308 0.999950496 2.462539518
Cybrd1 -0.562704877 4.255167109 7.704134675 0.005509448 0.999950496 30.44594313
Dmgdh 0.673213975 0.429710774 4.920207515 0.026544329 0.999950496 1.193958554
Dmrt2 0.707757415 1.787678706 6.48293492 0.0108915 0.999950496 2.910273976
Dnah11 -0.671441508 1.614234652 4.611154507 0.031764641 0.999950496 4.551966988
Enpp1 -0.763783999 2.382504183 10.70924429 0.001066016 0.999950496 6.641394457
Fam124b -0.792765411 0.186873444 5.434335823 0.019744598 0.999950496 1.343203373
Fau 0.727718998 0.569239239 6.869139885 0.008769685 0.999950496 1.044713735
Gbp9 -0.684664956 1.630312456 3.937820483 0.047211908 0.999950496 3.283386024
Gem 0.715813254 1.461190797 4.133536156 0.042041414 0.999950496 1.865560241
Gpr139 -0.837909327 0.373321548 3.949576245 0.046883172 0.999950496 0.447734458
Gprin2 -0.652382262 0.537745427 4.619945848 0.031602236 0.999950496 1.044713735
Hcrt -2.848471734 1.039234119 11.29059645 0.000779007 0.999950496 1.567070602
Hgf -0.558037521 1.577448753 3.885503021 0.04870467 0.999950496 3.358008434
Ifi44 -1.482104307 0.457670279 3.88595688 0.048691509 0.999950496 1.119336145
Ifit3 -1.069615045 1.39716801 4.38883107 0.036175107 0.999950496 1.865560241
Irf6 0.511516581 1.17634579 4.088578321 0.043173942 0.999950496 1.567070602
Isg15 -1.63340756 0.949065547 5.874939532 0.0153579 0.999950496 1.268580964
Itprip 0.664016697 1.846866079 4.280989638 0.038540902 0.999950496 4.253477349
Lama3 -0.705424073 2.507138622 7.280907788 0.006969131 0.999950496 9.103933975
Lgr5 -1.216975174 2.909316086 7.869996189 0.005026176 0.999950496 9.551668433
Lmo1 0.53731941 4.309506179 5.025220293 0.024980748 0.999950496 17.8347559
Lrriq1 -0.684613919 0.518181032 4.137777903 0.041936185 0.999950496 1.119336145
Ndnf -0.749761705 4.079744347 6.782823964 0.009203916 0.999950496 20.52116265
Ngfr -0.559622232 2.490528207 4.575237869 0.032437242 0.999950496 6.04441518
Npsr1 -0.764242944 1.011314198 4.803524705 0.028401574 0.999950496 0.895468916
Npy -0.542887972 5.687831324 20.39473468 6.30E-06 0.090648577 56.41454168
Nxph2 0.811575913 2.550277869 8.676164277 0.003223988 0.999950496 3.805742891
Pde3a -0.519372652 2.081456878 4.0276598 0.044759988 0.999950496 4.02961012
Pdlim3 -0.84269185 0.364487813 5.27306195 0.021657885 0.999950496 0.820846506
Plaur 0.715639709 0.515372154 5.10949819 0.023795202 0.999950496 0.970091325
Procr -0.772270218 0.423875759 5.638071891 0.017574524 0.999950496 1.716315422
Ptch2 -0.596638528 1.3310543 4.15929674 0.041406593 0.999950496 2.611784337
Ptgs2 1.294763252 2.146588135 4.25862426 0.039051535 0.999950496 2.462539518
Rsg1 -0.765850199 0.123862497 5.645872938 0.017496503 0.999950496 1.044713735
Slc17a8 0.675206627 3.498275692 7.202822208 0.007278902 0.999950496 7.611485783
Slfn5 -0.612101932 3.480450754 4.179400266 0.040918178 0.999950496 15.29759397
Sp6 0.651640133 0.694490878 6.488371732 0.010858239 0.999950496 1.268580964
Stat5a -0.595781701 1.59077568 6.150648903 0.013136389 0.999950496 4.02961012
Sypl2 0.509677159 1.943978912 3.943965755 0.047039761 0.999950496 4.328099759
Syt15 -0.536869419 1.532643159 5.196396669 0.02263376 0.999950496 4.253477349
Tacr1 -0.680489784 3.159452115 7.210685768 0.00724708 0.999950496 7.536863373
Th -1.172384632 4.077428075 4.027208774 0.044771957 0.999950496 18.05862313
Thbs4 0.801379171 2.103129008 5.970080765 0.014550614 0.999950496 4.328099759
Tktl2 0.607309669 0.480938091 4.314552526 0.037787708 0.999950496 1.268580964
Tnfsf10 -0.658015965 1.578522245 4.036667645 0.044521653 0.999950496 3.805742891
Tnn 1.03194014 0.151517913 8.472932997 0.003604697 0.999950496 0.373112048
Ush1g -1.173075378 0.828904162 4.857412336 0.027527594 0.999950496 2.01480506
Zfp831 -0.513799202 2.775137871 7.685720158 0.005565946 0.999950496 5.895170361
P10VWT_2 P10VWT_3 P10VWT_4 P10VWT_5 P10VWT_6 P10VGCG_1
2.395347905 1.387459964 2.165214015 1.487396305 1.688630346 3.524123542
3.443312614 5.111694603 4.798582412 3.661283213 4.643733451 2.610461883
1.272528575 1.022338921 0.702231572 0.972528353 0.63323638 1.56627713
0.823400842 2.774919927 0.351115786 1.601811406 2.884743508 0.717877018
2.769621016 3.797258848 2.80892629 2.574339759 3.799418278 1.1094463
0.673691598 1.022338921 0.877789466 0.800905703 0.773955575 0.978923206
1.272528575 1.022338921 1.228905252 0.858113253 1.54791115 2.479938789
13.39897735 6.645202984 7.724547297 16.93343486 6.2620042 7.048247084
1.197673953 0.876290503 1.228905252 1.258566104 1.125753564 0.391569282
1.497092441 1.387459964 0.994828061 1.086943454 1.196113162 1.239969394
1.571947063 1.387459964 0.702231572 0.972528353 0.773955575 1.370492489
1.721656307 1.60653259 1.228905252 1.830641606 2.251507128 2.349415695
14.22237819 27.74919927 22.17881383 22.88302008 21.03751973 16.90274069
54.3444556 51.99323654 55.47629422 56.97872 42.49719704 54.16708407
2.095929417 1.60653259 1.52150174 2.116679357 1.407191955 1.370492489
24.7768799 14.60484172 18.72617526 21.56724642 20.68572174 19.44794103
0.823400842 0.730242086 1.111866656 1.315773655 0.63323638 1.305230941
1.646801685 3.870283057 3.04300348 2.80316996 1.54791115 3.002031165
3.218748748 3.943307265 3.394119267 2.459924658 3.236541496 2.936769618
5.83866052 6.426130358 5.85192977 6.064000321 5.769487015 4.698831389
1.347383197 1.022338921 1.697059633 0.858113253 1.055393966 1.1094463
0.973110087 0.803266295 1.053347359 0.972528353 1.54791115 1.892584865
6.063224386 4.162379891 2.516329801 2.002264257 3.166181899 2.610461883
2.021074795 3.213065179 1.287424549 1.659018956 2.462585921 2.414677242
2.095929417 1.460484172 1.697059633 1.659018956 1.125753564 0.326307735
1.871365551 1.825605215 1.931136824 1.430188755 1.196113162 1.305230941
7.186043716 0.219072626 5.85192977 0.286037751 2.744024312 0.522092377
2.91933026 5.25774302 3.56967716 2.059471807 2.603305117 1.892584865
6.138079008 1.752581007 0.585192977 0.400452851 0.422157586 0.587353924
8.383717669 3.578186222 1.345943847 1.372981205 2.81438391 1.305230941
2.245638661 2.482823093 1.404463145 1.887849157 1.336832357 1.957846412
8.458572291 2.62887151 0.643712275 0.800905703 1.477551553 0.913661659
2.54505715 1.679556798 2.984484183 2.91758506 2.392226323 3.132554259
6.811770606 7.521493488 5.442294686 4.233358715 6.543442591 5.547231501
5.389532787 17.8179069 3.160042076 6.693283373 15.12731352 5.155662219
18.18967316 9.858268163 12.52312971 25.05690699 16.53450547 23.95098778
1.122819331 1.460484172 2.574849099 1.716226506 1.125753564 0.717877018
13.77325046 26.87290877 16.03428757 20.07985012 23.00758846 13.77018643
10.47964709 4.600525143 6.203045556 6.750490923 3.799418278 3.915692824
1.721656307 2.409798884 2.28225261 2.631547309 3.588339485 1.044184753
48.35608584 70.97953078 60.15783804 53.20302168 63.74579556 39.41797443
2.170784039 5.695888272 6.144526259 4.748226666 3.658699083 5.677754595
4.341568079 5.038670395 4.974140305 4.576604016 5.065891038 3.654646636
2.470202527 1.460484172 1.697059633 1.144151004 0.914674771 0.652615471
0.823400842 1.095363129 0.643712275 0.972528353 1.688630346 0.913661659
1.721656307 0.730242086 1.580021038 1.773434056 1.196113162 0.978923206
4.266713457 2.336774676 3.101522778 1.887849157 2.462585921 2.610461883
3.218748748 3.359113596 1.814098229 3.489660562 1.758989944 1.305230941
1.122819331 1.168387338 1.228905252 1.029735904 1.336832357 0.45683083
9.281973134 12.7062123 9.480126228 7.036528674 7.950634545 8.679785761
22.30667737 10.95363129 10.35791569 8.924377831 9.217107305 8.745047308
1.571947063 1.314435755 1.053347359 1.144151004 0.914674771 2.349415695
4.04214959 2.920968345 2.457810503 3.432453012 3.236541496 2.023107959
3.443312614 3.578186222 2.223733313 3.203622811 2.321866726 3.589385089
3.742731102 2.701895719 2.574849099 2.631547309 3.166181899 2.349415695
10.47964709 11.61084917 14.51278583 8.69554763 9.3578265 6.982985537
31.51379588 31.91157917 5.442294686 11.61313269 31.2396614 19.25215639
4.640986567 3.870283057 1.287424549 2.688754859 2.532945519 6.134585425
0.973110087 0.949314712 0.819270168 1.315773655 0.914674771 2.284154148
5.688951275 2.482823093 3.335599969 2.116679357 2.81438391 2.871508071
0.598836976 0.803266295 0.585192977 0.743698153 0.985034368 1.174707847
1.272528575 4.381452517 0.702231572 1.487396305 3.095822301 1.762061771

































































GeneID logFC logCPM LR PValue FDR
4933408B17Rik 0.579091639 0.055006113 4.177739051 0.040958307 0.999997108
9430083A17Rik 0.511784765 1.596558445 9.815551584 0.001730424 0.999997108
Akr1c18 -1.306520236 0.218075601 9.291332147 0.002302407 0.999997108
Bves 0.732521579 0.770939191 7.865188531 0.005039557 0.999997108
Ccl17 0.657693847 0.577792674 5.970376851 0.014548171 0.999997108
Cdsn 0.766204185 0.122257474 7.331907227 0.006774114 0.999997108
Chat -1.004878675 0.411526518 4.106280334 0.042724231 0.999997108
Chrna2 -0.781840639 0.324703269 4.937960158 0.026273025 0.999997108
Cpz -0.874211602 0.588078007 11.0690786 0.000877793 0.999997108
Crabp1 -0.615887168 2.767550531 5.033426658 0.02486266 0.999997108
Cyp27a1 -0.520204545 1.13217301 4.375327001 0.036462833 0.999997108
Ddx60 -0.848814172 -0.065859197 4.267018651 0.038859053 0.999997108
Dmrt2 0.609282635 1.83983127 8.08326508 0.004467588 0.999997108
Dock2 -0.576500465 0.291119246 4.896960901 0.026904003 0.999997108
Fam221a 0.636753421 0.322481535 7.92717509 0.004869777 0.999997108
Fgf16 -0.536823144 0.472141141 6.112877953 0.013420043 0.999997108
Fosb 1.434050578 2.892021766 4.012353069 0.045168071 0.999997108
Frmd7 -1.053950365 3.619401436 4.94964099 0.026096087 0.999997108
Gbp3 -0.666946419 2.861058238 5.016479307 0.025107168 0.999997108
Gpnmb -0.638373319 0.190695286 4.571925797 0.032500011 0.999997108
Hmga2-ps1 -0.595649193 0.377617527 5.423347727 0.019869228 0.999997108
Ifi44 -1.395168149 0.27854544 6.414527664 0.011319043 0.999997108
Isg15 -1.510403778 0.755149307 9.023310517 0.002665582 0.999997108
Lgr5 -1.054594756 2.780517629 10.42380186 0.001244015 0.999997108
Lrrc36 0.756823768 0.53066812 7.965104013 0.004768775 0.999997108
Mafa -0.752019433 -0.186687922 5.08209059 0.024174205 0.999997108
Mdh1b 0.594036323 -0.082773357 4.697138863 0.030212873 0.999997108
Mmrn1 -0.538129271 0.373935057 4.08565078 0.043248794 0.999997108
Msx2 0.574294618 -0.049511746 4.565814677 0.032616158 0.999997108
Mybl2 0.57436258 0.818172394 7.510647209 0.006133533 0.999997108
Myh8 0.618988174 1.478142104 9.070499819 0.002597661 0.999997108
Myo1h 0.580207447 -0.076515013 4.283988923 0.038472958 0.999997108
Ndnf -0.519147734 4.064452846 5.482124398 0.019211897 0.999997108
Ngfr -0.640121005 2.364216324 7.446091057 0.006357437 0.999997108
Nppa -0.713923751 0.931222648 4.507493911 0.033746651 0.999997108
Npsr1 -0.598819316 0.965220669 5.705296066 0.016913802 0.999997108
Ntrk1 -1.418805036 0.005712389 9.094583129 0.002563676 0.999997108
Nxph2 0.779916044 2.664626199 15.31221476 9.11E-05 0.991034909
Oasl2 -0.876637933 2.055484402 5.165194742 0.023043874 0.999997108
Omp -1.183439856 1.019075338 4.530174278 0.033302226 0.999997108
Pdlim3 -0.734268072 0.282395684 6.852004689 0.008854187 0.999997108
Plaur 0.567339328 0.533250439 5.248496747 0.02196574 0.999997108
Ptch2 -0.531197132 1.267085526 6.418782657 0.011291954 0.999997108
Rtp4 -0.831170566 1.623862664 4.296373064 0.038193744 0.999997108
S100a9 1.340227201 -0.044727568 4.570201523 0.032532738 0.999997108
Shisa8 -0.593407597 2.634608296 4.767398538 0.02900362 0.999997108
Slc6a4 -1.112597706 1.180794923 4.783078366 0.028740699 0.999997108
Socs1 -0.506307264 0.99054595 4.774918448 0.028877214 0.999997108
Sp6 0.579487448 0.752565491 8.662943914 0.003247462 0.999997108
Sp7 -1.228274434 1.351471364 7.531766124 0.006062045 0.999997108
Spata20 0.519803 4.66E-05 4.56747633 0.032584534 0.999997108
Spp1 -0.736192874 2.804216922 4.365552611 0.036672587 0.999997108
Tacr1 -0.619582515 3.076895606 10.781435 0.001025232 0.999997108
Th -1.11329817 3.915012525 6.354401152 0.011709046 0.999997108
Thbs4 0.757292611 2.208675033 5.612890708 0.017828828 0.999997108
Tktl2 0.50859598 0.517997152 4.950712812 0.026079913 0.999997108
Tnn 0.916596369 0.228018801 10.74692262 0.001044529 0.999997108
Ush1g -1.34298255 0.598968186 8.757294781 0.003083661 0.999997108
P10VWT_1 P10VWT_2 P10VWT_3 P10VWT_4 P10VWT_5 P10VWT_6 P10VGCG_1
1.047840564 0.900455484 0.944284673 0.701582027 0.288105706 0.424752155 0.718483227
1.79629811 2.401214625 2.905491301 1.870885406 2.823435918 2.123760777 2.939249565
1.122686319 0.825417527 2.760216736 0.350791014 1.613391953 2.902473062 0.718483227
0.898149055 1.275645269 1.016921955 1.227768548 0.864317118 1.55742457 2.482032966
0.748457546 1.575797097 1.380108368 0.701582027 0.9795594 0.778712285 1.371649797
0.673611791 0.525265699 0.435823695 0.876977534 0.806695977 0.707920259 0.783799884
0.598766037 2.77640441 1.961206628 2.923258447 1.037180541 0.849504311 1.698233082
1.496915092 1.650835054 1.888569346 0.760047196 0.633832553 2.619304958 1.436966454
2.469909902 2.101062797 1.598020216 1.520094392 2.131982224 1.415840518 1.371649797
6.361889141 7.878985487 8.789111187 11.2837776 5.013039284 10.76038794 6.596982358
3.667441975 2.551290539 2.324393041 1.63702473 1.44052853 3.539601295 2.090133024
1.047840564 3.076556238 0.508460978 0.643116858 1.094801683 0.424752155 0.979749855
2.918984429 1.650835054 3.849775974 3.040188784 2.823435918 1.55742457 3.004566222
1.496915092 1.050531398 0.944284673 0.993907872 1.210043965 2.477720907 0.783799884
1.047840564 0.900455484 0.799010108 0.935442703 0.576211412 0.849504311 1.045066512
1.347223583 1.725873012 1.743294781 1.520094392 1.555770812 1.345048492 1.110383169
3.891979239 2.326176668 5.011972495 1.870885406 3.630131895 5.238609917 1.698233082
16.3163745 6.753416132 30.28974682 2.514002264 15.3848447 32.77670799 12.86738143
7.933649988 23.5619185 7.554277383 4.560283177 5.30114499 5.734154098 4.506849333
1.422069337 0.675341613 2.033843911 1.227768548 0.749074835 1.628216596 0.914433198
1.79629811 1.425721183 1.162196521 1.461629223 1.555770812 1.345048492 1.110383169
1.122686319 6.153112476 1.743294781 0.584651689 0.403347988 0.424752155 0.587849913
1.272377828 8.479289143 2.614942171 0.643116858 0.806695977 1.486632544 0.914433198
9.580256589 5.402732906 17.72349694 3.157119122 6.741673519 15.22028557 5.160015904
1.047840564 1.50075914 0.58109826 0.818512365 0.864317118 0.849504311 2.482032966
1.122686319 0.75037957 1.598020216 0.52618652 1.037180541 0.920296337 0.849116541
0.449074528 0.75037957 0.58109826 0.935442703 0.518590271 0.495544181 1.110383169
2.245372638 1.200607312 0.87164739 1.520094392 1.9591188 0.707920259 0.587849913
0.673611791 0.825417527 0.363186413 0.701582027 0.749074835 0.566336207 1.045066512
1.047840564 1.50075914 1.016921955 1.169303379 1.267665106 1.628216596 1.828866396
2.170526883 1.950986883 1.670657498 1.461629223 2.765814777 2.123760777 2.286082995
0.673611791 0.675341613 0.363186413 1.169303379 0.576211412 0.283168104 1.110383169
20.58258252 13.80698409 26.73051997 16.01945629 20.22502056 23.14899247 13.78181463
6.062506123 10.50531398 4.5761488 6.197307907 6.799294661 3.822769399 3.91899942
1.347223583 1.650835054 4.212962387 0.876977534 1.901497659 3.893561425 2.351399652
0.898149055 1.725873012 2.397030324 2.280141588 2.650572495 3.610393321 1.045066512
0.523920282 2.626328496 1.598020216 2.046280913 0.46096913 1.061880389 0.65316657
3.817133485 2.176100754 5.665708038 6.138842738 4.782554719 3.681185347 5.68254916
4.191362258 17.1086542 3.995050539 2.689397771 2.708193636 2.336136855 2.351399652
8.981490552 1.350683226 3.995050539 0.467721351 1.152422824 1.20346444 3.396466164
0.823303301 2.476252582 1.452745651 1.695489899 1.152422824 0.920296337 0.65316657
0.97299481 0.825417527 1.089559238 0.643116858 0.9795594 1.699008622 0.914433198
2.619601411 4.27716355 2.324393041 3.098653953 1.901497659 2.477720907 2.61266628
2.76929292 12.38126291 3.413952279 1.753955068 1.728634236 1.911384699 1.95949971
0.449074528 0.075037957 0.363186413 0.175395507 0.403347988 1.20346444 0.457216599
5.239202822 6.828454089 11.91251434 3.098653953 6.626431237 11.68068427 5.747865817
7.559421215 2.77640441 0.653735543 0.935442703 1.094801683 5.87573815 3.004566222
2.694447166 2.77640441 2.251755759 2.104746082 1.267665106 2.477720907 1.763549739
1.272377828 1.575797097 1.307471086 1.052373041 1.152422824 0.920296337 2.351399652
3.817133485 1.575797097 5.73834532 0.935442703 2.765814777 7.07920259 3.135199536
0.673611791 0.600303656 0.58109826 0.818512365 0.749074835 0.707920259 1.110383169
15.71760847 3.451746023 13.51053455 3.80023598 7.029779225 10.05246768 9.536231923
7.559421215 10.50531398 11.54932792 14.49936189 8.758413461 9.415339445 6.9888823
18.11267261 31.59097991 31.74249247 5.437260711 11.69709166 31.4316595 19.26841382
4.341053767 4.652353335 3.849775974 1.286233716 2.708193636 2.548512932 6.139765759
1.272377828 0.975493441 0.944284673 0.818512365 1.325286247 0.920296337 2.286082995
0.374228773 0.600303656 0.799010108 0.584651689 0.749074835 0.991088363 1.175699826
2.020835374 1.275645269 4.358236952 0.701582027 1.498149671 3.11484914 1.763549739
P10VGCG_2 P10VGCG_3 P10VGCG_4 P10VDP24_1 P10VDP24_2 P10VDP24_3 P10VDP24_4
1.149544883 0.642020109 0.91560423 1.485283841 1.130931713 1.336552702 1.08082769
3.218725672 2.684811363 3.310261445 3.182751088 4.014807581 3.254215275 3.918000376
0.97711315 0.642020109 0.633879851 0.141455604 1.130931713 0.290554935 0.540413845
2.873862207 1.167309288 0.986035324 2.404745266 1.583304398 2.091995534 1.553689804
2.241612522 0.992212895 1.831208459 2.263289662 1.979130498 1.220330728 1.013275959
1.839271813 0.817116502 1.549484081 1.343828237 1.074385127 0.639220858 1.283482882
0.172431732 1.98442579 0.211293284 0.848733623 0.3958261 0.98788678 0.405310384
0.402340709 1.575867539 0.493017662 0.636550218 0.735105613 0.697331845 0.945724229
0.344863465 0.817116502 0.563448757 0.990189227 1.526757812 1.162219741 1.351034613
1.66684008 8.754819662 6.127505228 3.394934493 5.202285879 6.334097589 5.471690181
1.092067639 1.98442579 1.549484081 1.131644831 2.374956597 1.685218625 2.026551919
0.172431732 0.642020109 0.633879851 0.636550218 0.622012442 0.755442832 0.540413845
5.402860949 3.96885158 4.930176621 3.960756909 2.827329282 4.590767977 3.647793454
0.919635906 0.992212895 0.845173135 1.273100435 1.130931713 0.697331845 0.607965576
1.034590395 1.108943824 1.479052986 1.626739445 1.244024884 1.510885663 1.553689804
1.379453859 1.400771146 1.056466419 0.848733623 1.130931713 1.045997767 0.405310384
56.21274477 5.369622726 3.662416918 2.19256186 5.767751736 1.452774676 2.837172686
1.724317324 7.704241303 8.522162444 3.748573503 11.76168981 5.985431667 14.45607035
5.345383705 6.303470157 5.634487566 6.294774373 5.993938078 6.275986602 5.40413845
0.229908977 0.700385573 1.126897513 0.990189227 1.017838542 0.697331845 0.945724229
0.517295197 1.575867539 0.563448757 0.848733623 1.526757812 0.813553819 0.675517306
0.344863465 1.167309288 0.352155473 0.636550218 0.735105613 1.104108754 0.270206923
1.034590395 0.875481966 0.422586567 0.495094614 0.848198785 1.859551586 0.607965576
2.414044254 4.552506224 4.437158959 3.182751088 7.633789062 4.242102055 5.40413845
0.804681418 1.050578359 1.479052986 1.838922851 1.922583912 1.56899665 1.621241535
0.287386221 0.291827322 0.422586567 0.495094614 0.848198785 0.348665922 1.148379421
0.747204174 0.583654644 0.77474204 1.485283841 1.074385127 0.871664806 1.013275959
1.092067639 0.933847431 1.479052986 0.848733623 0.961291956 0.929775793 1.013275959
0.517295197 0.817116502 1.197328608 1.202372633 1.187478299 1.162219741 0.675517306
1.149544883 1.634233004 2.535519405 1.838922851 1.922583912 1.917662573 2.431862303
3.391157404 2.159522183 2.676381594 3.394934493 3.845167824 4.358324029 2.769620956
1.034590395 0.817116502 0.986035324 1.060917029 1.017838542 1.045997767 0.540413845
4.770611264 13.949346 15.28354752 12.58954875 15.83304398 17.20085217 18.71182938
4.483225043 4.785968082 3.944141296 1.697467247 3.958260995 5.52054377 4.053103838
1.034590395 1.809329397 1.056466419 0.778005821 1.470211227 1.220330728 1.486138074
1.207022127 1.926060326 1.126897513 1.626739445 1.470211227 1.917662573 1.621241535
0.114954488 1.400771146 0.211293284 0.495094614 0.226186343 0.581109871 0.405310384
10.92067639 6.712028408 7.53612712 7.072780195 7.01177662 7.903094239 7.56579383
2.299089766 3.96885158 2.324226121 3.253478889 3.336248553 3.777214158 2.566965764
0.804681418 0.992212895 0.704310946 0.495094614 1.752944155 0.639220858 1.215931151
0.517295197 0.875481966 1.126897513 1.343828237 0.90474537 0.871664806 0.540413845
1.954226301 1.926060326 1.972070648 1.131644831 1.583304398 1.278441715 1.418586343
1.207022127 1.575867539 1.972070648 1.909650653 1.809490741 2.324439482 1.959000188
1.66684008 2.976638685 1.972070648 1.980378454 2.544596354 3.254215275 1.486138074
0.172431732 1.45913661 0.352155473 0.919461425 0.3958261 1.627107638 3.715345184
2.471521498 5.661450048 5.000607715 4.385123721 7.237962963 5.113766861 4.390862491
1.724317324 0.583654644 1.408621892 0.778005821 0.622012442 1.917662573 1.553689804
2.414044254 1.98442579 1.549484081 1.202372633 1.017838542 1.627107638 1.013275959
1.781794568 1.45913661 2.042501743 2.051106256 1.639850984 1.56899665 1.621241535
0.747204174 1.517502075 1.760777364 0.282911208 2.092223669 0.98788678 1.891448458
1.149544883 0.992212895 1.056466419 0.848733623 0.848198785 1.220330728 0.743069037
2.011703545 4.902699011 3.944141296 3.394934493 6.389764178 6.740874498 5.877000565
3.621066381 8.98828152 6.338798512 6.011863165 5.767751736 7.612539304 8.781724982
1.609362836 11.20616917 6.338798512 4.950946136 16.73778935 6.973318446 12.96993228
3.218725672 6.887124801 6.197936323 7.072780195 8.595081018 2.150106521 3.310034801
1.207022127 1.167309288 1.760777364 1.697467247 1.244024884 1.162219741 1.486138074
2.35656701 0.875481966 1.197328608 1.202372633 1.074385127 1.452774676 1.013275959
















































































































































































































































































































































































Figure 1: Biological validation of genes deregulated by disease in PA mutant mice by 
quantitative PCR (qPCR) analysis. Samples tested were RNA samples prepared from the 
cortex of vehicle-treated mice at postnatal day 10 across each genotype (WT; n = 6; PA1; n = 
4; PA2; n = 4; PApool; n = 4 PA1 + 4 PA2 samples combined). Expression values were 
normalised to the reference gene, β-Actin. (A) Genes of mostly higher counts per million from 
our RNAseq data, where qPCR results agreed with RNAseq results. (B) Control genes that 
were non-significant in both RNAseq and qPCR analysis. (C) Genes where the breadth of 
signal was variable across the three genotype groups between the RNAseq and qPCR analysis. 
Summary tables show results of these genes in RNAseq and qPCR data, with final column 
showing whether the qPCR results agreed with the RNAseq data. Grayscale colours in 
significance tables represent significance of result (lightest grey p<0.05, medium grey p<0.005 
and darkest grey p<0.0001). Individual graphs show relative quantity for each gene for WT 
(grey), PA1 (orange), PA2 (blue) and PApool (green). *p<0.05, **p<0.005, ***p<0.0001 (one-




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 3: WT and PA overlapping E2 genes
WT PA1 WT PA2 WT PAPOOL
Pitx2 2210408F21Rik Pitx2 1700001L05Rik Pitx2 Aldh1a3
Pou4f1 A230057D06Rik Pou4f1 1700010I14Rik Pou4f1 Aldh3a1
Lmx1a A830009L08Rik Lmx1a 1700019D03Rik Lmx1a Atp8b3
Plekhg4 Acr Plekhg4 2310002F09Rik Plekhg4 AW822252
Dsc1 Adam33 Dsc1 3632454L22Rik Dsc1 Barhl1
Crybb3 Adamtsl4 Crybb3 4930594C11Rik Crybb3 C5ar1
Edn3 Amy1 Edn3 A330074K22Rik Edn3 Calca
Apoc1 Ap1g2 Apoc1 Abi3bp Apoc1 Cbln3
Nlrp3 Arc Nlrp3 Acad10 Nlrp3 Cbln4
Ptpn18 Arhgap28 Ptpn18 Acta2 Ptpn18 Chrna6
Cldn1 Bdnf Cldn1 Adcy4 Cldn1 Col17a1
Uba52 C5ar1 Uba52 Adgrg2 Uba52 Col1a1
Recql4 C920006O11Rik Recql4 Agt Recql4 Cpz
Ebi3 Cacna1h Ebi3 Akr1c14 Ebi3 Dbh
Bmp3 Cckbr Bmp3 Aldh1a3 Bmp3 Dhrs7c
Gpr151 Cdk3-ps Gpr151 Arc Gpr151 Dock2
Cdk3-ps Col16a1 Cdk3-ps Arhgap6 Cdk3-ps Dpy19l2
Cd163 Col1a1 Cd163 Arhgef33 Cd163 Ebf3
Mirg Col1a2 Mirg Arsj Mirg En2
Pparg Col6a5 Pparg Atp6v1c2 Pparg Eps8l2
Fmod Colq Fmod AW551984 Fmod Fat2
Slc22a6 Cox6a2 Slc22a6 B330016D10Rik Slc22a6 Fosb
Syt15 Cpz Syt15 Barhl2 Syt15 Foxl2os
Cryba4 Dbh Cryba4 BC048546 Cryba4 Galr1
Pgm5 Dcdc2b Pgm5 Best1 Pgm5 Gata3
Slc13a4 Dnah9 Slc13a4 C1ql2 Slc13a4 Gbgt1
Six3 Dusp5 Six3 C2 Six3 Gmnc
Rxfp2 Efna1 Rxfp2 Calca Rxfp2 Hsbp1l1
Lat2 Egr2 Lat2 Calcr Lat2 Hspb2
Pcdhb6 Egr3 Pcdhb6 Car13 Pcdhb6 Ido1
Ttn Egr4 Ttn Cbln3 Ttn Lhx1
Ush1g Eln Ush1g Cbln4 Ush1g Lhx1os
4930426D05RikEps8l1 4930426D05RikCcdc180 4930426D05RikLhx5
Henmt1 Epx Henmt1 Ccdc36 Henmt1 Mab21l1
Myoc Exoc3l Myoc Ccl12 Myoc Mybpc3
Rsg1 Fam129c Rsg1 Chodl Rsg1 Myh2
Arhgef39 Fanca Arhgef39 Chrm5 Arhgef39 Myo3b
Tusc5 Fat2 Tusc5 Chrna6 Tusc5 Nlrp3
Slc6a20a Fbln5 Slc6a20a Clrn1 Slc6a20a Nr4a2
Pin1rt1 Fhod1 Pin1rt1 Cmbl Pin1rt1 Olfr1344
Dnase1l1 Flna Dnase1l1 Cngb1 Dnase1l1 Pex11g
Dsc3 Fos Dsc3 Col6a6 Dsc3 Phex
Lect1 Fosb Lect1 Colq Lect1 Ppp1r17
C230091D08RikFoxl2os C230091D08RikCox7a1 C230091D08RikRmi2
Aox3 Ggnbp1 Aox3 Crb1 Aox3 Rps13
Gngt2 Gipr Gngt2 Crhr2 Gngt2 Serpinb1b
C4a Gm11549 C4a Ctxn2 C4a Shox2
Scara5 Gm14420 Scara5 Dcn Scara5 Siglec1
Msx1 Gm15446 Msx1 Des Msx1 Siglece
4930481A15RikGm20219 4930481A15RikDiap3 4930481A15RikSpp1
Ccdc33 Gm2115 Ccdc33 Dnaaf3 Ccdc33 T2
Ybx2 Gm38413 Ybx2 Dock2 Ybx2 Twist1
Aldh1a2 Gpr139 Aldh1a2 Drd5 Aldh1a2 Uncx
Gm20219 Gpr3 Gm20219 Dsc3 Gm20219 Upp2
Cpz Gsap Cpz Ebf2 Cpz Zfp114


















Overlapping genes - WT + PAPOOLOverlapping genes - WT + PA2Overlapping genes - WT + PA1
Overlapping genes in 








































































































GeneID logFC logCPM PValue P10VDP24_1 P10VDP24_2
1700001L05Rik -0.549307505 2.660856812 0.000859115 7.154181856 8.479808966
1700010I14Rik -0.571938331 0.688133884 0.01784733 1.983337544 1.695961793
1700019D03Rik -0.517201126 1.930462873 0.001333566 4.391675991 4.239904483
2310002F09Rik -0.736804454 0.402394742 0.028815468 2.195837995 1.639429733
3632454L22Rik -0.582488424 0.969988783 0.013696485 1.629170126 2.091686212
4930594C11Rik 0.840589064 0.483544537 0.002410886 0.920835288 0.961045016
A330074K22Rik -0.698796869 1.148481724 0.025362551 2.408338446 3.109263288
Abi3bp 0.619292845 4.539483008 0.047830099 14.30836371 14.01995082
Acad10 0.509319601 0.947677941 0.048266045 1.983337544 1.413301494
Acta2 -0.644476103 3.027348345 2.87E-05 10.76668953 10.79762342
Adcy4 -0.506918624 2.159981449 0.00369895 5.241677795 4.861757141
Adgrg2 -0.512675545 2.498275354 0.008100158 7.650016242 4.692160961
Agt -0.851770933 5.802526808 0.00302737 95.12936864 82.42374315
Akr1c14 0.587391514 0.953038247 0.033913869 1.062502256 1.695961793
Aldh1a3 1.232775852 2.770964656 5.56E-09 4.462509474 3.278859467
Arc 0.795810351 5.432898654 5.37E-06 21.53337905 44.32113486
Arhgap6 -0.539956197 3.169433608 0.000216181 9.1375194 11.64560431
Arhgef33 -0.83115306 0.760976838 0.002787027 1.700003609 1.582897674
Arsj -0.728127665 0.664229303 0.010701483 2.054171028 1.695961793
Atp6v1c2 -0.564812394 1.425933274 0.010014596 3.61250767 2.54394269
AW551984 -0.521050177 6.323952466 0.00061255 74.87099229 92.65604597
B330016D10Rik -0.806756957 1.320261613 0.000324941 3.470840702 3.731115945
Barhl2 -0.526840604 0.883494109 0.025655224 2.195837995 1.469833554
BC048546 -0.598660592 3.037014903 0.000202402 11.19169043 10.23230282
Best1 -0.696510936 0.768786747 0.024068527 2.266671479 1.469833554
C1ql2 -0.896486173 2.55314801 5.50E-05 8.00418366 9.214725743
C2 -0.825074841 0.697092565 0.004087788 2.054171028 2.035154152
Calca -0.759765168 1.666031595 0.004524027 3.541674186 2.939667108
Calcr -0.961979029 2.128444014 0.00346846 4.250009023 8.027552488
Car13 -0.522402284 0.795087221 0.042424594 1.91250406 1.582897674
Cbln3 -1.379505424 1.154088077 0.005243862 1.770837093 1.752493853
Cbln4 -0.615818384 4.393837061 0.007635041 19.83337544 23.06508039
Ccdc180 0.564508695 0.419900477 0.039850967 0.991668772 0.791448837
Ccdc36 -0.62074907 0.201906001 0.03920111 0.779168321 1.187173255
Ccl12 -1.087574982 0.387352079 0.001078468 2.125004512 1.526365614
Chodl -0.608026959 1.922042899 0.021348597 3.470840702 4.409500662
Chrm5 -0.588433106 1.030076817 0.048865113 1.700003609 2.939667108
Chrna6 -0.623380073 0.810345714 0.031100526 1.91250406 2.204750331
Clrn1 -0.986186656 0.657538298 0.000941506 2.054171028 1.074109136
Cmbl -0.51632138 3.349774382 5.41E-06 10.76668953 12.60664933
Cngb1 -0.783294764 0.910377019 0.000922595 2.833339349 2.204750331
Col6a6 -0.701383213 0.264266538 0.0181173 1.13333574 1.300237375
Colq 1.166550494 1.309075148 1.28E-05 1.204169223 1.865557973
Cox7a1 -0.612802848 0.327789773 0.025680217 1.416669674 1.300237375
Crb1 -0.746358644 0.320065684 0.033289232 1.700003609 0.904512956
Crhr2 -0.559319101 1.387679743 0.004817913 2.833339349 2.770070929
Ctxn2 -0.639245301 3.079211745 0.000256724 11.12085694 9.553918102
Dcn -0.590803258 4.911261766 2.25E-05 27.69589213 35.50213354
Des -0.510558407 0.935272044 0.022759757 1.770837093 2.43087857
Diap3 0.531886419 1.770088088 0.001576148 2.904172833 2.826602989
Dnaaf3 -0.505199738 1.258109255 0.012953568 2.904172833 2.317814451
Dock2 0.869947243 0.518838913 0.042597151 1.275002707 1.130641196
Drd5 -0.525878699 2.023702233 0.00103474 4.604176442 4.409500662
Dsc3 -1.698558181 0.686757234 0.000223312 1.558336642 1.413301494
Ebf2 -0.546404738 1.973014418 0.017130966 5.383344763 3.222327407
Ebf3 -1.046697432 2.936468318 7.05E-06 9.987521205 6.727315113
Edar 0.575064425 0.700672298 0.036688968 1.13333574 1.243705315
Egfl6 -0.574574231 2.461171062 0.004375609 5.52501173 8.197148667
Egr1 0.583569124 6.716375583 7.62E-05 78.12933254 107.3543815
Egr2 0.507039653 2.075545777 0.046574087 3.754174637 3.674583885
Eps8l2 -0.768386981 0.519216865 0.008738003 1.345836191 2.204750331
Exoc3l4 -1.010427447 0.276221055 0.000274261 1.275002707 1.469833554
F13a1 -0.543167544 2.627029301 0.00027507 7.154181856 6.388122755
Fam221a -0.597715223 0.430492014 0.025670824 1.629170126 1.243705315
Fam228a -0.523418326 1.260148294 0.021729284 2.691672381 2.60047475
Fat2 -2.109760698 1.560372716 0.00172836 1.275002707 2.148218271
Fos 0.748196804 3.989772994 0.004775958 8.712518498 17.92066295
Foxr2 -0.763097493 0.295111557 0.020410778 1.13333574 1.639429733
Gabrq -0.78364339 3.582694775 0.000607423 10.41252211 17.52493853
Galr1 -1.162476107 0.313516424 8.03E-05 1.770837093 1.413301494
Gata3 -1.506613043 0.569032866 0.016371184 2.125004512 1.695961793
Gatsl3 -0.70137311 1.671835727 0.023377931 5.170844312 4.013776244
Gimap1 -0.635233482 0.720801311 0.01970221 1.629170126 1.922090032
Gm10638 -0.852853638 0.637356845 0.000549851 1.983337544 2.035154152
Gm14634 0.56476181 0.478066587 0.046441724 1.204169223 1.130641196
Gm5148 -0.908688177 1.020648391 4.92E-05 2.620838898 2.374346511
Gm5741 1.429372892 0.837061647 0.007161992 0.850001805 0.847980897
Gm694 -0.583473456 1.009063991 0.018080516 3.116673284 2.148218271
Gmnc 0.543328893 0.89780242 0.022550812 1.416669674 1.526365614
Gpr101 -0.951275984 3.445337264 1.77E-05 10.48335559 15.0375279
Hap1 -0.555217443 8.331017058 7.41E-06 336.6007146 402.90399
Hpcal1 -0.745957857 5.273685971 1.12E-11 45.82926397 45.28217988
Hspb2 -0.849722798 -0.090504847 0.034810484 1.13333574 1.300237375
Hspb3 0.546816808 1.886553055 0.014774251 3.683341153 2.43087857
Ifit3 -0.761526682 1.167095966 0.009739468 3.400007219 2.317814451
Igfbp6 -0.593038149 1.661429398 0.002953991 3.258340251 3.222327407
Inhba 0.640387239 1.632606656 0.004135228 1.275002707 2.60047475
Irs4 -0.950640859 4.15176908 0.004235182 14.73336461 32.11020995
Itgal 0.618338999 1.382972308 0.030650726 1.204169223 2.317814451
Itgb3 0.510084927 3.59440939 0.000921226 8.145850628 10.1192387
Jph2 -0.585561001 0.908579209 0.011115651 2.47917193 1.809025913
Lars2 -1.381902691 8.022417582 0.010659213 1031.052189 189.7781247
Lhx1 -1.329399586 0.701683655 0.000126513 1.629170126 1.865557973
Lhx1os -1.105021105 -0.093650864 0.007687635 1.204169223 1.130641196
Lhx5 -1.079821303 0.861267896 0.000186777 1.841670577 1.978622092
Lppos -0.640686073 1.915404911 0.002803928 5.666678698 4.013776244
Lrrn4 -0.663228127 0.181797258 0.036284918 1.345836191 0.904512956
Ltbp2 -0.730504335 0.531037207 0.022816693 0.850001805 1.752493853
Mab21l1 -1.088427769 1.52475113 0.008873557 3.825008121 1.469833554
Magel2 -0.544449928 4.190142226 4.20E-06 17.14170306 22.38669567
Map3k15 -0.525457931 1.797921025 0.00665973 3.470840702 3.618051826
Map3k6 -0.592279469 0.969037419 0.010920734 1.91250406 1.809025913
Meig1 -0.718685131 0.881639444 0.001974246 2.125004512 2.60047475
Mir6236 -1.60565234 3.109078172 0.011313831 37.25841244 6.953443352
Mxd3 0.541522451 1.709036838 0.006395974 2.408338446 2.60047475
Myh2 0.748552127 0.111796155 0.019195139 0.991668772 0.282660299
Myo3b 0.654563127 1.947198763 0.030464264 2.762505865 3.222327407
Myoc -0.560624468 4.633742219 0.001921645 36.19591018 26.45700397
Myzap -0.6118644 0.58600323 0.01700407 1.558336642 1.469833554
Neil2 0.545197699 0.582578782 0.031089758 0.920835288 1.243705315
Neurl2 -0.551910458 1.636129641 0.0145674 3.754174637 3.957244184
Nhej1 -0.509870458 0.74452257 0.043822089 1.91250406 1.469833554
Nkx2-1 -0.53649901 1.548311462 0.006105182 2.762505865 3.109263288
Nod2 0.582757232 0.347834207 0.039667372 0.991668772 0.734916777
Npas4 0.656331832 4.280686133 0.000146658 12.89169404 16.56389351
Nppa 0.709438979 0.82606896 0.028002682 0.779168321 1.469833554
Npy2r -0.600519259 3.74784331 0.000342937 16.57503519 15.15059202
Nr2f2 -0.982605987 5.295544397 2.29E-16 42.28758978 49.97434084
Nrtn -0.663598452 0.382545385 0.028990401 1.91250406 1.187173255
Nupr1 -0.511514896 2.366949083 0.005275089 7.508349274 5.540141858
Olfm4 -0.966636044 0.4887757 0.000442045 2.125004512 1.526365614
Optc -1.007264125 0.744057509 5.69E-05 1.983337544 1.695961793
Ovgp1 -0.557637272 2.419598884 0.013924717 8.57085153 6.727315113
Ovol2 0.500896073 1.544067859 0.044761248 2.125004512 2.317814451
Oxt -1.639510519 2.125680412 0.005305517 7.862516693 10.1192387
Pappa2 0.705780221 2.525549017 0.001611913 4.17917554 3.900712125
Pdzd3 -0.568235987 0.27143488 0.042616204 1.062502256 1.469833554
Pex11g 0.95731891 0.370746507 0.001046017 1.275002707 0.678384717
Pla2g3 -0.660991552 3.833960394 9.37E-05 19.19587409 13.34156611
Plk5 -0.750674265 1.777138632 0.000213676 3.825008121 3.448455646
Plp2 0.502276716 0.81375429 0.043301738 1.345836191 1.469833554
Popdc3 -0.898611909 0.955414205 0.000555148 2.054171028 2.148218271
Ppp1r17 -0.886806475 0.816385772 0.00369195 1.983337544 1.922090032
Prlr -0.754911938 2.215536284 0.000126486 4.250009023 6.670783053
Prr15 -0.635388033 0.163471275 0.035463452 1.558336642 0.904512956
Ptafr 0.716442103 0.228950685 0.032973218 0.495834386 1.017577076
Rad54l 0.547830202 0.628356178 0.043653579 0.850001805 1.130641196
Rhoh -0.639289976 0.367541151 0.02734038 1.983337544 1.356769435
Rn45s -1.921240752 11.52914222 0.002048231 13815.15016 2256.251038
Rtl1 -0.697110488 0.628865117 0.013664534 1.487503158 2.035154152
Rxfp2 0.790696298 1.474896967 0.009960121 2.266671479 3.278859467
Samd11 -0.614468378 1.720608327 0.001040268 3.61250767 3.391923587
Serpinb1b -0.960536454 0.653870227 0.010611567 1.275002707 1.300237375
Sim1 -1.829660546 0.075187105 3.07E-07 1.558336642 1.639429733
Slc35d3 0.653330751 2.654289655 0.012187972 3.683341153 4.126840364
Slc47a1 -0.597631308 1.456896324 0.022563926 2.266671479 2.883135049
Snord22 -0.757731199 0.18233395 0.039092995 1.700003609 1.017577076
Stpg1 -0.877421689 0.934117682 0.02234336 4.037508572 1.413301494
Susd3 -0.5364457 0.938315698 0.021091606 2.47917193 2.261282391
Tacr3 -0.687975349 2.671502996 0.00142822 5.808345665 5.766270097
Tal1 -0.610358651 2.363857239 0.002447418 6.233346567 5.483609798
Tbx15 -0.608360846 0.827812141 0.018753528 1.629170126 2.148218271
Tmem140 -0.646798546 0.765574011 0.009902117 2.195837995 2.204750331
Trhr -0.59270469 3.017885633 0.00051864 7.295848823 9.327789863
Trim34a -0.506103054 0.912992197 0.037050871 1.770837093 1.922090032
Ttc32 -0.649185273 1.127953054 0.002757828 2.47917193 2.770070929
Wnt9b -0.867764859 0.921635301 0.021396757 1.700003609 1.243705315
Zan -0.76634195 0.828515348 0.001404795 1.91250406 1.922090032
Zc2hc1c -0.66473974 1.161650432 0.003681833 2.833339349 2.148218271
Zfp599 0.529158817 2.349606859 0.00679351 3.400007219 3.278859467
Zfp953 -0.533881312 0.818050571 0.022950094 2.125004512 1.582897674
P10VDP24_3 P10VDP24_4 P10E2DP24_1 P10E2DP24_2 P10E2DP24_3
5.9440069 7.92877395 4.514040982 5.821495552 4.349446577
1.515139014 1.965251663 1.057978355 1.133388515 1.175526102
4.312318732 4.472641715 2.891807504 3.142577245 3.35024939
0.932393239 1.287578676 0.634787013 1.287941494 1.116749797
2.680630563 2.371855455 1.340105917 1.236423834 1.763289153
0.757569507 1.016509481 0.987446465 1.906153411 1.880841763
2.97200345 1.829717065 2.609679943 0.824282556 1.234302407
33.68270577 10.84276779 23.27552381 28.74685414 40.02666377
1.165491549 1.423113273 1.97489293 1.648565112 1.939618068
9.149108661 8.403145041 7.546912267 4.997212996 6.289064645
4.953339084 5.353616599 3.667658298 2.678918307 4.349446577
6.992949295 6.776729872 3.808722079 5.769977892 4.408222882
55.71049605 53.46839869 59.52891545 31.42577245 19.51373329
1.748237324 1.219811377 1.904361039 1.390976813 2.762486339
2.97200345 5.353616599 7.970103609 9.685320033 7.758472272
26.68975647 33.27374367 56.00232094 58.73013212 47.55003082
10.19805105 10.97830239 7.758507938 5.615424913 7.582143357
2.855454295 1.897484364 1.410637807 1.339459154 0.822868271
1.923061056 1.626415169 0.846382684 0.618211917 1.234302407
2.622355986 3.523899533 1.97489293 1.751600432 1.880841763
122.2017889 87.28428075 55.64966148 65.06680426 59.30529184
2.389257676 2.507390053 1.551701588 1.648565112 1.939618068
2.272708521 2.236320858 1.410637807 1.442494473 1.234302407
10.02322732 7.454402859 7.687976048 5.357836614 6.23028834
2.214433943 1.897484364 1.340105917 0.669729577 0.881644576
5.769183168 6.912264469 5.642551228 4.12141278 2.644933729
2.447532253 1.084276779 1.410637807 0.978835535 0.764091966
5.186437394 3.659434131 2.327552381 1.442494473 1.998394373
6.701576407 3.388364936 3.314998846 2.16374171 1.645736543
1.981335633 2.168553559 0.775850794 1.597047452 1.116749797
7.167773027 1.355345974 1.057978355 1.442494473 0.705315661
35.37266852 22.83757967 12.62520837 17.25841602 11.69648471
1.048942394 1.084276779 1.410637807 1.030353195 1.704512848
1.689962746 1.287578676 0.634787013 0.875800216 0.705315661
1.165491549 1.694182468 1.410637807 0.618211917 0.705315661
6.701576407 3.049528442 2.11595671 2.627400647 3.35024939
3.263376338 1.219811377 1.763297259 1.597047452 1.351855017
1.748237324 2.033018962 2.11595671 0.875800216 0.764091966
1.923061056 2.778459247 0.916914575 1.081870855 0.999197187
11.8880138 12.13034647 8.675422513 8.603449178 8.052353797
1.864786479 2.033018962 1.269574026 1.236423834 1.116749797
1.340315281 1.558647871 0.916914575 0.618211917 0.528986746
1.515139014 1.152044078 3.667658298 2.00918873 3.996788746
1.340315281 1.423113273 0.987446465 0.721247237 0.705315661
1.282040704 1.829717065 0.846382684 1.442494473 0.470210441
2.73890514 3.591666832 1.97489293 2.266777029 1.763289153
12.12111211 7.725472054 7.405848487 5.821495552 5.289867458
43.47283478 37.33978159 27.43690535 26.27400647 21.57090397
2.214433943 1.965251663 1.199042136 1.597047452 1.528183932
2.505806831 2.507390053 4.09084964 3.966859801 3.702907221
2.73890514 2.710691949 1.904361039 1.545529793 2.115946983
0.699294929 0.609905688 1.057978355 0.927317876 1.293078712
4.545417042 5.082547404 3.667658298 3.245612564 3.11514417
4.836789929 1.219811377 1.057978355 0.618211917 0.705315661
4.079220422 5.489151196 2.04542482 3.245612564 3.761683526
8.508088309 15.51871141 4.937232324 4.842660017 4.290670272
1.515139014 0.880974883 1.833829149 1.236423834 1.704512848
6.526752675 5.421383897 5.007764215 4.12141278 3.056367865
59.84799105 90.94371488 128.2975085 135.4914451 131.8940286
1.923061056 4.20157252 3.738190188 6.542742788 4.819657017
1.223766127 1.829717065 0.916914575 1.184906174 1.175526102
1.573413591 1.490880572 0.846382684 0.669729577 0.646539356
7.517420492 7.657704755 4.796168544 4.12141278 5.113538543
1.515139014 1.558647871 0.916914575 1.287941494 0.764091966
2.505806831 2.913993845 2.11595671 1.184906174 1.822065458
13.28660366 1.423113273 0.564255123 1.081870855 1.645736543
7.867067957 12.46918296 15.30542021 29.67417202 16.75124695
1.981335633 0.745440286 0.634787013 1.133388515 0.646539356
18.06511901 13.89229624 9.028081965 6.23363683 6.935604001
1.864786479 1.152044078 0.493723232 0.618211917 0.646539356
2.156159366 2.168553559 0.916914575 0.10303532 0.058776305
2.272708521 3.794968728 3.385530737 2.781953627 1.234302407
1.631688169 2.236320858 1.481169697 0.978835535 0.705315661
1.689962746 1.694182468 0.987446465 1.184906174 1.057973492
0.757569507 1.016509481 0.916914575 1.648565112 1.998394373
2.330983098 2.64292465 1.340105917 1.184906174 1.057973492
1.107216972 0.813207585 1.481169697 0.618211917 1.822065458
2.156159366 1.694182468 1.199042136 1.390976813 1.880841763
1.048942394 1.694182468 1.622233478 2.369812349 2.292275899
18.82268852 12.33364837 7.476380377 4.688107037 7.640919662
422.9568832 369.7383818 254.4790604 242.1330008 215.2976055
58.21630288 43.77767497 30.89296797 24.831512 29.21182363
0.699294929 1.084276779 1.340105917 0.309105959 0.352657831
2.389257676 3.18506304 3.879253969 5.563907253 4.290670272
3.67129838 1.287578676 1.410637807 1.545529793 1.645736543
4.079220422 4.066037923 1.97489293 2.215259369 2.351052204
2.389257676 2.981761144 3.526594517 3.245612564 4.173117661
28.03007176 18.09386876 12.62520837 7.160954705 7.288261831
1.515139014 2.778459247 2.962339395 2.215259369 4.231893966
10.13977648 11.04606969 10.79137922 17.30993368 13.57732648
2.156159366 2.033018962 1.128510246 1.648565112 1.234302407
108.7986361 173.3487501 180.3500436 143.4766824 131.7176997
2.797179718 2.304088156 0.916914575 0.824282556 0.23510522
1.048942394 1.084276779 1.269574026 0.463658938 0.11755261
3.379925492 1.965251663 1.269574026 1.287941494 0.646539356
4.661966196 3.456132235 3.667658298 2.421330008 2.292275899
1.573413591 1.152044078 0.916914575 0.566694257 1.175526102
2.564081408 1.355345974 1.199042136 1.081870855 0.940420881
5.9440069 3.794968728 1.763297259 2.215259369 0.646539356
23.60120387 22.83757967 13.8947824 14.73405069 14.34141844
4.254044154 4.540409014 2.327552381 3.451683203 2.821262644
2.73890514 2.371855455 1.269574026 1.648565112 1.351855017
1.981335633 1.829717065 1.128510246 1.236423834 1.351855017
2.564081408 4.879245508 6.559465802 3.863824481 3.35024939
2.505806831 2.710691949 4.302445311 4.018377461 2.644933729
0.990667817 0.609905688 1.269574026 1.030353195 1.234302407
2.097884788 3.523899533 5.219359886 2.524365328 7.111932916
28.90419042 26.2259446 27.7895648 14.27039175 20.68925939
1.689962746 1.965251663 1.340105917 0.927317876 1.293078712
1.048942394 1.219811377 1.763297259 1.442494473 1.410631322
3.321650915 3.18506304 2.327552381 2.575882988 3.291473085
2.214433943 1.694182468 1.551701588 1.133388515 0.940420881
3.962671267 3.388364936 2.398084272 2.16374171 1.998394373
0.815844084 1.152044078 1.622233478 1.030353195 1.234302407
11.3635426 19.17814554 21.9354179 30.24086627 20.7480357
1.223766127 1.490880572 1.269574026 2.678918307 1.293078712
16.54998 15.9253152 13.68318673 12.415756 8.640116848
57.16736048 58.48317879 28.07169236 27.51043031 21.62968027
1.689962746 1.016509481 1.269574026 0.566694257 1.057973492
5.302986548 5.353616599 5.007764215 3.503200863 3.58535461
1.631688169 1.558647871 0.916914575 1.133388515 0.881644576
2.389257676 2.236320858 1.128510246 0.978835535 0.764091966
4.778515351 4.879245508 5.148827995 4.739624697 3.056367865
1.515139014 3.320597637 3.173935066 2.421330008 3.879236136
5.9440069 1.761949767 2.11595671 0.360623618 1.410631322
5.9440069 3.049528442 5.924678789 8.809519817 7.758472272
1.456864436 1.152044078 0.705318903 0.772764896 0.881644576
0.641020352 0.609905688 1.763297259 1.390976813 1.234302407
20.45437669 16.33191899 13.75371862 11.07629685 10.75606383
4.079220422 5.2858493 2.891807504 2.472847668 2.586157424
1.223766127 1.355345974 1.692765368 2.00918873 1.410631322
3.088552605 2.168553559 1.199042136 1.803118091 1.116749797
3.20510176 1.355345974 0.916914575 1.236423834 0.822868271
6.818125562 4.879245508 2.962339395 3.091059585 3.644130916
1.223766127 1.219811377 0.493723232 0.669729577 1.057973492
1.048942394 0.54213839 1.763297259 0.721247237 1.528183932
1.689962746 0.880974883 1.551701588 1.390976813 1.763289153
1.165491549 1.219811377 1.199042136 0.772764896 0.646539356
944.3395277 1688.761084 1313.162735 1158.529132 1302.776802
2.039610211 1.423113273 1.269574026 0.824282556 0.705315661
1.107216972 1.084276779 3.456062627 2.988024266 3.526578305
4.195769577 4.20157252 2.04542482 2.988024266 2.292275899
1.631688169 3.523899533 0.987446465 1.390976813 0.528986746
1.515139014 1.084276779 0.775850794 0.206070639 0.11755261
4.545417042 6.84449717 7.053189035 4.482036398 10.52095861
4.370593309 3.049528442 2.327552381 1.390976813 1.939618068
0.757569507 1.694182468 0.564255123 0.412141278 1.293078712
2.797179718 1.084276779 1.481169697 1.339459154 1.469407627
1.923061056 1.829717065 1.481169697 1.081870855 1.645736543
10.83907141 8.403145041 4.796168544 5.151765975 3.996788746
7.167773027 5.353616599 5.007764215 2.936506606 3.23269678
2.156159366 2.033018962 1.340105917 1.236423834 1.880841763
1.923061056 1.355345974 1.340105917 1.184906174 0.940420881
11.8880138 9.758491015 6.559465802 5.203283635 6.34784095
2.389257676 2.168553559 1.199042136 1.133388515 1.998394373
2.447532253 2.371855455 1.692765368 1.390976813 2.057170678
3.962671267 2.236320858 1.057978355 1.184906174 0.764091966
2.330983098 2.168553559 0.916914575 1.030353195 1.586960237
3.146827183 2.236320858 1.763297259 1.339459154 1.469407627
5.361261126 4.20157252 5.99521068 4.945695336 7.111932916



































































































































































GeneID logFC logCPM LR PValue FDR
2210408F21Rik -0.759162358 1.251211064 6.493864233 0.010824743 0.999653626
A230057D06Rik 0.555101373 3.91578165 3.842465461 0.049969992 0.999653626
A830009L08Rik -0.731944179 3.081118602 6.612625905 0.010125824 0.999653626
Acr 1.037587941 1.622797584 6.013162452 0.014199557 0.999653626
Adam33 0.836408024 1.137070443 4.324690243 0.03756325 0.999653626
Adamtsl4 0.76962167 0.586742654 4.053797317 0.044072102 0.999653626
Amy1 0.553694355 4.556351508 4.707940521 0.030023599 0.999653626
Ap1g2 0.856297264 3.778797342 6.993636794 0.008179998 0.999653626
Arc -0.774576505 5.539478364 5.006457181 0.025252936 0.999653626
Arhgap28 0.609261921 1.800554488 3.913556359 0.047898137 0.999653626
Bdnf -0.899492726 4.599640648 4.517356392 0.033552638 0.999653626
C5ar1 -0.62675033 0.178717324 3.902033536 0.048227699 0.999653626
C920006O11Rik 0.559633876 2.11059746 3.877875189 0.048926441 0.999653626
Cacna1h 0.501852579 6.939577112 6.84962669 0.00886598 0.999653626
Cckbr -0.510537023 4.97296319 5.30456556 0.021269603 0.999653626
Cdk3-ps 0.810724991 0.794706566 6.918613864 0.008530307 0.999653626
Col16a1 0.661219232 4.804803438 5.970745655 0.014545129 0.999653626
Col1a1 1.540626123 5.699305577 6.354883146 0.011705865 0.999653626
Col1a2 1.000509612 6.425939194 4.337970749 0.03727132 0.999653626
Col6a5 0.77958306 2.269000509 9.64110415 0.001902708 0.999653626
Colq -0.679869376 1.162029433 5.82025 0.015842693 0.999653626
Cox6a2 -0.587363472 2.931830524 4.991069653 0.025478455 0.999653626
Cpz 1.15484745 0.457326883 6.935147745 0.008451808 0.999653626
Dbh -0.778118363 0.638984858 6.476673381 0.010929936 0.999653626
Dcdc2b 0.81347127 1.341862146 5.925346689 0.014924602 0.999653626
Dnah9 0.542181405 3.279520589 5.259981308 0.021821253 0.999653626
Dusp5 -0.949066417 1.65754125 8.061700668 0.004521073 0.999653626
Efna1 0.597445364 1.992440197 5.454365749 0.019519489 0.999653626
Egr2 -0.95577968 2.323781921 5.287099968 0.021483968 0.999653626
Egr3 -0.503452287 6.333761214 3.898890784 0.048317999 0.999653626
Egr4 -0.676765863 4.586887556 4.003619295 0.04540267 0.999653626
Eln 0.524253847 6.171277639 7.510992652 0.006132357 0.999653626
Eps8l1 1.049504998 2.687805992 8.249603999 0.004076089 0.999653626
Epx 0.746256739 0.769960717 4.089327171 0.043154818 0.999653626
Exoc3l 0.521242146 1.54861144 3.926232598 0.047538329 0.999653626
Fam129c 0.793130797 1.264273805 5.573239117 0.018236994 0.999653626
Fanca 0.560715757 1.655094244 4.168924445 0.041171928 0.999653626
Fat2 -2.163391836 1.557570217 5.617399892 0.017783012 0.999653626
Fbln5 0.652932515 3.497344082 4.115064045 0.042502916 0.999653626
Fhod1 0.515588942 2.631281248 4.085847844 0.043243751 0.999653626
Flna 0.602402583 8.347645551 4.346756473 0.037079501 0.999653626
Fos -1.966085887 4.741566263 8.355720634 0.00384475 0.999653626
Fosb -2.649958106 3.313165948 9.443622029 0.002118846 0.999653626
Foxl2os 0.948509972 0.487133768 7.69960929 0.005523278 0.999653626
Ggnbp1 0.599276992 1.841457763 4.245364643 0.039357617 0.999653626
Gipr 0.66580427 2.420428231 5.077996891 0.024231349 0.999653626
Gm11549 -0.673495311 3.954163291 4.939141981 0.026255067 0.999653626
Gm14420 0.519165745 2.743985417 6.925118505 0.008499336 0.999653626
Gm15446 0.555511497 1.95039307 5.007950056 0.025231167 0.999653626
Gm20219 0.671093929 0.871451874 4.026478044 0.044791356 0.999653626
Gm2115 0.532924828 2.299878677 4.808938961 0.028312473 0.999653626
Gm38413 0.697335382 1.797752118 5.425296758 0.019847062 0.999653626
Gpr139 0.957985069 0.3871237 3.97380912 0.04621312 0.999653626
Gpr3 -0.767662745 2.365167089 4.828426394 0.02799417 0.999653626
Gsap 0.542411201 3.299187408 5.942721621 0.014778181 0.999653626
H19 0.845585875 3.602456815 4.854353987 0.027576439 0.999653626
H2-M5 0.714857007 1.280508136 3.963448521 0.046498353 0.999653626
Hcrt 2.470962514 0.561586301 58.03014508 2.58E-14 3.69E-10
Hspa1b 0.785413988 0.37512913 4.702300451 0.030122273 0.999653626
Ifit3b 0.827880798 0.115659743 4.071432763 0.043614266 0.999653626
Il18bp 0.653485735 2.84729028 3.929749473 0.047439011 0.999653626
Inhba -0.896404249 1.75697806 5.647548431 0.017479793 0.999653626
Itgbl1 0.819722011 1.900606517 7.010329459 0.008104077 0.999653626
Iyd 0.68856293 0.922230463 5.262586751 0.021788611 0.999653626
Kif20b 0.640476073 1.719353099 4.117577286 0.042439814 0.999653626
Leng8 0.563860987 8.097117936 5.352405015 0.020693708 0.999653626
Mab21l1 -1.023393437 1.737385452 7.5867821 0.005879781 0.999653626
Mbd6 0.521607723 5.706722635 3.865887281 0.049277132 0.999653626
Med12 0.52390389 5.844013941 4.8154693 0.02820539 0.999653626
Mfsd2b 0.85121248 0.91014852 5.227493118 0.022232554 0.999653626
Mvp 0.522835214 2.539313509 4.506756244 0.033761209 0.999653626
Myh11 0.673175889 1.953005733 6.948980188 0.008386703 0.999653626
Neat1 0.536084871 4.25445683 5.39809624 0.020158729 0.999653626
Nlrp3 0.98343933 0.837486468 5.965131063 0.014591516 0.999653626
Nox4 0.742560764 0.41876705 4.456600876 0.034766615 0.999653626
Npas4 -1.051955805 4.90900969 4.039438556 0.044448607 0.999653626
Npy2r 0.542532447 3.723825768 8.470099753 0.003610316 0.999653626
Nr3c2 0.541137389 4.725291674 6.872081397 0.008755262 0.999653626
Nt5e 0.513565843 2.999846341 4.608934891 0.031805782 0.999653626
Ovgp1 0.772626957 2.841867095 6.348235648 0.01174981 0.999653626
P3h3 0.530616649 5.088759879 5.487155296 0.019156688 0.999653626
Pabpc4l 0.776582445 0.245345344 4.581809457 0.032313076 0.999653626
Parp3 0.595308254 1.991607527 4.577579375 0.032392944 0.999653626
Pdgfrl 0.587796562 1.500301881 4.736739688 0.029524974 0.999653626
Pisd-ps1 0.798962305 7.991185456 9.586162483 0.001960493 0.999653626
Pisd-ps2 0.649741903 4.818221331 6.819578951 0.009016382 0.999653626
Plekha4 0.749728474 1.142912177 3.865573888 0.049286336 0.999653626
Plscr4 0.654969842 1.906280726 7.177871393 0.007380822 0.999653626
Pmch 1.664355273 2.763694178 11.1894817 0.000822623 0.999653626
Procr 1.044416091 0.524335015 10.69958633 0.001071595 0.999653626
Prox1 0.611709851 4.033802576 4.948154692 0.026118532 0.999653626
Psd4 0.519554307 1.441286582 4.32281241 0.037604722 0.999653626
Ptch2 0.660880189 1.319549442 4.475791601 0.034378274 0.999653626
Ptgs2 -1.820204728 2.148191997 5.669289227 0.01726445 0.999653626
Rad9b 0.507601256 1.962003239 5.352047474 0.020697951 0.999653626
Rbp4 -0.514938228 2.613112251 4.376571767 0.036436212 0.999653626
Reck 0.534352597 3.752343588 4.748285941 0.029327493 0.999653626
S100a4 0.556240528 2.4510559 4.5516354 0.03288732 0.999653626
Scarf2 0.630198689 2.909973262 5.988962517 0.014395667 0.999653626
Serpinb1a 0.902416035 0.765036277 4.941658283 0.026216873 0.999653626
Sgk2 -0.975747782 0.231753845 5.032175326 0.024880629 0.999653626
Siglec1 1.186676245 0.33010555 9.806439362 0.001739019 0.999653626
Slc17a8 -0.791277768 3.530067994 7.951773928 0.004804027 0.999653626
Slc2a9 0.549806852 1.340202041 4.716502883 0.029874441 0.999653626
Slc9a2 0.769307499 2.584793202 7.782463303 0.005275581 0.999653626
Sowahb -0.896552949 1.904390482 7.287037527 0.006945391 0.999653626
Spaca6 0.577753548 3.343848033 5.444553328 0.019629434 0.999653626
Spp1 1.326876452 3.176984413 5.930533097 0.014880739 0.999653626
Ssc5d 0.685446162 1.969938591 4.327324511 0.037505154 0.999653626
Styk1 0.663099102 1.512869545 4.981755762 0.025615973 0.999653626
Susd5 -0.562771788 3.521261858 6.212056426 0.012688315 0.999653626
Sypl2 -0.629678258 1.952012576 5.495142851 0.01906937 0.999653626
Tbxa2r 0.501138824 1.280391664 4.20210566 0.040373818 0.999653626
Tcap -0.733411791 1.125609971 5.957080005 0.014658298 0.999653626
Thbs3 0.658815486 4.664721446 5.877942365 0.015331729 0.999653626
Thbs4 -0.688177908 2.226860505 6.022715353 0.014122901 0.999653626
Tmc4 0.693735655 2.348737178 4.244527921 0.039377016 0.999653626
Tnxb 0.758237408 1.787081262 4.388582302 0.036180386 0.999653626
Traip 0.519505122 4.240608831 7.940969838 0.004832793 0.999653626
Trim68 0.532847689 2.702668612 5.70880699 0.016880007 0.999653626
Tspan18 0.519315543 4.086700933 4.210003456 0.040186255 0.999653626
Unc13d 0.705475979 0.016883508 4.003185479 0.045414356 0.999653626
Wnt10a -0.867485153 0.435822321 5.586126361 0.018103288 0.999653626
Wnt10b 0.939770383 0.369623528 4.151538942 0.041596702 0.999653626
Zan 0.591957772 1.026495554 4.044898217 0.04430505 0.999653626
Zfp456 0.787272514 0.344390315 5.312419882 0.021173926 0.999653626
Zfp69 0.842840359 0.955455495 4.004963673 0.045366475 0.999653626
Zkscan2 0.555746738 4.657923513 5.070458717 0.024336943 0.999653626
P10VGCG_1 P10VGCG_2 P10VGCG_3 P10VGCG_4 P10E2GCG_1 P10E2GCG_2
2.345823628 2.424230407 3.528213934 3.045333253 1.337990494 1.491964563
17.13754484 8.427086652 10.87865963 12.11051131 20.00295789 14.74749588
7.884573862 16.0460965 7.526856393 10.12750361 6.355454847 4.361127185
2.997441303 1.500714061 1.528892705 1.770542589 5.084363878 2.754396117
2.085176558 1.269834975 1.822910533 0.779038739 4.013971482 1.664114321
1.694205954 0.577197716 0.823249918 0.99150385 2.073885266 1.549347816
27.23761879 13.56414632 19.22876594 15.8640616 35.45674809 23.46975025
13.29300056 7.388130763 8.467713442 9.631751685 25.15422129 11.13235097
32.18991312 104.4727866 63.97827934 33.35702238 33.78425998 37.29911408
3.32325014 1.731593148 1.764106967 3.895193696 5.017464353 4.303743933
16.68141247 72.3228738 18.58192672 17.8470693 16.39038355 16.92805947
1.238073582 1.154395432 1.293678443 1.203968961 0.869693821 0.975515291
4.105191349 2.943708351 3.410606803 3.116154957 4.883665304 4.074210923
114.4892254 76.82501598 98.5547759 116.2184156 169.9247928 118.6111828
26.65116289 53.04447009 37.63428197 29.60347209 23.14723555 21.97778568
1.824529489 0.865796574 0.940857049 1.062325554 2.475282414 1.951030583
34.34025145 13.39098701 19.6403909 18.90939485 44.4212844 25.47816408
40.59578112 5.137059671 31.22469332 29.24936357 60.61096938 41.83239103
86.20901834 16.91189308 69.79983233 56.09078923 99.54649276 70.92570001
4.235514884 2.943708351 2.587356885 4.107658807 6.221655798 5.853091748
1.824529489 2.424230407 3.175392541 2.97451155 1.471789544 1.205048301
7.363279722 13.56414632 8.585320573 6.444775025 5.418861501 6.541690778
1.368397116 0.34631863 0.823249918 0.566573629 3.010478612 1.319814806
1.824529489 2.308790864 1.646499836 1.416434071 0.869693821 0.975515291
2.345823628 1.038955889 1.528892705 2.124651107 4.348469106 1.89364733
10.42588279 4.963900357 6.350785082 9.560929982 11.77431635 10.09945243
2.020014791 6.291455103 3.763428197 3.824371993 2.341483365 2.12318034
3.518735442 2.53966995 3.175392541 3.045333253 5.218162927 4.188977428
2.671632466 13.10238815 5.115910205 4.745054139 2.876679562 2.983929127
52.6507081 150.5331643 78.5615636 95.96340834 59.54057699 69.89280147
11.92460344 52.17867352 26.8144259 26.62896054 15.05239306 18.24787427
72.00375303 40.2306808 68.44735032 55.38257219 100.8175837 69.26158569
6.581338513 1.44299429 3.528213934 4.95751925 10.36942633 9.009170632
1.759367721 0.981236117 0.940857049 1.062325554 2.140784791 1.836264078
3.06260307 2.308790864 1.646499836 2.195472811 4.080871007 2.869162622
2.801956 1.038955889 1.234874877 1.628899182 3.010478612 2.926545874
2.671632466 2.135631549 1.764106967 3.257798364 3.612574334 3.213462136
1.954853024 0.230879086 0.999660615 15.72241819 1.271090969 1.032898544
10.62136809 3.751785153 12.58396303 7.790387393 18.39736929 10.44375194
6.711662047 3.001428123 5.762749426 4.532589028 8.563139162 6.082624758
345.3573675 171.7740402 194.9926234 322.4512163 481.8103769 297.8764634
9.252970978 126.0022614 19.6403909 14.30598412 12.04191445 11.53403374
1.694205954 56.44993661 5.409928033 3.682728586 2.609081464 2.926545874
1.172911814 0.634917487 0.646839221 1.062325554 1.940086216 1.262431554
3.58389721 1.847032691 2.704964016 2.903689846 5.351961977 2.926545874
4.887132559 3.347746752 2.352142623 5.665736285 7.225148668 5.049726214
11.72911814 22.62615046 19.40517664 21.8130847 9.232134409 7.804122331
6.38585321 4.271263098 5.939160123 5.028340953 7.626545817 7.05814005
3.06260307 2.308790864 3.763428197 2.97451155 5.218162927 3.672528156
1.498720651 0.981236117 1.646499836 1.133147257 2.675980988 1.319814806
4.170353117 4.675301499 3.351803238 3.470263475 5.619560075 4.418510438
2.736794233 2.885988579 2.469749754 2.124651107 5.619560075 3.385611894
0.325808837 0.577197716 1.352482008 0.920682146 0.735894772 2.869162622
4.235514884 11.89027295 4.704285246 4.390945621 3.344976235 4.016827671
10.36072102 5.425658529 7.762070655 8.14449591 13.71440256 10.90281796
15.37817712 2.943708351 7.468052827 8.640247835 19.60156074 17.32974224
2.801956 1.385274518 0.999660615 1.841364293 2.876679562 2.467479855
0.52129414 0.34631863 0.411624959 0.354108518 2.542181939 2.065797088
1.107750047 1.09667566 0.705642787 0.495751925 1.471789544 1.377198058
0.781941209 0.34631863 1.117267746 0.495751925 1.070392395 0.803365534
8.014897397 3.98266424 4.527874549 5.524092878 11.84121587 6.59907403
2.476147163 6.580053961 2.822571147 5.028340953 1.806287167 3.156078884
2.997441303 2.481950178 1.411285574 3.611906882 5.820258649 3.442995146
1.107750047 1.731593148 0.823249918 1.770542589 1.940086216 2.12318034
3.32325014 1.154395432 2.293339057 3.186976661 4.616067205 4.24636068
277.393644 148.5129723 215.9854963 241.7144743 425.3471781 238.7717134
6.841985582 2.077911777 2.881374713 5.524092878 1.873186692 2.008413835
55.0616935 26.72425425 42.04454938 47.37971969 78.74074058 46.36566797
60.53528196 27.30145196 45.86678115 54.46189004 77.46964961 57.32586918
1.824529489 0.808076802 0.999660615 1.416434071 3.211177186 1.549347816
5.669073768 3.463186295 4.821892377 4.745054139 7.091349619 4.877576457
3.453573675 2.135631549 3.410606803 2.549581328 4.749866254 3.270845389
21.11241265 11.54395432 14.70089139 14.58927094 27.8971018 15.95254418
1.629044186 0.692637259 1.176071311 0.99150385 1.538689068 1.262431554
0.716779442 0.865796574 1.176071311 0.849860443 2.006985741 1.549347816
19.67885377 106.6084181 19.22876594 15.72241819 21.74234553 19.9119886
11.66395637 8.138487794 11.99592738 10.83572065 14.11579971 12.73908204
17.46335368 16.73873376 22.05133709 29.60347209 25.02042224 29.4376085
5.603912001 4.386702641 8.056088483 7.9320308 8.763837737 10.78805146
8.471029769 4.098103783 3.822231762 4.461767325 10.36942633 6.312157768
35.70864856 19.97104097 25.16792606 30.17004572 51.31193545 30.35574054
0.716779442 0.461758173 0.646839221 1.345612368 1.739387642 1.434581311
3.714220745 2.251071092 3.410606803 2.903689846 3.612574334 3.328228641
2.606470698 1.789312919 1.470089139 2.832868143 3.278076711 3.270845389
205.2595675 128.7150906 196.0510876 212.6067541 415.9143451 221.3845879
25.217604 15.00714061 23.28621197 24.00855751 41.94600199 23.87143301
2.997441303 0.750357031 1.293678443 1.203968961 2.943579087 2.524863107
3.518735442 2.943708351 2.646160451 2.124651107 5.619560075 4.361127185
4.105191349 4.617581727 3.410606803 0.566573629 7.492746767 8.72225437
0.977426512 0.519477944 0.764446352 1.203968961 2.207684315 1.836264078
13.8142947 6.291455103 12.2899452 19.12185996 17.92907262 21.28918665
2.345823628 1.673873376 2.116928361 2.407937921 3.41187576 2.811779369
2.606470698 1.212115203 1.58769627 1.9830077 3.344976235 2.524863107
1.303235349 20.83683754 1.881714098 2.549581328 1.940086216 0.975515291
3.909706047 3.059147894 3.05778541 2.407937921 4.415368631 4.820193205
5.929720838 10.27411934 6.056767254 5.878201396 4.749866254 4.074210923
13.29300056 7.388130763 11.58430242 11.40229427 18.1297712 12.39478253
5.538750233 4.271263098 3.05778541 4.461767325 5.820258649 4.303743933
5.669073768 3.98266424 7.409249262 6.16148821 11.17222063 8.607487865
1.629044186 0.519477944 1.05846418 1.203968961 2.341483365 2.983929127
1.238073582 0.692637259 2.410946188 1.203968961 0.602095722 0.573832524
0.781941209 0.404038401 1.05846418 0.495751925 1.873186692 1.090281796
8.666515071 22.62615046 11.64310598 14.94337945 8.696938212 8.894404128
1.954853024 2.077911777 2.116928361 1.628899182 3.144277661 2.295330097
6.060044373 3.059147894 3.704624631 4.603410732 8.630038687 6.36954102
2.345823628 7.041812134 3.822231762 5.594914582 2.542181939 2.12318034
9.904588653 6.17601556 7.232838565 8.92353465 14.38339781 8.148421846
9.513618048 2.020192006 4.939499508 3.9660154 9.031435835 8.205805098
4.626485489 1.44299429 3.116588975 2.478759625 5.485761026 3.557761651
2.541308931 2.597389721 1.528892705 1.770542589 3.679473859 3.844677913
11.07750047 13.56414632 12.23114164 17.35131737 9.365933459 6.943373545
3.58389721 6.349174875 3.351803238 4.886697546 2.943579087 2.467479855
2.150338326 1.731593148 2.234535492 1.487255775 2.341483365 2.58224636
2.280661861 2.53966995 3.292999672 2.124651107 1.404890019 1.090281796
25.93438345 15.98837673 15.75935557 20.67993744 40.94250912 21.05965364
6.12520614 3.232307209 6.938820737 6.232309914 2.809780038 3.557761651
5.538750233 2.712829265 2.822571147 4.178480511 8.696938212 3.615144903
3.32325014 1.44299429 1.940517664 3.257798364 3.813272908 2.869162622
16.48592717 15.98837673 13.87764147 15.36830967 26.89360893 17.38712549
6.516176745 3.809504925 4.586678115 6.019844803 8.228641539 6.254774515
19.74401554 8.253927337 14.11285574 13.38530197 19.53466121 20.94488714
0.977426512 0.634917487 0.705642787 0.354108518 1.204191445 1.262431554
1.889691256 1.327554747 2.234535492 0.849860443 0.735894772 1.262431554
1.238073582 0.230879086 0.823249918 0.920682146 1.13729192 0.918132039
1.824529489 1.558433833 1.234874877 1.487255775 3.278076711 1.606731068
0.977426512 0.519477944 0.823249918 1.062325554 1.204191445 2.008413835
1.368397116 0.750357031 1.764106967 1.345612368 3.077378136 1.032898544
























































































































































Figure 2: Biological validation of genes deregulated by estradiol in PA mutant mice by 
quantitative PCR (qPCR) analysis. Samples tested were pooled RNA samples prepared from 
the cortex of vehicle and estradiol treated mice at postnatal day 10 across each genotype. WT 
pooled samples contained RNA from n = 6 cortex samples for each treatment group. PA1 and 
PA2 pooled samples contained RNA from n = 4 cortex samples for each treatment group. 
Expression values were normalised to the reference gene, B-Actin. (A) Summary table shows 
results of these genes in RNAseq and qPCR data, with final column showing whether the qPCR 
results agreed with the RNAseq data. Grayscale colours in significance tables represent 
significance of result (lightest grey p<0.05, medium grey p<0.005 and darkest grey p<0.0001). 
(B) Individual graphs of relative quantity for each genes for WT (vehicle = light grey; estradiol 
= dark grey), PA1 (vehicle = light orange; estradiol = dark orange), and PA2 (vehicle = light 
blue; estradiol = dark blue). Significance indicated by *p<0.05, **p<0.005 and ***p<0.0001, 
one-tailed t-test of vehicle treated WT, PA1 and PA2 mice compared to estradiol treated WT, 


















Present Markers Sparse Markers
f01 Vip Mybpc1 Crispld2, Cxcl14, Tpm2, Itih5, Cox6a2 Tmem182
f02 Vip Parm1 Cxcl14, Car4, Tac2 Dmp1, Syt10
f03 Vip Sncg
Reln, Npy2r, Tnfaip8l3, Cadps2, 
2310042E22Rik, Egln3, Tpd52l1, Megf10
Casq2, Edn3
f04 Vip Chat
Aebp1, Slc18a3, Pvrl4, Nrp1, Sema5b, 
Pcdh15, Phlda1
f05 Vip Gpc3 Bcar3, Mab21l1, Pbx3, Nrp1, Crh
f06 Ndnf Car4
Lamp5, Tnfaip8l3, Atp6ap1l, Gabrd, Npy, 
Pde11a, Has2, Krt12, 2310042E22Rik, 
Ndst4, Tnnt1, Reln, Mpped1
f07 Ndnf Cxcl14
Pde1a, Pcdh18, 4921511H03Rik, Rgs12, 




Lhx6, Cdca7, Myo5b, Pdlim3, Efcab6, 
Tnnt1, Cryab, Nfib, Kit, Lamp5
f09 Smad3 Cd34, Sln, Npy, Col14a1, Rasl11a
f10 Sncg
Frmd7, Edn3, Tnfaip8l3, Frem1, Scml4, 




Kcns3, Rasl11a, Timp3, Adamts18, Ano3, 
Rasl11a, Tnni3k, Bdnf
Nmbr, Bdnf
f12 Sst Th Gabrg1, Spp1, Nr4a2, Hspb3, Nts, Myh8
f13 Sst Myh8
Chrna2, Glra3, Kit, Ppapdc1a, Nr2f2, 
Gfra2, Myh1, Myh4,Myh13, Grm3, 
Il1rapl2, Tnni3k, Cartpt
f14 Sst Cdk6
Chrna2, Tmem90a, Nr2f2, Myh4, 
Myh13, Myh1, C1qtnf7, 4930503E14Rik, 




Crh, Pla2g4a, Sgpp2, Trpv6, Klhl14, 
Chrnb3, Grm3, Ano3, Fam5c, Htr2a, Irs4
f16 Sst Chodl
Tacr1, Nos1, Bace2, Ccdc109b, Dnase1l3, 
Gpr126, Gpr151, Gstm6, Hcrtr1, Htr7, 
Krt18, Insl6, Ndst4, Sit1, 
9430021M05Rik, Gabrg1, Cdca7, Ndst4, 
Gpr88, Man1a
Stac
f17 Pvalb Gpx3 Th, Calca, Nell1, Fxyd6, Tac1
f18 Pvalb Tpbg
Tacr3, Ednrb, Thsd7a, Fosb, Il1rapl2, Tll1, 
Col25a1, Calb1, Kit, Etv1, Bdnf, Aloxe3
Transcriptomic type
f19 Pvalb Cpne5
Nt5e, Cntnap5b, Thsd7a, Snca, 





Thsd7a, Gm1051, Caln1, Calb1, Il1rapl2, 
Col25a1, Tac1, Tpbg
Ndst4
f21 Pvalb Rspo2 Gpx3,Akr1c18,Ntf3,Lrrc61, Tac1
f22 Pvalb Wt1 Tusc5, Fign, Il1rapl2
f23 Pvalb Obox3 Acsbg1, Tac1, Il1rapl2 Ier5
f24 L4 Ctxn3
Rspo1, Inhba, Sparcl1, Pde1a, Lmo3, 
Rorb, Whrn
f25 L4 Scnn1a Rspo1, Endou, Tmem215, Rorb, Whrn
Shisa3, Barx2, Bglap2, 
Mbnl3
f26 L5a Hsd11b1
Pde1a, Endou, Plb1, Aldh1l1, Etv1, 
Deptor, Rorb, Whrn, Cpne7
Shisa3, Barx2, Bglap2, 
Crym
f27 L4 Arf5 Scnn1a, Endou, Rspo1, Whrn
Lemd2, Shisa3, Barx2, 
Bglap2, Mbnl3
f28 L2/3 Ptgs2
Stard8, Inhba, Wfs1, Otof, Enpp2, Palmd, 
Rgs8, Dgkb
Car12
f29 L2 Ngb Adamts2, Fst, Matn2, Cdh13, Dgkb, Otof
f30 L5a Tcerg1l





Nnat, Syt17, Myl4, D430036J16Rik, 
Deptor, Arhgap25, Cpne2, Il1rapl2
Crym
f32 L5a Batf3
Foxo1, Deptor, Myl4, Aldoc, Arhgap25, 
Il1rapl2
Pde1c, Crym
f33 L5 Ucma Hhatl, Itga7, Myl4, Arhgap25, Man1a
f34 L6a Car12
Penk, Anxa11, Cd7, Cited1, Lipg, Nnat, 
Ptchd2, Sorcs3, Inhba, C1ql3, Pter, 
Acvr1c
f35 L6a Syt17 Fst, Prss22, Traip, Ptprk, Il1rapl2
f36 L6b Serpinb11
Ctgf, Tnmd, Nxph4, Col24a1, Trh, 
Fam46a, Ngf, Moxd1, Ndrg1, Tmem40, 
Cplx3, Cidea, Inpp4b, Lman1l, Igsf3
Htr1d, Clic5
f37 L6b Rgs12
Ctgf, Nxph4, Cidea, Ly6g6e, Sla, Cplx3, 
Clic5, Lman1l, Gpr126, Arhgap25
Mup5, Mup2, Mup19, 
Pappa2, Mapk13, 
Defb1, Gm2083, 
Tceal7, Foxp2, Trh, 
Tnmd
f38 L6a Mgp Foxp2, Ly6d, Rprm, Ifitm2, Ctxn3, Crym
f39 L6a Sla




Chrnb3, Scml2, Ngb, Klk8, Plac9, Ddit4l, 
Fam84b
f41 L5b Tph2
Qrfpr, Samd3, Stac, Ddit4l, 
2310042E22Rik, Kcns3, Mc4r, Coro6, 




Qrfpr, Col6a1, Syt17, 2310042E22Rik, 
Crym, Man1a, Fam84b, Ctxn3
4921511H03Rik, Igfbp2
f43 Astro Aqp4
F3, Rorb, Acsbg1, Slc39a12, Ntsr2, Plcd4, 
Gja1, Gjb6, Cbs, Chrdl1, Prodh, Mlc1, 
Acsl6, Slc4a4, Gabrg1, Cxcl14, Slco1c1, 
Vcam1, Ednrb, Scrg1, Bcan
Gfap
f44 OPC Pdgfra
Cspg4, Pcdh15, Gria3, Cacng4, 
E130309F12Rik, Vcan, Ednrb, Scrg1, 
Bcan, Gpr17
F3, 1110015O18Rik 
f45 Oligo 9630013A20Rik 
Brca1, Rnf122, Mbp, Zcchc12, Enpp6, 
Kif19a, Enpp6, Dct, Tmeff2, Gpr17, 
1700040N02Rik, 1810041L15Rik, St18, 
Vcan, Bcan, 9530059O14Rik, Cldn11, 
1700047M11Rik
f46 Oligo Opalin
Mbp, Mog, Aspa, Mobp, Gpr37, 
Ppp1r14a, Gjb1, Tmeff2, St18, Cldn11, 
1700047M11Rik, Kctd13, Cntn2, Eml1,  
A530088E08Rik
f47 Micro Ctss
Cx3cr1, C1qb, Cd53, Csf1r, Itgam, Abi3, 
C1qa, Aif1, Trem2, P2ry13, Tmem119, 
C1qc, Cd14, Fcgr3, Gpr34, Inpp5d, 





Tbc1d4, AI467606, Exosc7, Eltd1, Fas, 
Hmgcs2, Nostrin, Paqr5, Slc16a4, Id1, 
Ptprb, Cd93, Sparc, Fli1, Ly6a, Ly6c1, 




Bgn, Nupr1, Casq2, Mylk, Gprc5c, 
Slc38a11, Slc6a20a, Pcolce, Vtn, Cnn2, 
Nid1, Gpr30, Higd1b, Ifitm1, P2ry14, 
Serping1, Sparc, Fli1, Cald1,  Abcb1a, 
Flt1, Ly6a, Ly6c1, Ly6c2, Pglyrp1, 
Slco1a4, Ahnak
Plac9, 0610007N19Rik, 
Ace2, Vtn,  Edn3, Sncg
